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Abstract
This thesis explores methods for improving the sustainability of peptide and polymer
chemistry, using alternative solvents and bio-based platform molecules.
Cyclic carbonates were first investigated as replacements for reprotoxic polar
aprotic solvents in peptide chemistry. Using the solution-phase approach several
tetrapeptides were first synthesised utilising propylene carbonate as the only reaction
solvent. Good to excellent yields were observed in all cases for both coupling (65-
91%) and deprotection (80-99%) steps. The use of propylene carbonate for solid-
phase peptide synthesis was then demonstrated, through the total synthesis of the
natural vasodilator bradykinin in an excellent 77% crude purity.
Extending this work, the use of alternative solvents in solid-phase organic synthesis
was then explored. The suitability of green solvents for solid-phase organic synthesis
was determined by their ability to solvate polymeric supports. In all cases, a
solvent was identified that was able to swell a desired resin to >4.0 mL g-1. The
outcomes of this investigation were then used to build a computational model of resin
swelling using the HSPiP software and verify resin/solvent compatibility through the
multicomponent Ugi reaction.
The second half of this thesis then explored the ring-opening metathesis
polymerisation of amide derivatives of a novel oxanorbornene-lactone. A number
of homo- and random co-polymers were prepared, which were found to possess good
molecular weights (Mn = 10,763-28,100) and narrow dispersities (Ð = 1.02-1.11).
Thermal analysis also revealed the polymers to be amorphous, possessing high
thermal degradation (>300 ◦C) and glass transition (115-203 ◦C) temperatures.
It was also possible to synthesise a block copolymer, but only when the second
monomer was added following 80% conversion of the first monomer. Finally, kinetic
data showed that the pendant side chains had a minimal influence on propagation
rate (2.3×10−3 s−1 - 3.1×10−4 s−1).
Finally, the synthesis and application of spirocyclic oxanorbornene-imides were
investigated. These monomers were found to be unsuitable for ROMP, but LLAMA
analysis showed that the hydrogenated variants were highly promising lead-like
compounds. The data suggests they lay perfectly within lead-like space (-1 ≤ cLogP
≤ 3 and Mw = 200-350 Da), are fairly three-dimensional by PMI analysis and had
0% likeness to a random 2% selection of the ZINC database.
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Chapter 1
General Introduction
1

Throughout the latter half of the twentieth century the human race has developed
at a rather alarming rate. Within the last 100 years alone the global population has
multiplied four-fold to 6.4 billion, global economic output has increased more than
twenty-fold, and global material consumption has increased eight-fold.1 This growth
has however come at a cost, with anthropogenic activity now widely accepted to have
been the root cause of a number of environmental issues, including climate change,
global warming, rising sea levels, ozone layer depletion and ocean acidification, to
name but a few.2 Even more worryingly, this growth is not expected to slow down,
with the United Nations (UN) predicting that global population will continue to
grow, reaching 9.3 billion by 2050 and 10.1 billion by 2100.3 Furthermore, this growth
is expected to be concentrated around the less developed nations of Africa, Asia and
Latin America, as they seek to obtain a comparable standard of living to that of more
developed regions. Meeting the needs of a more crowded, more consuming human
population will therefore result in the greater production of goods and services, which
will in turn increase demand for land, energy, materials and resources, placing an
ever greater strain on the environment.
In response, in 1972, the UN organised the Stockholm Conference on the Human
Environment, the first international meeting to address how human activity was
harming the environment and putting lives at risk.4 In the wake of this meeting
a number of reports sought to address the highlighted issues, however, none have
been more prominent than Our Common Future, a 1987 report from the World
Commission on Environment and Development.5 This report sought to forecast on
a global scale, how man-made activities would affect the environment, taking into
consideration the industrial, social and economic consequences. This investigation
however highlighted a major issue. Whilst it was obvious human activity was having
a detrimental effect on the environment, particularly in developed nations, it would
be inconceivable for the UN to impose restrictions on developing nations, inhibiting
their efforts to enhance their standard of living. Consequently, the report sought to
overcome these issues through promoting the concept of “sustainable development”
or “meeting the current environmental and human health, economic, and societal
needs, without compromising the progress and success of future generations”.5 The
concept of sustainable development has appeared in a number of variations since
1987, but has most recently been highlighted by the UN in the form of the Global
Goals, 17 sustainable development goals from the 2030 Agenda for Sustainable
Development, which are highlighted in Figure 1.1.6
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Figure 1.1: UN 2030 Agenda for Sustainable Development included with permissions
from the United Nations.6
1.1 Sustainable Development and the Chemical Industry
If sustainable development is to be realised, widespread change is likely to
be necessary. This change is perhaps going to be most impactful within the
chemical industry, as it has come to almost define modern society, with the
global population relying heavily upon an array of chemical products for their
quality of life. These include basic or commodity chemicals (e.g. petrochemicals,
petrochemical derivatives); speciality chemicals derived from basic chemicals (e.g.
adhesives, sealants, catalysts, coatings); products derived from life science (e.g.
pharmaceuticals, pesticides); and consumer care products (e.g. soap, detergents).7
Being one of the worlds largest industrial sectors it also makes up an important
part of the global economy, with recent estimates from The European Chemical
Industry Council (CEFIC) valuing turnover within the sector at e3,360 billion,
accounting for 7% of global income and 9% of international trade.8,9 Predictions
from the Organisation for Economic Co-operation and Development (OECD)
suggest this industry is also expected to grow by approximately 3% annually until
2050.7 Chemistry is therefore set to play a key role if the societal, economic and
environmental objectives set out by sustainable development are to be met.
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Unfortunately, public opinion often perceives chemistry as the cause of these
problems, rather than the potential solution. This perception is not entirely
unwarranted, as the effect of chemicals on human health and the environment is
far from benign. It is an industry founded upon petrochemicals, the building block
of more than 90% of current organic chemical manufacturing, a resource that is
susceptible to widely variable oil prices, and exploitation of which has been directly
linked to worsening air pollution and global warming.10 Moreover, the chemical
industry releases more hazardous waste to the environment than any other industrial
sector, and more in total than is released by the next nine sectors combined.9 This
is also becoming a growing issue for the industry as the remediation of this waste
continues to become more costly, with ever more stringent controls seeking to limit
chemical hazards.
There now therefore exist a formidable challenge for chemists, to develop new
products, processes and services that meet current and future social and economic
needs, but not at the detriment to the environment.11 This is more commonly
referred to as the three pillars of sustainability, which will be key if sustainable
development within the chemical industry is to be realised. Consequently, there
has been a growing interest in a branch of chemistry that seeks to embed core
environmental considerations into everyday practice, an approach that has come to
be more commonly known as green chemistry.
1.1.1 Green Chemistry
Green chemistry is defined as the “design of chemical products and processes to
reduce or eliminate the use and generation of hazardous substances”.12 It is a concept
that was first proposed in a seminal publication from Anastas and Warner in the
early 1990s.12 Fundamentally, green chemistry seeks to achieve sustainability at
the molecular level, with the aim of preventing pollution rather than dealing with
waste. Anastas and Warner therefore went on to propose the “12 Principles of
Green Chemistry”, a guiding framework for the design of new chemical products
and processes in accordance with sustainability (Table 1.1).13 Since its inception,
green chemistry has grown to receive widespread international interest, in part due
to its ability to meet both economic and environmental goals simultaneously.14
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Table 1.1: The 12 principles of green chemistry.
Principle Explanation
1. Prevention It is better to prevent waste than to treat waste
after it is formed
2. Atom Economy Synthetic methods should be designed to
maximise the incorporation of all materials used
in the process into the final product
3. Less Hazardous Chemical
Synthesis
Synthetic methodologies should be designed to
use and generate substances that pose little or
no toxicity to human health/the environment
4. Designing Safer Chemicals Chemical products should be designed to
preserve efficacy whilst reducing toxicity
5. Safer Solvents and
Auxiliaries
The use of auxiliary substances should be made
unnecessary whenever possible and, when used,
innocuous
6. Design for Energy
Efficiency
Energy requirements of chemical processes
should be recognised and their environmental
and economic impacts minimised
7. Use of Renewable
Feedstocks
A raw material or feedstock should be renewable
rather than depleting whenever technically and
economically practicable
8. Reduce Derivatives Unnecessary derivatisation should be minimised
or avoided if possible
9. Catalysis Catalytic reagents are superior to stoichiometric
reagents
10.Design for Degradation Chemical products should be designed so that
at the end of their function they break down
into innocuous degradation products and do not
persist in the environment
11.Real-Time Analysis for
Pollution Prevention
Analytical methodologies need to be further
developed to allow for real-time, in-process
monitoring and control prior to the formation
of hazardous substances
12.Inherently Safer Chemistry
for Accident Prevention
Substances and the form of a substance used in
a chemical process should be chosen to minimise
the potential for chemical accidents
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1.1.2 Thesis Intent
The concepts underpinning green chemistry however are obviously broadly
applicable to many sectors of the chemical industry, it is therefore important to
narrow the focus of this thesis, setting a general precedent for the proceeding research
chapters. The original aim of this project was to investigate the application of
cyclic carbonates as alternative solvents. However, as time went on, the focus
continued to deviate from this path, such that it is now best discussed in two distinct
parts. The first investigating the use of alternative solvents for solid-phase synthesis
methodologies, with a particular focus on improving the sustainability of peptide
chemistry. The second on improving the sustainability of polymer chemistry, with
an investigation into the ring-opening metathesis polymerisation (ROMP) of a novel
monomer framework, produced from bio-based platform molecules. The application
of green chemistry in the fields of alternative solvents and polymer synthesis will
therefore be introduced in more detail, providing relevant background for these
topics and highlighting notable developments along the way.
1.2 Green Chemistry and Alternative Solvents
The use of alternative solvents is perhaps one of the most active topics of research
within green chemistry.14 This is in part due to the many roles solvents play within
the chemical industry. Solvents are used in chemical processes to aid mass and heat
transfer, and to facilitate separation and purification. They are also often the most
important components of cleaning agents, adhesives, and coatings, such as paints
and varnishes. They often therefore account for the vast majority of waste generated
in synthesis and processing. In fact, estimates from GlaxoSmithKline (GSK) have
suggested solvent use accounts for between 80-90% of the total waste mass generated
in a given batch pharmaceutical or fine-chemical operation.15 More recently, the
American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable
(ACS GCIPR) have shown that for a commercial process, the synthesis of 1 kg of
active pharmaceutical ingredient (API) will typically generate 46 kg of waste, 56%
of which will be due to organic solvents, with a further 32% from aqueous waste.15
Furthermore, many conventional solvents are toxic, flammable, and/or corrosive.
Many are also regarded as volatile organic compounds (VOCs) which present an
increased risk of exposure or release to the environment. The environmental impact
of a given process is therefore almost always a consequence of the solvent. The
biggest gains in terms of reducing environmental impact can therefore be most
commonly had through optimisation of the solvent, rather than through changes
to the chemistry.14
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The greenest solvent is of course the use of no solvent at all, as according to the
12 Principles of Green Chemistry the use of auxiliary substances should be made
unnecessary whenever possible, this however is impractical in many situations.14
There has therefore been a great interest in recent years in the utilisation of solvents
that present more favourable environmental, health or safety (EHS) considerations.
An approach that is particularly prevalent in the pharmaceutical industry is that
of solvent selection guides, with companies such as GSK16, Pfizer17 and Sanofi18,
along with speciality groups including the ACS GCIPR19 and Innovative Medicines
Initiative (IMI)-CHEM2120 publishing their own selection guides. In an effort to
provide researchers with the ability to make a more informed choice with regards to
solvent selection, discouraging the use of harmful or toxic solvents. Alternatively,
there has been great interest in the development of neoteric solvents and solvent
technologies with more desirable EHS characteristics, such as the use of water, ionic
liquids, supercritical carbon dioxide or bio-derived solvents representing some of the
most common examples.21
1.2.1 Water
Water has long attracted interest as a reaction solvent due to its benign nature
and the fact it is the most abundant molecule on the planet. For this reason,
water is accepted as the most inexpensive and environmentally friendly solvent
available.14 Hydrophobic effects associated with the use of water have also been
shown to enhance reaction rates and improve selectivities, and the poor solubility of
oxygen in water has been shown to facilitate air-sensitive transition-metal catalysis
in open air.22 The ability to perform reactions in water therefore presents a number
of advantages, particularly for large scale process chemistry. A notable example of
the use of water in an industrial synthesis is the revised chemoenzymatic synthesis of
pregabalin 1.4 by Pfizer, a blockbuster drug used for the treatment of neuropathic
pain. The initial synthesis required 10 steps, producing pregabalin 1.4 in a 33% yield
and at a cost that was six times more than the target value.23 A revised biocatalytic
route in water greatly improved process efficiency, by setting the stereogenic centre
earlier in the synthesis the undesired enantiomer 1.3 could be efficiently recycled.
The remaining chemical steps could also be performed in water, greatly reducing
organic solvent waste, resulting in a five-fold reduction in overall E-factor (Scheme
1.1).23
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Scheme 1.1: Key chemoenzymatic transformation in the revised manufacturing
process for pregabalin 1.4.
1.2.2 Ionic Liquids
Ionic liquids are ionic salts that are liquid at or below 100 ◦C, they are a rather
more modern neoteric solvent technology that have received a substantial amount
of academic interest in the last few decades. This is due to their perceived
environmental benefits, as they are typically non-flammable and posses almost non-
existent vapour pressures, they are therefore regarded as excellent replacements to
conventional VOCs. Additionally, the wide variety of anions and cations that are
readily available make ionic liquids highly versatile solvents, that can be tuned to
suit a particular purpose. It should be acknowledged however that they are not
intrinsically green, due to issues regarding their synthesis and their widely unknown
toxicity. Regardless, ionic liquids have come to find use as solvents in a wide variety
of laboratory applications to date, including synthesis, catalysis, batteries, and fuel
cells.
A rather interesting example, from a green chemistry perspective, of ionic liquid
solvents is recent interest in a sub-set of reversible or switchable ionic liquids,
pioneered by Jessop and co-workers.24 These solvents are able to switch between
a high polarity or low polarity form, through the use of a CO2 trigger. Exposure
of a guanidine or amidine base to CO2 in the presence of an alcohol, results in
a high polarity ionic liquid. This reaction can then be reversed under a flow of
nitrogen (Scheme 1.2). Hart et al., for example, have then utilised this system
in the Pd-catalysed Heck reaction, with the intention that the switchable solvent
should allow for the sequential separation of product and by-product (Scheme
1.2).25 The Heck reaction between bromobenzene 1.5 and styrene 1.6 using a 1,8-
diazabicyclo[5.4.0]undec-7-ene 1.8 (DBU)/hexanol switchable solvent system under
high polarity conditions produced the target product 1.7 in 97% yield, following an
extraction with hexane. After switching back to the low polarity solvent mixture
the HBr/DBU salt by-product could then be removed using a simple filtration.
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The catalyst/solvent system was then found to retain activity in subsequent Heck
reactions, provided fresh DBU was added to compensate for losses.25
Scheme 1.2: Heck coupling reaction between styrene 1.6 and bromobenzene 1.5
using a DBU/hexanol switchable ionic liquid.
1.2.3 Supercritical Carbon Dioxide
Another neoteric solvent technology that has also received a considerable amount of
interest is that of supercritical carbon dioxide (scCO2). Supercritical fluids are fluids
that are simultaneously heated and compressed above their critical points, within
this region the fluid has properties intermediate between that of a liquid and a gas
(Figure 1.2).14 The use of carbon dioxide as a supercritical fluid is a particularly
interesting choice, as it is both plentiful and inexpensive, whilst also requiring fairly
mild temperatures and pressures to reach supercritical state (critical temperature
31 ◦C and critical pressure 74 bar). Additionally, with carbon dioxide being gaseous
under ambient conditions, degassing of a reaction vessel will result in the complete
removal of the solvent. Consequently, (scCO2) has found a number of industrial
applications, the most significant of which being the decaffeination of coffee and the
replacement of perchloroethylene in dry cleaning.14
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Figure 1.2: Pressure-temperature phase diagram of carbon dioxide highlighting the
supercritical region.
1.2.4 Bio-derived Solvents
Finally, there has also been a growing interest in the use of solvents sourced
from renewable feedstocks, such as food, forestry and agricultural waste. These
are more commonly referred to as bio-based solvents, which are either used as
direct replacements to conventional solvents, or functionalised to produce novel
molecular structures. Common examples include the bio-based alcohols, such as
bio-ethanol or glycerol, moderately polar aprotic solvents, such as 2-MeTHF 1.16
and γ-valerolactone 1.17, and the apolar aprotic terpene derivatives D-limonene 1.9
and para-cymene 1.10 (Scheme 1.3).26 Despite their advantages, bio-based solvents
are not necessarily safer, less toxic or more environmentally benign compared to
conventional solvents. Additionally, there is often a distinct lack of data on some
of the more novel bio-based solvents, particularly in terms of physical properties,
toxicity, performance and cost.20 For these reasons, the uptake of bio-based solvents
for industrial applications has been rather slow to date.26
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Scheme 1.3: A number of common bio-based solvent structures.
Despite the numerous advances in neoteric solvents and solvent technologies, polar
aprotic solvents still present a significant challenge. This is a tremendously
valuable class of solvents for chemists, due to their ability to solvate a wide
variety of compounds, and promote various chemistries through their high
polarities.27 However, many of the most common polar aprotic solvents, such as
dimethylformamide (DMF), dimethylacetamide (DMA) and N -methylpyrrolidone
(NMP), present human reproductive toxicity and are therefore coming under
increasing regulatory constraint. They are also a major environmental concern,
as their use is often associated with generating large quantities of mixed
aqueous/organic waste. The preferred disposal of which is incineration, this is not
only energy intensive but releases nitrogen and sulfur oxides (NOx and SOx).27
Given the utility of these solvents the need for less toxic and environmentally
damaging replacements is rather apparent. The first half of this thesis will therefore
investigate alternatives to conventional polar aprotic solvents, with a particular focus
on improving the sustainability of peptide synthesis.
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1.3 Green Chemistry and Polymer Synthesis
The second half of this thesis will then look at improving the sustainability
of polymer synthesis. Synthetic polymers have come to be ubiquitous in
modern society, finding widespread use in packaging, building materials and
consumer products, along with specialist applications including medical devices and
electronics. This prominence in such a wide variety of roles has meant that synthetic
polymers have come to provide a valuable contribution to our current standard of
living. Consequently, there is an ever growing demand for these materials, with
synthetic polymers currently produced on a scale of more than 300 million metric
tonnes annually.28 However, this growing demand has also highlighted a number of
environmental concerns associated with both the raw materials used to make them
and their end-of-life.
Due to their predominantly bulk, low value applications, synthetic polymers are
overwhelmingly derived from non-renewable petrochemical feedstocks. In fact, their
use accounts for 8% of the global crude oil and gas production, the second largest
sector behind fuels.29 Moreover, the short lifetime of most plastic products results
in the generation of large quantities of waste, with current estimates suggesting that
of the approximately 8.3 billion metric tonnes of plastic produced between 1905 and
2015, 30% is still in use, 60% has been discarded (landfill or to the environment),
and the remaining 10% is either incinerated or recycled.30 The vast quantity that is
discarded is a major concern, as issues surrounding bioaccumulation, particularly in
aquatic environments, are only now starting to be realised, presenting physical and
chemical hazards that are currently not fully understood.31
Whist there appears to be no single solution to this array of environmental problems,
one option that has begun to receive considerable attention is the synthesis of
more sustainable polymers. This is typically achieved through either replacing
petrochemically derived raw materials with renewable ones, such as biomass, or
developing alternatives that are more amenable to recycling or biodegradation.32 In
principle, this appears to be a simple idea, but in reality it is a rather complex one.
Whilst it is obvious there is a demand for more environmentally benign polymers,
these sustainable polymers will need to present more favourable economic or material
properties, if they are to be favoured over petrochemically derived polymers. It
is probably for this reason that currently only 1.7 million metric tonnes (ca.
0.6%) of polymers produced globally can be regarded as bio-based.32 Consequently,
there has been great interest in recent years, within both academia and industry,
in the development of renewable polymers that meet these social, economic,
environmental and material needs. This is generally achieved via two distinct
methods, either the development of sustainable routes to monomers chemically
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equivalent to those derived from petrochemical sources, termed bioreplacement, or
the synthesis of novel structures from biomass as new sustainable monomer species,
termed bioadvantage.33 Approaches for the synthesis of sustainable polymers from
four promising renewable raw materials, carbon dioxide, terpenes, vegetable oils and
carbohydrates, will therefore now be highlighted in more detail.
1.3.1 Carbohydrates
Carbohydrates represent the most abundant group of natural polymers on the
planet.34 Each year, more than 150 billion tonnes of these polysaccharides are
naturally produced, of which humans currently only consume 1%.32 This high
abundance, combined with their biocompatibility, nontoxicity and biodegradability
means they have long been utilised by humans, for uses such as clothing and paper,
or modified to produce fibres (rayon) and films (cellophane).35 The fact that only
1% of naturally produced carbohydrates are currently utilised makes them a highly
promising raw material for the future polymers market.
More recent approaches to carbohydrate utilisation in polymer synthesis has focussed
on their deconstruction to their constitute monomers, which have been widely
utilised as precursors for a number of promising platform molecules. In 2004, the US
Department of Energy (DOE) highlighted a number a promising platform molecules,
on the grounds of their availability and ability to be transformed into useful
products.36 Some examples include, 2,5-furandicarboxylic acid (FDCA), glycerol and
aspartic acid. These molecules have since inspired a great deal of research into their
use, or derivatisation, for the synthesis of polymers from renewable raw materials.
Perhaps one of the most interesting examples of this is the current contest between
the bioadvantage or bioreplacement approach to sustainable soft drink bottles.
Traditionally, soft drink bottles were composed of petrochemically derived
polyethylene terephthalate (PET) 1.23, formed through the polycondensation of
ethylene glycol 1.21 and terephthalic acid 1.22 (Scheme 1.4). PET for this purpose,
is annually produced on a scale of 15 million metric tonnes, or 5.9% of global plastic
production.37 In 2009, the Coca Cola Company announced that they would switch
to using bio-derived ethylene glycol 1.21, producing PET that was roughly 30%
bio-based. The current aim is to eventually be able to produce 100% bio-based
PET through the development of a route to bio-derived terephthalic acid 1.22.
Alternatively, Avantium have developed poly(ethylene furanoate) 1.25 (PEF), a
100% biobased alternative to PET, formed through the polycondensation of ethylene
glycol 1.21 and 2,5-furandicarboxylic acid 1.24 (FDCA) (Scheme 1.4). PEF 1.25
has been shown to have better gas barrier properties than PET and is currently in
development for use in soft drink bottles.32
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Scheme 1.4: Polycondensation of ethylene glycol 1.21 with terephthalic acid 1.22
or FDCA 1.24 to produce PET 1.23 or PEF 1.25.
1.3.2 Terpenes
Another very interesting source of renewable platform molecules from biomass are
terpenes. Terpenes are a family of unsaturated aliphatic structures 1.9/1.26-1.29
linked by a common isoprene unit (Figure 1.3).38 These structures are predominantly
derived from turpentine, the volatile fraction of pine resins, which is currently
produced on a 0.3 kilotonnes scale annually. The exception being D-limonene
1.9 which is most commonly extracted from citrus peel waste, on an scale of 0.7
kilotonnes.32 Whilst current annual production of terpenes is rather modest, they
are highly abundant and fairly inexpensive. For this reason, they are currently
widely utilised as key components of fragrances, pharmaceuticals, solvents and
flavours. They are therefore also rather ideal structures for the synthesis of
bio-based polymers. Whilst they have attracted a large amount of interest in
recent years, from academia and industry alike, commercialisation of terpene based
polymers is fairly limited.34 The most commonly reported example being the use
of thermoplastic polyterpene resins in adhesives and coatings, which has been in
commercial production since 1938.32
Figure 1.3: Chemical structures of some common terpenes 1.9/1.26-1.29.
1.3.3 Vegetable Oils
Vegetable oils, are also a particularly promising source of monomers for renewable
polymers, as they are already produced on a very large scale. In 2012 for example,
156 megatonnes of triglycerides were produced, whilst the majority of this was
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used for food or biofuel, 20 megatonnes was used a chemical feedstock.32 Whilst
almost all plants contain triglycerides to some extent, a major issue with their use
is the fact that the quantity available is typically rather limited, with even common
feedstocks, such as soybeans, containing only 20 wt% of triglycerides.34 Additionally,
the chemical composition of the triglycerides will vary significantly from crop to crop.
Despite this, there are currently a number of industrial processes utilising vegetable
oils, such as linoleum or the use of epoxidised oils in resins and coatings. Another
rather interesting example is the production of 100% bio-based polyamide nylons
derived from castor oil. The oil is first hydrolysed to give glycerol 1.31 and ricinoleic
acid 1.30 (Scheme 1.5).39 The ricinoleic acid 1.30 then undergoes pyrolysis and a
number of additional chemical steps, to produce 11-aminoundecanoic acid 1.32.
This is then polymerised to produce nylon-11 1.33, which has been widely utilised
in engineering and automotive applications.39
Scheme 1.5: Synthetic route to nylon-11 1.33 from castor oil derived ricinoleic acid
1.30.
1.3.4 Carbon Dioxide
The last three categories have all described sustainable feedstocks sourced from
biomass. In addition to biomass, carbon dioxide represents a highly promising
renewable feedstock for the future bio-economy. This is because carbon dioxide is
highly abundant, inexpensive and non flammable, it is also a common by-product of
many chemical processes. Additionally, growing concerns over atmospheric carbon
dioxide levels have facilitated interest in the use of carbon dioxide within synthetic
chemistry. Methods for the valorisation of carbon dioxide as a C1 building block are
rather limited at present, with only the synthesis of urea, salicylic acid and some
cyclic carbonates viably produced from CO2.40 There is however growing interest
in the utilisation of CO2 for the alternative copolymerisation of epoxides 1.34 and
carbon dioxide 1.35, producing aliphatic polycarbonates 1.36 containing between
30-50 wt% CO2 (Scheme 1.6).
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Scheme 1.6: Polycarbonate synthesis through the ring-opening copolymerisation of
epoxides 1.34 and carbon dioxide 1.35.
This process is currently on the verge of commercialisation for a number of
applications.41 The primary one being the production of low molecular weight
polycarbonate polyols, which are utilised predominantly in the production of
polyurethanes, used to make furniture foams, adhesives and resistant coatings.
Alternatively, high molecular weight polycarbonates are already used as binders, and
sacrificial materials in fabrication.41 Early observations are particularly promising,
with the use of waste carbon dioxide having been shown to have no detrimental
impact on the final product. Life cycle assessment has also shown that polyol
synthesis using copolymerisation would lead to a 11-20% reduction in emissions
and depletion of fossil resources, compared to the epoxide homopolymerisation.41
It is apparent from the aforementioned work that investigations into the use of
bio-derived or similarly renewable monomers for sustainable polymer synthesis
is a particularly active field of investigation. It is rather surprising then, that
despite the current demand for polymeric materials that bio-derived polymers
contribute so little (ca. 0.5%). This is most likely due to the need of sustainable
polymers to provide both an economic or performance advantage to be preferred
over petrochemically derived polymers. This suggests that additional research is
necessary. The second half of this thesis will therefore investigate approaches to
improving the sustainability of polymer chemistry. This will particularly focus on
building upon work investigating the use of itaconic anhydride and furfuryl alcohol,
both promising platform molecules, which have been shown to produce a novel
monomer structure suitable for ring-opening metathesis polymerisations.
1.4 Thesis Objectives
The core objectives of this thesis are therefore to investigate routes to improving the
sustainability of peptide and polymer synthesis, using methods revolving around the
use of alternative solvents and bio-based platform molecules. It has made most sense
to divide this body of work into four distinct chapters, the first two dealing with the
use of alternative solvents in solid-phase synthesis, with a particular focus on peptide
chemistry, whilst the last two look at the ring-opening metathesis polymerisation of
a novel bio-based molecular framework. Due to the wide variation in topics covered
17
Chapter 1. General Introduction
the relevant background for each chapter will be introduced in more detail in due
course. The objectives for each chapter are however as follows:
Firstly, Chapter 2 will explore the use of cyclic carbonates as promising replacements
to conventional polar aprotic solvents. This will start with solution-phase peptide
synthesis, with the aim of demonstrating the tolerance of cyclic carbonates to the
common chemistry associated with this methodology. Following this, the use of
cyclic carbonates in solid-phase peptide synthesis methodology will be investigated,
with the principal aim of producing a biologically relevant peptide.
Chapter 3 will then look at building on this work, extending the use of green
solvents to general solid-phase organic synthesis. It will then attempt to better
understand the factors that influence solvent suitability for this chemistry, through
the development of a computational model, and experimental verification.
Moving on to the second half of this thesis, Chapter 4 will focus on the use of
a novel bio-based molecular framework in ring-opening metathesis polymerisation.
Functionalisation of this framework with amines, to produce the corresponding
amides, will be attempted. The eventual aim is the production of fully bio-
based monomers derived from amino acids or peptides for material or therapeutic
applications.
Finally, an unusual spirocyclic species was identified during the previous
investigation. Chapter 5 will therefore look to better understand how this species
forms, and whether it holds any potential within polymer chemistry or therapeutics.
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2.1. Introduction
2.1 Introduction
2.1.1 Peptides and Peptide Synthesis
Peptides, routinely defined as macromolecules consisting of between 2-50 amino
acids, are ubiquitous in nature. More than 7000 naturally occurring peptides have
been identified, with many playing crucial roles in an array of physiological processes,
including as hormones, neurotransmitters, growth factors and anti-infectives, to
name but a few.42 Peptides have been recognised as being highly specific in their
binding to in vivo targets, resulting in them being highly potent and very selective,
whilst having very few negative side effects. However, limitations due to their short
plasma half-life and negligible oral bioavailability have previously hampered their
application as therapeutics.43 Recent developments in formulation and novel delivery
systems have since revitalised interest in this field.44 Currently, more than 60 peptide
therapeutics have been approved for use in the United States, with 150 currently in
clinical development and 260 in human clinical trials.43 A market that was estimated
to be worth US$14.1 billion in 2011 and is expected to grow to around US$25.4 billion
by 2018.42
Commercial scale manufacture of therapeutic peptides was however initially a very
expensive and inefficient process. The breakthrough came with Fuzeon, a treatment
for human immunodeficiency virus (HIV) developed by Roche, which demonstrated
for the first time that the synthesis of a 36-amino acid peptide on a ton-scale was
indeed financially viable.45 Nowadays, a number of methods exist for the commercial
scale production of peptides, which can be divided into two distinct categories,
chemical synthesis and biological manufacturing.46 The choice of which to use is
dependent on many factors including, sequence length, degree of modification and
scale. Generally, the majority of peptide drugs are produced by chemical methods,
this is due to flexibility, as the incorporation of unnatural D- and synthetic-amino
acids is not routinely possible with methods based on biotechnology.45 For this
reason, this chapter dealing with improving the sustainability of peptide synthesis
will exclusively deal with the chemical approach.
Two distinct methodologies exist for the chemical synthesis of peptides, solution-
phase and solid-phase. Others do exist, such as hybrid approaches and
chemoselective ligation, but are less explored.46 Solution-phase synthesis couples
suitably protected peptide fragments or single amino acids in solution. Each
intermediate is then isolated, allowing for analysis and purification. This method
benefits from the relatively cheap building blocks, but is particularly laborious.
Consequently, solution-phase peptide synthesis is typically used for small- to
medium-length peptides in quantities of hundreds of kilograms to metric ton scale.
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The solid-phase approach differs in that one of the amino acids is anchored to an
insoluble polymer support, the peptide sequence is then built by coupling protected
amino acids to the solid-support. Intermediates are not isolated, and impurities and
excess reagents are simply removed by filtration. Once the target sequence has been
built it is easily cleaved from the solid support. The simplicity of the solid-phase
approach makes it particularly amenable to automation, meaning it is far quicker
than the solution-phase approach for the synthesis of long chain peptides.
However, when considered in the context of green chemistry, both solution- and solid-
phase peptide synthesis are inherently wasteful processes. The need for a multitude
of auxiliary reagents, including protecting groups, solvents and coupling agents,
means peptide (or amide) bond formation is characterised by incredibly poor process
mass intensity, generating large quantities of waste. In fact, estimates suggest the
manufacture of 1 kg of peptide active pharmaceutical ingredient (API) can easily
result in 1000 L of waste, although in the majority of cases it is probably significantly
more.44 As previously discussed, solvent use will routinely account for between 80-
90% of waste by mass in a typical batch pharmaceutical/fine-chemical operation.15
Additionally, amide bond forming reactions are typically carried out in highly
undesirable solvents, with 86% being performed in either CH2Cl2 (36%) or common
polar aprotic solvents, such as DMF, NMP or DMA (47%).47 Although, SPPS is
nowadays almost exclusively performed in DMF. This is particularly concerning, due
to the number safety issues presented to humans with regards to the use of DMF,
which includes, hepatotoxicity, alcohol intolerance, possible embryotoxicity and
teratogenicity.48 Furthermore, there are a number of environmental issues associated
with DMF, as its use typically produces large quantities of mixed aqueous/organic
waste.15 This waste is both difficult to separate and costly to dispose of, as high
nitrogen content makes discharge to waste water problematic, whilst high water
content necessitates the addition of fuel in order to incinerate it, releasing NOx in
the process.27,49 Finally, both DMF and NMP are highlighted as two of 174 chemicals
regarded as substances of very high concern (SVHC), under EU Registration,
Evaluation and Authorisation of Chemicals (REACh) legislation, and are therefore
likely to face restrictions to their use within the next few years.50
It is therefore apparent that the biggest contributor to the environmental impact of
peptide synthesis is overwhelmingly from the solvent. The biggest gains in terms of
reducing environmental impact will therefore come from optimisation of the solvent,
rather than changes to the chemistry. For these reasons, it was felt that the issue
of solvent use in peptide synthesis needed to be addressed, in an effort to develop
a more sustainable approach to peptide synthesis. It is worth noting that Amgen
Inc. and Bachem have recently been awarded the 2017 Green Reaction Conditions
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Award by the Environmental Protection Agency (EPA) for their improvements
to the synthesis of Etelcalcetide, a peptide therapeutic used for the treatment of
secondary hyperparathyroidism.51 The improved process saw a reduction in solvent
waste of 71%, manufacturing operating time of 56% and manufacturing cost of
76%. Ultimately, eliminating 1,440 m3 of waste, 750 m3 of which was aqueous
waste. Herein, the various literature reports of sustainable peptide synthesis in both
solution- and solid-phase, that specifically utilise a green solvent, will be addressed,
in an effort to highlight that there is still substantial scope for an investigation into
the use of alternative solvents for improving the sustainability of peptide synthesis.
2.1.2 Greener Solvents for Peptide Synthesis
2.1.2.1 Solution-Phase Peptide Synthesis
Water
The use of water represents a highly desirable solvent choice as it is safe, cheap
and environmentally benign. Its use has been a long standing challenge in peptide
chemistry, as chemists tried to best replicate classical biosynthesis by chemical
means. However, poor solubility of common reagents and the susceptibility of the
activated intermediates to hydrolysis, means peptide synthesis in water is rather
problematic. Since the 1950s a wide variety of approaches have been reported in
an effort to overcome these limitations, including the development of water-soluble
protecting groups,52,53 coupling agents54,55,56,57 and water-compatible dehydrating
agents.58 Many of these however, suffer from limited scope, necessitate the use of
organic co-solvents or require extensive derivatisation.
More recent developments have sought to overcome these issues through the
development of novel technologies and reagents to enable solution-phase peptide
synthesis in water. A rather interesting example from Hojo et al. has shown that
amino acids with conventional Fmoc- or Boc-protection can be utilised without
derivatisation.59 The protected amino acids were wet milled in water using a
planetary ball mill and polyethylene glycol (PEG) as a dispersant, generating
dispersed nanoparticles. These nanoparticles were then used in the synthesis of Leu-
enkephalin amide (H-Tyr-Gly-Gly-Phe-Leu-NH2). Coupling was performed using
the water-dispersed nanoparticles of the appropriate Boc-amino acid in the presence
of 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM)
in neat water for 12 hours at room temperature. Whilst the deprotection steps were
performed using 4.0 M HCl in dioxane, which is undesirable, the target peptide was
obtained in 51% total yields over 9 steps. Additionally, minimal purification was
required as excess reagents were easily removed through filtration after coupling.
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Similarly, Mahindra et al. have shown that Boc- and Fmoc-protected amino acids
can be used without derivatisation in neat water, when used in conjunction with
microwave assisted heating.60 Coupling was performed using O-(benzotriazol-1-yl)-
N,N,N ’,N ’-tetramethyluronium tetrafluoroborate (TBTU), 1-hydroxybenzotriazole
hydrate (HOBt) and N,N -diisopropylethylamine (DIPEA) with either Boc- or Fmoc-
protected amino acids 2.1 (Scheme 2.1). The reagents were poorly soluble at the
start of the reaction, but produced a homogeneous solution after heating to 60 ◦C
for 30 mins in a microwave. A range of peptide sequences 2.3 were investigated,
typically producing the desired product in good to excellent yield and purity.
Finally, the microwave-assisted synthesis of pentagastrin (Boc-HN-Gly-Trp-Met-
Asp-Phe-NH2), a bioactive peptide that stimulates the secretion of gastric acid, was
investigated. The developed methodology was able to produce the target sequence
in 42% overall yield and excellent purity.
Scheme 2.1: Microwave-assisted solution-phase peptide synthesis in water using
Boc- and Fmoc-amino acids.
Finally, Lipshutz and co-workers have reported on a very interesting example
utilising micellar “nanoreactor” technology for aqueous solution-phase peptide
synthesis.61 TPGS-750-M 2.7 is a surfactant known to spontaneously assemble
into nanomicelles in water. It is these micelles that act as a “nanoreactor”,
solvating water-insoluble reagents. A range of di- to tetra-peptides 2.6
were prepared using this approach, with a combination of (1-cyano-2-ethoxy-2-
oxoethylidenaminooxy)-dimethylaminomorpholino carbenium hexafluorophosphate
(COMU) and 2,6-lutidine used for coupling (Scheme 2.2). Using this approach the
reactions were found to be complete in 0.5-4.0 hours, with excellent yields obtained
for all examples. Lipshutz and co-workers also highlighted that the reaction by-
products are very soluble in water, meaning the product can easily be isolated using
a small quantity of organic solvent (i -PrOAc). Additionally, the aqueous phase
can be recycled multiple times using this method, which resulted in incredibly low
E-factors of just 2.8 for peptide bond formation.
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Scheme 2.2: Peptide bond formation in neat water using TPGS-750-M 2.7 under
micellar catalysis conditions.
In a subsequent paper, Lipshutz and co-workers have further built upon their
micellar “nanoreactor” concept. As previously mentioned, solution-phase peptide
synthesis suffers from the laborious isolation and purification of intermediates.
Cortes-Clerget et al. have therefore looked to enhance the process efficiency by
improving the step-economy. The aim was to be able to perform both deprotection
and coupling reactions in a one-pot process, using micellar catalysis conditions
for both steps (Scheme 2.3).62 This was done by first performing deprotection of
the N -terminus 2.8, by hydrogenation of the Cbz-protecting group. The addition
of HCl was necessary to generate the amine salt, as formation of the free amine
seemed to inhibit further catalysis through what was believed to be strong chelation.
Argon was then bubbled through the reaction mixture to remove any residual HCl,
before coupling could be performed using 2.9, COMU and 2,6-lutidine. A range of
peptides 2.10 were prepared in good yield using this method, up to a decapeptide
using a convergent strategy. Coupling did however require addition of THF (10%)
as a co-solvent, but the methodology does represent a novel and very interesting
approach for developing sustainable peptide synthesis in water through enhanced
step-economy.
Scheme 2.3: Tri- to deca-peptide synthesis using a tandem deprotection/coupling
process under TPGS-750-M 2.7 micellar catalysis conditions.
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Chemoenzymatic Peptide Synthesis
Another highly explored method for performing peptide bond formation in water
is the chemoenzymatic one. Chemoenzymatic synthesis traverses the line between
the chemical and biological approach to peptide synthesis, but is worth mentioning,
particularly in the context of sustainability. It is the catalytic formation of peptide
bonds using protease enzymes. This approach has been utilised for several decades
and has attracted a large amount of interest during this time.63 This interest
is due to the many advantages it holds over the chemical approach. Namely,
peptide bond formation occurs in a very stereo- and regio-specific manner, will often
tolerate incorporation of non-protected functional groups and occurs under very mild
and benign reaction conditions.64 However, it is not without its limitations, the
specificity typically means the synthesis of peptides much longer than a dipeptide
is a substantial challenge. Optimisation can also be particularly laborious, due to
variations in enzyme activity being strongly influenced by many factors, such as pH,
temperature, solvent and additives. Additionally, the equilibrium for amide bond
formation using protease enzymes, in water, lies largely towards hydrolysis, rather
than aminolysis. A complete review of this field along with adequate explanations for
overcoming the hydrolysis equilibrium is much beyond the scope of this report, and
these topics have been excellently reviewed elsewhere.65,66 However, some recent
publications have acknowledged that neoteric reaction media can be particularly
useful for promoting peptide bond formation using hydrolyse enzymes, which are
worth highlighting.
The first example of this was reported by Noritomi et al. and their use of supercritical
carbon dioxide (scCO2)/acetonitrile (MeCN) solvent mixtures for enzyme catalysed
peptide bond formation.67 N -Acetyl-L-tyrosine ethyl ester 2.11 and various amino
acid amides 2.12 were coupled using an α-chymotrypsin enzyme, in either MeCN
or a mixture of scCO2/MeCN (Scheme 2.4). In all cases, observed yields for the
peptides 2.13 were significantly improved when a mixed solvent system was used,
rather than MeCN by itself. This is justified on the basis that sedimentation of
the enzyme in suspension means catalysis generally becomes a diffusion-controlled
process. The use of scCO2 is therefore believed to improve diffusion, significantly
enhancing catalysis. This appears to be a rather isolated example, as the use of
supercritical carbon dioxide for enzymatic peptide bond formation has not been
explored to any great degree since this initial communication.
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Scheme 2.4: α-Chymotrypsin catalysed peptide bond formation using either MeCN
or a mixed scCO2/MeCN solvent system.
More recently, Erbeldinger et al. have shown that ionic liquids (ILs) are
a suitable reaction media for the chemoenzymatic synthesis of peptides.68
The natural sweetener derivative Z-aspartame 2.17 was synthesised from
carbobenzoxy-L-aspartate 2.14 and L-phenylalanine methyl ester hydrochloride
2.15 through a thermolysin catalysed process, using a 1-butyl-3-methylimidazolium
hexafluorophosphate [BIMI][PF6] 2.16 ionic liquid as the reaction medium (Scheme
2.5). The target peptide was obtained in 95% yield, a result which is comparable to
results typically reported for conventional organic solvents. More importantly, due
to the significant cost of the solvent used, Erbeldinger et al. demonstrated that the
IL could be recycled multiple times, with minimal leeching of the target product.
Scheme 2.5: Thermolysin-catalysed synthesis of Z-aspartame 2.17 in [BMIM][PF6]
2.16 containing 5% (v/v) water.
Following the report by Erbeldinger et al. the use of ionic liquids in peptide synthesis
has been rather limited, even though they have been highlighted as highly promising
solvents on a number of occasions.69,70 This is most likely due to difficulties in finding
a suitable extraction protocol for separating the products from the IL.71 Additionally,
most of the focus has been on the chemical approach to peptide bond formation,
rather than the chemoenzymatic one. Most of these reports demonstrate the
suitability of various IL cation/anion combinations, which tend to show comparable
results to traditional organic solvents. It therefore seems unnecessary to cover this
field in considerable detail, particularly since it has been reviewed fairly extensively
only recently.70,71
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Solvent Free Peptide Synthesis
Finally, the use of no solvent would of course be the greenest protocol in terms
of minimising solvent waste in solution-phase peptide synthesis. Whilst this is not
practical in many cases, Lamaty and co-workers have shown that peptide synthesis
in the solid state is possible using ball-milling technology.72 Amino acids 2.19 were
coupled using urethane-protected α-amino acid N -carboxyanhydrides (UNCA) 2.20
in the presence of NaHCO3 (Scheme 2.6). The reaction mixture was agitated for 1
hour using steel balls at a frequency of 30 Hz. In this time quantitative conversions
were typically obtained, with a diverse range of peptides 2.20 isolated in good to
excellent yields following purification. The use of UNCAs is a rather interesting
approach, as in this class of mixed anhydride the amino group is protected whilst
the carboxylate is simultaneously activated. This means the majority of reagent
mass is incorporated into the final peptide, resulting in a very atom economical
procedure.
Scheme 2.6: Synthesis of dipeptides under solvent-free ball-milling conditions using
urethane-protected α-amino acid N -carboxyanhydrides 2.20.
The original report only demonstrated the synthesis of short di- and tri-peptides,
Bonnamour et al. have since looked to extend this methodology, to longer sequences
and on a larger scale.73 This however presented an initial problem, as increasing
the milling load to 22.5 mg mL-1, from 5.9 mg mL-1, caused serious mass transfer
limitations, significantly reducing yields. To remedy this, the addition of small
quantities of EtOAc (1.4 μL mg-1) was necessary. The pentapeptide Leu-enkephalin
was then synthesised using this liquid-assisted ball-milling approach, with the target
peptide obtained in an excellent 46% total yield over the 9 steps.
It is also worth highlighting a recent report from Maurin et al., that directly
compares the green credentials of ball-milling, against the more traditional solution-
and solid-phase approaches.74 The VVIA tetrapeptide (H-Val-Val-Ile-Ala-OH) 2.21
was synthesised using all three methods (Table 2.1). Overall, the ball-milling
approach produced the target peptide in 59% yield and 88% crude purity. A result
that is comparable to the solid-phase approach and significantly better than the
solution-phase one. The major advantage of the ball-milling technology is more
obvious when the E-factors are considered, with E-factor being defined as the ratio
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of the mass of waste per mass of product. Maurin et al. showed that the solid-phase
approach to peptide synthesis produced 80 times more waste than the ball-milling
approach. Maurin et al. also noted than the cumulative number of risk phrases for
the ball-milling approach was more favourable than both solution- and solid-phase
methods. The final conclusion was that, in terms of peptide yield and purity, ball-
milling can be considered comparable to that of solid-phase for the synthesis of long
peptides, but presents a much more desirable approach for environmental reasons.
Table 2.1: Yield and purity comparison for the synthesis of the VVIA peptide 2.21 by ball-
milling-, solution- and solid-phase peptide synthesis.
Ball-milling Solution Solid
Peptide Yielda Purity Yielda Purity Yielda Purity
Boc-IA-OBn 89% 93% 88% 96% - -
AH·H-IA-OBn >99%b 97%b >99%c 99%c - -
Boc-VIA-OBn 89% 99% 77% 90% - -
AH·H-VIA-OBn 96%b 97%b >99%c 92%c - -
Boc-VVIA-OBn 78% 88% 64% 85% - -
Overall 59% 88% 43% 85% 54%d 96%d
a Isolated yield.b HCl.c TFA salt.d Obtained as TFA·H-VVIA-OH. Result highlighted in
bold represents the best result for each peptide sequence.
Building on their work on microwave-assisted peptide synthesis mentioned previously
Mahindra et al. have also recently reported an example using a solventless
approach.75 Coupling was performed using N,N ’-diisopropylcarbodiimide (DIC)
N -hydroxy-5-norbornene-2,3-dicarboximide (HONB) and DIPEA 60 ◦C under
microwave irradiation (Scheme 2.7). No solvent was necessary, and coupling was
found to be complete in only 15 minutes. Yields and purities were typically
found to be excellent, however a slight drop in yield was observed when coupling
longer peptide species. Mahindra et al. then used the methodology to prepare the
therapeutic pentapeptide Thymopentin (H-Arg-Lys-Asp-Val-Tyr-OH) or TP-5. The
total synthesis of which was complete in 10 steps, with an overall yield of 53% and
a purity of 97%.
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Scheme 2.7: Solvent-free peptide synthesis assisted by microwave irradiation.
Finally, Hernandez et al. have combined many aspects of some of the more popular
solution-phase methodologies in their mechanoenzymatic approach to sustainable
peptide synthesis.76 Peptide bond formation was catalysed using the cysteine
protease papain. The biocatalyst was found to be tolerant to the mechanical stress
of ball milling, facilitating peptide bond formation in the absence of a solvent in
2 hours. A diverse range of α,α- 2.27 and α,β-dipeptides 2.28 were generated in
moderate to high yields (Scheme 2.8). Whilst yields varied substantially with the
substrate this process represents a really interesting approach to sustainable peptide
synthesis. Due to the use of a biocatalyst and a mixing method that requires no
solvent. It will be interesting to see whether the methodology can be applied to
more complicated and longer peptide sequences in the future.
Scheme 2.8: Solvent-free ball milling approach to peptide bond formation catalysed
by the cysteine protease papain.
2.1.2.2 Solid-Phase Peptide Synthesis
Nowadays, peptides are more commonly synthesised via the solid-phase (SPPS)
approach rather than the previously discussed solution-phase method. The use of
alternative reaction media for solid-phase peptide synthesis is however rather more
challenging. This is because the use of an insoluble solid-support, or resin, places
additional considerations on the solvent. Most notably, adequate solvation of the
resin, more commonly known as swelling, which is often considered as the most
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important prerequisite for SPPS, as inadequate swelling will result in poor active
site accessibility and diminished reaction rates. The importance of swelling will be
explored in much more detail in a subsequent chapter, for now it is merely important
to know that a solvent must be able to solvate the solid-support. This additional
complication has meant the use of alternative reaction media for sustainable SPPS
is rather limited, with all examples reported within the literature either falling into
the category of water or alternative organic solvents.
Water
As was discussed previously, water represents a highly desirable solvent choice for
sustainable peptide synthesis. However, its use in SPPS presents an even more
substantial challenge than it did for solution-phase peptide synthesis. This is due to
the poor solubility of conventional Fmoc-protected amino acids and to the fact that
traditionally SPPS was performed on insoluble polystyrene (PS) based resins. Due
to the hydrophobic nature of PS, water is unable to adequately solvate the resin,
meaning efficient coupling could not be realised. Because of this the use of water in
SPPS remained an unexplored challenge for many years.
It was not until the work of Kawasaki and co-workers in 2001 that the entire process
of SPPS in water was finally realised.77,78 This was only made possible however
with the advent of PEG-PS hybrid resins, which being amphiphilic in nature are
more easily swollen by a wider variety of solvents.79 However, the issue of classical
reagents being poorly soluble and activated intermediates being prone to hydrolysis
still remained. Consequently, a range of interesting approaches have been developed
to overcome these complications.
One of the most common approaches to overcoming the limitations of SPPS in
water, like solution-phase peptide synthesis, has been the development of novel
water soluble N -protecting groups and coupling agents. The first example of this
was reported by Hojo et al. with the development of the 2-phenyl(methyl)sulfonio
ethoxycarbonyl (Pms) 2.29 protecting group (Figure 2.1). This water soluble N -
protecting group is easily removed by simply treating the peptide with a 5% sodium
bicarbonate solution.77 Hojo et al. then utilised this protecting group in the synthesis
of the endogenous opioid peptide Leu-enkephalin amide (H-Tyr-Gly-Gly-Phe-Leu-
NH2). Coupling was performed using water soluble 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (WSCD) and HONB upon a PEG-grafted Rink
amide resin, producing the target peptide in 61% yield. Notably, the addition of
0.2% Triton X, a non-ionic surfactant, was necessary for the coupling and washing
procedures to enhance the swelling of the resin. Additionally, the method for
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preparing the Pms-amino acids was not initially applicable for Met or Cys, however
this was addressed in a subsequent communication.80
Figure 2.1: Water soluble protecting groups reported by Kawasaki and co-workers.
The presence of the onium salt in the Pms group meant that unfortunately this
protecting group was rather unstable. Kawasaki and co-workers therefore went on
to develop a series of additional N -protecting groups for SPPS in water (Figure 2.1).
The 2-ethanesulfonylethoxycarbonyl (Esc) group 2.30 was found to be moderately
base labile and polar, meaning it demonstrated good solubility in both aqueous and
organic solutions.81 The test synthesis of Leu-enkephalin amide was able to produce
the target compound in a 71% isolated yield. The lack of aromatic functionality,
excluding the aromatic amino acids, made it unsuitable for automated SPPS, as
it could not be detected by optical absorbance spectroscopy. Kawasaki and co-
workers therefore went on to develop the 2-(4-sulfophenylsulfonyl)ethoxycarbonyl
(Sps) 2.31, which was found to have high base lability and high water solubility,
and was used to produce the Leu-enkephalin amide peptide in 61% yield.82 Whilst
these results were highly promising, demonstrating for the first time that SPPS in
water was possible, none of the conditions outlined produced Leu-enkephalin amide
in an isolated yield greater than control reactions using more conventional methods.
The synthesis of these protecting groups of course comes with additional steps,
which is not favourable in the context of green chemistry. Hojo and co-workers have
therefore sought an alternative approach that utilises the more conventional, but
sparingly soluble, Fmoc- and Boc-protecting groups for SPPS in water. In a similar
manner to the approach utilised for solution-phase peptide synthesis Hojo and co-
workers have enhanced the solubility of Boc- and Fmoc-amino acids through the
preparation of nanoparticle dispersions in aqueous solutions. Fmoc-protected amino
acids were milled using zirconium oxide beads and PEG as an aqueous suspension,
generating nanoparticles of between 250-500 nm, that were found to be more soluble
due to the enhanced surface area.78,83
The prepared water-dispersible nanoparticles were then applied to the synthesis of
Leu-enkephalin amide, producing the target peptide in 67% yield. Control reactions
using the unprocessed amino acids failed to produce the target peptide in any
discernible yield. The synthesis of Leu-enkephalin amide was further improved
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to 79% through the addition of a non-ionic surfactant (Triton X 0.5%), which is
known to enhance the swelling of PEG-PS graft resins in water. It must also be
acknowledged that Hojo and co-workers were able to remove excess nanoparticles
from the aqueous waste through a simple filtration followed by ultracentrifugation.
Subsequent publications from Hojo and co-workers have also gone to demonstrate
the application of similar water-dispersed Boc-nanoparticles for SPPS, as well as the
use of efficient microwave irradiation for reducing coupling times from 1 h to just 3
min.84,85
Galanis et al. have also reported an interesting approach to overcoming the
limitations of hydrophobic protecting groups in aqueous SPPS.86 The coupling of
Boc-protected amino acids was successfully achieved in water, using water soluble
coupling agents WSCD and HONB, under microwave irradiation. The use of
the Boc-protecting group is important as they are easily removed under acidic
conditions, with Galanis et al. using 1N HCl(aq) for the deprotection steps. This
represents the first example of SPPS that utilises water for both coupling and
deprotection steps. The developed methodology was then applied to the synthesis of
Leu-enkephalin (H-Tyr-Gly-Gly-Phe-Leu-OH). Initially, the target peptide was only
obtained in a 67% crude purity, but the addition of a non-ionic surfactant (0.5%
Trition-X100) resulted in a much improved 81% crude purity.
The chemoenzymatic approach to peptide synthesis in water has also recently been
realised for more sustainable SPPS. As previously mentioned, protease enzymes
typically favour hydrolysis rather than amide bond formation in water. However,
Flitsch and co-workers have shown that by having the amino component affixed to a
solid support, in this case a PEGA, a copolymer of PEG and polyacrylamide (PA),
the equilibrium can be forced to favour amide bond formation (Scheme 2.9).87 As
is the case with chemoenzymatic amide bond formation, the peptide was formed in
a highly enantioselective manner, with only the L,L-diastereomer observed when a
racemic acyl donor was used.
Scheme 2.9: Thermolysin catalysed peptide synthesis upon a solid-support.
Initially, the chemoenzymatic approach for SPPS was restricted to the synthesis of
simple dipeptides, with good yields only obtained when hydrophobic amino acids
were used.88 This could be remedied by simply protecting the polar or charged
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functionalities with hydrophobic protecting groups. The methodology does present
some limitations for the synthesis of longer sequences, as chain growth requires
removal of the Fmoc-protecting group using 20% (v/v) piperidine in DMF which
is undesirable. Moreover, in the preparation of polyleucine peptides, beyond
tetraleucine, the enzymatic hydrolysis of the peptide was observed to compete with
amide bond formation, resulting in a mixture of products.
Finally, the use of N -carboxyanhydrides (NCAs) 2.35 for SPPS in water has been
recently reported by De Marco et al. in their synthesis of the opioid tetrapeptide
endomorphin-1 2.36 (H-Tyr-Pro-Trp-Phe-NH2) (Scheme 2.10).89 The NCAs were
first prepared in quantitative yield from the unprotected amino acid and triphosgene,
using a solvent-free microwave assisted process. The synthesis of endomorphin-1 was
then performed using the NCAs in a borate buffer (pH=10.4) upon a ChemMatrix-
Rammage resin. Washing the resin with citrate buffer (pH=3.0) facilitated the
decarboxylation, yielding the free amine for the next coupling. Following assembly
of the endomorphin-1 sequence and subsequent cleavage, the peptide was obtained
in a 73% crude purity and 52% yield after isolation. Whilst this is a disappointing
result, the use of minimal quantities of bulk chemicals, the excellent atom economy
and complete removal of all organic solvents represents a highly desirable approach
to sustainable SPPS.
Scheme 2.10: SPPS of endomorphin-1 2.36 using NCAs 2.35 in an aqueous media.
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Alternative Organic Solvents
Whilst water is often cited as the “greenest” solvent, due to the many favourable
properties it possesses, its use does not necessarily constitute a benign or “green”
process. The contamination of aqueous waste streams with organic compounds or
metal catalysts can be a substantial economic and environmental burden, which
will vary on a case-by-case basis.90 More recent approaches to greener solid-phase
peptide synthesis have preferred the use of organic solvents that present an advantage
in terms of their environmental, health and safety (EHS) characteristics. The use
of unconventional solvents, i.e. not DMF, NMP or CH2Cl2, for greener SPPS was
first explored by Acosta et al. in 2009.91,92 Whilst MeCN is not often considered
a green solvent Acosta et al. cite that it represents a more desirable and user
friendly polar aprotic solvent. This is due to it not being a reproductive toxin
and possessing a lower viscosity and boiling point than DMF. The model peptides
Leu-enkephalin amide and acyl carrier protein (ACP 65-74) (H-Val-Gln-Ala-Ala-
Ile-Asp-Tyr-Ile-Asn-Gly-NH2) were prepared, using MeCN for both coupling and
deprotection reactions upon a Fmoc-Rink-ChemMatrix resin. The use of the
ChemMatrix resin was necessary as MeCN was not able to adequately solvate a
conventional PS-based resin. Both peptides were obtained in an excellent crude
purity of >95%. Subsequently, Albericio and co-workers have investigated a range
of more conventional green solvents in SPPS.
A 2015 paper further explored the use of MeCN, along with tetrahydrofuran
(THF), in solid- and solution-phase peptide synthesis.93 Again, THF does not
necessarily constitute a green solvent, due to the low boiling point and tendency
to form peroxides, but can be considered a usable solvent relative to DMF.17
Jad et al. first studied a series of solution-phase control reactions, using MeCN
and THF in combination with DIC and a range of additives 2.37-2.40 (Figure
2.2). Overall, both solvents minimised racemisation in the various peptide models,
performing better than DMF in the majority of cases. The same solvent and
coupling agent combinations were then applied to solid-phase peptide synthesis,
with the synthesis of the hindered Aib-enkephalin pentapeptide (H-Tyr-Aib-Aib-
Phe-Leu-NH2) and Aib-ACP decapeptide (H-Val-Gln-Aib-Aib-Ile-Asp-Tyr-Ile-Asn-
Gly-NH2), upon ChemMatrix resin. Misincorporation of one of the Aib residues
(des-Aib) is one of the most common side products observed in the synthesis
of these peptides. The best results by far were observed when THF was used
in conjunction with DIC/OxymaPure 75, producing Aib-enkephalin pentapeptide
in 93.6% yield (des-Aib=6.4%) and the Aib-ACP decapeptide in 69.8% yield
(des-Aib=26.8%). Control samples prepared in DMF could only produce the
Aib-enkephalin pentapeptide in 53.0% yield (des-Aib=47.0%) and the Aib-ACP
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decapeptide in 37.8% yield (des-Aib=34.0%).
Figure 2.2: Structures of some common coupling additives.
These promising results have since encouraged Albericio and co-workers to report
on a diverse range of solvents, the majority of which resemble more classical green
solvents. The first example of this looked at the use of 2-MeTHF and cyclopentyl
methyl ether (CPME) as more sustainable alternatives to THF.94 Interestingly,
2-MeTHF and CPME were able to adequately solvate both PS- and PEG-based
resins. The synthesis of Aib-enkephalin pentapeptide was therefore investigated
in both solvents upon PS and ChemMatrix resins. The use of 2-MeTHF with
DIC/OxymaPure 2.39 was found to be optimal, producing the target peptide in
97% yield (des-Aib=3.0%) on the PS resin and 81.9% (des-Aib=18.1%) on the
ChemMatrix resin. Whilst Jad et al. did still use DMF for the deprotection
steps, this work excellently demonstrates that green organic solvents can be viable
alternatives to DMF for SPPS.
In an effort to address the use of ungreen solvents in the deprotection steps Jad et
al.95 went on to investigate a series of different deprotection and washing protocols,
to completely remove the use of ungreen solvents in SPPS. Couplings were performed
using the previously optimised conditions of 2-MeTHF/DIC/OxymaPure 2.39,
with washings and deprotection steps then carried out using combinations of 2-
MeTHF, IPA and EtOAc. Synthesis of the Aib-enkephalin pentapeptide was optimal
when performed upon ChemMatrix resin, using 2-MeTHF for the deprotection and
washing between steps with a combination of 2-MeTHF and EtOAc, producing the
target peptide in 95% yield. The Aib-ACP decapeptide however proved a much
tougher challenge, with identical conditions only producing the target peptide in
37.3% yield, a poor result when compared to the use of DMF which produced the
target peptide in 70.0%. Eventually though the use of more forcing conditions,
which meant performing both coupling and deprotection at 40 ◦C, produced the
peptide in a much improved 87.1% yield.
Identifying in their preceding communication that Fmoc-removal in green solvents
can be particularly troublesome for SPPS Jad et al. have further investigated a
variety of green solvents for Fmoc-removal.94 Nine green solvents were investigated,
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which included; N -formylmorpholine, 2-MeTHF, CPME, dimethyl isosorbide,
EtOAc, DMC, GVL, isopropyl alcohol (IPA) and α,α,α-trifluorotoluene. The
ability of these solvents to adequately solvate PS- and ChemMatrix-resin was first
investigated. Overall, much better results were obtained using ChemMatrix with
7 of 9 solvents giving good swelling, with only 2 of 9 able to solvate PS resins.
The success of the Fmoc-deprotection was then determined by first synthesising
the Fmoc-Ile-Asp(tBu)-Tyr(tBu)-Ile-Asn(Trt)-Gly-NH-RinkAmide-resin sequence
on both ChemMatrix and PS in DMF. Fmoc-deprotection was then performed
using 20% (v/v) solution of piperidine in the chosen solvent. Boc-Gly-OH was
then coupled to the peptide sequence. Residual Fmoc-groups were then deprotected
using 20% (v/v) piperidine in DMF and Boc-Leu-OH coupled to the remaining
free amino groups. Simultaneous Boc-deprotection and cleavage from the resin was
then performed. The ratio of H-Gly-Ile-Asp-Tyr-Ile-Asn-Gly-NH2 to H-Leu-Ile-Asp-
Tyr-Ile-Asn-Gly-NH2 was then used to determine deprotection success. Overall,
the results obtained were fairly poor, with most solvents giving <30% conversion,
even with extended deprotection times. GVL however, did adequately remove the
Fmoc-protecting group with 95.5% and 100% conversion on PS and ChemMatrix
respectively, using only 7 min deprotection times. Efficient removal of the Fmoc-
protecting group was also observed for the use of N -formylmorpholine, but only
when using a ChemMatrix resin, the results for PS were substantially worse, with
only 47.9% conversion reported.
Unsurprisingly, Kumar et al. have recently evaluated the use of N -formylmorpholine
and GVL in SPPS.96 Initially, GVL and N -formylmorpholine were only used for the
coupling steps. Aib-ACP-decapeptide was produced in 89.7% yield for GVL and
94.4% for N -formylmorpholine, with minimal evidence for the des-Aib species. The
synthesis of the Aib-ACP-decapeptide was then reattempted but using GVL and N -
formylmorpholine for all procedures, including washing. Unfortunately, the obtained
yields were found to drop significantly to around 50%, a substantial reduction
compared to the equivalent synthesis performed exclusively in 2-MeTHF.95
In summary, the use of alternative solvents and solvent technologies has been
widely explored within the literature, in an effort to develop sustainable routes
to peptide synthesis. The vast majority of examples have reported the use of water.
However, the poor solubility of classical reagents and susceptibility of activated
intermediates to hydrolysis has meant reagents often require significant modification
or preprocessing. Additionally, the use of water does not automatically constitute
a green or environmentally benign process. This is due to the issues associated
with contaminated aqueous waste, which will greatly vary on a case-by-case basis.
More recent approaches have demonstrated highly promising results for the use of
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alternative organic solvents, in an effort to replace conventional polar aprotic solvents
without having to significantly modify existing protocols. However, in many of these
reported examples the green credentials of the solvent are often questionable and
deprotections still necessitate the use of DMF. It therefore seems as though there is
still substantial scope for an investigation into alternative solvents in solution- and
solid-phase peptide synthesis for sustainable peptide bond formation.
2.1.3 Cyclic Carbonates as Solvents
Cyclic carbonates, specifically ethylene carbonate (EC) 2.41 and propylene
carbonate (PC) 2.42, have been highlighted as highly promising replacements to
conventional polar aprotic solvents.97 This is due to the many EHS advantages they
present as eco-friendly solvents, such as being non-toxic, completely biodegradable
and displaying low ecotoxicity. Additionally, incineration also produces no NOx or
SOx, which has traditionally been a major issue associated with the disposal of other
polar aprotic solvents. They also posses many desirable physical properties (Table
2.2). Both EC and PC posses a much wider liquid temperature range, although
EC is a solid at ambient temperature. They also have much higher boiling points,
resulting in low vapour pressures and higher flash points, meaning cyclic carbonates
are also suitable replacements to VOCs. This does however present an issue when it
comes to product purification, as distillative removal of cyclic carbonates is known
to be rather challenging. Finally, cyclic carbonates also posses very high dielectric
constants and dipole moments, which are significantly higher than the other dipolar
aprotic solvents listed. This makes cylic carbonates particularly well suited for
anhydrous electrochemical applications.
Table 2.2: Physical properties of some common polar aprotic solvents.
Solvent MP
(◦C)
BP
(◦C)
FP
(◦C)
Density
(g mL-1)
Dielectric
Constant
Dipole
Moment
EC 2.41 36 248 150 1.34 90.0 4.81
PC 2.42 -49 242 132 1.20 64.0 5.36
DMF 2.43 -60 153 58 0.94 36.7 3.82
NMP 2.44 -24 202 96 1.03 32.2 4.09
DMA 2.45 -20 166 70 0.94 37.8 3.81
DMSO 2.46 18 189 95 1.10 46.7 3.96
MeCN 2.47 -44 82 2 0.79 37.5 3.92
CH2Cl2 2.48 -97 40 - 1.325 8.9 1.60
MP - melting point, BP - boiling point, FP - flash point.
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Identification of suitable green alternatives to traditional solvents also requires
quantification of the solvation properties before accurate comparisons can be
made. Although many different solvent parameters exist for this, Kamlet-Taft
solvatochromic parameters are probably the most comprehensive and frequently used
measure of solvation properties. The Kamlet-Taft parameters quantify solvation
properties according to hydrogen-bond donating ability (acidity α), hydrogen-bond
accepting ability (basicity β) and dipolarity/polarizability (pi*).98 Polar aprotic
solvents typically have negligible α-values, comparing β and pi* is therefore a good
indication of relative solvation properties. It can be observed that the common polar
aprotic solvents (DMSO 2.46, DMF 2.43, DMA 2.45 and NMP 2.44) all cluster
to the top right hand side (red shaded area) of the generated diagram (Figure 2.3).
Indicating they all possess high values for both β and pi*. In comparison, cyclic
carbonates are observed to have essentially equivalent values for pi*. The hydrogen-
bond basicity β of cyclic carbonates is much lower however, being essentially half of
the traditional polar aprotic solvents. This value is essentially equivalent to that of
MeCN 2.47. Suggesting that cyclic carbonates fall into the region of solvatochromic
space that could be considered as polar-aprotic. It can therefore be concluded that,
on the basis of Kamlet-Taft solvation parameters, cyclic carbonates should present
a suitable alternative to traditional polar aprotic solvents.
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Figure 2.3: Comparison of Kamlet-Taft H-bond basicity (β) and dipolarity (pi*) for
cyclic carbonates and common polar aprotic solvents.
Finally, cyclic carbonates have been in commercial production since the mid-1950s
meaning they are readily available, in large quantities and at low cost.99 This is
an incredibly important consideration for an alternative solvent. Moreover, the
synthesis of cyclic carbonates has facilitated a growing interest in their use and
application. Cyclic carbonates 2.41/2.42 are most commonly produced through
the 100% atom economical reaction between epoxides 2.53 and carbon dioxide 2.54
(Scheme 2.11).100 This transformation is one of the few commercially important
reactions which utilises carbon dioxide as a chemical feedstock. Current production
of cyclic carbonates is approximately 100 ktonnes per annum, but is expected to
grow with increasing demand.101 The synthesis of cyclic carbonates from epoxides
and carbon dioxide has therefore attracted a large amount of interest as a highly
promising approach to dealing with rising atmospheric carbon dioxide levels, caused
by anthropogenic emissions.102
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Scheme 2.11: Synthesis of cyclic carbonates from the epoxides and carbon dioxide.
Currently commercial production relies on quaternary ammonium and phosphonium
salts as catalysts, which requires the use of high temperatures and pressures. It
is envisioned that being able to perform this reaction under conditions closer to
ambient would mean cyclic carbonate formation would be a net consumer of carbon
dioxide. As a result, there has been great interest in the development of highly
active catalysts and catalyst systems, based around privileged metal complexes and
organocatalysts, for the synthesis of cyclic carbonates.103,100
The many advantageous physical and chemical properties outlined, combined with
the fact that they have been in commercial production for over 50 years, has meant
cyclic carbonates have found a myriad of uses and applications. This however
has predominantly been for electrochemical and extractive processes, the earliest
examples of which typically come from the oil processing industry. The FLUOR
process, first commercialised in the 1960s and still in use to this day, utilises PC as
a solvent for the removal of impurities from natural gas streams.104 More recently,
the Huntsman Corporation have employed PC in combination with carbon dioxide
for the recovery of oil from maturing reservoirs.105 Due to their low toxicity, cyclic
carbonates have also proved to be excellent co-solvents for cleaning and cosmetic
products. They are approved for use in high concentration for applications that
involve contact with human skin.106 There has also been growing interest in their
use as reactive intermediates, whether that is for the synthesis of fine chemicals, or
monomers for the production of polycarbonates or polyurethanes.107 Finally, their
high dielectric constants make cyclic carbonates particularly suitable for use as
non-aqueous electrolytes in lithium batteries, most commonly found in consumer
electronics.108
2.1.4 Application of Cyclic Carbonates in Organic Synthesis
In comparison, the use of cyclic carbonates in synthetic chemistry is rather
underexplored. Sporadic reports have appeared within the literature over the
last 30 years, with examples predominantly demonstrating the suitability of cyclic
carbonates in homogeneous catalysis. Reactions that have been reported include
hydroformylations,109 hydrogenations,110 hydroaminations111 and some examples of
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metal catalysed cross couplings.112 This work has recently been excellently reviewed
by Schaffner et al.97 For this reason, the following literature review will focus on
synthetic chemistry utilising cyclic carbonates as the reaction solvent published
since 2010. The use of cyclic carbonates for homogeneous metal catalysis is
particularly well established. For this reason, homogeneous metal catalysis makes
up the majority of the proceeding literature review, followed by limited examples of
heterogeneous metal catalysis, organocatalysis and finally anything that falls outside
of these three categories.
2.1.4.1 Homogeneous Metal Catalysis
Heck Reaction
The use of PC in the Heck reaction was one of first examples that utilised cyclic
carbonates as the reaction solvent in homogeneous catalysis. Reported by Reetz et
al. electrochemically prepared nanostructured Pd clusters, stabilised by PC, were
found to efficiently catalyse the Heck reaction.113 More recently, Parker et al. have
investigated the Heck reaction between various aryl halides 2.55 and methyl acrylate
2.56, to produce the corresponding methyl cinnamate derivatives 2.57 (Scheme
2.12).114 Yields were generally better in cyclic carbonates than in control reactions
using NMP, with quantitative results typically observed for most reactions carried
out in EC. Interestingly, Parker et al. were also able to correlate the reaction rate
to solvent polarity, demonstrating PC was an excellent replacement for NMP in this
reaction.
Scheme 2.12: Palladium catalysed Heck reaction of methyl acrylate 2.56 in cyclic
carbonates.
Wacker Oxidation
In a similar manner to the work reported by Reetz et al., Wang et al. has
demonstrated the use of ethylene carbonate for the stabilisation of palladium
nanoparticles in the Wacker oxidation.115 Using molecular oxygen as the sole oxidant,
a series of higher alkenes and aryl alkenes 2.58 were converted to the corresponding
ketones 2.59, catalysed by colloidal Pd nanoparticles that were stabilised by EC
(Scheme 2.13). Yields were variable, being poor to good depending on the substrate,
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but the product was easily separated from the catalyst system, through extraction
with n-hexane. Unfortunately, the catalyst system could not be reused following
the reaction, as agglomerates were observed, reducing the catalyst surface area and
severely affecting the overall yields in the second cycle.
Scheme 2.13: Wacker oxidation reaction catalysed by EC stabilised colloidal Pd-
nanoparticles.
Hydroformylation of Piperylene
Hydroformylation in cyclic carbonates had been investigated fairly extensively
prior to 2010 by Behr and co-workers.109,111 More recently though, Neubert
et al. have reported on the hydroformylation of piperylene 2.60, using a
Rh(CO)2acac/Xantphos 2.63 catalyst system (Scheme 2.14).116 The catalyst system
afforded the desired aldehydes in 82% yield with a liner:branched ratio 2.61:2.62 of
1:3.8 in 7 hours, using only 0.3 mol% catalyst loading. This reaction had previously
been optimised in toluene, but Neubert et al. showed the use of PC was more
convenient for recycling the expensive catalyst system. The large difference in boiling
point between the products and solvent meant the products could be easily removed
by distillation. Catalyst performance was slightly impaired after each reuse, but
ligand refreshment after 5 cycles adequately restored performance.
Scheme 2.14: Hydroformylation of piperylene using a recyclable rhodium/Xantphos
catalyst system in PC.
Intermolecular Alkyne Hydroacylation
PC has also been found to be an excellent solvent for the hydroacylation of
alkynes. Lenden et al. first reported this transformation when they found
that PC was a suitable replacement for dichloroethane in the rhodium-catalysed
intermolecular alkyne hydroacylation. A series of β-S -aldehydes 2.64 and alkynes
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2.65 were coupled to produce the corresponding enone products 2.66 (Scheme 2.15).
Generally, excellent yields were observed in only 1 hour, demonstrating comparable
results to control reactions in either acetone or dichloroethane. Unfortunately
though, the reaction products had to be purified by flash column chromatography
due to the high boiling nature of PC.
Scheme 2.15: Rhodium-catalysed intermolecular alkyne hydroacylation in PC.
Direct Aerobic Oxidation of 2-Benzylpyridines
The higher boiling points associated with cyclic carbonates may not always be a
disadvantage, as recently demonstrated by Pieber at el. In their report the direct
aerobic oxidation of 2-benzylpyridines 2.67 to the corresponding ketones 2.68 was
investigated, using a cheap and abundant FeCl3 catalyst system under continuous
flow conditions.117 Using conventional solvents, such as DMSO or NMP, typically
resulted in poor conversions unless very high temperatures were used. However,
this often resulted in discolouration of the reaction mixture due to decomposition
of the solvent. When PC was used it was found to be much more tolerant to the
higher temperatures necessary, resulting in quantitative conversion under otherwise
identical conditions to conventional solvents.
Scheme 2.16: Direct aerobic oxidation of 2-benzylpyridines under continuous flow
using propylene carbonate.
Carboxylation of Terminal Alkynes
Finally, Yu et al. have utilised EC in the CuI catalysed carboxylation of terminal
alkynes (Scheme 2.17).118 A range of terminal alkynes 2.69 and aryl halides were
coupled under mild conditions, to produce the corresponding esters 2.70 in excellent
yields. Control reactions demonstrated that EC was superior to DMF for this
transformation. This was revealed by DFT calculations to be due to a reduction in
the energy barrier for CO2 insertion.
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Scheme 2.17: Copper catalysed carboxylation of terminal alkynes in EC.
2.1.4.2 Heterogeneous Metal Catalysis
Phenoxycarbonylation
In comparison to homogeneous metal catalysis, heterogeneous metal catalysis using
cyclic carbonates is relatively unexplored. Gautam et al. have recently reported
on the use of PC in the phenoxycarbonylation of aryl halides 2.71, using N -
formylsaccharin 2.73 as a CO surrogate and a heterogeneous Pd/C catalyst (Scheme
2.18).119 The corresponding phenyl esters 2.74 were obtained under mild conditions
in good to moderate yields, in a one-pot process that is free of any co-catalyst, ligand
or additive. Gautam et al. also demonstrated that the catalyst could be recycled
up to four times, and the reaction performed on a gram scale.
Scheme 2.18: Phenoxycarbonylation of aryl halides 2.71 to phenyl esters 2.74 using
a heterogeneous Pd/C catalyst in PC.
Suzuki-Miyaura Cross-Coupling
Using a similar approach to their work on phenoxycarbonylation, Gautam et al.
have also recently reported on the carbonylative Suzuki-Miyaura cross-coupling
reaction.120 A range of aryl iodides 2.75 and boronic acids 2.76 were coupled using
a heterogeneous Pd/C catalyst and N -formylsaccharin 2.73 as a CO surrogate,
producing a range of aryl ketones 2.77 (Scheme 2.19). Reaction optimisation
demonstrated that PC tended to outperform both DMF and 1,4-dioxane in terms of
both conversion and selectivity for the aryl ketone 2.77 over a biaryl side-product
2.78. Additionally, the catalyst could be reused at least 5 times, with minimal losses
observed in yield and selectivity.
45
Chapter 2. Cyclic Carbonates as Solvents for Peptide Synthesis
Scheme 2.19: Carbonylative Suzuki-Miyaura reaction for the synthesis of biaryl
ketones 2.77 in PC.
2.1.4.3 Organocatalysis
Proline Catalysed Aminations
There are very few reports of organocatalysed reactions being performed in cyclic
carbonates. North and co-workers have previously reported on the use of cyclic
carbonates as sustainable solvents in asymmetric aldol reactions.121,122 More recently
though, they have extended their methodology to include the proline catalysed α-
hydrazinations of aldehydes and ketones by diazodicarboxylates.123 The reaction of
various aldehydes 2.79 with dibenzyl azodicarboxylate 2.80 produced the target
alcohol 2.82, following reduction of the intermediate aldehyde 2.81 with sodium
borohydride, in good to excellent yields (Scheme 2.20). However, the reaction
had to be performed at a lower temperature and for 24 hours, rather than 2
hours, to obtain enatioselectivities comparable to the control reaction in CH2Cl2.
The α-hydrazination of ketones was less successful with moderate yields and
enatioselectivities observed.
Scheme 2.20: Proline catalysed α-hydrazination of aldehydes in cyclic carbonates.
2.1.4.4 Miscellaneous
Diastereoselective Synthesis of Tetrahydroquinoline Scaffolds
Finally, Forero et al. have utilised propylene carbonate as a replacement for common
chlorinated solvents in the one-pot imino Diels-Alder cycloaddition reaction, for the
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diastereoselective preparation of tetrahydroquinoline scaffolds.124 Various derivatives
of aniline 2.83 and benzaldehyde 2.84 were combined with isoeugenol 2.85 in the
presence of a molecular iodine catalyst to produce the tetrahydroquinoline species
2.86 in good to excellent yield and diastereoselectivity, in under 1 hour (Scheme
2.21). Notably, the authors were able to remove PC using a warm aqueous wash,
producing pure product without the need for chromatographic purification.
Scheme 2.21: Diastereoselective synthesis of tetrahydroquinoline scaffolds 2.86 in
propylene carbonate.
2.1.5 Chapter Aims
It can be concluded from the preceding investigation that cyclic carbonates posses
many desirable solvent properties, particularly when considered in the context of
green chemistry. However, whilst they have been widely considered for extractive
and electrochemical applications, their use in organic synthesis is rather limited.
Analysis of the literature indicates that of the few reports of synthetic chemistry
utilising cyclic carbonates the majority come from the field of homogeneous metal
catalysis. Consequently, the following chapter seeks to expand on the current
use of cyclic carbonates as replacements for conventional polar aprotic solvents
in synthetic chemistry. Cyclic carbonates would therefore seem particularly well
suited as solvents for sustainable peptide synthesis. The preceding literature review
identified that more recent approaches to sustainable peptide bond formation have
favoured the use of alternative organic solvents, with cyclic carbonates not having
been previously investigated. The following chapter will therefore look to analyse
the suitability of cyclic carbonates as replacements for DMF, NMP and CH2Cl2 in
both the solution- and solid-phase synthesis of peptides.
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2.2 Results and Discussion
2.2.1 Solution-Phase Peptide Synthesis
Initial investigations sought to determine whether the synthesis of peptides in cyclic
carbonates was indeed feasible. Due to the additional complexities associated with
using a solid-support in solid-phase peptide synthesis, the use of cyclic carbonates
in solution-phase peptide was first investigated. This would make it much easier to
identify any compatibility issues between the solvent and the chemistry used. To
begin with a simple coupling reaction between unfunctionalised amino acids was
investigated. The coupling reaction between phenylalanine benzyl ester 2.88 and
Boc-alanine 2.87 to produce the Boc-Ala-Phe-OBn dipeptide 2.89 was therefore
chosen, the results of this study are summarised in Table 2.3. This coupling has
been previously reported in a conventional solvent system of CH2Cl2:DMF (25:75,
v/v%) by Nam et al. producing the target peptide in an 86% isolated yield (Table
2.3, Entry 1).125
Table 2.3: Reaction optimisation for the synthesis of Boc-Ala-Phe-OBn dipeptide 2.89.
Entry Coupling
Agent
Additive T
(◦C)
Base Solvent Yield
(%)a
1 EDC HOAt 20 NaHCO3 CH2Cl2:DMF 86b
2 DCC PFP 20 NEt3 CH2Cl2:DMF 76
3 DCC PFP 20 NEt3 PC 83
4 DCC PFP 40 NEt3 ECc 96
5 EDC HOBt 20 NEtiPr2 PC 93
6 EDC HOBt 20 NEtiPr2 CH2Cl2:DMF 81
7 EDC HOBt 20 NEtiPr2 DMF 83
8d EDC HOBt 70 NEtiPr2 DMF 78
9d EDC HOBt 70 NEtiPr2 PC 82
a isolated yield.b literature result.c ethylene carbonate melting point is 35-38 ◦C.d
performed under microwave irradiation.
Entry 2 demonstrates that when the coupling agent, additive and base are varied,
but the solvent system is not, the target dipeptide 2.89 was still obtained in an
acceptable 76% yield. Repeating this coupling procedure, but exchanging the solvent
for either PC or EC, produced the target dipeptide 2.89 in 83% and 96% yield
respectively (Entries 3 and 4). It should however be highlighted that the amino
acids were not fully soluble in either EC or PC at the given concentration (0.2 M),
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until preactivated, which presents a distinct difference between cyclic carbonates
and either DMF or CH2Cl2. These promising early results do however demonstrate
that it is indeed feasible to use cyclic carbonates as suitable replacements for
conventional polar aprotic solvents in solution-phase peptide synthesis. Although,
higher temperatures were necessary for couplings performed in ethylene carbonate,
in order to maintain a homogeneous reaction mixture, due to the high melting point
of ethylene carbonate.
The need for higher temperatures for couplings performed in EC was at the time
discouraging, because of concerns over racemisation and the desire to perform the
coupling at conditions as close to ambient as possible. It was therefore decided that
this coupling reaction would be further optimised for the use of PC. Eventually,
optimal yields were obtained when using a combination of EDC, HOBt and DIPEA
in PC, producing the target peptide in an excellent 93% yield (Entry 5). The
obtained yield being significantly higher than control reactions using the same
coupling reagents in either a mixed solvent system of CH2Cl2:DMF or pure DMF
(Entries 6 and 7).
Finally, whilst it was preferable at the time to carry out coupling reactions under
ambient conditions, the use of microwave irradiation for elevated temperature
peptide synthesis has become increasingly commonplace in recent years, particularly
for challenging sequences.126 For this reason, the last two entries deal with the
synthesis of dipeptide 2.89 at 70 ◦C in DMF or PC under microwave irradiation
(Entries 8 and 9). In both cases the target peptide was obtained in high yield,
indicating PC is also suitable for peptide synthesis performed under microwave
irradiation.
It is appropriate to highlight at this point that there is literature precedent
for the reaction of amines with cyclic carbonates, to produce the corresponding
carbamate.127 No evidence for this was observed in the previously described coupling
reactions, but it was felt necessary at the time to investigate this further. A control
reaction was therefore performed, phenylalanine benzyl ester 2.88 was first dissolved
in PC and NEtiPr2 (3.0 eq). The mixture was then heated to 70 ◦C using microwave
irradiation and held at this temperature for 3 hours. Even under these conditions,
only 1% of the amine was found to react with the solvent, suggesting that even
under forcing conditions carbamate formation will not compete with peptide bond
formation. The reaction of amines with cyclic carbonates will however be discussed
in greater detail in section 2.2.3.1.
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2.2.1.1 Racemisation of Activated Amino Acids
A consequence of the strong activation of the carboxy group, necessary to promote
amide bond formation, is the increased acidity of the Cα proton, as this proton
is easily removed promoting loss of stereochemical integrity. This is one of the
most troublesome side reactions in peptide synthesis, as even a small degree of
racemisation or epimerisation will lead to a substantial reduction in yield, along with
complications in separation, particularly in longer peptide chains. Racemisation
is exclusively a base induced process and occurs through two distinct pathways
(Scheme 2.22). Firstly, direct enolisation, where the Cα proton is lost during
activation. This generates an intermediate enolate 2.91, that can be reprotonated
from either face, generating the corresponding (R)- or (S )-enantiomer 2.92/2.90
(Route A). Alternatively, the activated intermediate can cyclise to generate the
oxazolone intermediate 2.93 (Route B). The oxazolone can still be regarded as
activated and is therefore still able to form the target peptide bond. This however,
is much slower than racemisation through the stabilised anion 2.94, so any product
formed will be derived from a mixture of (R)- 2.95 and (S )- 2.93 enantiomers.128
Scheme 2.22: Racemisation mechanisms route A) direct enolisation route B)
oxazolone formation.
In order to demonstrate that racemisation is not promoted by the use of PC as
a reaction solvent, the diastereomeric dipeptide 2.96 was prepared from Boc-(R)-
alanine (≥98% e.e.) using the optimised reaction conditions (Table 2.3, Entry 5).
Analysis of the (S,S )-dipeptide 2.89, (R,S )-dipeptide 2.96 and a 1:1 mixture of the
two by chiral HPLC indicated that the dipeptides were formed with diastereomeric
excesses of >98.4% (Figure 2.4). This suggests the use of PC as the reaction
solvent in peptide coupling does not actively promote racemisation of the activated
intermediates.
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Figure 2.4: Chiral HPLC chromatograms for Boc-Ala-Phe-OBn dipeptide, (S,S )-top
2.89, (R,S )-middle 2.96 and 1:1 mixture-bottom.
To ensure that the observed retention of stereochemistry in the Boc-Ala-Phe-OBn
2.89/2.96 dipeptide could be regarded as general, a few additional peptidic systems
were investigated, the results of which have been summarised in Table 2.4. The Boc-
Leu-Phe-OBn dipeptide was produced in 99.7% and 98.7% diastereomeric excess for
the (S,S ) and (R,S )-dipeptide 2.97/2.98 respectively (Entries 3 and 4). A longer
peptide system was also investigated, with both the (R,S,S ) and (S,S,S ) derivatives
of the Boc-Leu-Ala-Phe-OBn tripeptide 2.99/2.100 obtained in >98.1% purity
(Entries 5 and 6). Finally, the synthesis of Boc-Ala-Phe-OBn 2.89 using microwave
irradiation in either PC or CH2Cl2:DMF was found to produce the target (S,S )-
dipeptide as a single enantiomer in both cases (Entries 7 and 8). This suggests
that performing coupling reactions at elevated temperatures may not be as much of
an issue as first believed, warranting a further investigation into the use of EC for
solution-phase peptide synthesis in the future.
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Table 2.4: Summary for the investigation into amino acid racemisation during couplings
performed in PC.
Entry Sequence TR1
(min)
Area TR2
(min)
Area d.e.
%
1 Boc-Ala-Phe-OBn 2.89 29.44 99.21 39.63 0.79 98.4
2 Boc-(R)-Ala-Phe-OBn 2.96 30.40 0.34 37.49 99.66 99.3
3 Boc-Leu-Phe-OBn 2.97 17.16 99.84 23.94 0.16 99.7
4 Boc-(R)-Leu-Phe-OBn 2.98 18.01 0.67 22.20 99.33 98.7
5 Boc-Leu-Ala-Phe-OBn 2.99 28.24 0.97 34.15 99.03 98.1
6 Boc-(R)-Leu-Ala-Phe-OBn 2.100 27.16 99.72 35.22 0.28 99.4
7 Boc-Ala-Phe-OBna 2.89 27.65 100 - - 100
8 Boc-Ala-Phe-OBnb 2.89 27.54 100 - - 100
a performed under microwave irradiation in CH2Cl2:DMF (25:75, v/v%).
b performed
under microwave irradiation in PC.
To summarise, PC has been found to perform as well as, if not better than,
conventional solvents for solution-phase coupling reactions. Isolated yields for the
Boc-Ala-Phe-OBn dipeptide 2.89 under identical coupling conditions, were found to
be greater for PC than the corresponding reactions in CH2Cl2:DMF (25:75) or pure
DMF. Couplings were then found to proceed smoothly under microwave irradiation,
with PC performing as well as CH2Cl2:DMF. Most importantly, the reaction between
PC and an amine was found to not compete with peptide bond formation, even
under forcing conditions using microwave irradiation. Finally, racemisation of the
amino acid chiral centres, due to activation during coupling, was found not to be
a concern when couplings were performed in PC, with diastereomeric excesses of
>98.1% observed in all cases.
2.2.1.2 N -Boc Deprotection in Propylene Carbonate
The other key process in solution-phase peptide synthesis is selective removal of the
N -Boc protecting group. This is important as it allows the peptide chain to be
grown selectively in one direction, from the C - to the N -terminus. This is typically
performed using a strong acid such as hydrochloric acid (HCl) or trifluoroacetic acid
(TFA), and has been reported in a variety of solvents, including 1,4-dioxane, CH2Cl2,
THF, MeCN and DMF. The use of PC for this process has not been previously
reported.
The deprotection of the Boc-Ala-Phe-OBn dipeptide 2.89 in various solvents was
therefore investigated. Under conventional reaction conditions, 4 M HCl in 1,4-
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dioxane, the corresponding hydrochloride salt 2.101 was obtained in an excellent
93% yield in 3 hours (Table 2.5, Entry 1). Performing the equivalent reaction in PC
however initially proved challenging, as a solution of hydrochloric acid in PC is not
commercially available. It was found that the generation of hydrochloric acid in situ,
from methanol and acetyl chloride, produced the hydrochloride salt 2.101 in 89%
yield (Entry 2). However, in the interest of convenience it was eventually decided
that the use of excess trifluoroacetic acid (60 eq.) was optimal, as this furnished
the corresponding trifluoroacetate salt 2.102 in a quantitative 99% yield in 3 hours
(Entry 3).
Table 2.5: N -Boc deprotection of Boc-Ala-Phe-OBn 2.89.
Entry Base Solvent X Yielda
1 4 M HCl 1,4-dioxane HCl 2.101 93
2 HClb PC HCl 2.101 89
3 CF3COOH PC CF3COOH 2.102 99
a Isolated yield. b generated in situ.
Consequently, both coupling and deprotection reactions have been successfully
carried out in PC. This demonstrates the solution-phase synthesis of peptides using
PC as the only reaction solvent is indeed feasible, indicating that PC appears to
be a suitable replacement for DMF, CH2Cl2 and 1,4-dioxane. It is apparent from
the results obtained that PC does not promote the various side reactions associated
with peptide coupling, including racemisation, and appears to tolerate the harsh,
acidic conditions associated with N -Boc deprotection.
2.2.1.3 Tetrapeptide Synthesis using Solution-Phase Methodology in
PC
To illustrate the generality of the developed methodology, a series of five fully
protected tetrapeptides 2.107a-e were then prepared (Scheme 2.23). This was
achieved by first coupling N -Boc- and O-Bn-protected amino acids, according
to the optimised conditions developed previously, producing the corresponding
dipeptides 2.103a-e. Selective removal of the N -Boc protecting group using TFA
in PC then gave the dipeptide salts 2.104a-e. Repeating the aforementioned
coupling/deprotection process furnished the tripeptides 2.105a-e, followed by the
tripeptide salts 2.106a-e, with a final coupling giving the desired tetrapeptides
2.107a-e.
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Scheme 2.23: Synthesis of tetrapeptides in propylene carbonate, i) EDC (1.1 eq),
HOBt (1.1 eq), DIPEA (3.0 eq), PC (0.2 M solution), 16 h ii) TFA (60 eq), PC, 3 h.
Tetrapeptide sequences 2.107a and 2.107b contain only unhindered and
unfunctionalised amino acid side chains. This was initially used to demonstrate
that it was possible to efficiently build up to the tetrapeptide stage using the
optimised conditions for coupling and deprotection described previously. Sequences
2.107c-d were then chosen to demonstrate the use of functionalised side chains that
are protected (Ser(Bn), Lys(Z), Asp(Bn) and Gln(Trt)), functionalised side chains
that are not protected (Met and Trp) and unfunctionalised but sterically hindered
side chains (Val). This also demonstrates tolerance of the methodology to the key
orthogonal protecting groups necessary in solution-phase peptide synthesis (Bn, Z
and Trt). Finally, sequence 2.107e demonstrates incorporation of the only non-
proteinogenic amino acid investigated Aib, which is also regarded as very sterically
hindered and thus difficult to couple. Along with the only secondary proteinogenic
amino acid residue Pro.
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Overall, the target sequences were produced with no significant issues, with the
products of both coupling (65-93%) and deprotection (80-99%) typically obtained
in good to excellent yield, in all cases (Table 2.6). This demonstrates that
the methodology developed is tolerant to a wide variety of amino acid residues.
Irrespective of whether they contain functionalised (Met, Ser, Lys, Asp, Trp, Gln,
Tyr), unfunctionalised (Phe, Ala, Leu, Gly, Pro) or sterically hindered (Aib, Val)
side chains.
Table 2.6: Summary of results for the synthesis of tetrapeptides 2.107a-e.
Entry Sequence Step R1 R2 R3 R4 Yield
(%)a
1 a 2.103 Phe Ala - - 93
2 a 2.104 Phe Ala - - 99
3 a 2.105 Phe Ala Leu - 75
4 a 2.106 Phe Ala Leu - 96
5 a 2.107 Phe Ala Leu Gly 72
6 b 2.103 Phe Leu - - 80
7 b 2.104 Phe Leu - - 99
8 b 2.105 Phe Leu Gly - 78
9 b 2.106 Phe Leu Gly - 94
10 b 2.107 Phe Leu Gly Ala 91
11 c 2.103 Val Met - - 91
12 c 2.104 Val Met - - 80
13 c 2.105 Val Met Ser(Bn) - 83
14 c 2.106 Val Met Ser(Bn) - 84
15 c 2.107 Val Met Ser(Bn) Lys(Z) 65
16 d 2.103 Val Asp(Bn) - - 70
17 d 2.104 Val Asp(Bn) - - 85
18 d 2.105 Val Asp(Bn) Trp - 68
19 d 2.106 Val Asp(Bn) Trp - 99
20 d 2.107 Val Asp(Bn) Trp Gln(Trt) 78
21 e 2.103 Leu Aib - - 78
22 e 2.104 Leu Aib - - 97
23 e 2.105 Leu Aib Pro - 73
24 e 2.106 Leu Aib Pro - 97
25 e 2.107 Leu Aib Pro Tyr(Bn) 72
a Isolated yield.
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2.2.1.4 Global Deprotection of a Tripeptide
Finally, as the terapeptides produced are still protected at the C - and N -terminus, it
was deemed necessary to demonstrate the complete deprotection of a peptide. This
was to specifically highlight the ability to perform the hydrogenation reaction, for
cleavage of the O-Bn protecting group, in PC. The Boc-Leu-Ala-Phe-OBn tripeptide
2.105a was chosen as a test sequence. The fully deprotected tripeptide 2.110 can
be obtained either by first removing the N -Boc group, followed by the O-Bn group,
or vice versa. Both routes were therefore investigated (Scheme 2.24).
Scheme 2.24: Global deprotection of the Boc-Leu-Ala-Phe-OBn 2.105a tripeptide.
Firstly, it has previously been shown that the N -Boc deprotection can be performed
using TFA in PC. The Boc-Leu-Ala-Phe-OBn tripeptide 2.105a was deprotected
to give the intermediate amine salt 2.108 in a quantitative 99% yield (Route A).
Problems arose however when trying to perform the subsequent hydrogenation.
Efforts to do so in PC failed to produce the target tripeptide 2.110, even
when performed at high pressure (75 bar). This was unexpected as there is
significant literature precedent for hydrogenation reactions in PC.110,129 However,
observations suggest the use of PC promotes leeching of the palladium from the solid
support, deactivating the catalyst. Even the use of methanol, a more conventional
hydrogenation solvent, failed to produce the target peptide 2.110. This is believed
to be due to residual PC from the proceeding step deactivating the catalyst.
The obvious solution to this issue is to perform the hydrogenation reaction first
(Route B). When the hydrogenation is performed first, under conventional reaction
conditions, the target intermediate 2.109 is formed in an excellent 96% yield.
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This N -Boc protecting group could then be removed producing the target fully
deprotected tripeptide 2.110 in a 96% yield, or 92% over the two steps.
It has therefore been shown that cyclic carbonates, specifically PC, represent suitable
solvents for the common transformations associated for solution-phase peptide
synthesis. Control reactions showed PC was found to produce a target dipeptide
in excellent yield, compared to control reactions performed in conventional solvent
systems. The use of PC was also found to have little influence on the many side
reactions associated with peptide bond formation, particularly racemisation. PC
was then shown to tolerate the harsh acidic conditions associated with N -Boc
deprotection, furnishing the corresponding dipeptide salt in quantitative yield, when
exposed to excess TFA. The use of PC for the key reactions for chain elongation in
peptide synthesis meant a range of tetrapeptides could be produced, with good to
excellent yields observed in all cases for both coupling (65-93%) and deprotection
(80-99%) steps. Finally, it was observed in an effort to obtain a fully deprotected
tripeptide species that PC was not suitable for the hydrogenation step associated
with the removal of the O-Bn protecting group. However, performing this reaction
under conventional conditions, followed by a N -Boc deprotection in PC gave a
completely deprotected tripeptide in an excellent 92% yield over the two steps.
2.2.2 Solid-Phase Peptide Synthesis in Cyclic Carbonates
Having demonstrated that PC could be successfully used as a solvent for solution-
phase peptide synthesis, its application in solid-phase peptide synthesis was duly
investigated. However, there are additional considerations that must be made when
performing reactions upon a solid-support, particularly when choosing to do so in
an alternative solvent. The most important being the ability of the solvent to
adequately solvate the solid-support.130 As ultimately, poor solvation results in
limited accessibility to active sites and diminished reactivity.131 The ability of a
solvent to adequately solvate a solid-support, more commonly referred to as resin
swelling, will be discussed in much greater detail in Chapter 3. For now, the ability
of cyclic carbonates to swell common solid-phase peptide synthesis resins will be
investigated.
2.2.2.1 Resin Swelling in Cyclic Carbonates
For this study nine commercially available resins were chosen. These broadly fall into
four distinct categories based on the polymer backbone; polystyrene (PS) (Merrifield,
Paramax, JandaJel), polyethylene glycol grafted polystyrene (PEG-PS) (TentaGel,
ArgoGel, HypoGel 200, NovaGel), polyethylene glycol (PEG) (ChemMatrix) and
polyamide (PA) (SpheriTide). The ability of these resins to swell in EC 2.41,
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PC 2.42, DMF 2.43 and CH2Cl2 2.48 was then investigated using the method
previously reported by Santini et al (Figure 2.5).131 This semi-quantitative approach
for determining resin swelling measures the increase in occupied volume of the resin
when exposed to a given solvent. Santini et al. then defined a solvent in which the
resin swells to greater than 4.0 ml g-1 as a good solvent, between 4.0-2.0 mL g-1 a
moderate solvent and less than 2.0 mL g-1 a bad solvent.
Figure 2.5: Graph of resin swelling for nine commercial solid-phase peptide synthesis
resins in EC 2.41, PC 2.42, DMF 2.43 and CH2Cl2 2.48. Green = cyclic carbonates,
Red = undesirable solvents.
It is immediately apparent that the undesirable solvents DMF and CH2Cl2 swell
the commercial resins to a much greater extent than EC or PC. Cyclic carbonates
appear to be very poor solvents for the PS based resins, as a value below 2.0 mL g-1 is
indicative of no swelling. This was initially a rather disappointing result as Merrifield
resin, even after 50 years, still remains one of the most commonly used supports for
solid-phase peptide synthesis.132 Only the use of EC with ParaMax and PC with
JandaJel produced marginally better swelling for PS resins. Moderately improved
swelling was observed with the PEG-PS based resins, with seven of eight results
falling within the 2.0-4.0 mL g-1 range. Only the use of PC with ArgoGel produced
a result that could be regarded as good swelling. ChemMatrix on the other hand,
the only 100% PEG based resin, produced good swelling for both cyclic carbonates,
with values of 6.8 mL g-1 and 6.0 mL g-1 obtained for EC and PC respectively.
Finally, SpheriTide the only PA based resin, barely produced moderate swelling in
both EC and PC. For the above reasoning, the use of ChemMatrix as a suitable
resin for solid-phase peptide synthesis in cyclic carbonates was further explored.
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2.2.2.2 Synthesis of a Model Tripeptide
The synthesis of tripeptide H-Leu-Ala-Phe-OH 2.110, which had previously been
prepared via the solution-phase approach, was chosen as a model substrate.
The synthesis of this tripeptide was investigated using a solid-phase approach in
both PC and DMF (Scheme 2.25). The synthesis began with the commercially
available ChemMatrix resin, preloaded with the acid labile 4-(4-hydroxymethyl-3-
methoxyphenoxy)butyric acid (HMPB) linker 2.111 and the phenylalanine amino
acid residue as the free amine. Coupling was then performed using three equivalents
of the desired N -Fmoc protected amino acid, 3-[bis(dimethylamino)methyliumyl]-
3H -benzotriazole-1-oxide hexafluorophosphate (HBTU), HOBt and DIPEA in the
chosen solvent as a 0.2 M solution, preactivated for 3 minutes. Whilst the amino
acids examined were soluble in DMF, they were not in PC, they did however become
soluble once preactivated. Removal of the N -Fmoc protecting group was then
achieved using 20% piperidine (v/v) in either DMF or PC. Once the tripeptide
sequence was complete, the peptide was cleaved from the resin using TFA:TIPS:H2O
(95:2.5:2.5), precipitated into cold ether, triturated and isolated to give the target
tripeptide H-Leu-Ala-Phe-OH 2.110.
Scheme 2.25: Solid-phase synthesis of H-Leu-Ala-Phe-OH 2.110, i) Fmoc-Amino
Acid (3.0 eq), HBTU (3.0 eq), HOBt (3.0 eq), DIPEA (6.0 eq), 2×1 h, DMF or PC
(0.2 M solution), ii) 20% piperidine in DMF or PC, 10 and 20 min, iii) TFA:TIPS:H2O
(95:2.5:2.5) 3 hours.
2.2.2.3 Alternative Washing Procedures
Typically, between synthetic steps the resin is washed with large quantities of solvent
to remove any soluble impurities and excess reagents. This is usually done using
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solvents such as DMF, CH2Cl2 and MeOH. To ensure that the use of non-green
solvents was completely avoided, alternative washing procedures were investigated.
Initially, just the reaction solvent was used for the washing procedure. However, due
to the high boiling points associated with DMF (153 ◦C) and PC (242 ◦C), vacuum
filtration failed to remove trace impurities of solvent, leading to contamination of
the final product. This is apparent in the 1H NMR spectrum of the H-Leu-Ala-Phe-
OH tripeptide 2.110 prepared using PC, as residual solvent peaks are clearly visible
(Figure 2.6). This was eventually remedied by either washing the resin prior to
coupling with a green solvent with appreciable vapour pressure, such as 2-MeTHF,
or performing multiple triturations using cold ether.
Figure 2.6: NMR spectra for H-Leu-Ala-Phe-OH 141 washed with just PC (top)
and washed with 2-MeTHF prior to cleavage (bottom), * PC peaks, + PEG backbone
peak.
Analysis of both samples by 1H NMR spectroscopy indicated that the target peptide
produced using PC was obtained in comparable crude purity to that which was
prepared in DMF. It has therefore been shown that solid-phase peptide synthesis
using PC as the reaction solvent is indeed achievable. Although it was necessary to
use a less common solid-support, as ChemMatrix was the only resin found to give
appreciable swelling in PC. Finally, it was also found that the use of any undesirable
solvents for the washing procedure could be completely removed. This meant a
single, green solvent could be used for both reaction and washing procedures, with
only a final wash before cleavage necessary to remove any residual PC.
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2.2.3 Total Synthesis of Bradykinin in Cyclic Carbonates
Having demonstrated that PC could be used as a solvent for solid-phase peptide
synthesis, when used in conjunction with the high swelling ChemMatrix resin,
the limitations of the developed methodology was further explored. Therefore,
the synthesis of a the naturally occurring nonapeptide bradykinin (H-Arg-Pro-Pro-
Gly-Phe-Ser-Pro-Phe-Arg-OH) 2.112, a biologically relevant peptide was chosen to
demonstrate the synthetic usefulness of the developed procedures.
First isolated using the venom of the Brazilian Lancehead snake Bothrops Jararaca,
bradykinin was identified as being a potent vasodilator, which was in turn found
to be particularly important in blood pressure regulation and in inflammatory
mediation.133 In fact, braykinin was found to be one of many pharmacologically
active peptides released during the breakdown of kininogen by kallikrein enzymes,
more commonly known as the kallikrein-kinin system.134 Greater understanding
of this system led to the development of angiotensin-converting enzyme (ACE)
inhibitors, which mitigates bradykinin metabolism, a blockbuster range of drugs
used in the treatment of heart failure and hypertension.135 This is significant as the
discovery of bradykinin represents the first time in which the pharmacophore of a
protein toxin had been used in the design of peptide-mimetic drugs.136 Bradykinin
was also one of the first physiological peptides synthesised by R. B. Merrifield to
demonstrate the utility of solid-phase peptide synthesis.137,138 Additionally, it was
considered that bradykinin was of suitable length and contained a good balance
of functionalised and unfunctionalised amino acid residues. For the above reasons,
bradykinin represented a suitable target and a reasonable challenge for the developed
methodology.
The synthesis of bradykinin was to be carried out starting from ChemMatrix-
HMPB preloaded with the Arg(Pbf) amino acid residue (Scheme 2.26). Coupling,
deprotection, cleavage and washing steps were to be carried out under the conditions
described for the synthesis of the model tripeptide using the solid-phase approach.
To allow a direct comparison between the developed methodology and a conventional
approach the synthesis of bradykinin was also to be carried out in DMF. This plan
immediately hit issues, as repeated attempts to synthesise bradykinin using PC as
the reaction solvent failed to produce the target peptide. Meanwhile, the control
sample using DMF as the reaction solvent had proven to be successful. The reason
for this difference was not immediately obvious, considering the synthesis of a model
tripeptide had proceeded without issue. It was not until doubts were raised about
the stability of cyclic carbonates, as briefly mentioned earlier, that the underlying
issue was finally elucidated.
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Scheme 2.26: Solid-phase synthesis of bradykinin 2.112. i) Fmoc-Amino Acid (3.0
eq), HBTU (3.0 eq), HOBt (3.0 eq), DIPEA (6.0 eq), 2×1 h, DMF or PC (0.2 M
solution). ii) 20% piperidine in DMF or PC, 10 and 20 min. iii) TFA:TIPS:H2O
(95:2.5:2.5) 3 hours.
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2.2.3.1 Reactivity of Cyclic Carbonates
The use of cyclic carbonates as reactive intermediates first appeared within the
literature more than 50 years ago. Consequently, the reaction of cyclic carbonates
with aliphatic and aromatic amines, alcohols, thiols and carboxylic acids for the
preparation of small molecules and polymers, is well established.107 Our interest of
course lies predominantly in the reaction of cyclic carbonates with amines.
The reaction of cyclic carbonates with aliphatic and aromatic amines is typically
known to proceed through two possible reaction mechanisms, depending on amine
nucleophilicity (Scheme 2.27). The ring opening of cyclic carbonates 2.114 by alkyl
amines is known to proceed under ambient conditions (25-50 ◦C), generating the
corresponding N -alkyl carbamates 2.113. This reaction has been well explored in
the context of non-isocyanate polyurethane (NIPU) synthesis.139 However, of the
cyclic carbonates structures widely explored (5-, 6-, 7-, 8-membered or thio-cyclic
carbonates), 5-membered cyclic carbonates are known to be the least reactive.140
The reactivity of 5-membered cyclic carbonates is also known to be very dependent
on ring substitution, solvent and temperature.139 For this reason, aminolysis of 5-
membered cyclic carbonates under ambient conditions is typically performed in the
presence of a suitable Lewis acid- or organo-catalyst.
Scheme 2.27: Reaction of cyclic carbonates with alkyl- or aryl-amines.
On the other hand, N -aryl amines typically required much harsher conditions due to
their low nucleophilicity. However, under these harsh conditions chemoselectivity is
compromised, with Cα attack preferred over carbonate attack, generating a range of
decarboxylated side-products including N -aryl amines 2.115. More recently, Kleij
and co-workers have shown that the poor nucleophilicity can be overcome when a
suitable organocatalyst is used, demonstrating the first chemo- and regio-selective
synthesis of N -aryl carbamates.141 In a recent communication Kleij and co-workers
have extended this methodology to include geminal disubstituted cyclic carbonates
and secondary amines.127 Geminal dimethyl-substituted cyclic carbonate 2.116 were
cleanly converted to the corresponding N -alykl carbamate 2.118 within 18 hours in
the presence 20 mol% triazabicyclodecene (TBD), with >99:1 selectivity for 2.118
over 2.119 (Scheme 2.28).
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Scheme 2.28: Reaction of geminal dimethyl-substituted cyclic carbonate 2.116 with
morpholine 2.117 to generate N -alkyl carbamate 2.118/2.119.
More importantly, Kleij and co-workers reported that this transformation occurs but
is much slower in the absence of TBD, with 60% conversion observed in 24 hours
and a regioselectivity of 63:37 (2.118:2.119). With this in mind, we had previously
investigated the reaction of amino acid amines with cyclic carbonates observing
that only 1% conversion was observed within 3 hours under forcing conditions. The
reaction of cyclic carbonates with piperidine 2.120, used in removal of the N -Fmoc
protecting group, had not been considered. It turns out this reaction has only been
explored on two occasions prior to our investigation by Baizer et al. and Najer et
al. more than 50 years ago.142,143 We therefore decided to carry out the reaction
between PC 2.42 and piperidine 2.120, neat under ambient conditions. As expected
the corresponding N -alykl carbamate is formed as a 50:50 mixture of regioisomers
2.121/2.122 (Scheme 2.29). Monitoring the progress of this reaction by 1H NMR
spectroscopy indicates that roughly 80% of the piperidine is consumed within 30
minutes.
Scheme 2.29: Reaction of PC with piperidine to generate the N -alkyl carbamate as
a mixture of regioisomers 2.121/2.122.
Returning to the challenge at hand, the total synthesis of bradykinin 2.112, it
was now apparent what the issue had been. Previously, a large quantity of 20%
piperidine in PC (v/v) had been prepared beforehand. This of course would rapidly
become inactive as the piperidine is quickly consumed. This obviously presents
a major issue, however, the half life (t1/2) for N -Fmoc deprotection is known to
be on the scale of 7 seconds. This means 99.99% conversion is obtained within
approximately 1.5 minutes.144 It was therefore hoped that N -Fmoc deprotection
would occur suitably quickly, relative to the consumption of piperidine, providing
the 20% piperidine solution in PC was freshly prepared for each deprotection.
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It is also worth acknowledging at this point that prior to attempting the manual
synthesis of bradykinin the use of automated SPPS had been investigated.
Bradykinin, ACP 65-74 and β-amyloid were identified as suitable targets for the
developed methodology using the two days that were available with the instrument.
A major issue was initially realised when the amino acids were found to not be
soluble at 0.2 M in PC, this could however be overcome using a solvent mixture of
80:20 PC:2-MeTHF, with histidine the only amino acid that appeared to precipitate
out of solution upon standing. Unfortunately, following cleavage, no evidence of the
target peptides could be identified by high-resolution mass spectroscopy (HRMS).
On reflection, this is most likely also due to the fact that the 20% piperidine (v/v)
solution in PC was prepared in bulk prior to starting the instrument. Having now
realised that the ring-opening of PC by nucleophilic amines is a major side-reaction
in this methodology, it may very well be worth revisiting the use of PC in automated
SPPS in future.
The total synthesis of bradykinin was therefore reattempted, according to the
synthetic procedure outlined previously (Scheme 2.26). Except this time the solution
of piperidine in PC (20% v/v) was freshly prepared before each use. Following
construction of the desired sequence the crude peptide was precipitated into cold
ether, triturated and lyophilised. The presence of bradykinin was then confirmed
using HRMS.
Having identified that bradykinin had been successfully synthesised using PC as
the reaction and washing solvent, the sample prepared in PC, the control sample
prepared in DMF, and a commercial standard were analysed using LCMS. The
major peak identified in each case is consistent with bradykinin (Peak 1), with the
samples prepared in PC and DMF found to have crude purities of 77% and 79%
respectively. Clearly the use of PC as the solvent has no detrimental effect on the
overall synthesis when compared to a control sample (Figure 2.7).
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Figure 2.7: HPLC-UV traces of bradykinin 2.113, commercial standard (top),
sample prepared in DMF (middle) and sample prepared in PC (bottom). Peak
numbers correlate to the distinct peaks that were identified for HRMS analysis. They
do not represent equivalent compounds and have no relation between distinct runs.
Identity of these products will be discussed in due course.
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2.2.3.2 Identification of Impurities in Bradykinin Total Synthesis
Whilst the use of PC appeared to have no detrimental effect on the synthesis of
bradykinin in terms of crude purity. It does appear to have an influence on the
impurities generated during the synthesis, as clearly distinct peaks are observed
when compared to the control sample (Figure 2.7). Analysis of the control sample
spectrum identifies a single impurity on the shoulder of the bradykinin peak. Using
the HRMS data generated for this peak, three major impurities can be identified. All
of these were found to be deletion sequences, with H-Pro-Phe-Arg-OH 2.123a, H-
Ser-Pro-Phe-Arg-OH 2.123b and H-Phe-Ser-Phe-Arg-OH 2.123c detected (Figure
2.8). It should be noted that the presence of deletion sequences of peptidic nature
is an issue, as it can often be difficult to remove these impurities using HPLC, due
to their similarities relative to the target species.
Figure 2.8: Impurities identified in the control sample of bradykinin 2.112 prepared
using DMF.
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Figure 2.9: Impurities identified in the sample of bradykinin 2.112 prepared using
PC.
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Analysis of the spectrum obtained for the bradykinin sample prepared using PC
identified the presence of five distinct impurities (Figure 2.9). Peak 2, which also
appears to be present in the control sample but was not integrated, could not
be identified using the HRMS data obtained. The remaining peaks on further
analysis appear to be missed couplings, but show very different retention times
to those observed in the control sample. This is because each impurity appears
to be end-capped with PC, producing the corresponding carbamate, altering the
retention time. The four impurities observed have been assigned to the following
species; PC-Ser-Pro-Phe-Arg-OH 2.124a, PC-Gly-Phe-Pro-Ser-Pro-Phe-Arg-OH
2.124b, PC-Pro-Gly-Phe-Ser-Pro-Phe-Arg-COOH 2.124c and PC-Pro-Pro-Gly-
Phe-Ser-Pro-Phe-Arg-OH 2.124d. The most abundant (peak 4 2.124c) represents
15.2% of the peak area, for the impurities observed. This may be expected as
the glycine residue is the least hindered and likely to be the most nucleophilic
amino acid in the bradykinin sequence. This is a disappointing observation as
it suggests that cyclic carbonates may be more prone to ring-opening than had
been first anticipated. On the other hand, the ring-opening of cyclic carbonates by
nucleophilic amines does not appear to impair peptide synthesis, as both coupling
and deprotection reactions, at first glance, were not affected. The end-capping of
the N -terminus could also be regarded as advantageous as it makes separation of
the target compound from impurities easier, in a similar manner to how long-chain
sequences are often acetylated following coupling to make removal of any unreacted
sequences easier.
At the time of writing, Olsén et al. have reported on the ring-opening of cyclic
carbonates using α-amino acids in water.145 In their investigation Olsen et al. found
that divinylethylene carbonate 2.125 underwent a ring-opening reaction by glycine
2.126 in the presence of NEt3 and H2O, to produce the corresponding carbamate
2.127 (Scheme 2.30). This reaction was found to be fairly general, with a range
of carabamates produced in good yield from the corresponding cyclic carbonate,
although the reaction could not be performed regioselectively. Variation of the
amino acid also showed that more sterically congested side chains generally resulted
in lower yields. This report from Olsén et al. therefore reaffirms the observation
that cyclic carbonates are susceptible to ring-opening by α-amino acids, particularly
for unhindered amino acids.
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Scheme 2.30: Ring-opening of divinylethylene carbonate 2.125 by glycine 2.126 to
produce the corresponding carbamate 2.127.
2.3 Conclusions
In conclusion, this chapter has identified that the growing interest in therapeutic
peptides is likely to be a major issue in the future, due to their inherently ungreen
synthesis. The need for numerous auxiliary reagents, including protecting groups,
undesirable solvents and coupling agents, means chemical peptide synthesis is
commonly associated with poor PMIs and the generation of large quantities of waste.
As solvent is often the biggest contributor to waste the largest gains to be had, in
terms of reducing environmental impact, will often come with solvent optimisation,
rather than changes to the chemistry.
The various approaches within the literature to performing both solution- and solid-
phase peptide synthesis have therefore been reviewed. Many of these approaches
have sought to utilise water as the principal solvent. These however often require
significant changes to the chemistry, in order to overcome the limitations associated
with peptide bond formation in water. More recently, the use of alternative organic
solvents has attracted much interest, of which cyclic carbonates have not been
investigated. Due to the many desirable chemical and physical properties they
possess as solvents, cyclic carbonates appear to be ideally suited to the development
of a more sustainable approach to peptide synthesis. The use of cyclic carbonates
for solution- and solid-phase peptide synthesis has therefore been explored.
Initial investigations into the solution-phase synthesis of a model Boc-Phe-Ala-
OBn dipeptide demonstrated PC was able to perform as well, if not better, than
conventional DMF or DMF:CH2Cl2 solvent mixtures. The model dipeptide was
produced in excellent yields, under optimised coupling conditions using EDC, HOBt
and DIPEA. This was also shown to occur without racemisation of the chiral centres.
Investigation into N -Boc deprotection then demonstrated that PC was tolerant
to the strongly acidic conditions. The dipeptide salt was typically obtained in
quantitative yield, with the use of TFA and PC found to be most convenient.
The developed methodology was then applied to the synthesis of a diverse range
of tetrapeptides. Good to excellent yields were typically observed for both coupling
(65-91%) and deprotection (80-99%) reactions. More importantly, PC was shown to
be tolerant to the protecting groups and functionalised side-chains commonly used in
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peptide synthesis. Finally, the global deprotection of a tripeptide was investigated.
Whilst the N -Boc deprotection proceeded smoothly in PC, the O-Bn deprotection
did not, which is believed to be due to leeching and deactivation of the catalyst
by PC. This was eventually remedied by performing the hydrogenation reaction in
methanol, with the final H-Leu-Ala-Phe-OH tripeptide obtained in a 92% yield over
the two steps.
Extending the use of PC to solid-phase peptide synthesis initially hit a problem, as
PC was unable to swell a PS-based resin. This meant that use of the PEG-based
ChemMatrix resin was necessary. The model tripeptide H-Leu-Ala-Phe-OH was
then successfully synthesised using the HBTU, HOBt and DIPEA in PC, upon a
ChemMatrix-HMPB resin. The removal of all undesirable solvents, including those
used in the washing procedures, was then attempted. Unfortunately, the use of PC
as the only solvent for SPPS resulted in contamination of the final product with the
solvent. This was resolved by either washing the resin with a more volatile solvent,
such as 2-MeTHF, before cleaving from the resin, or through extended trituration
of the final product. The synthesis of bradykinin, a biologically relevant peptide,
was then attempted in an effort to test the methodology. Initially, this failed due to
what was eventually identified as a side reaction between piperidine and PC. This
was easily overcome by freshly preparing the 20% (v/v) solution of piperidine in PC
each time, as it was realised that the rate of ring-opening is significantly less than
the rate of Fmoc-deprotection. Bradykinin was then synthesised in an excellent 77%
crude purity, which is comparable to a control sample produced in DMF. Analysis
of the distinctly different impurities generated in the bradykinin synthesis using
PC, found that end-capping of the amino acids was occurring via the previously
mentioned side-reaction. This however, does not appear to inhibit the synthesis
in anyway and actually facilitates separation, due to the vastly different retention
times observed within the LC. Cyclic carbonates have therefore been shown to be
excellent solvents for a more sustainable approach to both the solution- and solid-
phase synthesis of peptides.
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3.1 Introduction
Over the course of the previous investigation (Chapter 2) it became apparent the use
of green solvents in SPPS had only seen limited investigation. In comparison, the
use of green solvents in the closely related Solid-Phase Organic Synthesis (SPOS)
methodology was almost non-existent. SPOS is where an organic transformation
is performed upon an insoluble polymer support. This approach has established
itself as a powerful tool for the construction of complex biological structures and
small organic molecules. This was first reported more than half a century ago by
Bruce Merrifield, in his pioneering work on the development of Solid-Phase Peptide
Synthesis (SPPS).146 In his seminal report, Merrifield covalently bound an amino
acid to an insoluble polymer, in the form of a resin bead, through the use of a
chloromethylated copolymer of styrene and divinylbenzene (DVB). The peptide
sequence could then be built upon the resin bead through the stepwise addition
of subsequent amino acids. Once the desired sequence was complete, the peptide
could simply be cleaved from the solid support and isolated. The advantage of
this approach is that when the target product is firmly immobilised to an insoluble
support, purification becomes a trivial matter, as excess reagents and soluble by-
products can be removed by a simple filtration. Thus, the laborious isolation and
purification methods commonly associated with solution-phase peptide synthesis
are eliminated. This approach however, was initially met with scepticism by the
majority of organic chemists.147 It took a number of brilliant achievements, such as
the total synthesis of a series of biologically active peptides, including bradykinin
and the 124-amino acid sequence of ribonuclease A, before the majority could be
convinced.148,137 Merrifield was eventually rewarded for his perseverance with the
1984 Nobel Prize in Chemistry.147
Nowadays, advances in the use of synthesis robots has established SPPS as
an automated task, resulting in SPPS being the favoured approach for the
synthesis of complex biological molecules, such as polypeptides, oligonucleotides and
oligosaccharides.149 Consequently, the speed and efficiency associated with SPPS
has led to many synthetic transformations being demonstrated upon solid-supports.
This combined with advances in combinatorial techniques has led to a revolution in
the drug discovery process, as automated SPOS has allowed for the rapid generation
of vast compound libraries, greatly accelerating the search for lead structures and
their optimisation, in the preparation of novel pharmaceuticals.
In the context of green chemistry this rapid and efficient synthesis of diverse
molecular structures using a variety of synthetic procedures, with minimal steps
required for isolation and purification is highly appealing. There are however major
issues associated with SPOS, in that the removal of excess reagents and soluble
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by-products requires the resin to be washed between procedures, generating large
quantities of contaminated solvent waste. Much like SPPS, the most commonly
used solvents for SPOS include the reprotoxic polar aprotic solvents, DMF, NMP
and DMA. All of which are classified as substances of very high concern under
REACh, meaning they are likely to see restriction in their use in the near future.50
Other common solvents for SPOS also include diethyl ether and CH2Cl2, both
of which have been highlighted as solvents of concern in recent solvent selection
guides.16 Furthermore, solvent has been typically found to account for as much
as 80-90% of the waste mass generated in a given batch pharmaceutical or fine-
chemical operation.15 The overall environmental impact of a process is therefore
overwhelmingly a consequence of the solvent, meaning the biggest gains in terms
of reducing the environmental impact will come from optimisation of the solvent,
rather than changes to the chemistry.
Having previously investigated the use of cyclic carbonates as green solvents for
both solution- and solid-phase peptide synthesis (Chapter 2), it made sense to
extend this methodology to SPOS. Cyclic carbonates however proved to be poor
solvents for the majority of common SPPS/SPOS resins, the focus therefore sought
to investigate a wide range of green solvents, in order to find suitable replacements
applicable to a number of common SPOS/SPPS resins. Prior to the investigation
into SPPS, analysis of the associated literature highlighted that the use of green
solvents had been extensively investigated, with water and neoteric organic solvents
proving particularly promising. Rather surprisingly, in comparison SPOS has seen
relatively little investigation, in fact only two distinct examples could be found
within the literature that explicitly utilise a green solvent.
3.1.1 Previous Reports of Greener Solid-Phase Organic
Synthesis
The earliest example of this was first reported by Coats et al., in their investigation
into the use of a range of unconventional solvents for the solid-phase thionation
of amides.150 The requirement for high temperatures to drive the reactions to
completion when performed in parallel, due to less efficient heating and stirring,
necessitated the use of a solvent with a high boiling point and low vapour
pressure. This is because previous attempts utilising THF or toluene had resulted
in various issues, such as solvent evaporation, migration and exposure. In an
initial screening benzyl benzoate was identified and found to perform comparably
to control reactions in either THF or toluene when the reaction was carried out at
65 ◦C. Subsequently, the thionation of polystyrene-supported (PS) aryl and alkyl
derivatives of phenylalanine 3.1 using Lawesson’s reagent 3.3 was investigated under
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parallel conditions. When benzyl benzoate was used as the reaction solvent the
target thioamides 3.2 were obtained in good to excellent conversions at 100 ◦C in
only 8 hours, an appreciable improvement over the use of THF or toluene (Scheme
3.1).
Scheme 3.1: Thionation of PS-supported phenylalanine 3.1 using Lawesson’s
reagent 3.3 in benzyl benzoate.
More recently, Stobrawe et al. have investigated the use of compressed carbon
dioxide as a neoteric green reaction medium for SPOS.151 As previously discussed,
solid-supported reactions often suffer from diminished reaction kinetics, due to poor
mass transfer between the solid and liquid phase. An issue that is exacerbated in
reactions that occur under triphasic conditions (g/l/s). It was hoped that these mass
transfer limitations could be overcome with the use of compressed carbon dioxide,
as either a supercritical fluid (scCO2) or gas expanded liquid (GXL). Stobrawe et
al. began their investigation with the rhodium catalysed hydroformylation of 1-
hexen-5-ol 3.4 upon a PS resin (Scheme 3.2). Initial attempts using scCO2 were
disappointing, resulting in only 10% yield of the target hydroformylation products.
It was hypothesised that this was due to inadequate solvation of the PS support in
scCO2. This was eventually overcome through the addition of an organic co-solvent,
such as 1-hexene, CH2Cl2 or toluene, producing the hydroformylation products in a
>98% yield, and a 1.2:1 ratio of 3.5:3.6.
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Scheme 3.2: Catalytic hydroformylation upon PS-resin in scCO2 and subsequent
Hantzsch pyridine synthesis.
To demonstrate the applicability of the developed methodology to a more
complicated product synthesis Stobrawe et al. went on to investigate the use of
scCO2 in the solid-supported Hantzsch synthesis of pyridines. After formation
of the hydroformylation products under the previously described conditions, the
solid supported aldehydes 3.5:3.6 were utilised in a multi-component coupling with
methyl acetoacetonate 3.7 and methyl 3-aminocrotonate 3.8. Aromatisation of the
intermediates 3.9:3.10 using ceric ammonium nitrate and subsequent cleavage from
the solid support using TFA produced the target isomeric pyridines 3.11:3.12 in a
99% yield and a 1.4:1 ratio.
Stobrawe et al. then went on to investigate a second benchmark reaction, in the
cobalt-catalysed Pauson-Khand reaction (PKR).151 The PKR between norbornene
3.14a and 1-pentyn-5-ol 3.13 upon a solid support was first investigated using THF
as the reaction solvent, in the presence of a catalytic amount of [Co2(CO)8] under
CO2 (20 bar) at 120 ◦C. After 17 h, cleavage using TFA in CH2Cl2 produced the
target product 3.15a in an 80% yield (Scheme 3.3). A significant enhancement
was observed when the same reaction was performed in the presence of compressed
carbon dioxide. Under GXL conditions quantitative formation of the PKR product
3.15a was observed. A similar increase in yield was also noted under GXL conditions
when using the more challenging norbornadiene 3.14b as a substrate.
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Scheme 3.3: Solid-supported Pauson-Khand reaction under conventional and GXL
conditions.
3.1.2 Determining the Suitability of Green Solvents for SPOS
The lack of investigation into greener solvents for SPOS could possibly be justified
on the basis that solvents such as DMF, NMP, DMA and CH2Cl2 are still the most
common solvents for SPPS. Since it was identified previously (Chapter 2) that the
use of alternative organic solvents in SPPS is something that has only began to
receive a significant amount of interest in more recent years.152 It was therefore
reasoned that a systematic investigation into the suitability of various common
green solvents for SPOS was indeed necessary, in an effort to aid chemists in their
selection of an appropriate green solvent for a given reaction. This however poses
a rather substantial challenge, as the use of an insoluble solid support places many
additional considerations on the solvent, when compared to traditional solution-
phase chemistry. Not only must the polymer resin be insoluble in the desired solvent
at a macroscopic level, to facilitate purification by filtration, but the solvent must
also be able to adequately solvate or swell the resin. This is something that has
been briefly discussed in the previous chapter (Chapter 2), but will now be explored
in greater detail.
3.1.2.1 Resin Swelling
Swelling of a cross-linked polymer is essentially equivalent to dissolution of a linear
polymer. However, rather than dissolving the polymer, the crosslinker inhibits the
excessive motion in the polymer chains necessary to form a solution. Instead the
solvent ends up occupying the space between polymer chains, causing an increase
in the total volume of the polymer, or causing it to swell. This is often considered
to be one of the most important prerequisites for SPOS, as a solvent that does
not adequately solvate the solid-support presents little opportunity for reagents to
interact with the active sites.130 This makes sense from a statistical perspective as
an even distribution of active sites within a resin sphere results in >99% of active
sites residing within the sphere, rather than at the surface.153 In this regard, the
swollen polymer now assumes the role of the solvent, forming an admixture that
constitutes the media in which the reaction will occur.
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The importance of this phenomenon was actually acknowledged by Merrifield in
his initial communication of SPPS.146 However, early understanding was quickly
proved to be inadequate, as a number of failed attempts at the synthesis of difficult
peptides, peptides that posses sequences prone to the formation of secondary
structures, were attributed to the polymer-supported nature of the reactions.154 This
resulted in Merrifield revising his previous model for resin-swelling. In a subsequent
communication by Sarin et al. Merrifield addressed two key questions (1) How
are the properties of the peptide-resin influenced by each of the components of the
system (the peptide, the resin and the solvent)? (2) Is there a fixed maximum volume
for a swollen resin bead, which is eventually filled by the growing peptide?155
To answer these key questions Sarin et al. prepared a range of peptides of up
to 6000 molecular weight by SPPS, using the repeating model sequence Leu-Ala-
Gly-Val-oxymethylphenylacetic acid upon copoly(styrene-1% divinylbenzene). This
produced a series of immobilised peptides ranging from 11-81% peptide (w/w). The
diameters of the dry resin beads were then determined by microscopic measurements.
These measurements were then repeated for the solvated state, using either CH2Cl2
or DMF, to determine the degree of resin swelling. The total swollen volume of
the beads against the peptide loading was then plotted for both solvents (Figure
3.1). The volumes for the swollen peptide-resins showed a dramatic increase over
the course of the synthesis, and at 80% peptide the volumes per gram of peptide
resin were 12 mL in CH2Cl2 and 28 mL in DMF.
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Figure 3.1: Total swollen volumes of peptide-resins of various molecular weights in
either CH2Cl2 or DMF.155
From the results obtained Sarin et al. were able to come to the following
conclusions. Firstly, it could be explicitly stated that the initial swollen volume
of the unsubstituted resin is not the final volume of the highly loaded peptide-resin
bead. There was also no evidence for a maximum solvated volume for the range
of peptides examined in this study, since the peptide-resin volume increased with
the growing peptide chain. Secondly, it is clear that the swelling properties of the
resin are influenced by each of the components of the system. Over the course of
SPPS solvation of the resin is initially defined by the polymer backbone, but is more
strongly influenced by the peptide sequence with increasing peptide content. The
polystyrene and protected peptide exert a complimentary solubilising effect on each
other, and together they determine the swelling behaviour of the peptide-resin in a
given solvent. CH2Cl2 is a better swelling solvent than DMF for PS resin, whereas
DMF is the better solvating medium for protected peptides.155
This report undoubtedly had a marked influence on the SPPS community, as
the widespread use of DMF in SPPS is most likely a consequence of Sarin et al.
identifying that it is an excellent solvent for peptides upon a solid support. It has also
generated a major effort to develop a more diverse range of solid supports, specifically
ones that have solvation properties similar to those of the peptide product.155
Consequently, there is now a plethora of solid supports readily available that utilise
a variety of resin compositions, cross-linkers and functionalities for optimal SPPS,
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a complete review of which would be much beyond this report.132 Finally, the most
important outcome of the report from Sarin et al., with regards to the use of greener
solvents for SPOS, is the acknowledgement that solvation of the resin is initially
defined by the polymer backbone. Bearing in mind that SPOS is typically used
for the construction of small organic molecules, the ability of a solvent to swell a
particular resin should be a strong indicator of whether or not it will be a suitable
solvent for SPOS. For this reason an investigation into the ability of various green
solvents to swell a number of common SPOS resins was planned.
A number of methods for quantifying the degree of swelling have been reported,
including, measurements of changes in volume for a single bead, like Sarin et al.,
or measuring changes in weight after centrifugation.130 These methods however are
rather labour intensive. More recently, Santini et al. have reported on a simple
and rapid method for determining resin swelling.131 A sample of dry resin was first
weighed into a graduated syringe, equipped with fine polypropylene filter. The
appropriate solvent was then added and the plunger inserted. Following agitation
for 1 hour the solvent was removed by compressing the syringe barrel. The degree of
swelling could then be determined by measuring the increase in volume of the resin.
As a rough guideline, Santini et al. suggested that a swelling of greater than 4.0
mL g-1 was indicative of a good solvent, between 2.0-4.0 mL g-1 a moderate solvent,
and less than 2.0 mL g-1 a bad solvent. This method was then used to record the
swelling of four common SPOS resins in thirty nine solvents. Whilst this method is
only semi-quantitative, it has proved to be a useful guide for the selection of suitable
resin/solvent pairs.130 For this reason it was deemed that the suitability of a range of
green solvents for SPOS would be best demonstrated by determining their ability to
solvate SPOS resins according to the method outlined by Santini et al. This would
allow for a variety of green solvents to be screened against a range of common SPOS
resins in a swift and efficient manner.
3.1.3 Resin Swelling and the Physical Properties of Solvents
In an effort to better understand the factors that influence resin swelling, many
attempts have been to made to correlate the degree of solvation with various physical
properties of the solvent. This has most often been reported in the context of the
chemical formulation of polymers, in applications such as coatings, pharmaceuticals
and cosmetics.156 In comparison, linking the swelling of SPOS/SPPS resins to the
physical properties of solvents has seen rather little investigation. Whilst Sarin et
al. had identified that polar solvents were generally better for SPPS with increasing
peptide content, a critical evaluation relating solvent properties to resin and peptide-
resin solvation was not realised until 1991 and the work of Fields et al.157
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In this investigation, Fields et al. sought to rationalise efficient solvation
of (aminomethyl)copoly(styrene-1%DVB) with a number of common solvent
parameters, including dipole moment (D), Hildebrand solubility parameter (δ),
hydrogen-bonding solubility (δh), dielectric constant () and hydrogen-bonding
index (γc). Fields et al. found that the best correlation between solvent properties
and resin solvation is observed for the contour plot where both δ and either δh or γc
are considered (Figure 3.2).157
Figure 3.2: Contour solvation plot of (aminomethyl)copoly(styrene-1%DVB) as a
function of the Hildebrand solubility parameter (δ) and hydrogen-bonding solubility
(δh).157
The Hildebrand solubility parameter (δ), first described by J. H. Hildebrand in 1936,
is a numerical description of solvency behaviour. It is defined as the square root of
the cohesive energy density, the heat of vaporisation divided by the molar volume,
and has proved to be a good indication of solvent/solute interaction, particularly for
non-polar molecules (Equation 3.1). Materials with similar values for δ, will be able
to interact, resulting in solvation, miscibility or swelling. It is difficult to directly
predict values of δ for polymers as they will most likely degrade before vaporisation
occurs.130 They can however be estimated by various methods, with a δ value of
9.1 (cal cm-3)0.5 having been previously reported by Suh et al. for cross-linked
polystyrene, which was determined using turbidimetric titration.158 It is therefore
no surprise that maximum solvation was observed by Fields et al. for a range of
solvents having solubility parameters similar to those of the polymer. In general,
species are considered miscible when the difference in δ values is <1. This is most
clearly observed in Figure 3.2, as maximum swelling is seen for solvents possessing
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values for δ of 9.0-9.8 (cal cm-3)0.5, such as THF, CH2Cl2 and CHCl3. Contour plots
for the other solvent parameters investigated by Fields et al. did not appear to give
quite such a convincing correlation to resin solvation.
δ =
√
∆Hv −RT
Vm
(3.1)
Fields et al. then extended their study to investigate peptide-resin solvation,
with a particular focus on how solvation is influenced by the side-chain protecting
group strategy used. The tridecapeptide [Lys9]-α-conotoxin G1 (Gly-Cys-Cys-Asn-
Pro-Ala-Cys-Gly-Lys-His-Tyr-Ser-Cys) was therefore synthesised three times, using
either a tert-butyl (tBu), benzyl (Bzl) or para-methoxybenzyl (mob)/Bzl protecting
group strategy. Regardless of the protecting group strategy used, optimal solvation
of the peptide-resin was shifted to higher values of δ/δh compared to the peptide
resin alone. Analysis of the contour plot generated for the Bzl protecting strategy
shows that optimal solvation is now found for δ values of 10.8-12.1 (cal cm-3)0.5 and
δh values of 3.5-5.5 (cal cm-3)0.5 (Figure 3.3). A result that is consistent with the
observation from Sarin et al., that as the peptide-resin system becomes more peptidic
in character, highly polar solvents, such as DMF, NMP and DMA are preferred.155
This result suggests that there is a good correlation between optimal solvation of
SPPS resins, and peptide-resins, with the Hildebrand solubility parameter (δ) and
the hydrogen-bonding solubility parameter (δh). It is also worth noting that Fields
et al. were successfully able to optimise mixed solvent systems based on these
parameters, by simply combining solubility parameters (δ) according to the relative
volume fractions (φ) (Equation 3.2).
δ1+2 = φ1δ1 + φ2δ2 (3.2)
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Figure 3.3: Contour solvation plot of Bzl-protected (Lys9)-α-conotoxin G1 as a
function of the Hildebrand solubility parameter (δ) and hydrogen-bonding solubility
(δh).157
More recently, Wilson et al. have investigated the influence of mono-, di-, tetra- and
hexa-ethylene glycol tethers in cross-linked polystyrene beads, and their influence
upon swelling and reagent diffusion.79 The polystyrene-polyethylene glycol (PS-
PEG) copolymers were investigated using a series of solvents possessing a range
of Hildebrand solubility parameters. It was found that whilst the 2% PS-PEG
copolymers were able to swell to a much greater extent than 2% PS-DVB, the tether
link seemed to have little influence on the polymer δ value, as toluene remained the
best solvent (Figure 3.4). This was presumed to be due to the low degree of cross-
linking relative to the PS-backbone, meaning the tethers would have little synergistic
influence on the swelling. When the cross-linking density was increased to around
20% the degree of swelling was found to drop, returning to levels similar to the
control sample using 2% PS-DVB. Unfortunately, Wilson et al. did not investigate
whether the use of a more polar solvent would enhance the swelling of the 20% PS-
PEG copolymers, as the Hildebrand solvent parameter (δ) values would be expected
to be better matched, based on the previously reported findings of Fields et al.
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Figure 3.4: Swelling of 2% PS-DVB and 2% PS-PEG beads in various solvents as a
function of Hildebrand solubility parameter (δ).79
Nakaie and co-workers have also reported a strong link between peptide-resin
solvation and the sum of electron acceptor (AN) and electron donor (DN)
numbers.159 These solvent parameters were first proposed by Gutmann, with the
intention of describing the solvent effect on a solute molecule simply as an acid-base
reaction.160 Cilli et al. therefore believed that the solvation properties of peptide-
resins would be influenced by the number of electrophilic (N-H) and nucleophilic
(C=O) groups found in the peptide backbone. In order to investigate this, Cilli
et al. synthesised a model repeating peptide sequence (Asp-Ala-Asp-Pro)4 bearing
benzyl protecting groups on the Asp side chains, and bound to a 1.4 mmol g-1
benzhydrylamine-resin (BHAR). The swelling was then determined and correlated
to a number of solvent parameters, including, , the Dimroth-Reichard’s parameter
(ET30), AN, and DN, along with the additive AN+DN parameter in a 1:1 ratio.
Cilli et al. observed poor relationships between resin solvation and a number
of the solvent parameters investigated. However, a fairly convincing correlation
was observed for the AN+DN parameters, with maximum solvation appearing for
solvents or solvent mixtures with AN+DN number of around 40 (Figure 3.5), with
1-22 representing a number of solvents and solvent mixtures. The two deviations, 21
and 22, which are 50% TFE:DMF and 50% TFE:DMSO respectively, are believed to
be due to high AN or DN solvents preferring to self associate, rather than solvate the
peptide-resin. Subsequently, Cilli et al. went on to investigate the swelling properties
of a number of other species, which included the Asp-Ala-Asp-Pro sequence at 0.2
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mmol g-1 loading, the aggregation prone Ile-Asp-Gly fragment and the 1.4 mmol g-1
BHAR resin as a peptide-free resin model. In most cases a very good correlation
between observed swelling and solvent AN+DN values was observed.
Figure 3.5: Swelling of (Asp-Ala-Asp-Pro)4 resin as a function of (AN+DN) solvent
values. The numbers 1-22 represent the solvents and solvent mixtures investigated by
Cilli et al.159
More recently, Malavolta et al. have further expanded on the application of the
AN+DN solvent parameter for resin swelling.161 In this study the swelling properties
of a much broader range of resin species were investigated, including a highly charged
variant of the BHAR resin (BHAR-NH3
+, 2.4 mmol g-1), an aminoalkyl cross-linked
polydimethylacrylamide resin (SPAR-50, 0.6 mmol g-1) and the tetraethylene glycol
diacrylate cross-linked polystyrene resin (PS-TTEGDA, 0.7 mmol g-1). Additionally,
along with the previously investigated solvent parameters Malavolta et al. included
the Kamlet-Taft solvent parameters. Kamlet-Taft parameters split the solvent
into three distinct parameters quantifying hydrogen-bond accepting ability (α),
hydrogen-bond donating ability (β), and polarity/polarisability (pi*). In their
investigation Malavolta et al. attempted to correlate both (α+β), and (pi*+α+β)
to resin solvation. The results obtained however suggest that the best correlation
between solvent properties and resin swelling is still given by the combination of
AN+DN in a 1:1 ratio.
In summary, a number of investigations have attempted to correlate resin solvation
with various physical properties of solvents, in an attempt to better optimise
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SPOS/SPPS reactions. Various solvent parameters have been utilised, including
dipole moment (D), dielectric constant (), Hildebrand solubility parameter (δ),
hydrogen-bonding solubility parameter (δh), hydrogen-bonding index (γc), Dimroth-
Reichardt’s polarity parameter (ET30), acceptor number (AN), donor number (DN)
and Kamlet-Taft (α, β and pi*). The most convincing correlation between the degree
of resin swelling and these parameters was observed for the use of δ with either δh
or γc, or the use of AN+DN.
Review of the literature has also identified that the degree of resin swelling has not
been previously investigated with regards to Hansen Solubility Parameters (HSP).
HSP has been proposed as an extension to Hildebrand solubility parameters, and
has become an incredibly powerful method for predicting solubility in a wide variety
of applications, including pigments, nanoparticles and even DNA.162 For this reason,
it was felt that an investigation into HSP and resin swelling should be incorporated
with this investigation into the suitability of green solvents for SPOS.
3.1.4 Hansen Solubility Parameters
A common criticism of the Hildebrand solubility parameter (δ) is that it is a vast
oversimplification of solvation theory. The approach had been based of the use of
hydrocarbon solvents, meaning no contributions from hydrogen bonding or polarity
were incorporated into the calculation. For this reason, the notion that solubility
could be based on similarities in δ values soon unravelled, as the use of a single solvent
parameter was clearly not powerful enough. In an effort to compensate for these
limitations Hansen proposed that the cohesive energy could be regarded in terms
of three components, rather than just one. Hansen’s approach therefore considered
the cohesive energy (E or ΔH v-RT ) as the sum of energies arising from dispersion
forces (ED), polar forces (EP) and hydrogen bonding forces (EH) (Equation 3.3).156
E = ED + EP + EH (3.3)
When considered in terms of cohesive energy density, i.e. dividing by molecular
volume (VM), and substituting δ2 for each energy contribution, where δ2 = E/VM,
this equation is simplified to the following (Equation 3.4);
δ2 = δD2 + δP 2 + δH2 (3.4)
These solvent parameters D, P and H can then be imagined as co-ordinates in
a three-dimensional space, commonly referred to as Hansen space. The relative
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closeness of molecules within Hansen space can then be used to predict an array of
properties such as solvent miscibility or polymer solubility. This relative distance
(Ra2) can be easily calculated based on the difference between the various parameters
(Equation 3.5). It is worth acknowledging that the factor of 4 incorporated into the
difference in δD values has been highly controversial, but a full explanation for this
is far beyond the scope of this report.162
Ra2 = 4(δD1 − δD2)2 + (δP1 − δP2)2 + (δH1 − δH2)2 (3.5)
A major appeal of the Hansen approach is that Hansen, in collaboration with Abbot
and Yamamoto, went on to develop a software package for HSP, known as Hansen
Solubility Parameters in Practice (HSPiP).162 This has meant that HSP can be
easily visualised and manipulated in three-dimensional space. This has also made
it incredibly easy for users to predict HSP values for a multitude of systems based
on experimental data, rather than by measuring enthalpies of vaporisation. For
example, the user is able to arbitrarily define whether a solvent is suitable or not for
a given process based on whatever determinant they deem most appropriate. The
HSPiP software is then able to predict optimal HSP values based on the best fit of
the data, using the Hansen fitting algorithm. This is most easily represented as a
sphere in Hansen space of radius R0, more commonly referred to as the interaction
radius, which represents the region in which suitable solvents should lie. A relative
energy difference (RED) can then be determined to predict likeness, using the
relative distance and the interaction radius (Equation 3.6). A RED of <1 means the
molecules are alike and will dissolve, RED=1 suggest the molecules will partially
dissolve, and RED of >1 will not dissolve.
RED =
Ra
R0
(3.6)
The figure below constitutes a typical HSPiP plot for such a system, where the
green sphere of radius R0 represents the predicted optimal region in which the most
suitable solvents should reside (Figure 3.6). The smaller central sphere represents
the “optimal” solvation parameters as calculated by the HSPiP fitting algorithm.
Finally, the blue spheres represent solvents that are regarded by the user as suitable,
whilst the red cubes are regarded as unsuitable.
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Figure 3.6: An example of an HSPiP plot.
With this in mind, it was hypothesised that the suitability of green solvents for
SPOS could be rationalised on the basis of HSP. Santini et al. have previously
demonstrated how solvent selection for SPOS can be made on the basis of simple
resin swelling experiments. This would therefore allow the suitability of a solvent
for a particular SPOS resin to be determined in an efficient and quantifiable manner
that could be easily input into HSPiP. Optimised solvent parameters could then be
predicted for a particular SPOS resin using the HSPiP solvent optimiser algorithm,
allowing for the straightforward selection of the most suitable solvent, and also the
rapid screening of additional solvents based on relative solvent parameters.
3.1.5 Chapter Aims
It has so far been established that the use of alternative solvents for SPOS has
been relatively unexplored, in comparison to the parent methodology SPPS. This is
justified on the basis that the use of undesirable solvents is still the most common
practice for SPPS, with alternative organic solvents having only recently received
notable investigation. This does however present an interesting opportunity to
investigate the suitability of green solvents for SPOS. Solvent choice in SPOS is
however rather critical to the success of the reaction, as the solvent must be able
to adequately solvate, or swell, the solid support. Accordingly, the remainder of
this chapter seeks to determine the suitability of a diverse range of green solvents
for SPOS, on the basis of their ability to swell various common SPOS resins. A
number of attempts within the literature have also attempted to correlate swelling
of these supports to physical properties of the solvent, with the Hildebrand solubility
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parameter (δ) proving particularly effective. This has however been found to have
notable limitations, particularly with regards to polar or hydrogen-bonding solvents.
HSP is an extension of Hildebrand’s approach that seeks to incorporate these terms,
but has not been previously investigated in the context of resin swelling in SPOS. It
is therefore believed that a computational model using HSPiP can be built from the
outcomes of the resin swelling data, in order to predict and model solvent suitability
for SPOS.
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3.2 Results and Discussion
3.2.1 Resin Swelling Studies
In order to first determine the suitability of green solvents for solid-phase organic
synthesis (SPOS) a number of readily available resins were selected for investigation,
the properties of which are summarised in Table 3.1. These resins can generally be
grouped into four distinct categories depending on the composition of the polymer
backbone. These categories are as follows, polystyrene (PS), grafted polystyrene-
polyethylene glycol (PS-PEG), polyethylene glycol (PEG) and polyamide (PA). A
number of other resins, consisting of various polymer backbone compositions and
functionalities are commercially available, however it is felt that the nine selected
represent a broad enough selection for determining the suitability of green solvents
for SPOS.132
Table 3.1: Physical properties of the commercial solid-phase resins investigated in the solvent
swelling study.
Resin Polymer Backbone Functionality Bead
size
(mesh)
Capacity
(mmol g-1)
Merrifield PS 1% DVB Wang
(ArCH2OH)
200-400 0.6-1.0
ParaMax PS 1% DVB para-
ArCH2OH
100-200 2.0
JandaJel PS 2% 1,4-bis (vinyl-
phenoxy)-butane
CH2Cl 100-200 0.8-1.2
TentaGel PS-PEG Hybrid 50-
70% (w/w) PEG
Rink-Fmoc 80-100 0.23
ArgoGel PS-PEG Hybrid 67-
82% (w/w) PEG
Cl 200-400 0.48
HypoGel 200 PS-PEG Hybrid 16%
(w/w) PEG
CO2H 110-150 0.8
NovaGel PS-PEG Hybrid 48%
(w/w) PEG
HMPA
(ArCH2OH)
Not
stated
0.74
ChemMatrix PEG 100% Wang
(ArCH2OH)
35-100 0.5-1.2
SpheriTide PA Rink-Fmoc 45-140 0.21
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Merrifield146, ParaMax163 and JandaJel164 can all be classified as polystyrene (PS)
based resins, differing only in their functionality and cross-linkers. Merrifield resin
is polystyrene cross-linked with 1% divinylbenzene (DVB). Traditionally Merrifield
resin was functionalised with the chloromethyl group, which was first utilised by
Merrifield in his seminal report on the synthesis of a tetrapeptide by SPPS.146
Even after 50 years, this resin remains one of the most commonly employed resins
for SPPS/SPOS.130 The sample in this case is functionalised with a Wang (2-
hydroxybenzyl alcohol) linker. Paramax is very similar to Merrifield resin, being
a PS based resin containing a 1% DVB cross-linker, except that functionalisation
of the resin, using a hydroxymethyl group, occurs exclusively in the para-position
of the PS backbone. JandaJel has been specially designed to be a high swelling
PS-based resin. This has been achieved through the use of a more flexible 1,4-
bis(vinylphenoxy)-butane cross-linker, rather than use the more conventional DVB
one. JandaJel in this case is obtained as the chloromethyl derivative.
The next category is the grafted PS-PEG resins, consisting of TentaGel165,
ArgoGel166, HypoGel 200167 and NovaGel168. These structures typically consist
of a 1% DVB cross-linked PS core, with a PEG unit of various lengths grafted
to the active site. TentaGel contains PEG chains of approximately 2000-3000 Da
resulting in a matrix that is 50-70% PEG w/w, and functionalised with a Fmoc-
protected Rink linker. Early generations of PS-PEG graft resins, such as TentaGel,
typically suffered from low loading and poor stability, due to the use of benzylic
or amide-based linkages to the PS-core.132 ArgoGel was an attempt to overcome
these limitations through the use of a branched bifunctional PEG chain. This
results in a PS-PEG graft polymer with a very high degree of PEG content (67-82%
w/w) and double the loading (0.48 mmol g-1) of the early PS-PEG resins utilising
monofunctional linkers. Additionally, the use of chemically inert aliphatic ethers to
join the PEG chains to the PS-core resulted in a greatly enhanced stability towards
strong acids and nucleophilic reagents. The ArgoGel resin investigated in this case
is terminated with a chloro-group. In contrast, HypoGel 200 was developed in an
effort to slightly enhance the kinetics of SPOS reactions, but maintain the stability
of the PS-core. The use of short 200 Da PEG chains, terminated with carboxylic
acid groups, results in a PS-PEG graft polymer containing only a very small quantity
of PEG (16% PEG w/w). Finally, NovaGel is a high swelling resin in which the
PEG grafts are attached to the PS resin using urethane groups. It is only 48%
PEG w/w, resulting in a resin that is intermediate to that of HypoGel 200 and
TentaGel/ArgoGel. It was functionalised with (4-hydroxymethylphenyl)acetic acid
(HMPA) to provide alcohol functionalities for substrate immobilisation.
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More recent approaches to the design of solid supports have tried to completely
avoid the use of PS. Instead favouring more amphiphilic polymers, that are able
to adequately swell in a much broader array of solvents. For this reason the final
two resins chosen contain no PS. ChemMatrix169 is a solid support that exclusively
contains highly cross-linked PEG chains through primary ether bonds. This results
in a resin that displays high chemical stability and an ability to swell in a large
variety of solvents. The sample chosen in this case is functionalised using a Wang
linker. The final resin chosen, which again does not contain any PS in the polymer
backbone, was SpheriTide. SpheriTide170 is an interesting resin choice, as it is a
polyamide (PA) matrix made up entirely of cross-linked poly-ε-lysine. Poly-ε-lysine
is a naturally occurring short-chain polyamide consisting of 25-35 lysine residues,
produced through bacterial fermentation, typically for use as a food preservative.
SpheriTide can therefore be regarded as a bio-based SPOS resin, making it rather
unique in the context of improving the sustainability of SPOS. SpheriTide is supplied
as the low loading Rink-Fmoc derivative.
In order to determine whether or not a green solvent would be suitable for SPOS
upon the chosen resins, it was decided that the ability of the chosen solvent to
adequately solvate, or swell, the support would be investigated. This is one of
the most important considerations for SPOS/SPPS to ensure a complete and rapid
transformation, as poor resin swelling results in poor reaction site accessibility and
diminished reaction rates.131 This was discussed extensively within section 3.1, with
it established that the semi-quantitative method previously described by Santini et
al. being the most suitable approach for rapidly quantifying resin swelling.
A broad array of solvents covering a wide range of polarities and hydrogen bond
donor/acceptor properties were then selected for screening against the chosen resins,
according to the methodology outlined by Santini et al. A total of 30 solvents
were investigated, 27 of which are known for possessing promising green credentials,
along with 3 reference solvents 3.43-3.45 (Figure 3.7). Cyclic carbonates 3.16
and 3.17, Cyrene 3.18 and N -butyl-2-pyrrolidone 3.42 have all been used as green
replacements to traditional polar aprotic solvents. As discussed previously, cyclic
carbonates can be prepared through the 100% atom economical reaction between
epoxides and waste carbon dioxide,100 whilst Cyrene is prepared in two steps from
cellulose.171 N -butyl-2-pyrrolidone is a non-reprotoxic derivative of N -methyl-2-
pyrrolidone (NMP) 3.43, although the reprotoxicity is only just below the currently
accepted limit.172
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Figure 3.7: Structures of the green solvents (3.16-3.42) and undesirable reference
solvents (3.43-3.45) used in this study.
The majority of ethers, ketones, esters and acyclic carbonates can be considered as
moderately polar aprotic solvents. Two well-known conventional solvents, acetone
3.19 and ethyl acetate 3.23, were included due to their reasonable green credentials.
γ-Valerolactone (GVL) 3.26 and 2-methyl tetrahydrofuran (2-MeTHF) 3.27 are
both produced from renewable sources of lignocellulosic biomass.173,174 The acyclic
carbonates, dimethyl carbonate 3.32 and diethyl carbonate 3.33, can be prepared
from carbon dioxide and sustainably sourced alcohols.175 Cyclopentanone 3.22,
isobutyl acetate 3.25 and anisole 3.29 were included as they scored very highly
in the most recent iteration of the GSK solvent sustainability guide.16 Dimethyl
isosorbide 3.30, cyclopentyl methyl ether 3.31, butan-2-one 3.20, 4-methyl-pentan-
2-one 3.21 and isopropyl acetate 3.24 were identified as promising solvents on the
grounds of a computational modelling study using HSPiP, which will be discussed
in due course.
2,2,5,5-Tetramethyloxolane (TMO) 3.28 is a non-peroxide forming ether derived
from readily available and potentially renewable feedstocks.176 Whilst it would
be expected to be similar to 2-MeTHF in terms of polarity, it is actually a
suitable replacement for toluene, making up the apolar aprotic solvents, along
with D-limonene 3.34 and para-cymene 3.35. D-Limonene is a natural product,
readily available from citrus peels, it is also easily converted to para-cymene via
isomerisation and dehydrogenation.177 The polar protic solvents selected include
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three common alcoholic solvents, methanol 3.36, ethanol 3.37 and isopropanol 3.38,
all of which can be obtained from sustainable sources. 1-Heptanol 3.39 was also
included, due to it scoring very highly in the most recent GSK solvent sustainability
guide, along with water 3.40.16 The ionic liquid 1-butyl-3-methylimidazolium
tetrafluoroborate ([BMIM][BF6]) 3.41 was also included as an example of a non-
conventional solvent. The final three solvents selected NMP 3.43, DMF 3.44 and
CH2Cl2 3.45, are undesirable solvents commonly associated with SPPS/SPOS. This
was done in order to provide a direct comparison against the chosen green solvents
and to validate the swelling methodology.
To begin with, the swelling of Merrifield-Wang resin was investigated using the
conventional SPOS solvents 3.43-3.45, according to the procedure reported by
Santini et al. The results obtained indicate an excellent correlation with those
previously reported within the literature using this approach.131,178 To further
validate the methodology the swelling of a small subset of 8 solvents (3.17, 3.19,
3.23, 3.27, 3.32, 3.36, 3.40, 3.45) with three of the chosen resins (Merrifield,
ArgoGel and ChemMatrix) was investigated. The swelling was determined for all
24 combinations of these resins and solvents. This was then repeated a further 4
times, in order to confirm the reproducibility of the method (Figure 3.8-3.10). The
error bars plotted represent the maximum deviation from the mean, indicating that
the determination of resin swelling using this method is reproducible to ±0.5 mL
g-1. Having validated the methodology, by demonstrating it is both consistent with
literature and reproducible, the ability of all 30 solvents to swell the 9 chosen resins
was then investigated, the outcomes of which are summarised in Figures 3.11-3.19.
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Figure 3.8: Reproducibility of Merrifield resin swelling tests.
Figure 3.9: Reproducibility of ChemMatrix resin swelling tests.
Figure 3.10: Reproducibility of ArgoGel resin swelling tests.
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Analysis of the swelling data obtained then allowed for direct comparisons to be
made between the various resins, and their associated categories. Comparison of
the data in Figures 3.11-3.13 shows differences in the swelling behaviour between
the three PS-based resins. The results obtained for Merrifield resin are suggestive
of a preference for the moderately polar solvents, as good swelling is observed for
solvents 3.20, 3.22, 3.27, 3.29, 3.30 and 3.31. The remaining solvents in this
category 3.19, 3.21, 3.23, 3.24, 3.25, 3.26, 3.28, 3.32 and 3.33, only display
moderate swelling, with 3.19 and 3.28 displaying what could be considered as
borderline poor swelling. Essentially no swelling is observed for the remaining polar
aprotic 3.16-3.18, apolar aprotic 3.34-3.35 and polar protic 3.36-3.40 solvents,
along with the ionic liquid 3.41. Notably, good swelling is observed for 3.42, the
only nitrogen-containing polar aprotic solvent, which produced results comparable
to the conventional reference solvents 3.43-3.45. This could probably have been
predicted, due to the structural similarities between 3.42 and 3.43.
Rather surprisingly, ParaMax, which only differs to Merrifield in regards to
functionalisation being exclusively in the para-position, rather than being a mixture
of ortho/para, displays good swelling in a much wider range of solvents. In this
case, the moderately polar aprotic solvents 3.19-3.32 all display good swelling for
ParaMax resin. However, very little difference is observed for the remaining solvents,
with essentially identical results obtained between Merrifield and ParaMax. The
exceptions being that moderately better swelling of ParaMax is observed in solvents
3.16, 3.33 and 3.34 which had been unable to swell Merrifield resin, along with
3.42 which now displays better swelling than the reference solvents 3.43-3.45.
Finally, JandaJel, which has been designed to be a higher swelling PS resin, through
the use of a more flexible 1,4-di(4-vinylphenoxy)butane cross-linker, generally
displayed a similar trend to Merrifield resin. Again, the moderately polar aprotic
solvents 3.19-3.35 appeared to be most suitable for this resin. Whilst solvents 3.20,
3.22, 3.27, 3.29, 3.30 and 3.31 all had displayed good swelling for Merrifield resin,
a significant enhancement in total swollen volume was now observed. Additionally,
solvents 3.21, 3.23, 3.24, 3.25 and 3.26 can now be regarded as good solvents,
rather than just moderate ones. It is also worth noting that a similar enhancement
was not observed for solvents 3.19 and 3.28, but solvents 3.34 and 3.35, which
had not previously swollen Merrifield resin, could now be considered good swelling
solvents. Ever so slight swelling was also observed for the polar protic solvents
3.36-3.39, although this is so minimal it is unlikely to be practical.
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Figure 3.11: Swelling of Merrifield Resin.
Figure 3.12: Swelling of ParaMax Resin.
Figure 3.13: Swelling of JandaJel Resin.
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Figure 3.14: Swelling of TentaGel Resin.
Figure 3.15: Swelling of ArgoGel Resin.
Figure 3.16: Swelling of HypoGel 200 Resin.
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Figure 3.17: Swelling of NovaGel Resin.
Figure 3.18: Swelling of ChemMatrix Resin.
Figure 3.19: Swelling of SpheriTide Resin.
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The next series of figures (Figure 3.14-3.17) deal with the PS-PEG grafted resins
(TentaGel, ArgoGel, HypoGel 200 and NovaGel), which differ predominantly
through the quantity of PEG incorporated into the resin bead. Firstly, TentaGel,
which is between 50-70% PEG (w/w) was found to swell in a wide range of solvents,
but only to a moderate degree. Swelling of more than 4.0 ml g-1 was only observed
for solvents 3.22 and 3.30. The remaining solvents, with the exception of 3.35,
3.37, 3.38 and 3.39, could only swell the resin to between 2.0-4.0 mL g-1. The next
PS-PEG grafted resin, ArgoGel (Figure 3.15), was found to perform much better in
swelling tests. It displayed an ability to swell in a much broader range of solvents
than any of the other PS-PEG resins, with the majority of polar aprotic 3.17, 3.18,
and 3.42, moderately polar aprotic solvents 3.20, 3.22, 3.23, 3.26, 3.27, 3.29,
3.30, 3.32, 3.33 and para-cymene 3.34 all producing good swelling. These results
are consistent with ArgoGel possessing the highest quantity of PEG (67-82% w/w)
of the PS-PEG resins. Four other oxygenated polar aprotic solvents 3.16, 3.19,
3.24 and 3.25 swelled the resin, but only to just below 4.0 mL g-1, as did 3.36 and
the ionic liquid 3.41. The poor solvents were rather similar to those observed with
TentaGel with 3.28, 3.31, 3.35 and the polar protics 3.38 and 3.39 all producing
a swelling value of less then 2.0 mL g-1. HypoGel 200 (Figure 3.16) and NovaGel
(Figure 3.17) both gave very similar results to those observed for TentaGel, although
3.27 and 3.29 gave good swelling of HypoGel 200 whilst they only swelled TentaGel
to just below 4.0 mL g-1. For NovaGel the polar aprotic solvent Cyrene 3.18 swelled
the resin to over 4.0 mL g-1, whilst it swelled TentaGel to just below 4.0 mL g-1.
Notably, TentaGel, HypoGel 200 and Novagel were all functionalised in different
ways (Fmoc-protected amine, carboxylic acid and benzylic alcohol) yet had very
similar swelling properties in the green solvents, which suggests that the observed
variation in swelling with solvent is a function of the resin backbone and not of the
way in which it is functionalised. This is important for synthetic applications as
the nature of the functionality attached to the resin will change during solid-phase
synthesis. This also suggests that the grafting of PEG-chains to a PS core only
has an appreciable benefit when very high values by weight (w/w) are used, hence
ArgoGel displayed the best swelling properties of all the PS-PEG grafted resin.
The final two figures (Figures 3.18 and 3.19) deal with the two resins that contain
no PS. ChemMatrix resin (Figure 3.18) was found to swell in a wide range of green
solvents. The only solvents that were found not to be suitable for ChemMatrix were
3.21, 3.24, 3.25, 3.28, 3.31, 3.35, 3.37 and 3.38. The incompatibility of this resin
with aromatic solvents is understandable, due to the lack of aromatic functionality
within the resin. The lack of swelling in the more non-polar ketones and esters 3.21,
3.24 and 3.25, when very similar but more polar ketones 3.19, 3.20 and ester 3.23
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swell the resin well probably reflects the polar nature of the PEG-based polymer.
Curiously, whilst 3.37 and 3.38 were poor solvents for ChemMatrix, good swelling
was observed in both the more polar alcohol 3.36 and the less polar one 3.39.
The SpheriTide resin displayed rather disappointing results for the majority of
solvents investigated. Only 3.42 was able to swell the resin to an acceptable degree,
though 3.22, 3.36 and 3.37 did swell it to just below 4.0 mL g-1. The SpheriTide
resin was functionalised with an Fmoc-protected linker, which is exactly the same
functionality as that present for TentaGel resin. Comparison of both results (Figures
3.14 and 3.19) demonstrate very different behaviour for these two resins across the
range of green solvents, again suggesting that interactions between the solvent and
polymer backbone overwhelmingly determine the resin swelling, not the nature of
the functionalisation.
Comparison of the swelling data obtained (Figure 3.11-3.19) shows that
cyclopentanone 3.22 and dimethyl isosorbide 3.30 were able to swell all of the
PS, PS-PEG and PEG based resins to more than 4.0 ml g-1. NBP 3.42 was the
only solvent that was able to swell the PA based SpheriTide resin. In contrast,
ethanol 3.37 and isopropanol 3.38 were not able to swell any of the resins to 4.0
mL g-1 and ionic liquid was only suitable for use with ChemMatrix resin. Overall,
ChemMatrix and ArgoGel resins appear to have the best overall compatibility with
a range of green solvents. Additionally, this swelling study has identified at least
one solvent that is able to swell each of the common SPOS resins to over 4.0 ml g-1,
making them a promising replacement for the conventional SPOS solvents.
103
Chapter 3. Greener Solvents for Solid-Phase Organic Synthesis
3.2.2 Computational Prediction of Resin Swelling
In an effort to better understand and be able to predict resin swelling in green
solvents, a modelling study was undertaken using the HSPiP software. In order to
do this a training set of 18 solvents were selected which included 3.16-3.19, 3.22,
3.23, 3.26, 3.27, 3.32-3.38 along with the control solvents 3.43-3.45. The ability
of these solvents to swell each resin was quantified in the previous section (Section
3.2.1). HSPiP however requires that this data is input in the form of a series of
ranked groups, rather than as raw swelling data. It also requires that two solvents
occupy the highest swelling group. For each resin, the solvents were divided into n
groups based on their ability to swell the resin. Not knowing the number of groups
that would be optimal, values for n = 4-6 were investigated. Thus, the difference
between the maximum (Smax) and minimum (Smin) observed swelling for a given
resin with these 18 solvents was divided by n and the solvents allocated to groups
based on their ability to swell a particular resin, given by equation 3.7. Where n =
4, 5 or 6 and a = 1 to n. Full data for the grouping allocation can be found in the
appendix.
Group "a" lower boundary = Smax − a
(
Smax − Smin
n
)
(3.7)
The HSPiP software can then be used to analyse the solvents in terms of their
ability to swell the resin. A three-dimensional plot based on the dispersion (D),
hydrogen-bonding (H) and dipolar (P) energies (MPa0.5) of the solvents is then
generated, which predicts optimal solvent parameters based on the best fit of the
data, according to the Hansen fitting algorithm. This is represented by a green
sphere of radius R0, which indicates the area in which suitable solvents for resin
swelling should exist in Hansen space, as shown in Figure 3.20 for Merrifield resin
with n = 5 (plots for all resins with n = 4, 5 and 6 can be found within the appendix).
In this plot, the centre of the green sphere represents the optimal HSP values, as
predicted by HSPiP, with the blue circles being all the rank 1 (highest swelling)
solvents, whilst the red squares are all the other solvents in the training set.
104
3.2. Results and Discussion
Figure 3.20: HSPiP prediction for Merrifield resin based on n = 5 groups.
Table 3.2 summarises the numerical values obtained for all nine resins investigated
in the previous swelling experiments, using four, five or six groups (n = 4, 5 or 6).
As previously mentioned, the HSPiP software requires that there be at least two
solvents allocated to the highest swelling group (rank = 1). However, in a number
of cases one solvent was able to swell the resin much better than any other, meaning
the software is unable to adequately perform the fitting. This was found to be the
case with ArgoGel, where CH2Cl2 3.45 produced a much greater swelling than any
other solvent. In addition, as the value of n increases, it becomes increasingly likely
that there will be only one solvent in the highest swelling group. This was found to
be the case for TentaGel, ArgoGel, NovaGel and ChemMatrix where n = 6. These
issues were overcome by giving equal weighting to solvents found in groups 1 and 2
before allowing the HSPiP software to perform the best fit algorithm.
Table 3.2: HSPiP resin swelling predictions.
n = 4 n = 5 n = 6
Resin D P H R0 D P H R0 D P H R0
Merrifield 17.48 8.51 4.27 3.3 17.47 8.27 4.77 4.9 17.65 11.24 9.43 3.0
ParaMax 17.68 7.87 7.71 4.0 17.68 7.87 7.72 4.0 17.68 7.82 7.75 4.0
JandaJel 17.13 9.34 4.09 3.4 17.30 9.16 4.09 3.4 16.97 10.23 2.48 5.5
TentaGel 17.76 10.88 6.49 1.7 17.72 10.82 6.41 1.7 17.69* 10.78* 6.35* 1.7*
ArgoGel 18.37* 8.44* 8.44* 3.3* 17.68* 10.93* 6.40* 1.7* 17.71* 10.81* 6.40* 1.7*
HypoGel 17.33 11.72 9.05 4.9 17.57 12.02 8.68 3.9 17.78 12.27 9.10 4.9
NovaGel 17.78 11.37 9.57 4.7 17.21 10.87 10.22 3.0 17.90* 12.10* 9.07* 4.9*
ChemMatrix 18.58 9.89 7.04 1.0 18.60 9.82 6.98 1.0 17.80* 11.20* 9.27* 3.2*
SpheriTide 17.45 11.10 9.61 3.0 17.14 11.33 9.35 3.0 17.26 11.24 9.43 3.0
*Value calculated giving equal weighting to solvents in groups 1 and 2
Analysis of the data in Table 3.2, suggests the best predictions are obtained when n
= 5, in terms of having the lowest values of R0 (in all cases except Merrifield resin)
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and optimal values of D, P and H (DPH) that are comparable to the results for both
n = 4 and 6. Comparison of the predicted optimal parameters for swelling of PS and
PEG based resins were then be compared to the DPH parameters for ethylbenzene
(D = 17.8, P = 0.6 and H = 1.4) and ethylene glycol dimethyl ether (D = 15.4, P
= 6.3 and H = 6.0) as models for the monomer units. It was observed that for PS
resins, the dispersion energies (D) of the model monomer unit and predicted optimal
solvents matched quite well (17.1-17.7 to 17.8), but the dipolar (P) and hydrogen-
bonding (H) energies were very different. For the PEG based ChemMatrix resin,
none of the energy parameters were a particularly good fit. This indicates that it
is not possible to assume “like swells like” on the basis of the monomer unit, as the
resins are clearly quite distinctly different to the monomer in terms of HSP values.
Having determined the DPH values for an optimal solvent for each resin, the HSPiP
software can then be used to predict other suitable solvents from a database of over
1200 compounds. The generated list was then ordered according to the root-mean
squared relative distance (Ra), as compounds closest to optimal in three-dimensional
space would be most likely to be able to adequately solvate the resin. The solvents,
excluding those initially utilised within the training set, were then colour coded
green, amber or red, according to the latest version of the GSK green solvents
guide.16 Table 3.3 lists those green or amber solvents that were predicted to swell
at least 4 of these resins.
Table 3.3: Resin swelling predictions.a
Solvent
Resin 3.20 3.21 3.24 3.30 3.31 3.46 3.47
Merrifield 3.1 4.9 - 3.0 4.3 - -
ParaMax 4.4 6.2 6.5 0.8 5.3 4.3 -
JandaJel 2.8 5.0 7.9 4.0 5.0 7.0 -
TentaGel 4.1 7.1 8.7 3.9 7.2 7.3 8.5
ArgoGel 4.1 7.2 8.4 4.0 7.2 7.4 8.5
HypoGel 5.6 - - 5.1 - - 6.8
NovaGel 6.0 - - 4.7 - 6.6 4.7
ChemMatrix 5.6 - - 3.4 - - -
SpheriTide 5.4 - - 4.7 - - 5.6
a The number given for each solvent is its RMS (Ra) deviation from the DHP
parameters for an optimal solvent for the resin.
Glycerol triacetate 3.46 was found to be a very viscous solvent and this prevented
experimental determination of its ability to swell resins. Glycerol diacetate 3.47 is
only available as a mixture of 1,2- and 1,3-regioisomers, so it was also omitted from
experimental studies. The remaining solvents in Table 3.3 (3.20, 3.21, 3.24, 3.30
and 3.31) were included in the solvents used in the experimental determination of
resin swelling (Figures 3.11-3.19), which allowed the accuracy of the solvent selection
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predictions to be tested. The experimental swelling data as compared to the Ra
value of each solvent for each resin are shown in Figures 3.21-3.25. The data in
these figures is presented as a percentage of the maximum observed swelling for that
resin, to compensate for the fact that some resins swell more than others, which
allows the data to be compared. The equivalent data comparing the actual swelling
values with Ra for each resin can be found within the appendix.
Figure 3.21: Comparison of observed swelling in dimethyl isosorbide 3.30. Resins
are ranked from highest predicted swelling (left) to lowest (right) with the RMS
deviation of the solvent parameters for dimethyl isosorbide from those of an ideal
solvent given as a number above each bar.
Figure 3.22: Comparison of observed swelling in cyclopentyl methyl ether 3.31.
Resins are ranked from highest predicted swelling (left) to lowest (right) with the
RMS deviation of the solvent parameters for cyclopentyl methyl ether from those of
an ideal solvent given as a number above each bar.
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Figure 3.23: Comparison of observed swelling in butan-2-one 3.20. Resins are
ranked from highest predicted swelling (left) to lowest (right) with the RMS deviation
of the solvent parameters for butan-2-one from those of an ideal solvent given as a
number above each bar.
Figure 3.24: Comparison of observed swelling in 4-methylpentan-2-one 3.21. Resins
are ranked from highest predicted swelling (left) to lowest (right) with the RMS
deviation of the solvent parameters for 4-methylpentan-2-one from those of an ideal
solvent given as a number above each bar.
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Figure 3.25: Comparison of observed swelling in isopropyl acetate 3.24. Resins are
ranked from highest predicted swelling (left) to lowest (right) with the RMS deviation
of the solvent parameters for isopropyl acetate from those of an ideal solvent given as
a number above each bar.
It is apparent from Figure 3.21 that there is a good correlation between how close the
HSP values for dimethyl isosorbide 3.30 are to the HSP values for the ideal solvent
for each resin, and how much the resin was experimentally found to swell in 3.30.
The only exceptions are NovaGel for which the experimental swelling was 10-20%
higher than predicted and HypoGel 200. In the latter case dimethyl isosorbide 3.30
was actually found to swell the resin more than any solvent in the training set. This
suggests that the swelling of HypoGel 200 is influenced by one or more parameters
not adequately covered by the training set. All nine of the resins investigated were
predicted to swell in dimethyl isosorbide 3.30 on the basis of the HSPiP model,
experimentally all but SpheriTide were found to swell to more than 4.0 mL g-1.
A similar situation is observed for cyclopentyl methyl ether 3.31 (Figure 3.22). In
this case 3.31 is found to perform comparatively to NMP 3.43 in the swelling
of ParaMax, with the experimental result found to be about 30% higher than
would be predicted by the HSPiP study. Otherwise, the experimentally observed
swelling of the first five resins would appear to decrease as the Ra distance from the
optimal DHP values increases. For this solvent, only the PS based resins, Merrifield,
ParaMax and JandaJel were found to swell to more than 4.0 mL g-1.
The data for the resin swelling in butan-2-one 3.20 is more scattered, although a
general decrease in the percentage of maximum swelling as the Ra value increases is
observed (Figure 3.23). In Figure 3.23, the swelling of JandaJel appears to be very
low, and the swelling of HypoGel and NovaGel too high. However, this is largely a
feature of the swelling of these resins in other solvents affecting the results obtained,
when displayed as a percentage. There was actually very little difference in the
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range of swelling observed in 3.20 (2.3-4.8 mL g-1), which is largely responsible for
the scatter observed in Figure 3.23. Nevertheless, of the five resins with the lowest
Ra deviations for 3.20, four were found to swell to >4.0 mL g-1.
For 4-methylpentan-2-one 3.21 and isopropyl acetate 3.24 (Figures 3.23 and 3.25)
the Ra distances from the optimal DHP parameters in all the solvents were rather
large (>4.9). However, a general decrease in maximum swelling is observed with
increasing Ra values. This is particularly apparent for isopropyl acetate 3.24. For
both solvents, only two resins were found to swell to >4.0 mL g-1, which were
JandaJel and ParaMax.
Overall, the data obtained for resin swelling as predicted by the HSPiP software
(Figures 3.21-3.25) shows a good correlation between the degree of swelling and
Ra distance from optimal DHP values. This only holds true when differences in
swelling between resins is accounted for, by plotting the percentage of maximum
swelling. The trends observed suggests that the use of HSPiP can be valuable tool
for optimising swelling of SPOS resins on the basis of HSP values. The software has
also been shown to be a useful method for suggesting new or unusual green solvents
that would be suitable for SPOS.
3.2.2.1 Resin Swelling Prediction for Mixed Solvent Systems
To further investigate the use of HSPiP software in predicting resin swelling in green
solvents, its ability to predict mixed solvents systems capable of swelling resins was
investigated. The solvent optimisation within HSPiP was edited to contain solvents
3.16-3.41, except for 3.28 as this data was not available at the time. Optimal
solvent mixtures were then predicted for the ideal DPH parameters outlined for n
= 5 groups for each resin. This is done using the HSPiP software, which combines
solvent HSP values based on relative volume fractions to produce optimal values, in
a similar manner to that which was reported by Fields et al. in their investigation
into Hildebrand solubility parameters. The results of the mixed solvent optimisation
and corresponding swelling tests are summarised in Table 3.4.
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Table 3.4: Mixed solvent predictions for resin swelling.
Predicted Experimental
Resin Solvent 1 Solvent 2 Solvent 1 Solvent 2 Mixture
(%) (%) (mL g-1) (mL g-1) (mL g-1)
Merrifield 3.27 (52) 3.31 (48) 5.6 5.8 4.8
ParaMax 3.30 (95) 3.16 (5) 7.3 2.8 7.8
JandaJel 3.27 (75) 3.16 (25) 8.8 1.8 8.3
TentaGel 3.22 (84) 3.39 (16) 4.8 1.8 3.8
ArgoGel 3.22 (84) 3.39 (16) 5.8 1.8 5.8
HypoGel 200 3.22 (91) 3.40 (9) 4.8 1.8 5.3
NovaGel 3.22 (65) 3.37 (35) 4.8 1.8 4.3
ChemMatrix 3.18 (80) 3.30 (20) 8.3 7.8 8.8
SpheriTide 3.22 (71) 3.37 (29) 3.8 3.8 3.8
In five cases (JandaJel, TentaGel, ArgoGel, NovaGel and SpheriTide), the optimal
predicted solvent mixture were found to experimentally swell the resin to an amount
that was between or the same as the swelling observed for the individual solvents.
As would be expected in the absence of any cooperative effects between the two
solvents. However, in three cases (ParaMax, HypoGel 200 and ChemMatrix) the
predicted solvent mixture was found to swell the resin more than either solvent
individually, and in one case (Merrifield) the predicted optimal solvent was found
to swell the resin less than either solvent individually. These results could not have
been predicted just on the basis of the swelling observed by the solvent components
alone and are suggestive of positive or negative effects involving both solvents and
their interactions with the resin. The outcome of this investigation is suggestive
that HSPiP is able to make reasonable predictions on the swelling ability of mixed
solvent systems that are not intuitively obvious.
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3.2.3 Solid-Phase Ugi Reaction
In order to experimentally validate the predictions from the resin swelling
experiments, the Ugi multicomponent reaction was investigated, in the hope that
the reaction would be inhibited when a solvent was used that was deemed unsuitable
for the solid support. The Ugi reaction, is a four component condensation between
an amine, a carboxylic acid, an isocyanide and either an aldehyde or ketone, to
produce an α-acylamino amide.179 It was selected as a suitable test reaction on the
basis that it is pharmaceutically relevant, is known to be tolerant to a wide variety
of solvents and both solution- and solid-phase variants have been reported numerous
times within the literature.180
Two resins, Merrifield and ChemMatrix were chosen, along with two green solvents,
methanol 3.36 and 2-MeTHF 3.27. Methanol 3.36 was chosen over other
potentially green alcohols as it is a preferred solvent for solution-phase Ugi reactions.
This is due to the poor solubility of the Ugi products in this solvent, but good
solubility of the starting reagents.180 Based on the resin swelling results obtained
for this combination of resins and solvents (Figure 3.11 and 3.18), it would be
predicted that for a Merrifield resin-supported Ugi reaction, 2-MeTHF 3.27 would
be a much better solvent than methanol 3.36. This is because methanol 3.36 was
observed to be an unsuitable solvent for Merrifield resin. As for the ChemMatrix
supported reaction, both solvents would be expected to perform similarly, due to
both producing what can be regarded as good swelling.
Initially, the solution-phase Ugi reaction was performed in the two solvents, in order
to test the suitability of 2-MeTHF and obtain comparable yields in the absence
of any resin swelling effects (Scheme 3.4). The Ugi multicomponent coupling
was carried out between cyclohexyl isocyanide 3.48, pentanal 3.49, benzoic acid
3.51 and benzhydrylamine 3.50, in either 2-MeTHF 3.27 or MeOH 3.36. The
benzhydrylamine 3.50 was used in an effort to mimic the Rink amide linker that
would eventually be used for the solid-phase variant, in order to better compare
the solution- and solid-phase reactions. After 1.5 hours at 28 ◦C the intermediate
product 3.52 was obtained in almost identical yields (75-79%) in both solvents,
suggesting that when performed in solution the solvent has little influence on the
reaction. The benzhydrylamine protecting group was then removed in neat TFA,
producing the α-acylamino amide 3.53 in moderate to good yield, resulting in yields
of 38% and 50% for MeOH 3.36 and 2-MeTHF 3.27 respectively, over the two steps.
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Scheme 3.4: Solution-phase Ugi reaction in MeOH and 2-MeTHF.
In order to then perform the Ugi reaction upon the solid-phase the benzhydrylamine
was exchanged for either the Merrifield or ChemMatrix resin, functionalised with a
Rink amide linker (Scheme 3.5). Commercial resins supplied as the Fmoc-protected
Rink linker were first deprotected using 20% v/v piperidine in DMF. The Ugi
reaction was then performed in a similar manner to the solution-phase approach,
coupling the resin supported amine 3.54, benzoic acid 3.51, pentanal 3.49 and
cyclohexyl isocyanide 3.48 for 16 hours at room temperature, to produce the
intermediate 3.55. This reaction was performed in both MeOH 3.36 and 2-MeTHF
3.27 for both Merrifield and ChemMatrix resins. The intermediate 3.55 was then
cleaved from the resin using TFA in CH2Cl2, to yield the α-acylamino amide 3.56,
following purification by flash column chromatography. DMF and CH2Cl2 were used
for the initial resin swelling, Fmoc-deprotection and substrate cleavage as they are
known to be suitable solvents for both resins. The reason for this was to ensure
that the isolated yields for the α-acylamino amide 3.56 were a consequence of the
solvent used for the coupling reaction. All solid-supported syntheses were carried
out in duplicate to ensure that the results were reproducible, the outcomes of which
are summarised in Table 3.5
Scheme 3.5: Solid-phase Ugi reaction upon Merrifield and ChemMatrix resins in
MeOH and 2-MeTHF.
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Table 3.5: Summary of results for the solid-supported Ugi reaction upon PS- and PEG-based
resins in MeOH and 2-MeTHF.
Resin name Capacitya (mmol g-1) Solvent Yieldb 3.56 (%)
Merrifield 1.0 2-MeTHF 27 and 36
Merrifield 1.0 MeOH 3 and 4
ChemMatrix 0.49 2-MeTHF 52 and 57
ChemMatrix 0.49 MeOH 30 and 32
a Obtained from the manufacturer’s certificate of analysis and checked by CHN analysis.b
Isolated yields after purification by column chromatography from two separate reactions.
It is evident from the data summarised in Table 3.5, that when the solid-phase
Ugi reaction is performed upon a Merrifield resin the average isolated yield is
approximately ten times higher for 2-MeTHF 3.27 than MeOH 3.36. This is
consistent with the hypothesis that the outcome of the reaction would be dependent
on the ability of the solvent to adequately solvate the solid support, as 2-MeTHF
3.27 was shown to be a good solvent for Merrifield resin, whilst MeOH 3.36 was
shown to be a poor solvent (Figure 3.11). In contrast, for reactions carried out upon
a ChemMatrix resin, the average yields are remarkably similar to the results obtained
for the solution-phase control reactions (Scheme 3.4). This was to be expected, as
both solvents were found to adequately solvate ChemMatrix resin (Figure 3.18).
Evidently, the results obtained from the solid-supported Ugi reaction verify that the
experimentally determined resin swelling results are indicative of whether a green
solvent will (or will not) be suitable for SPOS on a particular resin.
3.3 Conclusions
When analysed from a green perspective SPOS has great potential to simplify
reaction work-up and purification. However, solvent will often make up the majority
of waste generated from a given synthetic transformation, and with SPOS typically
being performed in highly undesirable solvents, if SPOS is to be widely utilised this
must be addressed. This chapter has identified that the use of green solvents for
SPOS has seen rather little investigation when compared to the parent methodology
SPPS, that was investigated in the previous chapter (Chapter 2). In fact, only two
examples could be found within the literature that explicitly utilised what could be
regarded as a green solvent. For this reason, an investigation into the suitability of
a range of green solvents for SPOS was planned.
Solvent choice in SPOS is however rather important, as adequate solvation of the
solid support is critical for a successful synthetic transformation. This prerequisite
is most often investigated within the literature by quantifying the ability of the
solvent to swell the polymeric support. The ability of a range of green solvents to
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swell a number of common SPOS resins has therefore been investigated, by simply
measuring the increase in volume occupied by the resin following exposure to a
particular solvent. This investigation has identified a potentially suitable green
solvent for each resin, on the basis of its ability to swell the resin to >4.0 mL g-1.
In an effort to better understand and predict the ability of a green solvent to swell
SPOS resins a computational approach to modelling resin swelling was performed,
using the HSPiP software. The experimentally determined swelling data was
converted to data suitable for HSPiP, through the use of a ranking system, based on
the solvents ability to swell a particular resin. This was determined by dividing the
swelling range into a number of groups (n), with n = 5 being found to be optimal.
HSPiP could then be used to determine the best fit of the swelling data, predicting
both the region in which suitable solvents would exist within HSP space, along with
optimal DPH values.
This data could then be used to predict optimal solvents for a particular resin,
on the basis of the calculated DPH values. A number of suitable green solvents
that may not have been intuitively obvious choices prior to the investigation were
then identified. Overall, HSPiP was found to give fairly good predictions, as a plot
of maximum observed swelling for each resin was generally found to decrease as
distance from optimal DPH values increased (increasing Ra values). Additionally,
HSPiP was shown to be able to predict suitable mixed solvent systems by combining
DPH values according to volume ratios.
Finally, this data has been experimentally verified using the solid-supported Ugi
reaction. The multi-component coupling was performed upon ChemMatrix and
Merrifield resins, in both methanol 3.36 and 2-MeTHF 3.27. The results obtained
indicate that the ability of a solvent to swell a polymer support is paramount to
the success of a reaction, as the yields obtained for the α-acylamino amide product
were shown to be severely inhibited when an unsuitable solvent/resin combination
was used.
A number of suitable green solvents have therefore been identified for a range of
SPOS resins on the basis of their ability to swell the resin. The results have been
validated using both a computational and experimental approach.
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4.1 Introduction
The remaining chapters will now deal with the second aim of this thesis, on
improving the sustainability of polymer synthesis. As was discussed within
the introduction (Chapter 1) synthetic polymers have become ubiquitous in
modern society, finding widespread application in packaging, building materials and
consumer products, to name but a few. Consequently, there is a growing demand
for these materials, with synthetic polymers currently produced on a scale of more
than 300 million metric tonnes annually, the vast majority of which are derived from
non-renewable petrochemical feedstocks.28 This accounts for approximately 8% of
the global crude oil and gas production, the second largest sector behind fuels.29
However, fluctuating petroleum prices and environmental concerns, pertaining to
their depletion and climate change, is driving interest in the production of synthetic
polymers from renewable and sustainable resources.
At present, only 1.7 million metric tonnes (ca. 0.57%) of synthetic polymers can
be regarded as bio-derived, but market analysis has suggested that as much as
90% of the current global demand for these polymers could be realised with bio-
based alternatives.32,28 Consequently, there has been a rapidly growing interest in
the synthesis of bio-derived polymers. This is generally achieved using two distinct
approaches, either the synthesis of monomers that are chemically equivalent to those
derived from petrochemical sources (bioreplacement), or the development of novel
monomers from biomass or platform molecules (bioadvantage).33 It is the latter that
has formed the basis of the work reported herein.
North and co-workers have previously investigated the synthesis of novel
functionalised bio-based molecules via facile green synthetic routes, with a particular
focus the molecules itaconic anhydride 4.1 and furfuryl alcohol 4.2 (Figure
4.1).181 These structures represent highly promising platform molecules as they
are both abundantly available from biomass.182 Itaconic anhydride 4.1 is readily
obtained from citric acid 4.3, which undergoes a simultaneous decarboxylation and
dehydration when distilled.183 Currently, citric acid 4.3 is produced on over a one
million ton scale per annum through the fungal fermentation of glucose-containing
sugars, using Aspergillus niger.184,185 Furfuryl alcohol 4.2 is obtained through the
hydrogenation of furfural 4.4, which is currently produced on a scale of over 200,000
tons per annum, through the acid catalysed dehydration of 5-carbon sugars, such as
pentoses, which are readily obtained from agricultural waste.186
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Figure 4.1: Structures of the bio-based platform molecules itaconic anhydride 4.1,
furfuryl alcohol 4.2, citric acid 4.3 and furfural 4.4.
In their initial investigation Bai et al. were interested in the functionalisation of
itaconic anhydride 4.1 with furanic structures, such as furfuryl alcohol 4.2, to
produce bio-based itaconate esters of type 4.5 (Scheme 4.1). This interest was
motivated by the fact that the radical polymerisation of itaconic esters is well
explored within the literature. However, simple poly(alkyl)itaconates typically
possess glass transition temperatures (Tg) below room temperature, significantly
limiting their potential applications.187,188 In contrast, poly(benzyl)itaconates,
derived from aromatic itaconic esters, are reported to have much higher Tg values,
but are much less easily produced in a sustainable manner and have received little
investigation compared to the alkyl equivalents.189 Therefore, Bai et al. sought to
investigate the synthesis of poly(benzyl)itaconates from furanic itaconic esters in an
effort to produce a fully bio-based polymer possessing practical Tg values.
Scheme 4.1: Proposed synthesis of furanic itaconate esters 4.5 from itaconic
anhydride 4.1 and furfuryl alcohol 4.2 by Bai et al.
The reaction between itaconic anhydride 4.1 and furfuryl alcohol 4.2 did not
however produce the target itaconic esters 4.5, but instead produced the unexpected
oxanorbornene-lactone species 4.7 (Scheme 4.2). It was eventually determined that
the oxanorbornene-lactone 4.7 is formed via a tandem Diels-Alder-lactonisation
reaction between itaconic anhydride 4.1 and furfuryl alcohol 4.2. Rather
surprisingly, Bai et al. could not find any evidence for this reaction ever having
been previously reported, even though Diels-Alder reactions of the analogous maleic
anhydride and furans have been extensively explored.190 Moreover, both furfuryl
alcohol 4.2 and itaconic anhydride 4.1 were demonstrated to be suitable dienes and
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dienophiles, respectively, in the first two reports of the Diels-Alder reaction from O.
Diels and K. Alder almost 90 years ago.191,192
Scheme 4.2: Proposed tandem Diels-Alder-lactonisation for the formation of
oxanorbornene-lactone 4.7.
It was therefore even more remarkable that the same reaction was reported almost
simultaneously and independently by Pehere et al.183 In their investigation Pehere
et al. had been studying the thermodynamics of the Diels-Alder reaction of
itaconic anhydride 4.1 with various furans, with an aim to prepare a range of novel
reactive monomers for sustainable polymer synthesis. This investigation was planned
because the Diels-Alder reactions of furans is typically rather challenging, due to the
unfavourable enthalpic change upon product formation. This often results in low
equilibrium formation of the target [4+2] adduct, due to loss of heteroaromaticity
in the diene and ring strain in the oxanorbornene product.
Much like Bai et al., Pehere et al. then stumbled, rather serendipitously, upon the
oxanorbornene-lactone 4.7 after monitoring the reaction of itaconic anhydride 4.1
and furfural alcohol 4.2 over an extended period of time. Initially the reaction was
heated to 55 ◦C and only monitored for 10 minutes using 1H NMR spectroscopy.
Pehere et el. were then able to observe four intermediates, which were subsequently
identified as the equilibrium isomeric anhydrides 4.8-4.11 resulting from the Diels-
Alder step (Scheme 4.3). It was not until the sample was revisited a week later than
a unexpected fifth product was observed in approximately 15% yield.
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Scheme 4.3: Reaction equilibrium between itaconic anhydride 4.1, furfuryl alcohol
4.2, the isomeric anhydrides 4.8-4.11 and oxanorbornene-lactone 4.7.
This fifth product was eventually identified as the oxanorbornene-lactone 4.7,
formed through the ring-opening of the anhydride when in the 12-prox-exo 4.9
configuration. Pehere et al. reasoned that formation of the single oxanorbornene-
lactone 4.7 was a result of all isomeric anhydrides 4.9-4.11 existing in a rapid
dynamic equilibrium with itaconic anhydride 4.1 and furfuryl alcohol 4.2. The
driving force for the selective formation of oxanorbornene-lactone 4.7 then results
from ring opening of the anhydride being favoured for the 12-prox-exo 4.9
intermediate over the 12-prox-endo 4.8, and the resulting product crystallising from
the reaction solution.183
Rather interestingly, whilst reported independently, both Bai et al. and Pehere
et al. acknowledged that oxanorbornene-lactone 4.7 represents a highly promising
bio-derived molecular framework amenable to derivatisation for the synthesis of
sustainable polymers. This is because the Diels-Alder reaction is 100% atom
economical, is performed under ambient conditions, and occurs in the absence of
solvents, catalysts or other auxiliaries. The oxanorbornene-lactone 4.7 is also formed
exclusively with the endo configuration. Hence, in their initial report Bai et al.
went on to investigate the oxanorbornene-lactone 4.7 in Ring-Opening Metathesis
Polymerisation (ROMP). However, as the free acid, oxanorbornene-lactone 4.7 failed
to undergo ROMP using any of the commercially available Grubbs catalysts (G1,
G2 or G3). It was therefore deemed necessary to protect the acid functionality
through a Fischer type esterification using methanol, producing the corresponding
ester derivative 4.13, which was isolated in an excellent 77% yield (Scheme 4.4).
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Scheme 4.4: Esterification of oxanorbornene-lactone 4.7 with methanol to produce
methyl ester 4.13.
Methyl ester 4.13 was subsequently investigated for ROMP. Bai et al. found that
whilst G1 catalyst was inactive when using 4.13, both G2 and Hoveyda-Grubbs
HG2 were able to facilitate ROMP, producing the target homopolymer 4.14 over
the course of 72 hours (Scheme 4.5). The authors report that this is the first
example of ROMP of a norbornene or oxanorbornene molecule where the bridgehead
is substituted. Unfortunately though the resulting polymer was found to be insoluble
following reaction work-up through end-capping the polymer with ethyl vinyl ether
(EVE), meaning molecular weight data could not be determined using size-exclusion
chromatography (SEC).
Scheme 4.5: ROMP of methyl ester 4.13 to give homopolymer 4.14.
In an effort to overcome this Bai et al. went on to prepare a range of random
copolymers of the methyl ester 4.13 and a commercially available dimethyl endo-
cis-5-norbornene-2,3-dicarboxylate 4.15 monomer using ROMP (Scheme 4.6). The
resultant random copolymers 4.16 were now found to be soluble, provided a
minimum of 10% of monomer 4.15 was incorporated. SEC of these polymers
showed that they were obtained in good molecular weights (Mn = 9,500-63,200) with
narrow dispersities (Ð = 1.11-1.27). Additionally, a linear relationship was observed
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for copolymer molecular weight and monomer:catalyst ratio, which is indicative of
the polymerisation being a well-controlled chain growth polymerisation. Thermal
analysis by thermogravimetric analysis (TGA) and differential scanning calorimetry
(DSC) revealed the copolymers possessed high thermal decomposition temperatures
(T10% = 370 ◦C) and glass transition temperatures (Tg = 158-163 ◦C).
Scheme 4.6: ROMP of methyl ester 4.13 and commercial norbornene 4.15 to give
random copolymer 4.16.
Finally, in their initial report Bai et al. went onto investigate the influence of the
solvent on ROMP of this copolymer, as this is something that has begun to receive
a significant amount of interest in recent years and is particularly important in the
context of green chemistry.193 Previously the polymerisation has been carried out
in dichloroethane (CH2Cl)2, which is a fairly undesirable, due to it being highly
hazardous and regarded as a substance of very high concern under REACh.16 Bai
et al. therefore repeated the synthesis of copolymer 4.16 in various alternative
solvents, the results of which are summarised in Table 4.1. In the majority of
cases the results obtained indicated that (CH2Cl)2 was the most suitable solvent for
the synthesis of copolymer 4.16. The majority of alternative solvents gave rather
diminished molecular weights and in the case of THF and DMC poor dispersities
also. The results obtained for diethyl carbonate (DEC) were sightly more favourable,
but extended reaction times were necessary to obtain acceptable molecular weights.
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Table 4.1: SEC data obtained for the preparation of copolymer 4.16 in various solvents.
Solvent Mna Mwa Ðb
Calculated 21,700 - 1
DCE 21,500 23,700 1.11
EtOAc 2,300 2,400 1.08
THF 3,600 5,100 1.40
DMC 4,100 5,600 1.40
DEC 8,600 9,700 1.12
DECc 14,200 15,700 1.11
All polymerisations were carried out using a 50:50:1 molar ratio of
monomer:catalyst 4.13:4.15:G2 at room temperature for 24 hours.a molecular
weights were obtained by SEC in THF at 23 ◦C and calibrated relative to
polystyrene standards.b Ð = Mw/Mn.c Reaction time increased to 72 hours.
Bai et al. have since gone on to investigate a range of ester derivatives
of oxanorbornene-lactone 4.7 in a subsequent publication.194 This report was
particularly interested in the use of bio-based alcohols, in an effort to produce
wholly bio-derived ROMP homo- and co-polymers. Firstly, a range of aliphatic ester
4.13a-h derivatives were prepared in good to excellent yield, these were then subject
to homopolymerisation 4.17a-h under the optimal conditions reported previously
(Scheme 4.7). Much like the previous methyl ester, short chain esters were found
to be insoluble following polymerisation, it was eventually identified that at least
a C5 alkyl chain was necessary to produce soluble homopolymers. Those that
were found to be soluble however were obtained with good molecular weights (Mn
= 14,866-34,467) and narrow dispersities (Ð = 1.04-1.16). Additionally, thermal
analysis was found to be comparable to the previously reported copolymer 4.16,
with high decomposition (TD10%) (367-371 ◦C) and glass transition (Tg) (160-196
◦C) temperatures observed in most cases. A random copolymer of monomers 4.13a
and 4.13b was also prepared during this investigation, which was found to be rather
similar to the reported homopolymers.
Scheme 4.7: ROMP homopolymerisation of wholly bio-based ester monomers 4.13a-
h.
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The final part of the investigation into the use of wholly bio-derived ester monomers
4.13a-h sought to synthesise a block copolymer using ROMP. This was however
more troublesome than was first anticipated. Long reaction times meant it was
difficult to accurately judge the end-point of the first polymerisation, meaning
highly bimodal SEC traces were observed following polymerisation of the second
monomer 4.13b. This observation was attributed by the authors to be due to the
death of polymer chain ends following polymerisation. To overcome this, Bai et al.
monitored the polymerisation by 1H NMR spectroscopy. In doing this it was possible
to accurately judge the end-point of the first polymerisation, meaning the second
monomer 4.13b could be added slightly prior to 4.13a being fully consumed. In
turn, this produced the target block copolymer 4.19 in good molecular weight (Mn
= 10,857) and narrow dispersity (Ð = 1.08) following growth of the second block
(Scheme 4.8).
Scheme 4.8: Block copolymerisation of ester monomers 4.13a and 4.13b.
In summary, oxanorbornene-lactone 4.7 has been highlighted as a highly promising
bio-derived molecular framework for the synthesis of novel, 100% bio-based synthetic
polymers. To date, however, only the two reports from Bai et al. can be found in
the literature that utilise 4.7 within polymer synthesis, both of which focus on
derivatisation to the corresponding esters. These esters were then utilised in ROMP
producing a range of wholly bio-derived polymers in a well-controlled manner, with
SEC data confirming that they were formed with high molecular weights and narrow
dispersities. Thermal analysis also showed that in the majority of cases the polymers
posses high glass transition (Tg) and decomposition (T10%) temperatures.
The work herein therefore seeks to expand on these existing reports by investigating
the synthesis and polymerisation of the analogous amide derivatives. This however
presents a dilemma of sorts, as the major appeal of using 4.7 is that it is a
molecular framework that is 100% bio-based. It would therefore be counterintuitive
to functionalise 4.7 with petrochemically derived molecules, particularly when the
focus of this chapter is on improving the sustainability of polymer synthesis. Natural
sources of amines are however rather scarce, in fact there are only two main types,
chitin and amino acids.195 Chitin is the second most abundant polymer in the world
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after cellulose, commonly found in the shells of crustaceans, it is therefore unlikely to
be suitable for this investigation.195 Amino acids, and the corresponding peptides,
could however be a rather promising route to wholly bio-based amide derivatives
of 4.7, as the derivatisation of norbornenes using amino acids or peptides has
previously seen some investigation within the literature. Additionally, many of
these norbornene derivatives have been explored in the preparation of bioactive,
therapeutic and functional materials, which may be a viable and interesting avenue
for future investigations.196,197
4.1.1 Previous Reports of Amino Acid Derived Norbornenes
in ROMP
The use of amino acid derived norbornenes in ROMP was first reported in a series
of publications from Gibson, North and co-workers. In their initial report, Coles
et al. prepared a series of norbornene-imide monomers 4.20, from the equivalent
exo- or endo-himic anhydrides and either the (R)-, (S )- or racemic-alanine methyl
ester.198 Homopolymerisation using a molybdenum initiator 4.22 produced the
corresponding ROMP polymers 4.21 after 15-24 hours (Scheme 4.9). Analysis of
the polymers determined that they were produced with reasonably narrow molecular
weights, which were found to be comparable to the expected values. The polymer
backbone was also found to predominately consist of trans linkages (77-91%).
Finally, the polymers derived from optically pure monomers were found to retain
optical activity following ROMP, meaning they can be regarded as simple bio-derived
peptides in which the amide backbone has been replaced by an all carbon system.
In a follow up publication Biagini et al. has extended this work, investigating a
more diverse range of amino acids as the pendant side chains.199
Scheme 4.9: First reported example by Coles et al. for the ROMP of amino acid
derived norbornene-imides 4.20.
Subsequently, Biagini et al. have gone on to investigate the related peptide
derivatives. A series of exo- or endo-norbornene-imides prefunctionalised with
a glycine residue were treated with either an amino acid or dipeptide methyl
ester, to produce the corresponding di- or tri-peptide derivatives 4.23 in good
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yields.200 The polymerisation of each species using a range of molybdenum ROMP
initiators 4.25a-c was then investigated (Scheme 4.10). Analysis of the obtained
homopolymers 4.24 identified that they were comparable to the previously reported
amino acid derivatives. Optical activity was retained during the polymerisation
and the polymers were generally obtained with narrow dispersities (Ð = 1.05-1.60),
except for the highly hydrophobic species which were found to be insoluble in organic
solvents. Rather interestingly, Biagini et al. also observed that the cis/trans ratio in
the polymer backbone was directly influenced by the molybdenum initiator 4.25a-c
used, with increasing quantities of cis incorporation for increasing fluorination of
the ancillary ligands. This also had a direct influence on the reported Tg values,
which decreased with increasing cis content.
Scheme 4.10: ROMP of peptide methyl ester functionalised norbornene-imides 4.23
using molybdenum initiators 4.25a-c.
Biagini et al. have also reported that the polymerisation can be facilitated using
ruthenium based initiators, such as Grubbs 1st generation catalyst G1 (Scheme
4.11).201 This catalyst was particularly useful for the synthesis of homopolymers
4.27 when the amino acids were used as the free acids 4.26, rather than the methyl
esters reported previously, as the molybdenum based initiators were not tolerant
to the free acid. This was also only possible when the amino acid functionalised
norbornene-imide 4.26 had the exo-configuration. This is presumably due to the
acid lying much closer to the active catalytic species when in the endo-orientation,
inhibiting the metathesis cycle. Finally, Biagini et al. reported that a diverse
range of block-, tapered block- and random- copolymers could be prepared using
the aforementioned monomer/catalyst combinations.201,202
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Scheme 4.11: ROMP of amino acid functionalised norbornene-imides 4.26 using
Grubbs 1st generation catalyst G1.
More recently, Sutthasupa and co-workers have also broadly explored the use of
amino acid derived norbornenes in ROMP, differing to the monomers reported
by Gibson, North and co-workers in that they incorporate two chiral pendant
groups. Sutthasupa et al. first synthesised a series of norbornene monomers
of type 4.28, derived from the commercial cis-5-norbornene-endo-2,3-dicarboxylic
anhydride and the corresponding alanine, leucine or phenylalanine methyl esters.203
The homopolymerisation of these monomers using either G1 or G2 catalyst was
however not successful. This was reasoned on the grounds that the monomers were
derived from an endo-anhydride, as these are known to be less active than the
equivalent exo-monomers on the grounds of steric and electronic factors. Sutthasupa
et al. were eventually able to incorporate the monomers 4.28 into a copolymer 4.30
with norbornene 4.29 (Scheme 4.12). The results however were rather disappointing,
as polymerisation using G2 catalyst for 2 hours resulted in polymers with broad
dispersities (Ð = 2.0-4.7) in poor yield (2-54%).
Scheme 4.12: Copolymerisation of endo,endo-diamino methyl ester norbornene 4.28
and norbornene 4.29 using G2 catalyst.
Determined to improve on the results obtained for the diamino methyl ester
functionalised endo,endo-norbornene monomers 4.28 Sutthasupa et al. went on
to investigate the analogous monomers derived from the exo,exo- and exo,endo-
norbornenes.204 This time around G2 catalyst was able to furnish the desired
polymers 4.31 in good molecular weights (Mn = 7,300-18,600) and narrow
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dispersities (Ð = 1.1-1.4) in only 30 minutes (Scheme 4.13). However, yields after
this time were significantly better for the exo,exo- over exo,endo-norbornene.
Scheme 4.13: Homopolymerisation of diamino methyl ester derivatives of exo,exo-
and endo,exo-norbornene using G2 catalyst.
In a follow up report Sutthasupa et al. looked to extend the methodology to
the synthesis of self-assembling polymers derived from amino acid functionalised
norbornenes. Deprotection of the previously reported diamino methyl ester
norbornene 4.28 produced the corresponding diamino acid norbornene 4.32. This
was then found to smoothly undergo ROMP, but only for the monomers derived from
the exo,exo-norbornene, producing polymers in good molecular weight (Mn = 16,000-
30,000) and moderate dispersity (Ð = 1.20-1.70). Sutthasupa et al. then investigated
the synthesis of random- and block-copolymers using the diamino methyl ester
4.28 and diamino acid 4.32 norbornene monomers (Scheme 4.14).205 The block
copolymers are particularly interesting as they were found to form reverse micelles,
100 nm in diameter, in acetone, consisting of a hydrophilic core of poly(4.28) and
a hydrophobic shell of poly(4.32).205
Scheme 4.14: Synthesis of an amphiphilic block copolymer from diamino methyl
ester 4.28 and diamino acid 4.32 norbornene monomers.
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Following the reports of the aforementioned diamino derived norbornene monomers
Sutthasupa et al. have gone on to investigate a broader range of norbornene
structures incorporating amino acids. The most promising of these has been the
various derivatives where the amino acids are tethered to the norbornene via an
ester linkage to hydroxymethyl groups 4.33a-e (Figure 4.2). In the initial report
of this monomer species, 4.33a and 4.33b were found to polymerise using G2
catalyst incredibly rapidly, with complete consumption of the monomer observed
within 4 minutes, regardless of whether the monomer had an exo,exo- or endo,endo-
orientation.206 It was hypothesised that this is due to the additional distance from
the active site provided by the hydroxymethyl groups and the bulky t-Boc protecting
groups, meaning the pendant side chains are less able to inhibit polymerisation.
Figure 4.2: General structure of the hydroxymethyl functionalised norbornene
4.33a-e.
Sutthasupa et al. then investigated the unprotected variants of these amino acid
monomers 4.33c, by removing the bulky t-Boc protecting group. The results
obtained for the homopolymerisation of these monomers was rather poor though.
The exo,exo-norbornene produced polymers with moderate molecular weights (Mn
= 7,600) and reasonable dispersities (Ð = 1.39) once the quantity of catalyst relative
to the monomer was increased, the endo,endo-norbornene could not be converted
however.207 This is presumably due to catalyst deactivation through co-ordination
to the primary amine. Sutthasupa et al. therefore introduced a methyl group at this
position 4.33d, which significantly enhanced the results obtained, with the exo,exo-
norbornene now producing a polymer with good molecular weight (Mn = 12,500),
dispersity (Ð = 1.29) and in significantly improved yield (81%).
Attempts to then produce random copolymers of these monomers with the
previously reported diamino acid monomers 4.32 were found to produce some rather
interesting results. Copolymerisation of N -methyl-L-phenylalanine derived exo,exo-
disubstituted norbornene monomer 4.33e and the isoleucine derived exo,exo-
disubstituted norbornene diacid monomer 4.32 was carried out using a 1:1 feed
ratio using G2 catalyst (Scheme 4.15).208 Analysis of the polymerisation by 1H
NMR spectroscopy identified both monomers were consumed at the same rate,
a surprising result considering they were previously shown to have significantly
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different polymerisation rates. Analysis of the resultant polymer 4.34 confirmed
this, showing incorporation of 4.33e:4.32 in a 50:50 ratio.
Scheme 4.15: Acid-base assisted alternating copolymerisation of unprotected
diamino norbornene monomers 4.32 and 4.33e.
These observations are indicative of a rather unusual alternating copolymerisation
mechanism. This was confirmed using feed ratios of 2:1 and 1:2 of 4.33e:4.32, which
again produced polymers containing a 50:50 mixture of both monomers. Sutthasupa
et al. then determined that this alternating copolymerisation is a consequence of
a cooperative acid-base interaction between the two monomers, which is justified
on the basis of a control reaction using the corresponding methyl ester 4.28 not
producing an alternating copolymer with 4.33e.
Finally, Sutthasupa et al. investigated the synthesis of a number of block copolymers
using monomer 4.33e and the previously reported diamino acid 4.32 and methyl
ester 4.28 monomers, in various feed ratios (Scheme 4.16).209 Amphiphilic block
copolymers were then investigated for pH-dependent self assembly, with it being
found that micelles of block copolymer poly(4.32)-block -poly(4.33e) form in basic
media, consisting of a poly(4.33e) core and a poly(4.32) shell. These self
assembling block copolymers were then shown to be suitable for pH responsive drug
delivery, with a poly(4.33e)62-block -poly(4.28)38 block copolymer shown to release a
sample of the nonsteroidal anti-inflammatory indomethacin under acidic conditions.
Sutthasupa et al. have since gone on to explore a number of derivatives of the
aforementioned block copolymers in drug delivery in more recent publications.210
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Scheme 4.16: Block copolymer synthesis of unprotected diamino norbornene
monomers 4.32.
Maynard et al. have also shown an interest in the use of amino acid functionalised
norbornene polymers as therapeutic agents. Many extracellular matrix proteins
bind to cell surfaces through the short peptide sequence Arg-Gly-Asp (RGD). Since
cell attachment mediated by integrin-protein interactions influences cell survival,
differentiation, and migration, the RGD sequence and associated mimics have
therefore been investigated as therapeutics for tumour therapy.211 Maynard et
al. sought to produce synthetic norbornene polymers substituted with peptides
known to be potent cell-binding inhibitors. 5-Norbornene-exo-2-carboxylic acid was
functionalised with two known inhibitors (GRGDS and PHSRN), and an inactive
control peptide (GRGES). These monomers 4.35a-d were then polymerised using
G1 catalyst producing the target polymers in good molecular weight (Mn = 9,140-
12,000) and narrow dispersity (Ð = 1.30-1.37). The peptide protecting groups were
then removed from the polymer through treatment with TFA:TIPS:H2O to produce
the corresponding therapeutic peptide polymers 4.36a-d (Scheme 4.17).
Scheme 4.17: Synthesis of homo- and co-polymers with pendant bioactive
oligopeptides by ROMP.
The ability of these peptides to inhibit human foreskin fibroblast cell adhesion
to fibronectin coated surfaces was then investigated. The control sequence 4.36c
was found to be completely inactive, along with PHSRN sequence 4.36b which is
known to be inactive unless closely bound to an RGD containing sequence, such
as GRGDS. The polymer derived from the known inhibitor 4.36a was found to
be 750% more active than the free GRGDS peptide. Additionally, incorporation
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of the synergistic PHSRN to this sequence, as a random copolymer 4.36d, was
found to be 3300% more potent than the GRGDS peptide.212 The significant
enhancement observed further iterates that the synthesis of norbornene derived
polymers containing pendant amino acid and peptide side chains is a viable avenue
for the development of novel therapeutics.
It is therefore evident that the use of amino acid functionalised norbornene
monomers has been widely explored in the context of ROMP. A number of
examples have demonstrated that they produce well controlled polymers in good
molecular weight and with narrow dispersity, in the presence of either molybdenum
or ruthenium catalysts. However, orientation of the pendant side arms of the
norbornene has been shown to be an important consideration, as the endo-
norbornene has been found to be much less active than the exo-orientation,
particularly when the unprotected amino acid is used. Additionally, the distance of
the amino acid from the catalyst active site appears to have a major influence on the
polymerisation rate. These may be important considerations for the incorporation
of amino acids in the bio-derived framework 4.7 as it is formed exclusively with the
endo-orientation. Finally, a few interesting reports have investigated the application
of deprotected amino acid or peptide functionalised norbornene copolymers as
therapeutics and functional materials.
4.1.2 Chapter Aims
The remainder of this chapter will therefore deal with further investigating the
novel oxanorbornene-lactone 4.7 reported by Bai et al. and Pehere et al., for the
synthesis of novel bio-based polymers. Bai et al. have previously shown that ester
derivatives of 4.13a-h have produced ROMP polymers in good molecular weight
and dispersity. The analogues amide derivatives will therefore be investigated for
homopolymerisation using ROMP, and the corresponding polymers characterised by
SEC and thermal analysis. Particular attention will be paid to functionalisation of
4.7 with bio-based amines, such as amino acids or peptides, to yield wholly biomass
derived polymers. If successful the synthesis of random- and block-copolymers will
also be investigated, which may facilitate future investigations into the synthesis of
wholly bio-derived polynorbornenes as functional materials or therapeutics.
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4.2 Results and Discussion
4.2.1 Monomer Synthesis
To begin this investigation a number of tertiary amide monomers were synthesised in
the same manner as the previously reported esters.194 Acid 4.7 was first converted to
the corresponding acid chloride intermediate 4.37 through the use of oxalyl chloride
and catalytic quantities of DMF. The acid chloride was then treated with a number
of secondary amines 4.38a-k, to produce the corresponding tertiary amides 4.39a-
k, in good to excellent yields (Scheme 4.18). The structures of 4.39b, g and h have
also been confirmed by X-ray crystallography (Figure 4.3).
Scheme 4.18: Synthesis of tertiary amide monomers 4.39a-k from acid framework
4.7.
Figure 4.3: Ellipsoid representation of the crystal structures of monomers 4.39b, g
and h. The tetrahydropyrrole and butyrolactone of 4.39h were disordered and only
the major form of each is shown.
Due to the 100% bio-based nature of the monomer framework 4.7 it would have been
preferred that a broad range of bio-based amines could have been utilised. However,
as was discussed previously in section 4.1 this is rather difficult, as bio-based amines
are typically only readily available from either chitin or amino acids.195 For this
reason, a number of tertiary amide monomers from petrochemically derived amines
were first synthesised 4.39a-g. This was so that the ROMP procedure could be
first optimised for simple substrates, before using the potentially more complicated
amino acid 4.39h/i and peptide 4.39j/k derived monomers.
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It should also be acknowledged at this point as to why all the monomers investigated
are derived from secondary amines, producing a range of tertiary amides. This
makes little sense if the eventual aim is to utilise amino acids or peptides, because
the majority of proteinogenic amino acids are primary, which would yield secondary
amides using the procedure described above. The synthesis of secondary amides was
actually investigated in parallel with this study, but a rather unexpected result was
observed. Exposure of the intermediate acid chloride 4.37 to a primary amine, such
as butylamine, actually yielded two products (Figure 4.19). These were eventually
identified, using a combination of IR and HMBC spectroscopy experiments, as
the secondary amide 4.40 and the spirocyclic species 4.41. Definitive structural
conformation was eventually elucidated using X-ray spectroscopy (Figure 4.4). The
rather unusual nature of the spirocyclic species warranted further investigation,
which will be explored in much more detail within Chapter 5.
Scheme 4.19: Formation of the secondary amide 4.40 and spirocyclic imide 4.41
species from the acid framework 4.7.
Figure 4.4: Ellipsoid representation of the crystal structures of secondary amide
4.40 and spirocyclic imide 4.41 species.
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4.2.2 Polymerisation Optimisation
Having synthesised a range of tertiary amides 4.39a-k their applicability to ROMP
was investigated. The dibenzyl derived tertiary amide 4.39g was chosen as a suitable
model substrate for the initial investigation. Optimisation of the polymerisation
process was attempted using 1 mol% of commercial Grubbs catalyst (G1-G3),
in 1,2-dichloroethane ((CH2Cl)2) at various temperatures and concentrations.
Alternative solvents to (CH2Cl)2 were omitted from this investigation, as (CH2Cl)2
had previously been shown to be the most suitable solvent choice for the ester
derivatives.181 After 72 hours a sample was taken and analysed using 1H NMR
spectroscopy to determine conversion. The polymerisation was then quenched using
ethyl vinyl ether and the resulting polymer analysed by SEC, the results of this
optimisation are summarised in Table 4.2.
The polymerisation was first performed using identical conditions to those previously
reported for the esters.194 All three commercial Grubbs catalysts (G1, G2 and
G3) were investigated, with the polymerisation performed at room temperature
using 1 mol% of catalyst at a 0.1 M concentration (Entries 1, 9 and 11). Neither
Grubbs 1 or 3 were able to facilitate the polymerisation under these conditions,
with 0% conversion to the desired polymer 4.42g observed. Grubbs 2nd Generation
G2 catalyst however produced the target polymer 4.42g in a moderate 37%
conversion. This was further enhanced by performing the polymerisation at elevated
temperatures, with 82% of the monomer 4.39g converted at 30 ◦C and 91%
of monomer 4.39g converted at 40 ◦C (Entries 2 and 3). Diminishing returns
were observed when the temperature was elevated much beyond 50 ◦C, with
93% conversion of monomer observed for both 50 ◦C and 60 ◦C (Entries 4 and
5). Conversely, reducing the temperature down to 0 ◦C completely suppressed
polymerisation, with 0% conversion observed (Entry 6). In all cases the molecular
weight of the polymer 4.42g increased with increasing conversion, as would be
expected. Additionally, the elevated temperature appears to have no detrimental
effect on the dispersities of the polymers obtained (Ð <1.1), which is suggestive of
a well-controlled chain growth polymerisation process, where the rate of initiation
is fast relative to propagation for all temperatures in this range, and where no
significant side reactions exist. The temperature dependence of the polymerisation of
monomer 4.42g is also consistent with the dissociative loss of tricyclohexylphosphine
ligand (PCy3) fromG2, which is known to be the rate determining step of metathesis
initiation for this catalyst. This will be an endothermic process and hence will be
facilitated at elevated temperatures.213
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Table 4.2: Reaction optimisation for the ROMP of dibenzyl amide 4.39g.a
Entry Catalyst Temp
(◦C)
[4.39g]
(M)
Conv.
(%)b
Mnc Mwc Ðd
1 G2 rt 0.10 37 16,095 17,019 1.06
2 G2 30 0.10 82 18,513 19,118 1.03
3 G2 40 0.10 91 20,371 21,352 1.05
4 G2 50 0.10 93 23,520 25,083 1.07
5 G2 60 0.10 93 21,962 23,501 1.07
6 G2 0 0.10 0 - - -
7 G2 40 0.05 79 17,845 18,993 1.06
8 G2 40 0.20 91 16,934 17,714 1.06
9 G1 rt 0.10 0 - - -
10 G1 40 0.10 0 - - -
11 G3 rt 0.10 0 - - -
12 G3 40 0.10 0 - - -
a All polymerisations were carried out using a 4.39g:catalyst ratio of 100:1.b
Conversion was determined by 1H NMR spectroscopy.c Determined by SEC in THF
at 23 ◦C and calibrated relative to polystyrene standards.d Ð = Mw/Mn.
The influence of the catalyst concentration was then investigated for polymerisations
performed at the optimal temperature of 40 ◦C. Halving the concentration to 0.05 M
resulted in a slight decrease in monomer conversion over 72 hours to 79% (Entry 7),
but doubling the concentration to 0.2 M did not appear to increase the conversion
(Entry 8). Finally, for completeness, the use of G1 and G3 catalyst were revisited
at elevated temperatures, which again failed to convert the monomer 4.39g to the
corresponding polymer 4.42g, with 0% conversion observed in both cases (Entries
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10 and 11). Optimal conditions were therefore deemed to be 1 mol% G2 catalyst
at 40 ◦C in (CH2Cl)2 at a concentration of 0.1 M, which would be used for the
homopolymerisation of monomers 4.39a-k.
Prior to screening these conditions against the remaining tertiary amide monomers
4.39a-k the homopolymerisation of dibenzyl amide 4.39g was repeated under the
optimal polymerisation conditions for a range of 4.39g:G2 ratios. Values from 20:1
up to 100:1 were investigated, the results of which are summarised in Table 4.3. In
each case the polymer 4.42g was obtained with high molecular weight and narrow
dispersity (Figure 4.5). A plot of monomer:catalyst ratio against number averaged
molecular weight indicates an excellent linear correlation between the two values
(Figure 4.6). This is important as it is indicative of the polymerisation being a well
controlled chain-growth polymerisation under the previously optimised conditions.
Table 4.3: Molecular weight data for homopolymers 4.42g for various 4.39g:catalyst ratios.
Entry 4.39g:Catalyst Mna Mwa Ðb
1 20:1 8,372 8,885 1.06
2 40:1 14,107 14,882 1.05
3 60:1 18,437 19,634 1.06
4 80:1 23,078 25,092 1.09
5 100:1 26,150 28,887 1.10
a Determined by SEC in THF at 23 ◦C and calibrated relative
to polystyrene standards.b Ð = Mw/Mn.
Figure 4.5: SEC of homopolymer 4.42g prepared using various 4.39g:G2 ratios.
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Figure 4.6: Plot of Mn against 4.39g:G2 ratio for homopolymer 4.42g.
4.2.3 Homopolymersation of monomers 4.39a-k
Having demonstrated through the polymerisation of monomer 4.39g to polymer
4.42g that this investigation into amide derivatives of acid 4.7 was indeed
feasible, and that the polymerisation occurs in well controlled manner, a range
of homopolymers 4.42a-k were then prepared from amides 4.39a-k (Table 4.4).
Generally, the polymers were obtained with good molecular weights and narrow
dispersities. Starting with the polymers derived from petrochemical amines 4.39a-
g, polymers 4.42a and 4.42b could not be analysed by SEC as they were insoluble in
THF (Entries 1 and 2). These polymers are derived from monomers with the shortest
alkyl chains, suggesting that a minimum number of carbon atoms are necessary for
the polymers to be soluble in organic solvents, an observation that is consistent with
the previously reported esters.194 Soluble polymers with molecular weights close to
the expected values and narrow dispersities were obtained for the homopolymers
4.42c and 4.42d from the propyl and butyl amides 4.39c and 4.39d. In each case
conversions over 72 hours were found to be good to excellent with values of between
78-93% observed. However, monomers 4.42e and 4.42f which contain much longer
alkyl chains appear to inhibit the polymerisation, with conversions found to drop to
52% and 49% respectively (Entries 5 and 6). This produced polymers with molecular
weights much lower than would have been predicted, but polymers 4.42e and 4.42f
were still obtained with narrow dispersities. This effect seems to only be observed for
the larger aliphatic monomers, as monomer 4.42g which contains two large benzyl
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groups underwent ROMP without any difficulty (Entry 7).
Having shown symmetrical tertiary amides 4.39a-g derived from petrochemically
sourced secondary amines 4.38a-g all underwent ROMP, the use of monomers
derived from amino acids and peptides were subsequently investigated 4.39h-k.
Initially, this looked at the (S )-proline methyl ester, formed through the reaction
of acid 4.7 with (S )-proline methyl ester hydrochloride, which produced the target
amide 4.39h in a 1:1 mixture of diastereoisomers. This is due to a lack of facial
selectivity during the Diels-Alder addition step in the formation of acid framework
4.7, meaning it is formed as a mixture of enantiomers. Whilst monomer 4.39h did
undergo ROMP to form the corresponding polymer 4.42h, which was found to be
insoluble in THF, it was decided that the remaining monomers 4.39i-k would be
limited to achiral amino acid derivatives to simplify characterisation. The monomer
4.39i derived from sarcosine (N -methylglycine) benzyl ester was therefore prepared.
Monomer 4.39i was then cleanly converted to the corresponding polymer 4.42i,
with 87% conversion observed over 72 hours and the polymer obtained with good
molecular weight and narrow dispersity (Entry 9). Thus, it has been shown that the
use of amino acid derivatives of acid 4.7 in ROMP is indeed feasible, representing
a class of monomers that can be more convincingly regarded as 100% bio-based.
This study was then extended to monomers derived from peptides 4.39j and 4.39k,
again using achiral amino acids to prevent diastereoisomer formation and simplify
monomer characterisation. The two peptidic monomers only differ in either having a
hydrogen (4.39j) or methyl (4.39k) group off the nitrogen of the second amide bond.
The reason for this, as will be discussed in greater detail in Chapter 5, is due to the
incompatibility of secondary amide derivatives of acid 4.7 in ROMP. In this case,
both monomers were found to undergo ROMP, but produced polymers 4.42j and
4.42k that were found to be insoluble in THF, so molecular weight and dispersity
data could not be determined (Entries 10 and 11). Additionally, in the case of
polymer 4.42j conversion could not be easily determined by 1H NMR spectroscopy
as the polymer was found to precipitate from the reaction over the course of 72
hours. These results do however suggest that peptides are indeed tolerated and that
the presence of a secondary amide appears to not be a major issue when suitably far
from the ROMP active site. This means that the preparation of functional materials
or therapeutic agents from the ROMP of peptidic oxanorbornene derivatives could
indeed be a viable avenue for future investigation.
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Table 4.4: Molecular weight and thermal analysis data for homopolymers 4.42a-k.a
Entry Polymer Conv.
(%)b
Mnc Mnc Ðd Tg
(◦C)
T10%
(◦C)
1 4.42ae 93 - - - 115.0 344.7
2 4.42be 90 - - - 145.8 348.5
3 4.42c 78 25,680 28,100 1.09 203.3 350.4
4 4.42d 82 25,030 26,835 1.07 139.0 360.8
5 4.42e 52 23,253 23,662 1.02 136.9 269.2
6 4.42fe 49 10,941 12,115 1.11 171.0 321.3
7 4.42g 91 20,127 20,985 1.04 130.1 351.8
8 4.42hf 87 - - - 149.4 332.4
9 4.42i 87 18,274 19,930 1.09 - 326.9
10 4.42jf -g - - - 155.0 305.8
11 4.42kf 62 - - - - 314.5
a All polymerisations were carried out in 1,2-dichloroethane at 40 ◦C for 72 hours using
catalyst G2 and a 4.39a-k ratio of 100:1.b Conversion was determined by 1H NMR
spectroscopy.c Determined by SEC in THF at 23 ◦C and calibrated relative to polystyrene
standards.d Ð = Mw/Mn.e Amine 4.38f was used as a mixture of racemic and meso-
stereoisomers.f polymer was insoluble in THF.g Conversion could not be determined as
polymer precipitated out of solution over 72 hours.
Having prepared a diverse range of homopolymers 4.42a-k the thermal properties
were duly investigated using TGA and DSC analysis, the results of which are
summarised in Table 4.4. The polymers were found to be amorphous, as no melting
(Tm) or crystallisation (Tcryst) transitions were observed in any case, but showed
fairly high glass transition temperatures (Tg) ranging from 115-203 ◦C. The majority
of polymers also displayed very high decomposition temperatures, with temperatures
of 10% mass loss (T10%) typically observed between 305-361 ◦C (Figure 4.7). The
only exception was polymer 4.42e derived from octylamine which had a significantly
lower decomposition temperature of 269 ◦C. Unusual decomposition profiles were
also observed for polymers 4.42i and 4.42j which produced a step-wise weight loss,
losing 10-15% of the sample mass at 100-150 ◦C, before a second weight loss occurs
above 300 ◦C (Figure 4.7).
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Figure 4.7: TGA traces for homopolymers 4.42a, e, g and i.
The observed mass loss above 300 ◦C was assumed to be due to polymer
decomposition as this would be consistent with thermal data for the other
homopolymers. In order the better understand this unusual decomposition profile
the mass loss occurring between 100-150 ◦C was duly investigated. It was
first hypothesised that this could be due to either loss of the benzyl ester or
decarboxylation. However, when the a sample was heated to 150 ◦C for 10 minutes
and then analysed by 1H NMR spectroscopy no obvious structural changes were
observed. The mass loss was therefore investigated using TGA-FTIR (Figure 4.8).
It can clearly be seen that a mass loss of approximately 10% is observed when
the sample is heated to just below 150 ◦C. However, the IR data obtained at this
temperature suggests that the mass loss only corresponds to the loss of aliphatic
hydrocarbons. This data is consistent with the loss hexane, which was encapsulated
during precipitation. This is a rather unusual phenomenon, but it has also previously
been reported by Biagini et al., who observed that hexane and other aliphatic
hydrocarbons could be bound exclusively by glycine ester functionalised poly(exo)-
norbornenes.199
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Figure 4.8: TGA analysis (top) of the unexpected mass loss region for the
sarcosine homopolymer 4.42i with FT-IR analysis (bottom) of released gases at the
temperature indicated by the dotted line.
Overall, this investigation has so far shown that tertiary amide derivatives of acid 4.7
are amenable to ROMP. They do however require slightly elevated temperatures in
comparison to the previously reported ester derivatives, with the use of G2 catalyst
(1 mol%, 0.1 M) at 40 ◦C in (CH2Cl)2 found to be optimal.194 Under these conditions
the polymerisation was shown to be a well-controlled chain growth polymerisation for
a range of homopolymers, including amino acid and peptide derivatives. Generally,
the polymers are obtained with good molecular weights (Mn = 10,941-25,680) and
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narrow dispersities (Ð = 1.02-1.09). Thermal analysis has shown the polymers
obtained are amorphous and typically display high decomposition temperatures
(>300 ◦C) and glass transition temperatures ranging from 115-203 ◦C.
4.2.4 Random Copolymers of Monomers 4.39a-k
Having prepared and analysed a range of homopolymers 4.42a-k from monomers
4.39a-k a series of random copolymers were investigated. This primarily focused
on the monomers 4.39a, 4.39b and 4.39h which had previously produced insoluble
homopolymers (Table 4.4). Copolymers 4.43a-d were all prepared using a 50:50:1
ratio of the two monomers to G2 catalyst, under the previously determined
optimal conditions. The properties of these polymers could then be compared
to the homopolymers 4.42a-k prepared using a 100:1 monomer to catalyst ratio
(Table 4.4). Generally, high conversion (>80%) of monomers 4.39 to copolymer
4.43a-d was observed in all cases over 72 hours (Table 4.5). Polymer 4.43a
was derived from monomers 4.39c and 4.39i both of which had given soluble
homopolymers previously and not surprisingly gave a soluble copolymer (Entry 1).
The other three random copolymers 4.43b-d were derived from one monomer that
produced an insoluble homopolymer and one monomer that had produced a soluble
homopolymer. Two of these combinations 4.43b and 4.43c were found to give
soluble copolymers (Entries 2 and 3), but the third produced a polymer 4.43d that
was insoluble in THF (Entry 4). All the random copolymers that were soluble in
THF were found to posses good molecular weights (Mn = 10,763-25,060) and narrow
dispersities (Ð = 1.06-1.11) (Figure 4.9).
Thermal analysis of the random copolymers 4.43a-d also indicated that they
possessed very similar properties to the homopolymers 4.42a-k. Tg values were
only determined for polymers 4.43b and 4.43c, but were fairly high at 157 and
155 ◦C respectively (Table 4.5). Thermal decomposition temperatures (T10%) were
also found to be fairly similar to the homopolymers 4.42a-k, in the range 307-355
◦C. Additionally, random copolymer 4.43a, which included the sarcosine benzyl
ester monomer 4.43i, exhibited behaviour consistent with hexane encapsulation
previously observed for homopolymers 4.42i and 4.42j. The reason for random
copolymer 4.43d not displaying this behaviour is not currently understood.
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Table 4.5: Molecular weight and thermal analysis data for random copolymers 4.43a-d.
Polymer
(Monomers)
Conv.
(%)a
Mnb Mwb Ðc Tg
(◦C)
T10%
(◦C)
4.43a (4.39c:4.39i) 80 10,763 11,973 1.11 - 319.2
4.43b (4.39b:4.39g) 89 25,060 27,513 1.10 156.9 354.8
4.43c (4.39d:4.39h) 89 12,166 12,856 1.06 155.3 306.5
4.43d (4.39a:4.39i)d 95 - - - - 318.8
Polymerisations were carried out in 1,2-dichloroethane at 40 ◦C for 72 hours using
catalyst G2 and a monomer:catalyst ratio of (50:50:1).a Conversion was determined
by 1H NMR spectroscopy.b Determined by SEC in THF at 23 ◦C and calibrated
relative to polystyrene standards.c Ð = Mw/Mn.d Polymer was insoluble in THF.
Figure 4.9: SEC trace for the copolymer 4.43c formed from 50:50:1 mixture of
monomers 4.39d and 4.39h and G2 catalyst.
4.2.5 Block Copolymer Synthesis
Having prepared a series of homopolymers 4.42a-k and random copolymers 4.43a-d
from monomers 4.39a-k the final challenge was to prepare a block copolymer using
tertiary amides. It was therefore decided that the synthesis of a block copolymer
from the benzyl 4.39g and ethyl 4.39b monomers would be attempted using a
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50:50:1 monomer to catalyst ratio, as this had previously produced a soluble random
copolymer (Scheme 4.20). This however proved to be more challenging than initially
expected. Growth of the first benzyl block 4.44g proceeded smoothly, with SEC
and 1H NMR analysis indicating the polymer was formed with a high molecular
weight and narrow dispersity. However, analysis of the resultant polymer 24 hours
after the addition of the ethyl monomer 4.39b produced a bimodal SEC trace. This
is suggestive of the death of polymer chain ends prior to the addition of the second
monomer, an issue that was also observed for the analogous ester monomers reported
previously.194
Scheme 4.20: Block copolymerisation of monomers 4.39g and 4.39b to produce
block copolymer 4.45.
This issue was previously overcome through judicious addition of the second
monomer, which was achieved by monitoring the polymerisation of the first monomer
and adding the second monomer slightly prior to complete consumption of the
first. The homopolymerisation of monomer 4.39g was therefore monitored using
1H NMR spectroscopy to allow a more accurate determination of the polymer end-
point. Using this data, it was determined that 50 equivalents of monomer 4.39g
were 90% consumed after 19 hours. Addition of the second monomer after 19 hours
however again produced a bimodal SEC distribution. Eventually it was determined
that a well controlled block copolymer could be grown when the ethyl monomer
4.39b was added after 80% conversion or 13.6 hours. The SEC traces obtained
(Figure 4.10) show that after 24 hours a polymer is obtained with good molecular
weight (Mn = 10,020) and narrow dispersity (Ð = 1.06). The second block is then
grown in over the next 48 hours after the second monomer is added, with a clear
increase in molecular weight (Mn = 15,561) observed and the narrow dispersity (Ð
= 1.05) maintained, indicating that there are no issues of dead chain ends provided
the second monomer is added after 80% conversion of the first monomer.
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Figure 4.10: SEC trace for the block copolymer 4.45 formed from 50:50:1
4.39g:4.39b:G2. Black: 13.6 hours after addition of monomer 4.39g. Red: 48
hours after addition of monomer 4.39b.
4.2.6 Kinetics of Homopolymerisation
Monitoring the reaction profile by 1H NMR spectroscopy for the synthesis of the
block copolymer also made it possible to determine kinetic information for the
homopolymerisation of tertiary amides. The decrease in concentration of the
dibenzyl monomer 4.39g against time was found to fit first order kinetics at 40 ◦C
in deuterated (CH2Cl)2. An observed rate constant (Kobs) of 2.1×10−3 s−1 was then
determined by plotting the natural logarithm of concentration against time (Figure
4.11). In an effort to understand whether the amide side chain has a significant
influence of the reaction kinetics the study was extended to the homopolymerisation
of monomers 4.39a, d, e and i. Monomer 4.39a, derived from dimethyl amine, was
found to have the highest observed rate constant of 2.3×10−3 s−1, whilst monomer
4.39e, derived from dioctylamine, was found to the have the lowest observed rate
constant of 3.1×10−4 s−1. The relatively small difference in between these rate
constants suggests that the amide substituent incorporated onto the acid framework
4.7 does not have a large influence on the observed rate of polymerisation. This
relatively small difference in rate would also confirm that the aforementioned random
copolymers posses a truly random distribution, rather than producing discrete blocks
or tapered blocks within the polymer.
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Figure 4.11: First order kinetic plots for the determination of Kobs for monomer
4.39a, d, e, g and i.
4.3 Conclusions
In conclusion, the fortuitous discovery of the oxanorbornene-lactone 4.39, formed
via the 100% atom economical reaction between itaconic anhydride 4.1 and furfuryl
alcohol 4.2, presents an interesting molecular framework for the synthesis of novel
bio-based polymers. Bai et al. had previously shown that ROMP of 4.7, protected
as the ester, produced a range of wholly bio-based polymers.181,194 These polymers
were found to form in a well controlled manner, possessing high molecular weights
and narrow dispersities, with thermal analysis showing that they generally displayed
high glass transition and thermal decomposition temperatures.
The work reported herein has therefore built upon the previous reports from Bai et
al., investigating the analogous amide derivatives. ROMP of these amides was shown
to proceed in a well-controlled manner, producing a range of homo- and random co-
polymers with high molecular weights (Mn = 10,763-28,100) and narrow dispersities
(Ð = 1.02-1.11). Thermal analysis showed that the polymers were amorphous with
Tg values in the range of 115-203 ◦C and thermal decomposition temperatures
typically above 300 ◦C. A block copolymer could also be prepared by monitoring the
progress of the growth of the first polymer block to ensure that the second monomer
was added before death of living chain ends became significant. Monitoring the
homopolymerisation also provided kinetic data on the rate of polymerisation of the
monomers, showing the pendant side chain had little impact.
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5.1 Introduction
In the previous chapter (Chapter 4), functionalisation of the oxanorbornene-lactone
acid framework with primary amines to produce secondary amides was briefly
investigated. However, rather unexpectedly, the use of butyl amine resulted in a
mixture of products. These were eventually identified, using a combination of 1H
NMR and FT-IR spectroscopy, as the secondary amide 5.1 and the spirocyclic
oxanorbornene-imide 5.2. The use of X-ray crystallography also unequivocally
confirmed these structures (Figure 5.1). The unusual spirocyclic nature of
oxanorbornene-imide 5.2 is what has prompted further investigation into this
transformation, which will form the basis of this chapter.
Figure 5.1: Ellipsoid representation of the crystal structures of secondary amide 5.1
and spirocyclic imide 5.2 species.
Spirocyclic compounds are molecules that contain two ring systems fused at a
single atom. It is a motif that is widely found in natural products, but has
only recently began to attract interest in the development of pharmaceutically
relevant molecules. This is in part due to the inherent three-dimensionality of
spirocyclic scaffolds and their structural novelty.214 Furthermore, cyclic imides
are known to be an important class of organic compounds, widely utilised in
synthetic, medicinal, biological and polymer chemistry.215 A molecular framework
based around a spirocyclic oxanorbornene-imide, such as 5.2, hence presents a highly
novel and potentially valuable structure, that may have a multitude of applications.
This chapter will therefore deal with better understanding the conditions under
which oxanorbornene-imide 5.2 forms, along with exploring possible applications of
153
Chapter 5. Investigation into the Synthesis and Application of an Unusual
Spirocyclic Imide Species
this molecular framework. Since the focus of the previous chapters was on polymer
and therapeutic applications, this chapter will once again concentrate on these areas.
5.1.1 Applications of Oxanorbornene-Imides
An investigation into potential applications of oxanorbornene-imides would however
prove to be more of a challenge than was first anticipated, as analysis of the
literature quickly revealed no evidence for the spirocyclic oxanorbornene-imide 5.2
having ever been reported before. In fact, extending the search to structurally
similar compounds produced only a single result, which was that of the isomeric
anhydrides 5.5-5.8 reported by Pehere et al., in their initial report of the synthesis
of oxanorbornene-lactone 5.10 (Figure 5.2).183 Since these compounds were not
isolated, they have not been applied to any relevant applications to date. The
lack of reports within the literature for spirocyclic oxanorbornene-imides was rather
intriguing, suggesting that these compounds are more unique than initially thought.
The search parameters were therefore widened significantly.
Figure 5.2: Proposed mechanism for the synthesis of oxanorbornene-lactone 5.10
via the Diels-Alder-lactonisation of furfuryl alcohol 5.3 and itaconic anhydride 5.4.
It was eventually realised that spirocyclic oxanorbornene-imide 5.2 was strikingly
similar to the norbornene-2,3-dicarboximide framework 5.11 (Figure 5.3). The latter
only differs in the cyclic imide being attached at the 2,3-position, rather than only
at the 3-position, and the lack of an oxygen atom at the 7-position or norbornene
bridgehead. In comparison, this structure and associated derivatives have been
widely explored for polymer chemistry, particularly ROMP. This was previously
discussed in detail within Chapter 4, in the various reports by Gibson, North and
co-workers on the ROMP of N -amino acid and peptide functionalised norbornene-
2,3-dicarboximides.198 Additionally, numerous reports exist reviewing the use of
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simpler norbornene-2,3-dicarboximide derivatives for ROMP, this will therefore not
be covered in in any further detail.216,217 Instead, the remainder of this literature
review will cover the use of similar structures to spirocyclic oxanorbornene-imide
5.2 in therapeutic applications.
Figure 5.3: General structure of norbornene-2,3-dicarboximide framework 5.11.
In terms of therapeutic activity, the presence of a cyclic imide within spirocyclic
oxanorbornene-imide 5.2 is particularly promising, as this motif has been reported
numerous times within biologically active compounds and natural products 5.12-
5.17, a number of which are highlighted within Figure 5.4.215 What is particularly
striking is the structural similarities between the spirocyclic oxanorbornene-imide
5.2 and norcantharimide 5.17. Both species contain a cyclic imide, attached to
either a 7-oxanorbornene or 7-oxanorbornane scaffold, with the major difference
being the attachment of the imide occurring at the 2,3-position in norcantharimide
5.17, rather than exclusively at the 3-position. Norcantharimide 5.17 could
therefore be considered as a reasonable comparison for rationalising the therapeutic
activity of spirocyclic oxanorbornene-imide 5.2.
Figure 5.4: Examples of bioactive compounds containing cyclic imides.
Cantharimide 5.16 and norcantharimide 5.17 are natural products first isolated
from the Meloidae and Oedemeridae families of the Chinese blister beetle.218 The
dried bodies of these beetles have been utilised within Chinese medicine for over
2000 years, as a natural remedy for a number of ailments including rabies, impotence
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and fever.219 More recently, the closely related anhydride analogue of cantharimide
5.16, cantharidin 5.18, was shown to be a potent anti-proliferative against a
number of human cancer cell lines.220 Synthetic analogues of cantharimide 5.16
and norcantharimide 5.17 have therefore begun to attract significant interest from
chemists and pharmacologists for potential therapeutic applications.
The earliest example investigating cantharidin derivatives in such applications
was reported by McCluskey et al. In previous reports, McClusky et al. had
shown that cantharidin 5.18 and norcantharidin 5.19 are potent inhibitors of PP1
and PP2A, enzymes responsible for regulating cellular processes by controlling
phosphorylated protein levels.221 They therefore extended their investigation to a
number of norcantharimide analogues. The study began by first producing a range
of derivatives of norcantharimide 5.20, through the dehydrative condensation of
norcantharidin 5.19 with various D- or L-amino acids (Scheme 5.1).
Scheme 5.1: Synthesis of norcantharimide derivatives 5.20 through the dehydrative
condensation of norcantharidin 5.19.
These derivatives 5.20 were then screened for their ability to inhibit PP1 and PP2A.
Rather interestingly, only the analogues possessing basic amino acid side chains were
found to inhibit PP1 or PP2A. This was reasoned on the grounds of a modelling
study which suggested there was an “acidic groove” within the vicinity of the active
site, enhancing the binding of analogues possessing basic side chains.221 This was
found to be best when a histidine side-chain was present, which was shown to be
equipotent to cantharidin 5.18 and superior to norcantharidin 5.19 for the inhibition
of PP1 or PP2A.222
Further investigations fromMcCluskey and co-workers have subsequently shown that
the ability of these analogues to inhibit PP1 or PP2A has generally correlated well
with their cytotoxicity against various cancer cell lines.223 Consequently, McCluskey
and co-workers have extended their investigation to study the anti-cancer activities
of a much broader range of norcantharimide analogues. Following on from their
previous report, McCluskey et al. have synthesised a range of alkyl, allyl and
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aryl derivatives of norcantharimide, again through the dehydrative cyclisation
of norcantharidin 5.19.224 The allyl derivatives 5.21 are particularly interesting
as McCluskey and co-workers demonstrated that they are amenable to further
derivatisation, such as osmylation to the 1,2-diol 5.23 or epoxidation/methanolysis
to the methoxy alcohol 5.22 (Scheme 5.2).
Scheme 5.2: Synthesis of allyl norcantharimide 5.21 and corresponding routes to
the 1,2-diol 5.23 and methoxy alcohol 5.22 derivatives.
These norcantharimide analogues were then investigated for their cytotoxicity
against nine human cancer cell lines. In general, the majority of the 32 analogues
investigated were found to possess moderate to good cytotoxicity against the
majority of cancer cells, with the most potent analogues found to contain either
a C10, C12 or C14 alkyl chain, or a 1,2-diol moiety. These results are also shown to
be a marked improvement on those obtained for a control sample of norcantharidin
5.19.224
In their most recent study, McCluskey and co-workers have further extended
their study to norcantharimide analogues possessing terminal phosphate esters.225
Norcantharidin 5.19 was first functionalised with a series of terminal alcohols
through dehydrative cyclisation to yield the N -alcohol analogues 5.24 (Scheme 5.3).
Rather surprisingly, the N -alcohol derivatives demonstrated no cytotoxicity to any
of the cancer cell lines investigated, even though the previously reported 1,2-diols
5.23 had produced rather promising results.224 Robertson et al. therefore decided
to further derivatise these species to the corresponding phosphate esters 5.25.225
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Scheme 5.3: Synthetic route to terminal phosphate ester analogues 5.25 of
norcantharimide from norcantharidin 5.19.
Biological screening of these analogues against a number of cancer cell lines
revealed that the norcantharimide phosphate esters 5.25 presented a new series
of functionalised norcantharimides with enhanced broad spectrum anti-proliferative
activity.225 A number of the analogues were found to be at least equipotent to
norcantharidin 5.19, whilst many others were found to be five times more potent,
with the best results obtained for the diphenyl and bis-trichloroethyl phosphate
esters. Robertson et al. suggested that the observed cytotoxicity was generally
a consequence of how easily the phosphate ester was able to undergo hydrolysis.
Additionally, the synthesis of a pthalimido analogue of the diphenyl ester was
found to be completely void of anti-proliferative activity, demonstrating that the
cytotoxicity is highly dependent on the norcantharidin framework.225
Building upon this observation, McCluskey and co-workers have also reported a
number of investigations into the influence of the various functional groups around
the norcantharidin framework on cytotoxicity (Scheme 5.4).226 The amide acid
derivative 5.26, formed through the ring opening of norcantharidin with an amine,
were found to be poor growth inhibitors for the majority of cancer cell lines
investigated.223 This was also observed when McCluskey and co-workers removed the
5,6-ethyl bridge 5.27 or further functionalised the anhydride to the hydroxy ethyl
ester 5.28.227,228 This work therefore suggests that the 7-oxanorbornane scaffold
and cyclic imide are paramount for synthetic norcantharimides to display significant
cytotoxicity.
Scheme 5.4: Structural variations of the norcantharimide framework reported by
McCluskey and co-workers.
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An interest in the cytotoxicity of the cantharimide/norcantharimide 5.16/5.17
framework has also been reported by Kok et al.220 In their investigation, Kok
et al. functionalised cantharidin 5.18 with a range of 2-aminobenzothiazole
derivatives 5.29 to produce the corresponding cantharimide analogues 5.30 (Scheme
5.5). 2-Aminobenzothiazole 5.29 was chosen as it has long been recognised as a
therapeutically active framework for a number of applications, including antitumour
agents, neurotransmission blockers and neuroprotective agents.220 These analogues
were then screened against the hepatocellular carcinoma cell line, producing a
significant cytotoxic response, one that was found to be comparable to that of a
cantharidin 5.18 control sample.
Scheme 5.5: Dehydrative condensation of cantharidin 5.18 to produce the 2-
aminobenzothiazole cantharimide derivatives 5.30.
A major issue associated with the use of cantharidin 5.18-based therapies for cancer
treatment is their lack of selectivity, which results in a number of known side-effects,
including bone-marrow suppression, as well as gastrointestinal and urinary tract
toxicity.220 Kok et al. therefore chose to investigate the cytotoxicity of analogues
5.30 towards non-malignant bone marrow cell lines.220 The results obtained indicate
that the cantharimide derivatives 5.30 are 2- to 4- fold less active towards the benign
cells than cantharidin 5.18.220 These analogues therefore represent a highly potent
and selective anti-proliferative against hepatocellular carcinoma cell lines.
More recently, Galkin et al. have reported on a rather interesting route
to norcantharimide derivatives from bio-derived starting materials, which is
particularly interesting in the context of green chemistry and the focus of the current
chapter.229 In their report, Galkin et al. began by first investigating the reductive
amination of 2,5-diformylfuran (DFF) 3.31, a promising platform molecule readily
obtained through the oxidation of 5-hydroxymethylfurfural (HMF), which can be
directly obtained from fructose. The resulting products 5.32 then underwent a
modified one-pot Diels-Alder hydrogenation reaction to yield the corresponding
norcantharimide derivatives 5.33 (Scheme 5.6).229
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Scheme 5.6: Reductive amination of DFF 5.31 and subsequent one-pot Diels-Alder
hydrogenation to yield norcantharimide analogues 5.33.
Galkin et al. then went on to investigate the norcantharimide 5.33 analogues for
biological activity. A cytotoxicity study of 5.33 against the human colorectal
adenocarcinoma cell line was therefore carried out. Overall, norcantharimide
derivatives 5.33 were found to be fairly poor, except for when a phenylaminomethyl
moiety was incorporated into the bicyclic core. The cytotoxicity of this species
was found to be significantly higher than that of norcantharimide 5.17, but lower
than that of norcantharidin 5.19.229 Therefore, this demonstrates that the Diels-
Alder addition of bio-based platform molecules is a viable route to cytotoxic
norcantharimide derivatives.
Finally, Spare et al. have reported on a series of cantharimide derivatives based
around a tricyclic lactam core.226 These are particularly worth mentioning due to
their striking resemblance to the oxanorbornene-lactone scaffold 5.10, which has
formed the basis of this chapter as well as the previous one (Chapter 4). Spare et
al. were able to synthesise highly decorated scaffolds 5.35 in good yields, with a
1:1.2 ratio of cis- and trans-diastereoisomers using a two step Ugi intramolecular
Diels-Alder addition (Scheme 5.7).226
Scheme 5.7: Two step Ugi intramolecular Diels-Alder route to the
tetrahydroepoxyisoindole carboxamide scaffold 5.35.
The cytotoxicity of this framework was then investigated against a number of
cancer cell lines and compared to norcantharidin 5.19 and the widely used
chemotherapeutics, cisplatin and oxaliplatin. A number of the synthesised analogues
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were found to possess whole-cell cytotoxicity comparable to those of the control
samples.226 More importantly, this report contradicts some of the previous work
from McCluskey et al., which suggested molecules possessing significant alterations
of the central scaffold are devoid of cytotoxicity.227 The report from Spare et al.
suggested that the molecule is likely to present a degree of cytotoxicity provided
the bridgehead oxygen is intact and the molecules possess a cyclic imide or lactam
functionality, seemingly regardless of position.226 This is a really promising outcome
with regards to an interest in the application of spirocyclic oxanorbornene-imide 5.2
in therapeutic applications.
In summary, spirocyclic oxanorbornene-imides 5.2 represent a highly promising
molecular framework for a number of potential applications. Whilst analysis of
the literature highlighted that 5.2 has not previously been reported, the analogous
norbornene-2,3-dicarboximides 5.11 and norcantharimide derivatives have been
widely explored within polymer and medicinal chemistry respectively. The previous
chapter (Chapter 4) had extensively reviewed the use of amino acid and peptide
derived norbornene-2,3-dicarboximides 5.11 within ROMP and for this reason it
was not expanded upon further. This chapter has therefore predominantly focussed
so far on the potential of norcantharimide derivatives as therapeutics, highlighting
a number of investigations regarding the use of a range of diverse norcantharimide
analogues, and their associated cytotoxicity against a series of cancer cell lines.
These results suggest that oxanorbornene-imide 5.2 is rather likely to possess some
form of cytotoxicity, due to the presence of the oxygen bridgehead and the cyclic
imide.
5.1.2 Chapter Aims
This chapter will therefore aim to produce a number of derivatives of the
oxanorbornene imide 5.2 and isomeric secondary amide 5.1. These compounds
will then be investigated for use within polymer and medicinal chemistry. Firstly,
this investigation will look to build on the work reported in the previous chapter
(Chapter 4) looking at the use of both structures within ROMP. It will then look at
the suitability of the spirocyclic oxanorbornene-imides 5.2 as potential therapeutics,
with an eventual aim to investigate their cytotoxicity against a number of cancer
cell lines.
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5.2 Results and Discussion
It was immediately apparent that in order for an investigation into the applications
of N -substituted secondary amides and spirocyclic oxanorbornene-imides, such as
5.1 and 5.2, to be viable it would first be necessary to better understand the
circumstances under which they form. It was hypothesised that formation of the
secondary amide 5.1 occurs first, which then most likely undergoes an intramolecular
rearrangement where the secondary amide ring-opens the lactone, producing the
isomeric oxanorbornene-imide 5.2 (Scheme 5.8). Conventionally, cyclic imides
are most commonly formed by methods such as dehydrative condensation of an
anhydride with an amine at high temperatures or with the help of a Lewis acid, or the
cyclisation of a carboxylic acid amide in the presence of acidic reagents.215 The above
proposal therefore presents an interesting atom-economical route to cyclic imides,
which appears to have not been reported within the literature to date, although a
similar intramolecular elimination has previously been reported for the analogous
esters.230
Scheme 5.8: Proposed mechanism for the conversion of butyl secondary amide 5.1
to spirocyclic butyl oxanorbornene-imide 5.2.
If the proposed mechanism was indeed the case then the formation of imide 5.2 would
be dependent on the nucleophilicity of the amide. Since amides are known to be fairly
poor nucleophiles, due to conjugation of the nitrogen lone pair with the carbonyl,
nucleophilicity will be dependent on a number of factors such as substituents
and basicity of the reaction solution.215 The synthesis of either 5.1 or 5.2 from
oxanorbornene-lactone 5.10 was therefore revisited, using varying quantities of
butylamine to see whether this would have any influence on the preference towards
either 5.1 or 5.2 under otherwise identical reaction conditions (Scheme 5.9). The
observed trend suggests that the imide 5.2 is formed in greater quantities as the
equivalents of butyl amine are increased, with imide 5.2 not observed at all until
at least 2.5 equivalents are used. This is most easily seen in the 1H NMR spectrum
when the protons at the 7/7’ and 9/9’ carbons are monitored. This is in agreement
with the previous claim of a basic solution being necessary for 5.2 to form, as a
minimum of 2.0 equivalents are needed to neutralise the reaction mixture, due to
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1.0 equivalent acting as the nucleophile in this system, whilst another 1.0 equivalent
being necessary to neutralise the HCl generated from the acyl chloride.
Scheme 5.9: 1H NMR spectroscopy of 5.1 (Top), 5.2 (Bottom) and the crude
reaction mixture for varying quantities of butylamine.
Using this information, a number of bases were screened for the formation of the
amide to see if a link between basicity and preference for either 5.1 or 5.2 could be
discerned. The results of this investigation did not suggest an obvious trend, but
it was determined that the secondary amide could be selectivity produced through
the use of a weaker base than NEt3, such as pyridine. Again this provides even
more evidence to show that formation of the imide 5.2 is reliant on strongly basic
conditions. As such, a series of secondary amides could be produced by exposing the
intermediate acid chloride to one equivalent of the desired amine and one equivalent
of pyridine (Scheme 5.10). In this way a number of alkyl, benzyl and even amino acid
containing secondary amides were produced in moderate to good (31-69%) yields.
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Scheme 5.10: Synthesis of a series of secondary amide monomers 5.1a-f from
oxanorbornene-lactone 5.10.
Now that it was possible to selectively produce a number of secondary amide species
5.1a-f in reasonable quantities, the consequence of exposing 5.1b to an excess of
NEt3 was investigated. Monitoring the reaction mixture using 1H NMR spectroscopy
would also give an idea of whether, and how, the imide 5.2 forms over time following
exposure to a stronger base (pKb: pyridine 5.21, NEt3 11.01, n-butylamine 10.78)
(Scheme 5.11). It was observed that following the addition of 2.0 equivalents of
NEt3, the secondary amide 5.1b was slowly converted to the desired imide 5.2 over
the course of a few hours. The relative concentration of 5.2 was then found to peak
after about 8-10 hours. However, monitoring the reaction mixture over an extended
period of time revealed that a third species formed in reasonable quantities. It
was eventually identified that this was in fact two species, furfuryl alcohol 5.3 and
1-butyl-3-methylene-pyrrolidine-2,5-dione 5.38, formed as a result of a retro-Diels-
Alder reaction of imide 5.2. This unfortunately suggests that imide 5.2 is not as
stable as originally hoped when the alkene is still present within the norbornene
and the lactone is broken. Additionally, the approach of exposing the secondary
amide to a strong base like NEt3 to form the corresponding imide was subsequently
found not to be generally applicable, as the other secondary amides investigated
5.1a-f often produced complicated mixtures of products after 8-10 hours. It was
therefore decided that the application of norbornene 5.1b and imide 5.2 would be
investigated in ROMP before committing more time to investigating the factors that
influence the conversion of secondary amides 5.1a-f to imides.
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Scheme 5.11: Interconversion of butyl amide 5.1b to butyl imide 5.2 over time
and subsequent retro-Diels-Alder to furfuryl alcohol 5.3 and 1-butyl-3-methylene-
pyrrolidine-2,5-dione 5.38. Reaction was monitored using 1H NMR spectroscopy.
5.2.1 Ring-Opening Metathesis Polymerisation of Secondary
Amides and Spirocyclic Oxanorbornene-Imides
To begin with, the butyl secondary amide 5.1b was screened against a range of
commercial metathesis catalystsG1-G3, under similar conditions to those that were
deemed optimal for the previous investigation (Chapter 4). The use of G1 catalyst
proved unsuccessful, with reactions at room and elevated temperature both failing
to produce the target polymer 5.39b (Table 5.1, Entries 1 and 2). The use of G2
however produced a cloudy suspension when ROMP was performed at 40 ◦C, which
is most likely due to the oligomeric material precipitating out of the reaction mixture
(Entry 4). The use of alternative solvents to (CH2Cl)2 had previously yielded poor
results, an alternative secondary amide monomer was therefore investigated.181
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Table 5.1: Screening of reaction conditions for the polymerisation of secondary amides.
Entry R Group Catalyst Temp
(◦C)
Conv.
(%)a
Mn Mw Ðb
1 Bu 5.1b G1 rt - - - -
2 Bu 5.1b G1 40 - - - -
3 Bu 5.1b G2 rt - - - -
4c Bu 5.1b G2 40 - - - -
5 Oct 5.1d G1 rt - - - -
6 Oct 5.1d G1 40 - - - -
7 Oct 5.1d G2 rt - - - -
8 Oct 5.1d G2 40 - - - -
9 Oct 5.1d G3 rt - - - -
10 Oct 5.1d G3 40 - - - -
11 Gly-OBn 5.1f G1 rt - - - -
12 Gly-OBn 5.1f G1 40 - - - -
13 Gly-OBn 5.1f G2 rt - - - -
14 Gly-OBn 5.1f G2 40 - - - -
15 Gly-OBn 5.1f G3 rt - - - -
16 Gly-OBn 5.1f G3 40 - - - -
17d Gly-OBn 5.1f G2 40 - - - -
18e Gly-OBn 5.1f G2 40 - - - -
All polymerisations were carried out using a monomer:catalyst ratio of 100:1.a
Conversion was determined using 1H NMR spectroscopy.b Ð = Mw/Mn.c formed
a gel after a short period of time.d 10 eq. of a 0.4 M solution of LiCl in DMF was
added.e 10 eq. of Ti(OiPr)4 was added.
Subsequently, a similar catalyst screen was investigated for the octyl derivative 5.1d
(Entries 5-10). Polymerisation was attempted using each of the commercial ROMP
catalysts (G1, G2 and G3) at either room or elevated temperature. However, in
all cases no evidence for the target polymer 5.39d was observed. In the interest
of completeness, the same conditions were also investigated for the glycine benzyl
ester monomer 5.1f. Again, polymerisation using the commercial ROMP catalysts
at room or elevated temperature failed to produce the target polymer 5.39f (Entries
11-16). Even attempts using the most promising conditions (G2 at 40 ◦C) with
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additives that are known to disrupt aggregates and promote ROMP, such as lithium
chloride (LiCl) and titanium isopropoxide (Ti(OiPr)4), failed to produce the target
polymer 5.39f (Entries 17 and 18).231
This failure is most likely due to the nature of the secondary amides 5.1a-f, as any
pendant side chains will lie in the endo orientation. This was previously shown to
be much less reactive than the exo-counterparts in Chapter 4. Additionally, as the
amide is secondary it could be imagined that the amide bond is able to coordinate
to the active catalyst through the N-H bond, inhibiting catalysis, an issue that was
observed for deprotected amino acids in the endo-orientation by Sutthasupa et al.203
This is also reinforced by the observation that glycine secondary amide 5.1f does
not polymerise, but the N -methyl glycine derivative (Sarcosine) 4.42i was found
to polymerise in the previous chapter (Chapter 4). Based on these observations
and the results presented in Table 5.1, it was deemed that the secondary amides
5.1a-f would not likely undergo ROMP. Efforts therefore turned to the spirocyclic
oxanorbornene-imide 5.2.
Attempts to polymerise the butyl-imide 5.2 using the previously investigated
catalysts at various temperatures again failed to produce the target polymer
(Table 5.2, Entries 1-6). This monomer no longer contains the secondary
amide functionality, but the hydroxymethyl group now off the bridgehead was
anticipated to be an issue for catalyst deactivation. The standard condition
screening was therefore reattempted using the acetylated derivative 5.40 (Entries
7-12). Unfortunately, again this failed to produce the target polymer 5.41.
Closer investigation of the polymerisation of either 5.2 or 5.39 revealed that
both monomers would actually rather undergo a retro-Diels-Alder reaction back
to furfuryl alcohol 5.3, or the acetylated derivative and 1-butyl-3-methylene-
pyrrolidine-2,5-dione 5.38 rather than polymerise. It therefore seems very unlikely
that either secondary amide 5.1b or spirocyclic oxanorbornene-imide 5.2 will
undergo ROMP.
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Table 5.2: Screening of reaction conditions for the polymerisation of norbornene-imide 5.2.
Entry R Group Catalyst Temp
(◦C)
Conv.
(%)a
Mn Mw Ðb
1 H 5.2 G1 rt - - - -
2 H 5.2 G1 40 - - - -
3 H 5.2 G2 rt - - - -
4 H 5.2 G2 40 - - - -
5 H 5.2 G3 rt - - - -
6 H 5.2 G3 40 - - - -
7 Ac 5.40 G1 rt - - - -
8 Ac 5.40 G1 40 - - - -
9 Ac 5.40 G2 rt - - - -
10 Ac 5.40 G2 40 - - - -
11 Ac 5.40 G3 rt - - - -
12 Ac 5.40 G3 40 - - - -
All polymerisations were carried out using a monomer:catalyst ratio of 100:1.a
Conversion was determined using 1H NMR spectroscopy.b Ð = Mw/Mn.
5.2.2 DEMETA Catalysts
In a final last ditch effort to polymerise the secondary amides, as they were at least
stable to the polymerisation conditions, a range of catalysts supplied by DEMETA
S. A. S were investigated. These catalysts have been widely explored for ring-closing
metathesis (RCM), but have not previously been investigated for ROMP.232,233
Before investigating the secondary amides 5.1a-f, a model norbornene substrate
was investigated for ROMP using these catalysts, the results of which can be found
within the appendix. Structures M831 SiPr 5.42 and M73 SiPr 5.43 were then
selected for further investigation (Figure 5.5).
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Figure 5.5: Structures of the M831 SiPr 5.42 and M73 SiPr 5.43 catalysts supplied
by DEMETA S.A.S.
These catalyst were first screened against the octyl monomer 5.1d at room
temperature and at 40 ◦C (Table 5.3, Entries 1-4). No evidence for the target
polymer 5.39 was observed in any case. The same combinations were then tested
with the glycine benzyl ester 5.1f. Again, no polymer was observed for any of the
conditions investigated (Entires 5-8). It was therefore concluded that the secondary
amide monomers 5.1a-f are unsuitable for ROMP on the grounds of the endo-
pendent side chains not being suitably hindered to prevent catalyst deactivation.
Table 5.3: Demeta catalyst screening for the octyl 5.1d and glycine benzyl ester 5.1f secondary
amide monomers.
Entry R Group Catalyst Temp
(◦C)
Conc.
(M)
Conv.
(%)
Mn Mw Ð
1 Oct 5.1d M831 SiPr rt 0.10 - - - -
2 Oct 5.1d M831 SiPr 40 0.10 - - - -
3 Oct 5.1d M73 SiPr rt 0.10 - - - -
4 Oct 5.1d M73 SiPr 40 0.10 - - - -
5 Gly-OBn 5.1f M831 SiPr rt 0.10 - - - -
6 Gly-OBn 5.1f M831 SiPr 40 0.10 - - - -
7 Gly-OBn 5.1f M73 SiPr rt 0.10 - - - -
8 Gly-OBn 5.1f M73 SiPr 40 0.10 - - - -
.
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5.2.3 Spirocyclic Oxanorbornene-Imides as Therapeutics
Having shown in the previous sections (Sections 5.2.1 and 5.2.2) that the ROMP
of secondary amides 5.1a-f and the spirocyclic oxanorbornene-lactone 5.2 was
not viable for a multitude of reasons, attention then turned to an investigation
into derivatives of 5.2 as potential therapeutics. It was hypothesised that since
it was possible to selectively isolate the secondary amides 5.1a-f, hydrogenation
prior to converting to the spirocyclic-imide would then remove the possibility of the
retro-Diels-Alder reaction from occurring (Scheme 5.12). It would then hopefully
be possible to isolate stable spirocyclic 7-oxabicyclo[2.2.1]heptane-imide derivatives
5.45a-f that could potentially be investigated for therapeutic applications.
Scheme 5.12: Proposed synthetic route to derivatives of spirocyclic 7-
oxabicyclo[2.2.1]heptane-imide 5.45a-f.
This investigation therefore started by first hydrogenating the butyl secondary amide
5.2b as a model substrate (Scheme 5.13). A single species was isolated in good yield,
but characterisation of this product proved to be rather troublesome and ended up
producing a particularly unexpected result. Whilst the majority of the data agreed
with the formation of secondary amide 5.44b, the IR spectroscopy data obtained
was particularly peculiar. On the basis of this result, it was reasoned that it would
be perfectly plausible for the isomeric spirocyclic species 5.45b to form directly
following hydrogenation. It was eventually determined that this was in fact the
case, as 2D 1H and 13C heteronuclear multiple bond correlation (HMBC) NMR
spectroscopy indicated that a correlation was present between the protons at the 11
position and both carbonyl groups, a correlation that would only be possible in the
imide 5.45b configuration rather than as the amide 5.44b (Figure 5.6).
Scheme 5.13: Hydrogenation of the butyl secondary amide 5.1b and the two possible
products 5.44b and 5.45b.
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Figure 5.6: HMBC plot of species 5.45b.
The remaining amide monomers 5.1a-f were therefore hydrogenated and analysed
by IR and 2D 1H and 13C HMBC NMR spectroscopy, where applicable, to see if
this observation was general to this class of secondary amides (Table 5.4). It was
observed that in the case of long alkyl and benzyl derived amides, the spirocyclic
imides 5.45b-e are formed exclusively, which were all isolated in excellent yields
(>90%) (Entries 2-5). Issues however arose when using more hindered alkyl or
amino acid functionalised amides, which formed a mixture of both the hydrogenated
secondary amide 5.44a/f and the spirocyclic imide 5.45a/f (Entries 1 and 6).
This is most likely a consequence of reduced nucleophilicity as a result of steric or
electronic factors. It should also be acknowledged that the hydrogenation conditions
will remove the benzyl ester protecting group present in 5.1f, meaning the crude
material was actually a mixture of 5.44f and 5.45f as the free amino acid. Finally,
unequivocal structural conformation was obtained for the formation of spirocyclic
7-oxabicyclo[2.2.1]heptane-imides when a crystal of 5.45e was successfully grown
(Figure 5.7).
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Table 5.4: Hydrogenation of secondary amides 5.1a-f to yield either the secondary amides 5.44a-f
or spirocyclic imide 5.45a-f.
Entry R Group Selectivitya
5.44:5.45
Isolated Yield
(%)
1 iPr 5.1a 50:50 -b
2 Bu 5.1b 0:100 90
3 Hex 5.1c 0:100 94
4 Oct 5.1d 0:100 98
5 Bn 5.1e 0:100 95
6 GlyOBn 5.1f 32:68 -b
a Determined by 1H NMR spectroscopy.b Not isolated due to forming
a mixture of products.
Figure 5.7: Ellipsoid representation of the crystal structure of hydrogenated
spirocyclic benzyl oxanorbornene-imide 5.45e.
5.2.4 LLAMA Analysis
Unfortunately, time constraints have prevented any further investigation into the
synthesis of hydrogenated spirocyclic imides similar to 5.45a-f. This also meant
it was not possible to better understand the factors that influence formation of
the spirocyclic imide over the secondary amide, or investigate their properties as
potential therapeutic agents. It has however been possible to predict their suitability
as drug molecules and where they lie in drug-relevant chemical space using a
computational model. Lead-Likeness and Molecular Analysis (LLAMA) is an open
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access, web based tool for decorating and analysing molecular scaffolds. The software
is able to decorate structures using a number of common and pharmaceutically
relevant synthetic transformations to generate a library of chemical structures. This
library can then be analysed using a number of useful tools to rapidly assess the
novelty and lead-likeness of new molecular structures.234
Nadin et al. have previously described a number of physiologically important
properties of molecules, such that similar compounds will have greater flexibility and
potential for development into promising clinical candidates.235 Molecules within this
chemical space typically have a defined lipophilicity (-1 ≤ cLogP ≤ 3) and molecular
weight (Mw = 200-350 Da). Nadin et al. also suggested that promising candidates
should not contain chemically reactive, electrophilic or redox active functionalities,
and would be more 3D in structure, possessing a low degree of aromatic character.
It is the combination of these factors that form the basis of LLAMA analysis, as
the closer molecules lie to the chemical space described by Nadin et al. the more
lead-like they are deemed to be.
The spirocyclic imides 5.45a-f were therefore assessed using LLAMA. Each
structure was uploaded to create a new database, however derivatisation was turned
off, meaning only the structures 5.45a-f were assessed. Following assessment
LLAMA first plots the molecules in 2D space on the basis of their molecular weights
and predicted lipophilicity. The software then applies a lead-likeness penalty based
on heavy atom count, lipophilicity, number of aromatic rings and the presence of
reactive functional groups, the higher this penalty the less lead-like the structures
are. Analysis of compounds 5.45a-f showed that they were found to be very
promising candidates as potential therapeutics, with all compounds found to lie
perfectly within lead-like chemical space, based on their predicted lipophilicity
and molecular weight (Figure 5.8). Additionally, LLAMA applied no lead-likeness
penalty to 5.45a-f, except for 5.45e due to the presence of the benzylic functional
group.
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Figure 5.8: Plot of relative molecular mass against lipophilicity for 5.45a-f
highlighting lead-like chemical space.
LLAMA then analyses the structures to determine their 3-dimensionality using
principal moment of inertia (PMI) analysis. To generate the PMI coordinates for
each molecule, the system randomly generates a number of 3D conformers, minimises
their energy and selects the lowest-energy conformer. The system then calculates
the moments of inertia in the x, y and z axes. The PMI plot I1 coordinates
are calculated by dividing inertia(x) by inertia(z). The PMI I2 coordinates are
calculated by dividing inertia(y) by inertia(z).234 The reason for doing this is due
to current trends in medicinal chemistry to move into the relatively unexplored
3D space, as the region lying between rod-like and disc-like has been extensively
explored to date. For example, analysis of 1439 FDA approved small molecule
drugs has shown only 23% lie within 3D space.236 In this case, 3D chemical space
is defined as the region where (PMI X + PMI Y) > 1.2. PMI analysis of 5.45a-f
showed that 5.45a, b and f all lay within the 3D region of chemical space, whilst
the structures containing long alkyl or bulky benzyl units 5.45c, d and e were more
rod-like in structure (Figure 5.9).
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Figure 5.9: PMI analysis of structures 5.45a-f.
Finally, the structures are assessed by LLAMA for novelty. The molecules are
first stripped of any side chains to reduce them down to the ring systems and
any linkers between them, this is referred to as the Murcko framework.237 The
Murcko framework is then compared to a random 2% of molecules residing in the
ZINC database, a commercial database of over twenty million compounds from
Irwin et al.238 The Murcko frameworks of molecules 5.45a-f were found to possess
a 0% likeness to a random 2% of molecules within the ZINC framework, even when
analysed as a substructure. This suggests compounds 5.45a-f are novel molecular
frameworks that have not previously been investigated within medicinal chemistry.
The secondary amides were also analysed using LLAMA but have not been reported,
this is due to the heavy lead-likness penalty they suffer from, due to the presence of
undesirable functional groups. The lead-likeness and PMI plot for these compounds
can however be found within the appendix.
Overall, analysis of spirocyclic imides 5.45a-f using LLAMA has suggested they
represent very promising molecules for future investigations into their application
as potential therapeutics. They have been found to lie directly within lead-like
chemical space according to the criteria outlined by Nadin et al., with all molecules
also scoring very well for potential lead-likeness penalties. PMI analysis then found
that when the spirocyclic imides were functionalised with short alkyl or amino acid
side chains, they could be regarded as 3-dimensional in structure. Finally, stripping
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the molecules back to their Murcko framework suggested that they represented a
very novel cyclic structure, displaying a 0% similarity to a database of over twenty
million compounds.
5.3 Conclusions
In conclusion, the unusual oxanorbornene-imide and associated secondary amide,
resulting from the treatment of the acid chloride derivatives of 5.10 with butyl
amine, has been investigated. Initial analysis of the literature associated with
this compound revealed this structure represented a highly novel and functional
molecular framework. It was eventually realised that it possessed a number of
similarities to the norbornene-2,3-dicarboximides 5.11 and norcantharimide 5.17
frameworks, which have been widely utilised in ROMP and as chemotherapeutics
respectively. This chapter has therefore predominantly focussed on understanding
the factors that influence how the oxanorbornene-imide and secondary amide form,
along with their application in ROMP and as potential therapeutics.
Initial investigations found that the secondary amide 5.1b slowly converts to the
imide 5.2 under very basic conditions, by what is believed to be an intramolecular
rearrangement. However, extended reaction times result in the imide undergoing
a retro Diels-Alder to furfuryl alcohol 5.3 and the 1-butyl-3-methylene-pyrrolidine-
2,5-dione 5.38 species. It was eventually realised that a range of secondary amides
5.1a-f could be selectively synthesised using exact quantities of the nucleophile and
a weaker base than NEt3, such as pyridine. However, selective formation of a range
of the imides was unfortunately not possible.
To avoid losing too much time to this study, the use of secondary amides and
spirocyclic oxanorbornene-imides in ROMP was investigated. Unfortunately, neither
species produced the target polymer using a range of monomer derivatives, catalysts
and reaction temperatures. This is reasoned for the secondary amides on the grounds
of the pendant side chain lying in the endo-orientation, and not being suitably
hindered to inhibit catalyst deactivation through coordination. The spirocyclic
oxanorbornene-imides on the other hand appear to prefer the retro Diels-Alder
reaction over polymerisation.
Finally, the secondary amides were hydrogenated, with the intention of converting
the amide to the corresponding spirocyclic imide. It was however found that the
use of unhindered alkyl or benzyl amides produced the spirocyclic imides directly
following hydrogenation. These were subsequently investigated for potential as
therapeutics. LLAMA analysis suggests this framework falls perfectly within lead-
like space, is particularly three-dimensional with amino acid or short alkyl side
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chains, and represents a highly novel cyclic system. Unfortunately, time constraints
have limited any further investigation into the potential cytotoxicity of these
compounds. Nonetheless, initial analysis using LLAMA shows great promise for
investigating and potentially using these molecules as therapeutic agents.
177

Chapter 6
Concluding Remarks and Future
Work
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This thesis sought to investigate methods utilising green chemistry principles in
various approaches towards improving the sustainability of peptide and polymer
chemistry. The key findings from each chapter will therefore now be summarised
and possible avenues for future work discussed.
Chapter 2: Cyclic Carbonates as Solvents for Peptide Synthesis
The first two research chapters focussed on the use of green solvents in solid-
phase synthesis, with Chapter 2 investigating the use of cyclic carbonates as
replacements for conventional polar aprotic solvents in peptide synthesis. This
began by investigating the synthesis of a model Boc-Phe-Ala-OBn dipeptide using
the solution-phase approach, with cyclic carbonates found to produce the target
dipeptide in a greater yield than control reactions using DMF or a DMF:CH2Cl2
solvent mixture. Optimal coupling conditions were then found to use a combination
of PC, EDC, HOBt and DIPEA, producing the target dipeptide in an excellent
93% yield. Coupling was also found to occur with no evidence for racemisation
of the amino acids (d.e. >98.4%). PC was then shown to tolerate the harshly
acidic conditions associated with Boc-deprotections, with a combination of PC and
TFA found to conveniently produce the dipeptide salt product in a quantitative
yield. Using the developed methodology a number of tetrapeptides were prepared
using PC as the only reaction solvent. These were typically obtained with good
to excellent yields observed for all coupling (65-91%) and deprotection (80-99%)
reactions, demonstrating PC is tolerant to a range of structurally diverse amino
acids and protecting groups commonly associated with peptide synthesis. The only
issues arose when attempting to obtain a fully deprotected tripeptide, with PC found
to inhibit hydrogenation of the Bn-protecting group. This was eventually overcome
using MeOH, a more conventional solvent for hydrogenation reactions.
Having demonstrated the suitability of PC for solution-phase peptide synthesis
the associated solid-phase approach was investigated. This immediately hit an
issue, as one of the most important considerations for SPPS is the ability of
the solvent to adequately solvate, or swell, the solid support. Whilst PC was
unable to adequately swell polystyrene-based Merrifield resin, it was found to
swell polyethylene glycol based ChemMatrix resin. A model H-Leu-Ala-Phe-
OH tripeptide was then synthesised using HBTU, HOBT and DIPEA upon a
ChemMatrix resin, using PC as the only reaction solvent. In an effort to really
demonstrate the utility of this methodology the synthesis of the biologically relevant
peptide bradykinin was attempted. Multiple attempts however failed to produce
the target peptide, which was eventually determined to be due to a side-reaction
between piperidine and PC, inhibiting the deprotection step. This was overcome
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by simply freshly preparing the deprotection cocktail each time. Bradykinin was
eventually obtained in a 77% crude purity, an excellent result when compared to a
control sample which was obtained in 79% crude purity. Chapter 2 has therefore
successfully shown that cyclic carbonates are suitable solvents for both solution- and
solid-phase peptide synthesis.
Whilst solvents often present the biggest source of waste, there are still many issues
associated with peptide synthesis in the context of green chemistry, such as poor
coupling efficiency and the need for toxic reagents. Addressing these issues therefore
presents substantial scope for future work investigating methods for improving the
sustainability of peptide synthesis. GSK have for example, recently published both
an amide bond forming and acid/base reagent guide for embedding sustainability
into reagent selection.239,240 The use of HOBt and HBTU is something that presents
a major concern, due to the formation of a urea by-product that is cytotoxic. The
use of more desirable coupling agents, such as 1,1’-carbonyldiimidazole (CDI) or
COMU in PC, would therefore be a valuable investigation. A number of the bases
associated with peptide synthesis are also highlighted as being problematic, due to
their flammability and piperidine being a restricted drug precursor, an investigation
into suitable alternatives would therefore be worthwhile. This would be particularly
beneficial for the use of PC, as it may identify a base that is suitable for Fmoc-
deprotections but less prone to ring-opening PC.
Chapter 3: Greener Solvents for Solid-Phase Organic Synthesis
The investigation into the ability of PC to swell common SPOS resins in the previous
chapter highlighted that a systematic study into the ability of green solvents to swell
SPOS resins had not been previously reported. Chapter 3 therefore investigated the
ability of a wide variety of green solvents to swell common SPOS resins. Santini
et al. had previously reported a method for measuring resin swelling that defined
good swelling as >4.0 mL g-1.131 The swelling of nine common SPOS resins in thirty
solvents was then determined according to the method outlined by Santini et al. In
all cases at least one green solvent was identified to swell each SPOS resin to >4.0
mL g-1.
Having studied resin swelling in green solvents the results were further examined
using both a computational and experimental approach. To begin with, a
computational model of resin swelling was constructed using the HSPiP software.
Using this approach, a training set of solvents was grouped and ranked according
to their ability to swell a particular resin, with it found that n = 5 groups was
best. The HSPiP fitting algorithm was then able to predict optimal Hansen
solubility parameters for each resin. The solvent optimiser within HSPiP is then
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able to predict other suitable solvents based on these solubility parameters. Plotting
the percentage of maximum observed swelling for each resin for a specific solvent
generally demonstrated an excellent correlation between swelling and the distance
(Ra) from optimal HSP values.
The swelling data was then verified experimentally using the multicomponent Ugi
reaction. Solution-phase control reactions found that yields of the α-acylamino
amide product in either MeOH or 2-MeTHF were essentially equivalent. The same
coupling reaction was then performed upon either a Merrifield or ChemMatrix solid-
support, in both 2-MeTHF and MeOH. When a solvent was used that was found to
swell both resins the isolated yields of the α-acylamino amide product were found to
be comparable. However, when a poor solvent/resin combination was used, yields
were found to be substantially reduced, confirming that adequate solvation (>4.0
mL g-1) by a green solvent is a necessary prerequisite.
These results do of course present numerous avenues for future work, since it was
identified that SPOS using green solvents had only been reported twice previously.
There therefore exists numerous organic transformations that could be performed
in green solvents upon solid-supports. Particularly appealing options would be
synthetic reactions that already have green credentials, such as organocatalysed
reactions or further multicomponent reactions (Passerini, Biginelli etc.). Further
computational modelling of resin swelling using HSPiP could also be an interesting
avenue for future work. For example, Fields et al. had previously suggested that
peptide-resin swelling should be considered in two parts, the peptide and the resin.157
New capabilities in HSPiP allow for the modelling of two distinct regions through
the use of a dual sphere model. Using this approach it may be possible to optimise
the swelling of both components of the peptide-resin model, facilitating accurate
solvent selection for difficult peptide sequences.
Chapter 4: Ring-Opening Metathesis Polymerisation of a Novel Bio-
based Monomer Framework
The second half of this thesis then investigated a method for improving the
sustainability of polymer synthesis, with Chapter 4 specifically looking at the ROMP
of tertiary amide derivatives of a novel bio-based molecular framework. To begin,
a number of amide derivatives containing a variety of pendant side chains were
synthesised in good to excellent yields. This even included amino acid and peptide
derived monomers, in an effort to produce amide derivatives that could be more
easily conceived as 100% bio-based. Homopolymerisation of these substrates by
ROMP was then investigated. Using a simple dibenzyl species as a model substrate,
optimal conditions were found to be 1 mol% G2 catalyst at 40 ◦C and 0.1 M in
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(CH2Cl)2. A broad range of homo- and random co-polymers were then produced
with good molecular weights (Mn = 10,763-28,100) and excellent dispersities (Ð
= 1.02-1.11). Thermal analysis also revealed that the polymers were amorphous,
with Tg values in the range of 115-203 ◦C and thermal decomposition temperatures
typically above 300 ◦C. Finally, it was shown to be possible to synthesise a block
copolymer under these reaction conditions. This was only made possible however
after monitoring polymerisation of the first monomer by 1H NMR spectroscopy, to
ensure accurate addition of the second monomer following 80% consumption. This
information also provided some kinetic data, with additional investigations finding
that the pendant side chains appeared to have little influence on the observed rate
constants (Kobs = 2.3×10−3 s−1 - 3.1×10−4 s−1).
These results certainly present promising avenues for future investigations into
the use of amino acid or peptide derived ROMP polymers for therapeutic or
functional material applications. However, two issues should probably be addressed
beforehand. Firstly, functionalisation of a racemic monomer framework with
enantiopure substrates creates many issues with regards to characterisation, due
to the presence of diastereoisomers and rotamers. Methods for the isolation of
an enantiopure monomer framework, whether through stereoselective synthesis or
chiral resolution, would certainly prove to be very valuable. Secondly, the endo-
orientation of the molecular framework has been attributed to the slow propagation
rates observed for these monomers and the associated esters. Additionally, this has
prevented the use of primary amino acids in this investigation, as secondary amide
monomers appear to not be amenable to ROMP, due to deactivation of the active
catalyst. Further investigations into the Diels-Alder reactions of other bio-based
anhydrides with furfuryl derivatives could therefore be a valuable study, particularly
if exo-monomers are obtained.
Chapter 5: Investigation into the Synthesis and Application of Unusual
Spirocyclic Imide Species
Finally, the previous chapter had identified that when a primary amine was used
to functionalise the oxanorbornene-lactone framework a mixture of products was
formed. These were determined to be the expected secondary amide and a rather
unusual spirocyclic oxanorbornene structure. Chapter 5 therefore focussed on better
understanding how these two species form and whether they had potential in
polymer or therapeutic applications. It was identified rather quickly that formation
of either species generally coincided with the basicity of the reaction solution during
amide formation. Further investigations found that the secondary amide could be
selectively formed through use of exact quantities of a weak base, like pyridine.
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Exposure of the secondary amide to a base such of NEt3 was then shown to form
the spirocyclic oxanorbornene-imide over time, with the retro-Diels-Alder products
observed after several hours. Further investigation into this transformation was
put on hold, until the application of these species in ROMP had been investigated.
Unfortunately, extensive investigation found that neither substrate would undergo
ROMP. In the case of the secondary amide this was believed to be due to endo-
nature of the substituent side chain facilitating catalyst deactivation, whilst the
spirocyclic oxanorbornene-imide appeared to prefer the retro-Diels-Alder pathway
over polymerisation.
The use of the spirocyclic oxanorbornene-imides as a potential therapeutic agent was
therefore duly investigated. This was inspired by the structural similarities between
this species and the norcantharimide family of natural products. The secondary
amides were first hydrogenated to remove the possibility of the oxanorbornene-
imide undergoing a retro-Diels-Alder. However, it was identified that in a number
of cases the oxanorbornene-imide formed directly following hydrogenation. It is
not currently fully understood why this occurs, but it is hypothesised to be due to
the nucleophilicity of the associated amide, with sterically hindered and electron
deficient amides typically producing a mixture of products. To determine whether
these substrates had potential as therapeutics they were analysed using LLAMA
analysis. This determined that the spirocyclic oxanorbornene-imides fall perfectly
within lead-like space (-1 ≤ cLogP ≤ 3 and Mw = 200-350 Da), are rather three-
dimensional by PMI analysis and have a 0% similarity to a database of twenty
million compounds on the basis of their Murcko framework.
Unfortunately, time constraints have limited further investigation into these
spirocyclic oxanorbornene-imides. However the results obtained certainly present a
promising case for future work. The most pressing would be a better understanding
of the factors that influence formation of spirocyclic species following hydrogenation
of the secondary amide. It would also be worth investigating whether the species
that formed mixtures of the oxanorbornene-imide and secondary amide could be
encouraged to favour formation of the imide. Finally, LLAMA has highlighted
the spirocyclic oxanorbornene-imides as highly promising therapeutics. It would
therefore be worthwhile investigating their efficacy in cancer cell growth inhibition
assays, to check for any cytotoxicity.
This thesis has therefore highlighted a number of novel approaches for improving
the sustainability of peptide and polymer chemistry. The first research chapter
demonstrated the suitability of cyclic carbonates, highly promising green solvents
to replace reprotoxic polar aprotic solvents, in both solution- and solid-phase
peptide synthesis. This work was then extended to solid-phase organic synthesis.
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Chapter 6. Concluding Remarks and Future Work
Identifying suitable green solvents for a number of common SPOS resins through
swelling experiments, which were then validated through a computational and
experimental approach. The second half of this thesis then addressed polymer
chemistry, investigating a novel bio-based molecular framework. A number of novel
polymers derived from tertiary amides were successfully synthesised, including amino
acid and peptidic side chains, which could be more convincingly regarded as fully
bio-based. Finally, an unusual spirocyclic oxanorbornene-species derived from the
bio-based molecular framework was studied in more detail. Whilst it did not undergo
ROMP, it does have promising potential within therapeutics. At the time of writing,
the majority of this work is either published, or is currently under consideration
for publication in academic journals. It can therefore be unequivocally concluded
that the work reported herein presents a valuable contribution to improving the
sustainability of polymer and peptide chemistry.
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7.1. General Information
7.1 General Information
All air- and water-sensitive reactions were carried out in oven-dried glassware under
either a nitrogen or argon atmosphere. Analytical TLC was performed on aluminium
backed plates pre-coated (0.25 mm) with Merck KGaA silica gel 60 F254. Compounds
were visualised by exposure to UV-light (254 nm) and stained using KMnO4 or
phosphomolybdic acid (PMA) followed by heating. Flash column chromatography
was performed using Fluorochem silica gel LC60A (40-60 μM). Brine refers to
a saturated solution of aqueous sodium chloride. All mixed solvent eluents are
reported as v/v solutions. All amino acid derivatives have S -configuration unless
otherwise stated.
1H- and 13C-Nuclear Magnetic Resonance (NMR) spectra were acquired at various
field strength as indicated using a JEOL ECS 400 MHz spectrometer. 1H spectra
were referenced internally to the residual protic solvent resonance (CDCl3 = 7.27
ppm, CD3OD = 3.31 ppm, DMSO-d6 = 2.50 ppm, (CH2Cl)2 = 3.72 (br.), CF3COOD
= 11.50). 13C-spectra were referenced internally to the solvent resonance (CDCl3
= 77.16 ppm, CD3OD = 49.00 ppm, DMSO-d6 = 39.52 ppm). 1H- and 13C-NMR
coupling constants are reported in Hertz (Hz). Coupling constants are reported using
the following notation, or combination of; s = singlet, br. = broad, d = doublet,
t = triplet, q = quartet, quin = quintet, sex = sextet, sept = septet, oct = octet,
non = nonet, m = multiplet. Assignment of signals in 1H- and 13C-spectra was
performed using 1H-1H COSY, DEPT-135, 1H-13C HMQC and HMBC experiments
where appropriate.
High resolution mass spectra were recorded using Electrospray Ionisation (ESI),
on a Bruker micrOTOF mass spectrometer in tandem with an Agilent series 1200
Liquid Chromatography (LC) system. All Infra-Red (IR) data was obtained using a
Perkin-Elmer Spectrum Two or Spectrum 400 FT-IR spectrometer. Absorbances are
reported using the following notation; w = weak, m = medium, s = strong. Optical
rotations were obtained on a Jasco DIB370 polarimeter, with concentrations given in
g 100 mL-1. Melting points were determined using either a Stuart SMP3 or SMP20
hot stage apparatus and were not corrected.
Chiral normal phase HPLC was performed using Daicel Chiralpak OD or OD-H
columns (4.6 mm × 250 mm × 5 μm) fitted with the respective guard column and
monitored by Diode Array Detector (DAD) on an Agilent Infinity 1220 LC system
equipped with Agilent OpenLab software. Flow rate: 0.7 mL min-1, 97:3 Hexane:
i -PrOH, detection at 210 and 254 nm
Bradykinin samples were analysed on a Bruker microTOF mass spectrometer in
tandem with an Agilent series 1200 LC system with an additional diode array
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detector. Chromatography was carried out at 40 ◦C on a Waters Sunfire C18 column
(3.5 μm packing, 2.1 mm × 100 mm) with a solvent flow rate of 0.2 mL min-1 and
UV detection at 214 nm. A dual solvent system was employed:
Solvent A: MeCN + 0.1% (v/v) formic acid
Solvent B: Water + 0.1% (v/v) formic acid
The solvent system was varied following the sequence: 10% A / 90% B for 5 min,
then ramp to 50% A / 50% B over the next 10 min, hold at 50% A / 50% B for 5
min then ramp back to 10% A / 90% B.
Microwave reactions were carried out in a G10 microwave vial equipped with a
rare Earth stirrer bar, using an Anton Paar Monowave 300 microwave reactor.
The temperature was held at 70 ◦C (monitored using a ruby thermometer) for the
duration of the reaction.
Size-exclusion chromatography was carried out using a set of PSS SDV High
analytical columns (300 mm × 8 mm × 5 μm) of 1000, 105 and 106 Å pore
sizes, with corresponding guard columns, supplied by Polymer Standards Service
GmbH (PSS) and installed on a PSS SECcurity SEC system. Elution was with
THF stabilised by 0.025% butylated hydroxytoluene, at a flow rate of 1.0 mL-1, a
column temperature of 23 ◦C and detection by refractive index. 20 μL of a 1 mg
mL-1 sample in THF, containing one drop of toluene as an internal reference, was
injected for each measurement and eluted for 40 min. Calibration was carried out
in the molecular weight range 400-2×106 Da using ReadyCal polystyrene standards
supplied by Sigma Aldrich.
Modulated differential scanning calorimetry (MDSC) experiments were carried out
on a DSC TA Q2000, under nitrogen atmosphere, at a heating rate of 10 ◦C min-1
up to a temperature of either 100, 200 or 300 ◦C, and using a sample mass of
approximately 10 mg. Thermogravimetric analysis (TGA) was carried out using a
PL Thermal Sciences STA 625 instrument from ambient (22 ◦C) to 625 ◦C at a ramp
rate of 10 ◦C min-1 in an open aluminium sample pan under N2. TG-IR spectroscopy
data was collected using a Netzsch STA 409 instrument at a ramp rate of 10 ◦C min-1
under a 100 mL min-1 flow of nitrogen. This instrument was connected with a heated
gas transfer line to a Bruker Equinox 55 FT-IR spectrometer equipped with a gas
cell and an MCT detector.
Diffraction data were collected at 110 K on an Oxford Diffraction SuperNova
diffractometer with Cu-Kα radiation (λ = 1.54184 Å) using an EOS CCD camera.
The crystal was cooled with an Oxford Instruments Cryojet. Diffractometer control,
data collection, initial unit cell determination, frame integration and unit-cell
refinement was carried out with "Crysalis". Face-indexed absorption corrections
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were applied using spherical harmonics, implemented in SCALE3 ABSPACK
scaling algorithm. OLEX2 was used for overall structure solution, refinement
and preparation of computer graphics and publication data. Within OLEX2, the
algorithm used for structure solution was ShelXT, charge-flipping. Refinement by
full-matrix least-squares used the SHELXL algorithm within OLEX2. Hydrogen
atoms were placed using a ”riding-mode“ and included in the refinement at calculated
positions.
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7.2 Cyclic Carbonates as Solvents for Peptide Synthesis
7.2.1 Solution-Phase Peptide Synthesis
7.2.1.1 General Procedure for Peptide Coupling Reactions in PC
To a suspension of an N -Boc-amino acid (1.0 eq.) and an amino acid or peptide
benzyl ester (1.0 eq.) in PC (5 mL mmol-1), at 0 ◦C, was added a solution of HOBt
(1.1 eq.) and i -Pr2EtN (3.0 eq.) in a minimal quantity of PC. EDC (1.1 eq.) was
added dropwise and the reaction mixture was allowed to stir at room temperature
for 16 h. The reaction mixture was then diluted using EtOAc (50 mL) and washed
with 1 M HClaq (3 × 25 mL), saturated Na2CO3 (3 × 25 mL) and H2O (3 × 25
mL). The organic layer was dried (MgSO4), filtered and concentrated in vacuo. Any
residual PC was removed via short path distillation.
7.2.1.2 Synthesis of Boc-Ala-Phe-OBn 2.89 in a Microwave Reactor
N -Boc-alanine (189 mg, 1.0 mmol, 1.0 eq.), phenylalanine benzyl ester (292 mg, 1.0
mmol, 1.0 eq.) and HOBt (149 mg, 1.0 mmol, 1.1 eq.) were combined in a G10
microwave vial. PC (2 mL) and i -Pr2EtN (523 μL, 3.0 mmol, 6.0 eq.) were then
added. The vial was cooled to 0 ◦C and EDC (195 μL, 1.1 mmol, 1.1 eq.) was added
dropwise. The reaction mixture was then heated at 70 ◦C for 3 h using an Anton Parr
Monowave 300 microwave reactor. The reaction was then diluted with EtOAc (50
mL) and washed with 1 M HClaq (50 mL), saturated Na2CO3 (50 mL) and brine (50
mL). The organic fraction was dried (MgSO4), filtered and concentrated in vauco.
Residual PC was removed via short path distillation. The residue was purified using
flash column chromatography (40:60, EtOAc:PE) to give Boc-Ala-Phe-OBn 2.89 as
a white solid (352 mg, 82%).
7.2.1.3 General Procedure for Boc Deprotections in PC
An N -Boc-peptide benzyl ester (1.0 eq.) was dissolved in a minimum amount of PC
and trifluoroacetic acid (60 eq.) was added. The reaction mixture was allowed to
stir for 3 h at room temperature before being concentrated in vacuo. Any residual
PC was removed via short path distillation.
7.2.1.4 Procedure for Boc Deprotection of Dipeptide 2.89 using HCl in
PC
Boc-Ala-Phe-OBn 2.89 (50 mg, 0.117 mmol) was dissolved in PC (2.34 mL). MeOH
(0.40 mL, 9.8 mmol) was added and the solution cooled to 0 ◦C. Acetyl chloride
(0.67 mL, 9.36 mmol) was added dropwise and the solution allowed to stir at room
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temperature for 2 h. Residual PC was removed via short path distillation. The
residue was suspended in cold Et2O and triturated to give HCl·H-Ala-Phe-OBn
2.101 as a white solid (46 mg, 86%).
Boc-Ala-Phe-OBn (2.103a)
Boc-Ala-OH (324 mg, 1.71 mmol) and HCl·H-Phe-OBn (500 mg, 1.71 mmol) were
coupled according to the general coupling procedure. The residue was purified using
flash column chromatography (35:65, EtOAc:PE) to give Boc-Ala-Phe-OBn 2.103a
as a white crystalline solid (682 mg, 93%).125,241 RF = 0.34, (40:60, EtOAc:PE);
m.p. 95-96 ◦C; [α]23D = − 27.7 (c 1.0 in MeOH) [lit.125 − 35 (c 0.35 in MeOH)];
IR (Neat) νmax 3347 (m), 3063 (w), 3029 (w), 2928 (m), 2852 (w), 1735 (w), 1684
(w) 1666 (w) and 1521 (s) cm-1; 1H NMR (400 MHz, CDCl3): δ = 7.36-7.31 (m,
3H, ArH), 7.29-7.24 (m, 2H, ArH), 7.26-7.21 (m, 3H, ArH), 7.04-6.97 (m, 2H, ArH),
6.72 (d J 7.7 Hz, 1H, Phe-NH), 5.16-5.10 (m, 1H, Ala-NH), 5.13 (d J 12.1 Hz, 1H,
OCH2Ph), 5.07 (d J 12.1 Hz, 1H, OCH2Ph), 4.88 (dt J 7.7, 5.9 Hz, 1H, Phe-NCH),
4.11 (br, 1H, Ala-NCH), 3.13 (dd J 13.9, 6.1 Hz, 1H, CH2Ph), 3.08 (dd J 13.9, 6.1
Hz, 1H, CH2Ph), 1.41 (s, 9H, C(CH3)3), 1.29 (d J 6.6 Hz, 3H, CH3); 13C NMR (100
MHz, CDCl3): δ = 172.3 (C=O), 171.2 (C=O), 155.6 (NC=O), 135.7 (ArC), 135.1
(ArC), 129.5 (ArCH), 128.7 (ArCH), 128.6 (ArCH), 127.2 (ArCH), 80.2 (CMe3),
67.4 (OCH2Ph), 53.3 (Phe-NCH), 50.3 (Ala-NCH), 38.0 (CH2Ph), 28.4 (C(CH3)3),
18.5 (CH3); HRMS (ESI) m/z calculated for C24H30N2NaO5 449.2048 (M+Na)+,
found 449.2047, 0.6 ppm error.
Boc-(R)-Ala-Phe-OBn 2.96
Boc-(R)-Ala-OH (164 mg, 0.87 mmol) and HCl·H-Phe-OBn (250 mg, 0.87 mmol)
were coupled according to the general coupling procedure. The residue was purified
using flash column chromatography (40:60, EtOAc:PE) to give Boc-(R)-Ala-Phe-
OBn 2.96 as an off-white solid (323 mg, 87%). RF = 0.38, (40:60, EtOAc:PE);
m.p. 75-76 ◦C; [α]23D = 6.5 (c 1.0 in MeOH); IR (Neat) νmax 3294 (m), 3066 (w),
3030 (w), 2977 (m), 2930 (m), 1717 (m), 1687 (m) and 1648 (s) cm-1; 1H NMR
193
Chapter 7. Experimental
(400 MHz, CDCl3): δ = 7.39-7.32 (m, 3H, ArH), 7.32-7.27 (m, 2H, ArH), 7.25-7.16
(m, 3H, ArH), 7.06-6.98 (m, 2H, ArH), 6.80 (br, 1H, Phe-NH), 5.15 (d J 12.4 Hz,
1H, OCH2Ph), 5.11 (br, 1H, Ala-NH), 5.08 (d J 12.4 Hz, 1H, OCH2Ph), 4.90 (dt
J 7.7, 6.2 Hz, 1H, Phe-NCH), 4.20 (br, 1H, Ala-NCH), 3.13 (dd J 13.9, 6.0 Hz,
1H, CH2Ph), 3.07 (dd J 13.9, 6.0 Hz, 1H, CH2Ph), 1.42 (s, 9H, C(CH3)3), 1.27
(d J 7.1 Hz, 3H, CH3); 13C NMR (100 MHz, CDCl3): δ = 172.3 (C=O), 171.3
(C=O), 155.6 (NC=O), 135.7 (ArC), 135.2 (ArC), 129.4 (ArCH), 128.8 (ArCH),
128.7 (ArCH), 128.6 (ArCH), 127.2 (ArCH), 80.3 (CMe3), 67.4 (OCH2Ph), 53.2
(Phe-NCH), 50.1 (Ala-NCH), 38.0 (CH2Ph), 28.4 (C(CH3)3), 18.5 (CH3); HRMS
(ESI) m/z calculated for C24H31N2O5 427.2155 (M+H)+, found 427.2227, − 0.3
ppm error.
Boc-Leu-Phe-OBn 2.103b
Boc-Leu-OH (100 mg, 0.43 mmol) and HCl·H-Phe-OBn (110 mg, 0.43 mmol) were
coupled according to the general coupling procedure. The residue was purified using
flash column chromatography (40:60, EtOAc:PE) to give Boc-Leu-Phe-OBn 2.103b
as a white powder (162 mg, 80%).242 RF = 0.42, (30:70, EtOAc:PE); m.p. 100-102
◦C (lit. 103-105 ◦C); [α]23D = − 27.4 (c 1.0 in MeOH) [lit. − 33.8 (c 1.0 in MeOH)];
IR (Neat) νmax 3339 (m), 3064 (w), 3034 (w), 2956 (w), 2935 (w), 2879 (w), 1731
(s), 1679 (m), 1665 (s) and 1518 (s) cm-1; 1H NMR (400 MHz, CDCl3): δ = 7.39-
7.34 (m, 3H, ArH), 7.29-7.26 (m, 2H, ArH), 7.22-7.19 (m, 3H, ArH), 7.03-7.01 (m,
2H, ArH), 6.53 (d J 7.6 Hz, 1H, Phe-NH), 5.15 (d J 12.0 Hz, 1H, OCH2Ph), 5.10
(d J 12.0 Hz, 1H, OCH2Ph), 4.88 (dt J 7.7, 6.0 Hz, 1H, Phe-NCH), 4.86 (br, 1H,
Leu-NH), 4.08 (br, 1H, Leu-NCH), 3.14 (dd J 14.0, 6.4 Hz, 1H, CH2Ph), 3.09 (dd
J 14.0, 6.4 Hz, 1H, CH2Ph), 1.68-1.58 (m, 2H, CH2CHMe2), 1.43 (s, 9H, C(CH3)3),
1.45-1.35 (m, 1H, CH(Me)2), 0.90 (d J 6.4 Hz, 3H, CH(CH3)2), 0.89 (d J 6.4 Hz, 3H,
CH(CH3)2); 13C NMR (100 MHz, CDCl3): δ = 172.3 (C=O), 171.2 (C=O), 155.6
(NC=O), 135.7 (ArC), 135.1 (ArC), 129.5 (ArCH), 128.7 (ArCH), 128.6 (ArCH),
127.2 (ArCH), 80.1 (CMe3), 67.4 (OCH2Ph), 53.3 (Phe-NCH), 53.2 (Leu-NCH), 41.4
(CH2CHMe2), 38.0 (CH2Ph), 28.4 (C(CH3)3), 24.8 (CHMe2), 23.0 (CH(CH3)2), 22.0
(CH(CH3)2); HRMS (ESI) m/z calculated for C27H37N2O5 469.2697 (M+H)+,
found 469.2691, 1.2 ppm error.
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Boc-(R)-Leu-Phe-OBn 2.98
Boc-(R)-Leu-OH (100 mg, 0.43 mmol) and HCl·H-Phe-OBn (110 mg, 0.43 mmol)
and were coupled according to the general coupling procedure. The residue was
purified using flash column chromatography (20:80-30:70, EtOAc:PE) to give Boc-
(R)-Leu-Phe-OBn 2.98 as a white powder (187 mg, 92%).243 RF = 0.48, (30:70,
EtOAc:PE); m.p. 96-97 ◦C (lit. 97 ◦C); [α]23D = +4.8 (c 1.0 in MeOH); IR
(Neat) νmax 3334 (m), 3064 (w), 3031 (w), 2961 (w), 1739 (m), 1726 (m), 1686 (m),
1652 (s) and 1519 (s) cm-1; 1H NMR (400 MHz, CDCl3): δ = 7.39-7.34 (m, 3H,
ArH), 7.31-7.28 (m, 2H, ArH), 7.22-7.19 (m, 3H, ArH), 7.04-7.00 (m, 2H, ArH), 6.61
(d J 6.4 Hz, 1H, Phe-NH), 5.17 (d J 12.0 Hz, 1H, OCH2Ph), 5.10 (d J 12.4 Hz, 1H,
OCH2Ph), 4.89 (dt J 7.9, 6.0 Hz, 1H, Phe-NCH), 4.78 (d J 6.8 Hz, 1H, Leu-NH),
4.17-4.05 (m, 1H, Leu-NCH), 3.13 (dd J 14.0, 6.0 Hz, 1H, CH2Ph), 3.08 (dd J 14.0,
6.4 Hz, 1H, CH2Ph), 1.65-1.50 (m, 2H, CH2CHMe2), 1.42 (s, 9H, C(CH3)3), 1.41-1.30
(m, 1H, CH2CH(CH3)2), 0.88 (d J 6.0 Hz, 6H, CH(CH3)2); 13C NMR (100 MHz,
CDCl3): δ = 172.3 (C=O), 171.3 (C=O), 155.7 (NC=O), 135.7 (ArC), 135.1 (ArC),
129.4 (ArCH), 128.8 (ArCH), 128.7 (ArCH), 128.6 (ArCH), 127.2 (ArCH), 80.2
(OCMe3), 67.4 (OCH2Ph), 53.2 (Phe-NCH), 53.1 (Leu-NCH), 41.3 (CH2CHMe2),
38.0 (CH2Ph), 28.4 (C(CH3)3), 24.8 (CHMe2), 23.0 (CH(CH3)2), 21.9 (CH(CH3)2);
HRMS (ESI) m/z calculated for C27H37N2O5 469.2697 (M+H)+, found 469.2694,
0.2 ppm error.
Boc-Met-Val-OBn 2.103c
Boc-Met-OH (374 mg, 1.5 mmol) and H-Val-OBn (569 mg, 1.5 mmol) were coupled
according to the general coupling procedure. The residue was purified using flash
column chromatography (30:70, EtOAc:PE) to give Boc-Met-Val-OBn 2.103c as a
clear oil (603 mg, 91%).244 RF = 0.33, (30:70, EtOAc:PE); [α]23D = − 25.1 (c 1.0
in MeOH); IR (Neat) νmax 3314 (w), 2968 (w), 2932 (w), 1739 (m), 1658 (s) and
1521 (m) cm-1; 1H NMR (400 MHz, CDCl3): δ = 7.39-7.29 (m, 5H, ArH), 6.72 (d
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J 8.2 Hz, 1H, Val-NH), 5.23 (br, 1H, Met-NH), 5.19 (d J 12.4 Hz, 1H, OCH2Ph),
5.12 (d J 12.4 Hz, 1H, OCH2Ph), 4.56 (dd J 8.8, 4.7 Hz, 1H, Val-NCH), 4.31 (dt J
7.3, 7.1 Hz, 1H, Met-NCH), 2.58 (t J 7.2 Hz, 2H, CH2CH2SMe), 2.21 (dsept J 7.0,
4.7 Hz, 1H, CHMe2), 2.09 (s, 3H, SCH3), 2.03 (dt J 14.0, 7.1 Hz, 1H, CH2CH2SMe),
1.95 (dt J 14.0, 7.1 Hz, 1H, CH2CH2SMe), 1.43 (s, 9H, C(CH3)3), 0.91 (d J 7.0 Hz,
3H, CH(CH3)2), 0.86 (d J 7.0 Hz, 3H, CH(CH3)2); 13C NMR (100 MHz, CDCl3):
δ = 171.6 (C=O), 171.5 (C=O), 155.6 (NC=O), 135.4 (ArC), 128.7 (ArCH), 128.6
(ArCH), 128.5 (ArCH), 80.2 (CMe3), 67.2 (OCH2Ph), 57.3 (Val-NCH), 53.3 (Met-
NCH), 31.3 (CH2SMe), 31.2 (CHMe2), 30.2 (CH2CH2SMe), 28.4 (C(CH3)3), 19.1
(CH(CH3)2), 17.6 (CH(CH3)2), 15.2 (CH2SCH3); HRMS (ESI) m/z calculated
for C22H34N2NaO5 461.2086 (M+Na)+, found 461.2081, − 2.2 ppm error.
Boc-Asp(OBn)-Val-OBn 2.103d
Boc-Asp(OBn)-OH (808 mg, 2.5 mmol) and H-Val-OBn para-toluenesulfonate (949
mg, 25 mmol) were coupled according to the general coupling procedure. The residue
was purified using flash column chromatography (25:75, EtOAc:PE) to give Boc-
Asp(OBn)-Val-OBn 2.103d as a pale yellow oil (897 mg, 70%).245 RF = 0.29, (25:75,
EtOAc:PE); [α]23D = − 28.4 (c 1.0 in MeOH) [lit. − 33.3 (c 1.07 in MeOH)]; IR
(Neat) νmax 3332 (w), 3033 (w), 2967 (w), 2934 (w), 1734 (s), 1679 (s) and 1517
(m) cm-1; 1H NMR (400 MHz, CDCl3): δ = 7.40-7.29 (m, 10H, ArH), 7.07 (d J
8.9 Hz, 1H, NH), 5.75 (d J 8.2 Hz, 1H, NH), 5.19 (d J 12.0 Hz, 1H, OCH2Ph),
5.17-5.08 (m, 3H, 3×OCH2Ph) 4.61-4.50 (m, 2H, 2×NCH), 3.03 (dd J 17.2, 4.7 Hz,
1H, CH2CO2) 2.71 (dd J 17.2, 4.7 Hz, 1H, CH2CO2), 2.26-2.12 (m, 1H, CHMe2),
1.45 (s, 9H, C(CH3)3), 0.91 (d J 6.9 Hz, 1H, CH(CH3)2), 0.86 (d J 6.9 Hz, 1H,
CH(CH3)2); 13C NMR (100 MHz, CDCl3): δ = 172.1 (C=O), 171.4 (C=O), 170.8
(C=O), 155.8 (NC=O), 135.6 (CAr), 135.4 (CAr), 128.7 (ArCH), 128.6 (ArCH),
128.5 (ArCH), 128.4 (ArCH), 128.3 (ArCH), 80.6 (CMe3), 67.1 (OCH2Ph), 67.0
(OCH2Ph), 57.5 (Val-NCH), 50.7 (Asp(OBn)-NCH), 36.0 (CH2CO2), 31.3 (CHMe2),
28.4 (C(CH3)3), 19.1 (CH(CH3)2), 17.6 (CH(CH3)2); HRMS (ESI) m/z calculated
for C28H36N2NaO7 535.2429 (M+Na)+, found 535.2417, − 0.1 ppm error.
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Boc-Aib-Leu-OBn 2.103e
Boc-Aib-OH (508 mg, 2.5 mmol) and H-Leu-OBn para-toluenesulfonate (934 mg,
2.5 mmol) were coupled according to the general coupling procedure. The residue
was purified using flash column chromatography (30:70, EtOAc:PE) to give Boc-
Aib-Leu-OBn 2.103e as a white powder (794 mg, 78%).246 RF = 0.25, (25:75,
EtOAc:PE); m.p. 93-95 ◦C; [α]23D = − 16.3 (c 0.5 in MeOH); IR (Neat) νmax
3308 (m), 2953 (m), 2869 (w), 1720 (m), 1685 (s), 1659 (s), 1534 (m) and 1507 (s)
cm-1; 1H NMR (400 MHz, CDCl3): δ = 7.39-7.29 (m, 5H, ArH), 6.88 (br, 1H,
NH), 5.16 (d J 12.4 Hz, 1H, OCH2Ph), 5.11 (d J 12.4 Hz, 1H, OCH2Ph), 4.89
(br, 1H, NH), 4.66-4.60 (m, 1H, NCH), 1.72-1.56 (m, 3H, CH2CHMe2), 1.49 (s, 3H,
C(CH3)2), 1.45 (s, 3H, C(CH3)2), 1.42 (s, 9H, C(CH3)3), 0.91 (d J 6.6 Hz, 3H,
CH(CH3)2), 0.89 (d J 6.6 Hz, 3H, CH(CH3)2); 13C NMR (100 MHz, CDCl3):
δ = 174.5 (C=O), 173.0 (C=O), 154.7 (NC=O), 135.6 (ArC), 128.7 (ArCH),
128.5 (ArCH), 128.3 (ArCH), 77.4 (OCMe3), 67.1 (OCH2Ph), 56.9 (NCMe2), 50.9
(NCH), 41.7 (CH2CHMe2), 28.4 (C(CH3)3), 26.3 (CH2CHMe2), 24.8 (C(CH3)2), 23.0
(CH(CH3)2), 21.9 (CH(CH3)2); HRMS (ESI) m/z calculated for C22H34N2NaO5
429.2365 (M+Na)+, found 429.2373, − 2.7 ppm error.
TFA·H-Ala-Phe-OBn 2.104a
Boc-Ala-Phe-OBn 2.103a (340 mg, 0.8 mmol) was deprotected according to the
general procedure for Boc deprotections to give TFA·H-Ala-Phe-OBn 2.104a as an
off white solid (351 mg, 99%).247 m.p. 180-181 ◦C; [α]23D = − 8.1 (c 0.5 in MeOH);
IR (Neat) νmax 3333 (m), 3165 (w), 3031 (w), 2938 (w), 1725 (s), 1660 (s), 1547
(m) and 1523 (m) cm-1; 1H NMR (400 MHz, CD3OD): δ = 7.40-7.15 (m, 10H,
ArH), 5.16 (d J 12.1 Hz, 1H, OCH2Ph), 5.11 (d J 12.1 Hz, 1H, OCH2Ph), 4.76
(dd J 8.9, 5.8 Hz, 1H, Phe-NCH), 3.86 (q J 6.8 Hz, 1H, Ala-NCH), 3.20 (dd J
14.1, 5.9 Hz, 1H, CH2Ph), 2.98 (dd J 14.1, 5.9 Hz, 1H, CH2Ph), 1.42 (d J 6.9 Hz,
3H, CH3); 13C NMR (100 MHz, CD3OD): δ = 172.4 (C=O), 171.1 (C=O), 137.9
(ArC), 136.9 (ArC), 130.2 (ArCH), 129.6 (ArCH), 129.6 (ArCH), 129.6 (ArCH),
197
Chapter 7. Experimental
129.5 (ArCH), 128.0 (ArCH), 68.2 (OCH2Ph), 55.6 (Phe-NCH), 50.0 (Ala-NCH),
38.1 (CH2Ph), 17.6 (CH3); HRMS (ESI) m/z calculated for C19H23N2O3 327.1709
(M-CF3CO2
–)+, found 327.1695, 2.3 ppm error.
TFA·H-Leu-Phe-OBn 2.104b
Boc-Leu-Phe-OBn 2.103b (600 mg, 1.28 mmol) was deprotected according to the
general procedure for Boc deprotections to give TFA·H-Leu-Phe-OBn 2.104b as
an off white solid (1.33 g, 99%).248 m.p. 172-174 ◦C; IR (Neat) νmax 2960 (w),
2485 (w), 1731 (s), 1723 (s), 1679 (m), 1674 (s), 1665 (s) and 1518 (s) cm-1; 1H
NMR (400 MHz, CD3OD): δ = 7.35-7.30 (m, 3H, ArH), 7.29-7.23 (m, 4H, ArH),
7.22-7.16 (m, 3H, ArH), 5.12 (d J 12.0 Hz, 1H, OCH2Ph), 5.08 (d J 12.0 Hz, 1H,
OCH2Ph), 4.74 (dd J 8.8, 6.0 Hz, 1H, Phe-NCH), 4.59 (br, 1H, NH), 3.77 (dd
J 8.8, 6.0 Hz, 1H, Leu-NCH), 3.18 (dd J 14.0, 6.4 Hz, 1H, CH2Ph), 3.01 (dd J
14.0, 8.8 Hz, 1H, CH2Ph), 1.73-1.53 (m, 2H, CH2CHMe2), 0.91 (d J 6.4 Hz, 3H,
CH(CH3)2), 0.90 (d J 6.4 Hz, 3H, CH(CH3)3); 13C NMR (100 MHz, CD3OD): δ =
172.3 (C=O), 170.9 (C=O), 137.9 (ArC), 136.9 (ArC), 130.2 (ArCH), 129.6 (ArCH),
129.6 (ArCH), 129.6 (ArCH), 129.5 (ArCH), 128.0 (ArCH), 68.2 (OCH2Ph), 55.7
(Phe-NCH), 52.7 (Leu-NCH), 41.7 (CH2CHMe2), 38.0 (CH2Ph), 25.2 (CH(Me)2),
23.2 (CH(CH3)2), 21.8 (CH(CH3)2); HRMS (ESI) m/z calculated for C22H29N2O3
369.2173 (M-CF3CO2
–)+, found 369.2173, 0.3 ppm error.
TFA·H-Met-Val-OBn 2.104c
Boc-Met-Val-OBn 2.103c (603 mg, 1.37 mmol) was deprotected according to the
general procedure for Boc deprotections to give TFA·H-Met-Val-OBn 2.104c as a
white solid (474 mg, 80%). m.p. 169-170 ◦C; [α]23D = − 10.0 (c 1.0 in MeOH); IR
(Neat) νmax 3344 (w), 2975 (w), 1693 (s), 1663 (s), 1544 (m) and 1518 (m) cm-1; 1H
NMR (400 MHz, DMSO-d6): δ = 8.74 (d J 7.9 Hz, 1H, NH), 8.20 (br, 3H, NH3
+),
7.41-7.32 (m, 5H, ArH), 5.16 (d J 12.0 Hz, 1H, OCH2Ph), 5.13 (d J 12.0 Hz, 1H,
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OCH2Ph), 4.26 (dd J 7.5, 6.1 Hz, 1H, Val-NCH), 3.97 (t J 6.2 Hz, 1H, Met-NCH),
2.50-2.44 (m, 2H, CH2SMe), 2.19-2.06 (m, 1H, CHMe2), 2.01 (s, 3H, SCH3), 2.02-
1.89 (m, 2H, CH2CH2SMe), 0.91 (d J 6.8 Hz, 3H, CH(CH3)2), 0.90 (d J 6.8 Hz, 3H,
CH(CH3)2); 13C NMR (100 MHz, DMSO-d6): δ = 170.9 (C=O), 168.9 (C=O),
135.7 (ArC), 128.5 (ArCH), 128.2 (ArCH), 128.1 (ArCH), 66.2 (OCH2Ph), 57.8
(Val-NCH), 51.4 (Met-NCH), 31.2 (CH2CH2SMe), 29.7 (CHMe2), 28.0 (CH2SMe),
18.9 (CH(CH3)2), 18.0 (CH(CH3)2), 14.5 (SCH3); HRMS (ESI) m/z calculated
for C17H27N2O3S 339.1742 (M-CF3CO2
–)+, found 339.1737, 2.9 ppm error.
TFA·H-Asp(OBn)-Val-OBn 2.104d
Boc-Asp(OBn)-Val-OBn 2.103d (747 mg, 1.46 mmol) was deprotected according
to the general procedure for Boc deprotections to give TFA·H-Asp(OBn)-Val-OBn
2.104d as an off-white solid (650 mg, 85%). m.p. 147-148 ◦C; [α]23D = − 16.0 (c
1.0 in MeOH); IR (Neat) νmax 3328 (m), 3032 (w), 2976 (w), 2884 (w), 2586 (w),
1734 (m), 1705 (s), 1661 (s), 1558 (m) and 1519 (w) cm-1; 1H NMR (400 MHz,
DMSO-d6): δ = 8.77 (d J 8.2 Hz, 1H, NH), 8.34 (br, 3H, NH3+), 7.46-7.27 (m,
10H, ArH), 5.20-5.07 (m, 4H, 2×OCH2Ph), 4.33-4.24 (m, 2H, 2×NCH), 2.88 (dd J
17.6, 3.9 Hz, 1H, CH2CO2Bn), 2.78 (dd J 17.6, 8.9 Hz, 1H, CH2CO2Bn) 2.11 (oct
J 6.7 Hz, 1H, CHMe2), 0.89 (d J 7.3 Hz, 3H, CH(CH3)2), 0.87 (d J 7.3 Hz, 3H,
CH(CH3)2); 13C NMR (100 MHz, DMSO-d6): δ = 170.7 (C=O), 169.1 (C=O),
168.9 (C=O), 135.7 (ArC), 135.6 (ArC), 128.5 (ArCH), 128.5 (ArCH), 128.3 (ArCH),
128.3 (ArCH), 128.2 (ArCH), 66.4 (OCH2Ph), 66.3 (OCH2Ph), 57.8 (Val-NCH), 48.6
(Asp-NCH), 35.5 (CH2CO2Bn), 29.8 (CHMe2), 18.9 (CH(CH3)2), 17.9 (CH(CH3)2);
HRMS (ESI) m/z calculated for C23H29N2O5 413.2076 (M-CF3CO2
–)+, found
413.2060, 3.5 ppm error.
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TFA·H-Aib-Leu-OBn 2.104e
Boc-Aib-Leu-OBn 2.103e (100 mg, 0.25 mmol) was deprotected according to the
general procedure for Boc deprotections to give TFA·H-Aib-Leu-OBn 2.104e as a
yellow oil (102 mg, 97%). IR (Neat) νmax 2960 (w), 1728 (m), 1661 (s) and 1530 (m)
cm-1; 1H NMR (400 MHz, DMSO-d6): δ = 8.59 (d J 8.3 Hz, 1H, NH), 8.23 (s, 3H,
NH3
+), 7.42-7.31 (m, 5H, ArH), 5.13 (d J 12.9 Hz, 1H, OCH2Ph), 5.10 (d J 12.9 Hz,
1H, OCH2Ph), 4.44-4.37 (m, 1H, Leu-NCH), 1.77-1.52 (m, 3H, CH2CHMe2), 1.48
(s, 3H, C(CH3)2), 1.45 (s, 3H, C(CH3)2), 0.90 (d J 6.1 Hz, 3H, CH(CH3)2), 0.83 (d J
6.1 Hz, 3H, CH(CH3)2); 13C NMR (100 MHz, DMSO-d6): δ = 172.0 (C=O), 171.9
(C=O), 135.8 (ArC), 128.5 (ArCH), 128.2 (ArCH), 127.9 (ArCH), 66.2 (OCH2Ph),
56.4 (Aib-NC), 50.8 (Leu-NCH), 39.3 (CH2CHMe2), 24.4 (CHMe2), 23.4 (C(CH3)2),
23.3 (C(CH3)2), 22.8 (CH(CH3)2), 20.9 (CH(CH3)2); HRMS (ESI) m/z calculated
for C17H27N2O3 307.2022 (M-CF3CO2
–)+, found 307.2008, 2.0 ppm error.
Boc-Leu-Ala-Phe-OBn 2.105a
Boc-Leu-OH (185 mg, 0.8 mmol) and TFA·H-Ala-Phe-OBn 2.104a (352 mg, 0.8
mmol) were coupled according to the general coupling procedure. The residue was
purified using flash column chromatography (35:65-60:40, EtOAc:PE) to give Boc-
Leu-Ala-Phe-OBn 2.105a as a white solid (325 mg, 75%). RF = 0.35, (60:40,
EtOAc:PE); m.p. 143-145 ◦C; [α]23D = − 37.4 (c 1.0 in MeOH); IR (Neat) νmax
3326 (m), 2955 (w), 1983 (w), 1730 (m), 1688 (m), 1639 (s) and 1523 (m) cm-1; 1H
NMR (400 MHz, CDCl3): δ = 7.38-7.29 (m, 3H, ArH), 7.29-7.22 (m, 2H, ArH),
7.21-7.13 (m, 3H, ArH), 7.04-6.91 (m, 2H, ArH), 6.65 (d J 7.1 Hz, Ala-NH), 6.59 (d J
7.0 Hz, Phe-NH), 5.14 (d J 12.0 Hz, 1H, OCH2Ph), 5.06 (d J 12.0 Hz, 1H, OCH2Ph),
4.90 (br, 1H, Leu-NH), 4.87 (dt J 7.5, 6.9 Hz, 1H, Phe-NCH), 4.46 (q J 7.2 Hz, 1H,
Ala-NCH), 4.09 (br, 1H, Leu-NCH), 3.10 (dd J 14.2, 6.6 Hz, CH2Ph), 3.05 (dd J
14.2, 6.6 Hz, CH2Ph), 1.70-1.58 (m, 1H, CHMe2), 1.59-1.51 (m, 2H, CH2CHMe2),
1.42 (s, 9H, OC(CH3)3), 1.29 (d, J 7.2 Hz, 3H, NCHCH3), 0.90 (d J 6.6 Hz, 6H,
CH(CH3)2); 13C NMR (100 MHz, CDCl3): δ = 172.6 (C=O), 171.8 (C=O), 171.2
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(C=O), 155.8 (NC=O), 135.7 (ArC), 135.1 (ArC), 129.3 (ArCH), 128.7 (ArCH),
128.6 (ArCH), 127.2 (ArCH), 80.2 (OCMe3), 67.4 (OCH2Ph), 53.5 (Phe-NCH), 53.0
(Leu-NCH), 48.9 (Ala-NCH), 41.2 (CH2CHMe2), 37.9 (CH2Ph), 28.4 (OC(CH3)3),
24.8 (CH(CH3)2), 23.2 (CH(CH3)2), 21.9 (CHMe2), 18.3 (NCHCH3); HRMS (ESI)
m/z calculated for C30H41N3NaO6 562.3074 (M+Na)+, found 562.2888, − 1.3 ppm
error.
Boc-(R)-Leu-Ala-Phe-OBn 2.101
Boc-(R)-Leu-OH (69 mg, 0.3 mmol) and TFA·H-Ala-Phe-OBn 2.104a (164 mg, 0.3
mmol) were coupled according to the general coupling procedure. The residue was
purified using flash column chromatography (30:20:50-40:20:40, EtOAc:CH2Cl2:PE)
to give Boc-(R)-Leu-Ala-Phe-OBn 2.101 as a white solid (132 mg, 82%). RF = 0.18,
(30:20:50, EtOAc:CH2Cl2:PE); m.p. 131-133 ◦C; [α]23D = 9.3 (c 1.0 in MeOH);
IR (Neat) νmax 3319 (m), 3277 (m), 2930 (w), 1730 (m), 1686 (m), 1638 (s) and
1528 (s) cm-1; 1H NMR (400 MHz, CDCl3): δ = 7.37-7.32 (m, 3H, ArH), 7.29-
7.24 (m, 2H, ArH), 7.23-7.18 (m, 3H, ArH), 7.05-7.00 (m, 2H, ArH), 6.67 (br, 1H,
Phe-NH), 6.60 (d J 7.6 Hz, 1H, Ala-NH), 5.14 (d J 12.3 Hz, 1H, OCH2Ph), 5.08
(d J 12.3 Hz, 1H, OCH2Ph), 4.88-4.78 (m, 2H, Leu-NH + Phe-NCH), 4.50 (q J
7.3 Hz, 1H, Ala-NCH), 4.06 (br, 1H, Leu-NCH), 3.12 (dd J 14.0, 5.1 Hz, 1H,
CH2Ph), 3.05 (dd J 14.0, 5.1 Hz, 1H, CH2Ph), 1.69-1.55 (m, 3H, CH2CHMe2),
1.43 (s, 9H, C(CH3)3), 1.29 (d J 6.3 Hz, 3H, NCHCH3), 0.92 (d J 6.2 Hz, 3H,
CH(CH3)2), 0.91 (d J 6.2 Hz, 3H, CH(CH3)2); 13C NMR (100 MHz, CDCl3):
δ = 172.5 (C=O), 171.8 (C=O), 171.2 (C=O), 155.8 (NC=O), 135.2 (ArC), 129.4
(ArC), 128.7 (ArCH), 128.7 (ArCH), 127.2 (ArCH), 80.3 (OCMe3), 67.4 (OCH2Ph),
53.5 (Phe-NCH), 53.3 (Leu-NCH), 48.8 (Ala-NCH), 41.3 (Leu-CH2CHMe2), 34.7
(CH2Ph), 28.4 (C(CH3)3), 24.9 (CH(CH3)2), 23.1 (CH(CH3)2), 22.0 (CHMe2), 18.1
(NCHCH3); HRMS (ESI) m/z calculated for C30H41N3NaO6 562.2893 (M+Na)+,
found 562.2876, 1.9 ppm error.
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Boc-Gly-Leu-Phe-OBn 2.105b
Boc-Gly-OH (145 mg, 0.83 mmol) and TFA·H-Leu-Phe-OBn 2.104b (400 mg, 0.83
mmol) were coupled according to the general coupling procedure. The residue was
purified using flash column chromatography (50:50-60:40, EtOAc:PE) to give Boc-
Gly-Leu-Phe-OBn 2.105b as a white powder (371 mg, 78%).249 RF = 0.46, (50:50,
EtOAc:PE); m.p. 86-87 ◦C; [α]23D = − 23.4 (c 1.0 in MeOH); IR (Neat) νmax
3295 (w), 2958 (w), 1714 (s), 1640 (s) and 1546 (m) cm-1; 1H NMR (400 MHz,
CDCl3): δ = 7.38-7.34 (m, 3H, ArH), 7.30-7.27 (m, 2H, ArH), 7.24-7.20 (m, 3H,
ArH), 7.04-7.02 (m, 2H, ArH), 6.57 (d J 7.6 Hz, 1H, Phe-NH), 6.46 (d J 8.4 Hz,
1H, Leu-NH), 5.26 (t J 5.7 Hz, 1H, Gly-NH), 5.16 (d J 12.4 Hz, 1H, OCH2Ph),
5.10 (d J 12.4 Hz, 1H, OCH2Ph), 4.87 (dt J 8.0, 6.4 Hz, 1H, Phe-NCH), 4.50-
4.40 (m, 1H, Leu-NCH), 3.76 (dd J 16.8, 5.6 Hz, 1H, Gly-NCH2), 3.67 (dd J 16.8,
5.2 Hz, 1H, Gly-NCH2), 3.14 (dd J 14, 6.0 Hz, 1H, CH2Ph), 3.06 (dd J 14.0,
6.4 Hz, 1H, CH2Ph), 1.65-1.54 (m, 2H, CH2CHMe2), 1.53-1.46 (m, 1H, CHMe2),
1.45 (s, 9H, OC(CH3)3), 0.87 (d J 6.0 Hz, 3H, CH(CH3)2), 0.86 (d J 6.0 Hz, 3H,
CH(CH3)2); 13C NMR (100 MHz, CDCl3): δ = 171.6 (C=O), 171.2 (C=O), 169.6
(C=O), 156.1 (NC=O), 135.8 (ArC), 135.1 (ArC), 129.4 (ArCH), 128.7 (ArCH),
128.6 (ArCH), 128.6 (ArCH), 127.1 (ArCH), 77.4 (OC(CH3)3), 67.4 (OCH2Ph), 53.3
(Phe-NCH), 51.6 (Leu-NCH), 44.3 (Gly-NCH2), 40.1 (CH2CHMe2), 37.9 (CH2Ph),
28.4 (OC(CH3)3), 24.7 (CH2CHMe2), 22.9 (CH(CH3)2), 22.1 (CH(CH3)2); HRMS
(ESI) m/z calculated for C29H39N3NaO6 548.2731 (M+Na)+, found 548.2719, 2.4
ppm error.
Boc-Ser(OBn)-Met-Val-OBn 2.105c
Boc-Ser(OBn)-OH (313 mg, 1.1 mmol) and TFA·H-Met-Val-OBn 2.104c (478 mg,
1.1 mmol) were coupled according to the general coupling procedure. The residue
was then purified using flash column chromatography (47.5:52.5, EtOAc:PE) to
give Boc-Ser(OBn)-Met-Val-OBn 2.105c as a colourless oil (537 mg, 83%). RF =
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0.46, (47.5:52.5, EtOAc:PE); [α]23D = − 26.8 (c 1.0 in MeOH); IR (Neat) νmax
3299 (w), 2967 (w), 2930 (w), 1738 (m), 1714 (m) and 1644 (s) cm-1; 1H NMR
(400 MHz, CDCl3): δ = 7.40-7.26 (m, 10H, ArH), 7.22 (d J 6.9 Hz, 1H, Met-
NH), 6.79 (d J 8.4 Hz, 1H, Val-NH), 5.38 (d J 6.0 Hz, 1H, Ser-NH), 5.19 (d J
12.4 Hz, 1H, CO2CH2Ph), 5.12 (d J 12.4 Hz, 1H, CO2CH2Ph) 4.63 (dt J 7.6, 6.8
Hz, 1H, Met-NCH), 4.56 (d J 11.8 Hz, 1H, CH2OCH2Ph), 4.51 (d J 11.8 Hz, 1H,
CH2OCH2Ph), 4.56-4.51 (m, 1H, Val-NCH), 4.29 (br, 1H, Ser-NCH), 3.91 (dd J 9.4,
3.7 Hz, 1H, CH2OBn), 3.57 (dd J 9.4, 6.0 Hz, 1H, CH2OBn) 2.54 (t J 7.1 Hz, 2H,
CH2SMe), 2.24-2.13 (m, 1H, Val-CHMe2), 2.06 (s, 3H, SCH3), 2.06-1.95 (m, 2H,
CH2CH2SMe), 1.44 (s, 9H, OC(CH3)3), 0.89 (d J 7.0 Hz, 3H, CH(CH3)2), 0.85 (d
J 7.0 Hz, 3H, CH(CH3)2); 13C NMR (100 MHz, CDCl3): δ = 171.5 (C=O), 170.7
(C=O), 170.5 (C=O), 155.7 (NC=O), 137.4 (ArC), 135.4 (ArC), 128.7 (ArCH),
128.6 (ArCH), 128.6 (ArCH), 128.1 (ArCH), 127.9 (ArCH), 73.6 (OCH2Ph), 69.9
(CH2OBn), 67.2 (OCH2Ph), 57.5 (Val-NCH), 54.3 (Ser-NCH) 52.4 (Met-NCH), 31.1
(CHMe2), 30.8 (CH2CH2SMe), 30.0 (CH2SMe), 28.4 (OC(CH3)2), 19.2 (CH(CH3)2),
17.7 (CH(CH3)2), 15.0 (SCH3); HRMS (ESI) m/z calculated for C32H45N3NaO7S
638.2876 (M+Na)+, found 638.2870, 4.2 ppm error.
Boc-Trp-Asp(OBn)-Val-OBn 2.105d
Boc-Trp-OH (231 mg, 0.76 mmol) and TFA·H-Asp(OBn)-Val-OBn 2.104d (400 mg,
0.76 mmol) were coupled according to the general coupling procedure. The residue
was purified using flash column chromatography (50:50, EtOAc:PE) to give Boc-
Trp-Asp(OBn)-Val-OBn 2.105d as a pale yellow solid (363 mg, 68%). RF = 0.32,
(50:50, EtOAc:PE); m.p. 57-59 ◦C; [α]23D = − 36.2 (c 0.5 in MeOH); IR (Neat)
νmax 3320 (m), 3062 (w), 2967 (w), 2932 (w), 1729 (s) and 1646 (s) cm-1; 1H NMR
(400 MHz, CDCl3): δ = 8.17 (s, 1H, ArNH), 7.62 (d J 7.5 Hz, 1H, ArH), 7.40-7.27
(m, 11H, ArH), 7.19-7.09 (m, 3H, ArH), 7.03 (d J 2.1 Hz, 1H, Asp-NH), 7.01 (d
J 8.8 Hz, 1H, Val-NH), 5.18 (d J 11.8 Hz, 1H, OCH2Ph), 5.10 (d J 11.8 Hz, 1H,
OCH2Ph), 5.06-5.01 (m, 3H, OCH2Ph + Trp-NH), 4.80-4.72 (m, 1H, Asp-NCH),
4.46-4.39 (m, 2H, Val-NCH + Trp-NCH), 3.33 (dd J 14.4, 5.2 Hz, 1H, Trp-CH2),
3.18 (dd J 14.7, 6.6 Hz, 1H, Trp-CH2), 2.91 (d J 16.2 Hz, 1H, CH2CO2Bn), 2.36
(dd J 17.2, 6.6 Hz, 1H, CH2CO2Bn), 2.11 (oct J 6.8 Hz, 1H, CHMe2), 1.41 (s, 9H,
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OC(CH3)3), 0.87 (d J 6.7 Hz, 3H, CH(CH3)2), 0.78 (d J 6.7 Hz, 3H, CH(CH3)2);
13C NMR (100 MHz, CDCl3): δ = 172.2 (C=O), 172.0 (C=O), 171.4 (C=O),
170.1 (C=O), 155.6 (NC=O), 136.3 (ArC), 13.6 (ArC), 135.5 (ArC), 128.7 (ArCH),
128.6 (ArCH), 128.5 (ArCH), 128.5 (ArCH), 128.4 (ArCH), 128.4 (ArCH), 127.4
(ArC), 123.2 (ArCH), 122.5 (ArCH), 119.9 (ArCH), 118.9 (ArCH), 111.4 (ArCH),
110.3 (ArC), 80.5 (OCMe3) 67.1 (OCH2Ph), 66.9 (OCH2Ph), 57.7 (Val-NCH), 55.4
(Asp-NCH), 49.3 (Trp-NCH), 35.5 (Trp-CH2), 31.0 (CHMe2), 28.4 (C(CH3)3), 19.1
(CH(CH3)2), 17.7 (CH(CH3)2); HRMS (ESI) m/z calculated for C39H46N4NaO8
721.3213 (M+Na)+, found 721.3208, 1.8 ppm error.
Boc-Pro-Aib-Leu-OBn 2.105e
Boc-Pro-OH (357 mg, 1.66 mmol) and TFA·H-Aib-Leu-OBn 2.104e (700 mg, 1.66
mmol) were coupled according to the general coupling procedure. The residue was
purified using flash column chromatography (2:98-5:95, MeOH:CH2Cl2) to give Boc-
Pro-Aib-Leu-OBn 2.105e as a white powder (618 mg, 73%). RF = 0.18, (2:98,
MeOH:CH2Cl2); m.p. 157-158 ◦C; [α]23D = − 51.9 (c 0.5 in MeOH); IR (Neat)
νmax 3382 (w), 3274 (w), 3060 (w), 2974 (w), 2871 (w), 1735 (m), 1681 (s), 1643
(s), 1549 (m) and 1522 (m) cm-1; 1H NMR (400 MHz, CD3OD): δ = 7.40-7.22 (m,
5H, ArH), 5.17 (d J 12.6 Hz, 1H, CH2Ph), 5.11 (d J 12.6 Hz, 1H, CH2Ph), 4.57-
4.44 (m, 1H, Leu-NCH), 4.18-4.07 (m, 1H, Pro-NCH), 3.54-3.33 (m, 2H, CH2N),
2.26-2.09 (m, 1H, CH2CH2CH2N), 2.09-1.75 (m, 3H, CH2CH2CH2N), 1.73-1.57 (m,
3H, CH2CHMe2), 1.45 (s, 9H, OC(CH3)3), 1.43 (s, 3H, C(CH3)2), 1.41 (s, 3H,
C(CH3)2), 0.91 (d J 5.7 Hz, 3H, CH(CH3)2), 0.89 (d J 4.8 Hz, 3H, CH(CH3)2);
13C NMR (100 MHz, CD3OD, major rotomer): δ = 176.8 (C=O), 174.5 (C=O),
173.8 (C=O), 156.4 (NC=O), 137.3 (ArC), 129.5 (ArCH), 129.4 (ArCH), 129.3
(ArCH), 81.3 (OCMe3), 67.7 (OCH2Ph), 61.5 (Pro-NCH), 57.8 (Aib-NC), 52.5 (Leu-
NCH), 47.9 (CH2N), 41.5 (CH2CH2CH2N), 31.3 (CH2CH2N), 28.9 (OC(CH3)3), 26.5
(CHMe2), 25.7 (CH2CHMe2), 25.4 (C(CH3)2), 24.5 (C(CH3)2), 23.2 (CH(CH3)2),
22.2 (CH(CH3)2); HRMS (ESI) m/z calculated for C27H41N3NaO6 526.2893
(M+Na)+, found 526.2893, − 0.9 ppm error.
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TFA·H-Leu-Ala-Phe-OBn 2.106a
Boc-Leu-Ala-Phe-OBn 2.105a (260 mg, 0.48 mmol) was deprotected according
to the general procedure for Boc deprotections, giving TFA·H-Leu-Ala-Phe-OBn
2.106a as an off white solid (257 mg, 96%).250 m.p. 196-197 ◦C; [α]23D = − 15.2
(c 1.0 in MeOH); IR (Neat) νmax 3394 (w), 3262 (w), 2957 (m), 1732 (w), 1648 (s)
and 1516 (m) cm-1; 1H NMR (400 MHz, CD3OD): δ = 7.32-7.12 (m, 10H, ArH),
5.10 (d J 12.4 Hz, 1H, OCH2Ph), 5.06 (d J 12.4 Hz, 1H, OCH2Ph), 4.65 (dd J 7.8,
6.2 Hz, 1H, Phe-NCH), 4.39 (q J 7.2 Hz, 1H, Ala-NCH), 3.86-3.78 (m, 1H, Leu-
NCH), 3.10 (dd J 13.8, 6.1 Hz, 1H, CH2Ph), 2.99 (dd J 13.8, 6.1 Hz, 1H, CH2Ph),
1.71-1.55 (m, 3H, Leu-CH2CHMe2), 1.29 (d J 7.2 Hz, 3H, NCHCH3), 0.95 (d J
6.0 Hz, 3H, CH(CH3)2), 0.93 (d J 6.0 Hz, 3H, CH(CH3)2); 13C NMR (100 MHz,
CD3OD): δ = 174.3 (C=O), 172.6 (C=O), 172.5 (C=O), 137.8 (ArC), 136.9 (ArC),
130.3 (ArCH), 129.5 (ArCH), 129.5 (ArCH), 129.4 (ArCH), 127.9 (ArCH), 68.1
(OCH2Ph), 55.4 (Phe-NCH), 52.8 (Ala-NCH), 50.0 (Leu-NCH), 41.7 (CH2CHMe2),
38.3 (CH2Ph), 25.3 (CHMe2), 23.1 (CH(CH3)2), 22.0 (CH(CH3)2), 18.3 (NCHCH3);
HRMS (ESI) m/z calculated for C25H33N3NaO4 462.2369 (M-CF3COO
–+Na)+,
found 462.2363, 3.2 ppm error.
TFA·H-Gly-Leu-Phe-OBn 2.106b
Boc-Gly-Leu-Phe-OBn 2.105b (200 mg, 0.38 mmol) was deprotected according
to the general procedure for Boc deprotections to give TFA·H-Gly-Leu-Phe-OBn
2.106b as an off white solid (192 mg, 94%).249 m.p. 185-186 ◦C; [α]23D = − 28.4
(c 0.5 in MeOH); IR (Neat) νmax 3405 (w), 3277 (w), 2955 (w), 1721 (m), 1693 (m),
1641 (s) and 1528 (m) cm-1; 1H NMR (400 MHz, DMSO-d6): δ = 7.34-7.29 (m,
3H, ArH), 7.27-7.23 (m, 2H, ArH), 7.22-7.18 (m, 2H, ArH), 7.17-7.13 (m, 3H, ArH),
5.10 (d J 12.0 Hz, 1H, OCH2Ph), 5.06 (d J 12.0 Hz, 1H, OCH2Ph), 4.65 (dd J 8.0,
6.4 Hz, 1H, Phe-NCH), 4.42 (dd J 8.0, 6.8 Hz, 1H, Leu-NCH), 3.68 (d, J 16.0 Hz,
1H, Gly-NCH2), 3.62 (d, J 16.0 Hz, 1H, Gly-NCH2), 3.12 (dd J 14.0, 6.0 Hz, 1H,
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CH2Ph), 2.99 (dd J 14.0, 8.4 Hz, 1H, CH2Ph), 1.62 (non J 6.8 Hz , 1H, CHMe2),
1.53-1.42 (m, 2H, CH2CHMe2), 0.87 (d J 8.8, 6.4 Hz, 3H, CH(CH3)2), 0.85 (d J
8.8, 6.4 Hz, 3H, CH(CH3)2); 13C NMR (100 MHz, DMSO-d6): δ = 174.5 (C=O),
172.6 (C=O), 167.0 (C=O), 138.0 (ArC), 136.9 (ArC), 130.3 (ArCH), 129.6 (ArCH),
129.5 (ArCH), 129.4 (ArCH), 127.9 (ArCH), 68.1 (CH2Ph), 55.5 (Phe-NCH), 53.0
(Leu-NCH), 42.2 (CH2CHMe2), 41.4 (Gly-NCH2), 38.2 (CH2Ph), 25.8 (CHMe2),
23.4 (CH(CH3)2), 21.9 (CH(CH3)2); HRMS (ESI) m/z calculated for C24H32N3O4
426.2387 (M-CF3COO
–)+, found 426.2374, 2.6 ppm error.
TFA·H-Ser(OBn)-Met-Val 2.106c
Boc-Ser(OBn)-Met-Val-OBn 2.105c (300 mg, 0.49 mmol) was deprotected
according to the general procedure for Boc deprotections to give TFA·H-Ser(OBn)-
Met-Val-OBn 2.106c as an off-white solid (257 mg, 84%). m.p. 137-138 ◦C; IR
(Neat) νmax 3274 (w), 3035 (w), 2922 (w), 2964 (w), 1728 (m), 1671 (s), 1644 (s)
and 1553 (s) cm-1; 1H NMR (400 MHz, DMSO-d6): δ = 8.69 (d, J 8.1 Hz, 1H,
Met-NH), 8.38 (d J 7.7 Hz, 1H, Val-NH), 8.18 (br, 3H, NH3
+), 7.43-7.24 (m, 10H,
ArH), 5.15 (d J 12.4 Hz, 1H, CO2CH2Ph), 5.10 (d J 12.4 Hz, 1H, CO2CH2Ph)
4.66-4.53 (m, 1H, Met-NCH), 4.53 (d J 7.7 Hz, 1H, OCH2Ph), 4.49 (d J 7.7
Hz, 1H, OCH2Ph), 4.20 (dd J 7.9, 6.1 Hz, Val-NCH), 4.09 (dd J 6.3, 3.9 Hz,
1H, Ser-NCH), 3.75 (dd J 10.7, 4.1 Hz, 1H, CH2OBn), 3.67 (dd J 10.7, 4.1 Hz,
1H, CH2OBn), 2.49-2.36 (m, 2H, CH2SMe), 2.12-2.02 (m, 1H, CHMe2), 2.01 (s,
3H, SCH3), 1.97-1.72 (m, 2H, CH2CH2SMe), 0.86 (d J 6.8 Hz, 3H, CH(CH3)2),
0.85 (d J 6.8 Hz, 3H, CH(CH3)2); 13C NMR (100 MHz, DMSO-d6): δ = 171.2
(C=O), 170.9 (C=O), 166.4 (C=O), 137.6 (ArC), 135.9 (ArC), 128.5 (ArCH),
128.3 (ArCH), 128.2 (ArCH), 128.1 (ArCH), 127.8 (ArCH), 72.5 (CH2OCH2Ph),
68.5 (CH2OBn), 66.0 (CO2CH2Ph), 57.6 (Val-NCH), 52.4 (Ser-NCH), 51.9 (Met-
NCH), 32.4 (CH2CH2SMe), 29.7 (CHMe2), 29.3 (CH2SMe), 18.9 (CH(CH3)2), 18.1
(CH(CH3)2), 14.6 (SCH3);HRMS (ESI)m/z calculated for C27H38N3O5S 516.2532
(M-CF3COO
–)+, found 516.2527, 1.8 ppm error.
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TFA·H-Trp-Asp(OBn)-Val-OBn 2.106d
Boc-Trp-Asp(OBn)-Val-OBn 2.105d (100 mg, 0.14 mmol) was deprotected
according to the general procedure for Boc deprotections to give TFA·H-Trp-
Asp(OBn)-Val-OBn 2.106d as a yellow solid (102 mg, 99%). m.p. 78-79 ◦C;
[α]23D = − 27.0 (c 0.5 in MeOH); IR (Neat) νmax 3313 (m), 3032 (w), 2938 (w),
1693 (s), 1655 (s) and 1514 (s) cm-1; 1H NMR (400 MHz, CD3OD): δ = 7.67
(d J 7.9 Hz, 1H, ArH), 7.42-7.20 (m, 12H, ArH), 7.17-7.11 (m, 1H, ArH), 7.09-
7.03 (m, 1H, ArH), 5.17 (d J 12.1 Hz, 1H, OCH2Ph), 5.12 (s, 2H, OCH2Ph), 5.09
(d J 12.1 Hz, 1H, OCH2Ph), 4.91-4.86 (m, 1H, Asp-NCH), 4.34 (d J 5.5 Hz, 1H,
Val-NCH), 4.19-4.12 (m, 1H, Trp-NCH), 3.44 (dd J 15.1, 5.3 Hz, 1H, Trp-CH2),
3.18 (dd J 15.1, 8.7 Hz, 1H, Trp-CH2), 2.87 (dd J 16.7, 5.7 Hz, 1H, CH2CO2),
2.76 (dd J 16.7, 7.9 Hz, 1H, CH2CO2), 2.14 (oct J 6.8 Hz, 1H, CHMe2), 0.93 (d
J 6.6 Hz, 3H, CH(CH3)2), 0.91 (d, J 6.6 Hz, 3H, CH(CH3)2); 13C NMR (100
MHz, CD3OD): δ = 172.5 (C=O), 172.4 (C=O), 171.6 (C=O), 170.2 (C=O), 138.3
(ArC), 137.2 (ArC), 137.1 (ArC), 129.6 (ArCH), 129.6 (ArCH), 129.5 (ArCH), 129.4
(ArCH), 129.3 (ArCH), 128.2 (ArC), 125.7 (ArCH), 122.9 (ArCH), 120.3 (ArCH),
119.1 (ArCH), 112.6 (ArCH), 107.7 (ArC), 68.0 (OCH2Ph), 67.8 (OCH2Ph), 59.5
(Val-NCH), 54.7 (Trp-NCH), 51.3 (Asp-NCH), 37.1 (CH2CO2), 31.7 (CHMe2), 28.9
(Trp-CH2), 19.5 (CH(CH3)2), 18.5 (CH(CH3)2); HRMS (ESI) m/z calculated for
C34H38N4NaO6 621.2689 (M-CF3COO
–+Na)+, found 621.2684, − 4.0 ppm error.
TFA·H-Pro-Aib-Leu-OBn 2.106e
Boc-Pro-Aib-Leu-OBn 2.105e (200 mg, 0.39 mmol) was deprotected according
to the general procedure for Boc deprotections to give TFA·H-Pro-Aib-Leu-OBn
2.106e as a yellow solid (200 mg, 97%). m.p. 105-106 ◦C; [α]23D = − 52.7 (c
0.5 in MeOH); IR (Neat) νmax 3034 (w), 2957 (w), 1735 (m), 1670 (s) and 1645
207
Chapter 7. Experimental
(m) cm-1; 1H NMR (400 MHz, DMSO-d6): δ = 9.50 (br, 1H, NH2
+), 8.54 (s, 1H,
NHCMe2), 8.50 (br, 1H, NH2
+), 7.90 (d J 7.9 Hz, 1H, NHCH), 7.41-7.29 (m, 5H,
ArH), 5.11 (d J 12.5 Hz, 1H, OCH2Ph), 5.07 (d J 12.5 Hz, 1H, OCH2Ph), 4.37-4.30
(m, 1H, Leu-NCH), 4.18 (dd J 8.2, 6.4 Hz, 1H, Pro-NCH), 3.25-3.13 (m, 2H, CH2N),
2.31-2.20 (m, 1H, 1×Pro-CH2), 1.99-1.75 (m, 3H, 3×Pro-CH2), 1.73-1.45 (m, 3H,
Leu-CH2CHMe2), 1.40 (s, 3H, C(CH3)2), 1.37 (s, 3H, C(CH3)2), 0.86 (d J 6.4 Hz,
3H, CH(CH3)2), 0.81 (d J 6.4 Hz, 3H, CH(CH3)2); 13C NMR (100 MHz, DMSO-
d6): δ = 173.3 (C=O), 172.4 (C=O), 167.6 (C=O), 135.9 (ArC), 128.4 (ArCH), 128.1
(ArCH), 127.9 (ArCH), 65.9 (CH2Ph), 59.1 (Pro-NCH), 54.5 (Aib-NC), 50.6 (Leu-
NCH), 45.9 (CH2N), 39.8 (CH2CHMe2), 29.5 (CH2CH2CH2N), 25.0 (C(CH3)2), 24.5
(C(CH3)2), 24.1 (CHMe2), 23.5 (CH2CH2N), 22.9 (CH(CH3)2), 21.2 (CH(CH3)2);
HRMS (ESI) m/z calculated for C22H34N3O4 404.2549 (M-CF3COO
–)+, found
404.2379, 3.1 ppm error.
Boc-Gly-Leu-Ala-Phe-OBn 2.107a
Boc-Gly-OH (44 mg, 0.25 mmol) and TFA·H-Leu-Ala-Phe-OBn 2.106a (140 mg,
0.25 mmol) were coupled according to the general coupling procedure. The residue
was purified using flash column chromatography (95:5, EtOAc:PE) to give Boc-
Gly-Leu-Ala-Phe-OBn 2.107a as a white solid (109 mg, 72%). RF = 0.31, (95:5,
EtOAc:PE); m.p. 77-78 ◦C; [α]23D = − 22.5 (c 1.0 in MeOH); IR (Neat) νmax
3278 (m), 3066 (w), 2957 (m), 1742 (m), 1711 (m) and 1634 (s) cm-1; 1H NMR (400
MHz, CDCl3): δ = 7.40-7.30 (m, 5H, 3×ArCH + Phe-NH + Leu-NH), 7.28-7.23
(m, 2H, ArCH), 7.21-7.14 (m, 4H, 3×ArCH + Ala-NH), 7.07-7.00 (m, 2H, ArCH),
5.46 (br t, 1H, Gly-NH), 5.15 (d J 12.4 Hz, 1H, OCH2Ph), 5.07 (d J 12.4 Hz, 1H,
OCH2Ph), 4.96-4.87 (m, 1H, Phe-NCH), 4.75-4.63 (m, 1H, Ala-NCH), 4.63-4.52 (m,
1H, Leu-NCH), 3.89-3.72 (m, 2H, Gly-NCH2), 3.13 (dd J 13.9, 6.0 Hz, 1H, CH2Ph),
3.04 (dd J 13.9, 6.0 Hz, 1H, CH2Ph), 1.66-1.56 (m, 1H, CHMe2), 1.58-1.49 (m,
2H, CH2CHMe2), 1.43 (s, 9H, OC(CH3)3), 1.32 (d J 7.0 Hz, 3H, NCHCH3), 0.91
(d J 6.0 Hz, 3H, CH(CH3)2), 0.90 (d J 6.0 Hz, 3H, CH(CH3)2); 13C NMR (100
MHz, CDCl3): δ = 172.2 (C=O), 171.9 (C=O), 171.3 (C=O), 169.4 (C=O), 156.2
(NC=O), 136.0 (ArC), 135.2 (ArC), 129.4 (ArCH), 128.7 (ArCH), 128.6 (ArCH),
128.6 (ArCH), 127.1 (ArCH), 80.3 (OCMe3), 67.3 (OCH2Ph), 53.5 (Phe-NCH), 51.0
(Leu-NCH), 48.9 (Ala-NCH), 44.3 (Gly-NCH2), 41.9 (CH2CHMe2), 37.9 (CH2Ph),
28.4 (C(CH3)3), 23.1 (CH(CH3)2), 22.2 (CH(CH3)2), 18.6 (NCHCH3); HRMS
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(ESI) m/z calculated for C22H44N4NaO7 619.3108 (M+Na)+, found 619.3088, 2.7
ppm error.
Boc-Ala-Gly-Leu-Phe-OBn 2.107b
Boc-Ala-OH (35 mg, 0.19 mmol) and TFA·H-Gly-Leu-Phe-OBn 2.106b (100 mg,
0.19 mmol) were coupled according to the general coupling procedure. The residue
was purified using flash column chromatography (80:20, EtOAc:PE) to give Boc-Ala-
Gly-Leu-Phe-OBn 2.107b as a white powder (101 mg, 91%). RF = 0.49, (80:20,
EtOAc:PE); m.p. 119-121 ◦C; [α]23D = − 21.8 (c 1.0 in MeOH); IR (Neat) νmax
3287 (m), 2961 (w), 1718 (m), 1643 (s), 1564 (m) and 1510 (s) cm-1; 1H NMR
(400 MHz, CDCl3): δ = 7.37-7.34 (m, 3H, ArH), 7.30-7.27 (m, 2H, ArH), 7.24-7.20
(m, 3H, ArH), 7.06-7.04 (m, 2H, ArH), 6.79 (t J 6.2 Hz, 1H, Gly-NH), 6.76 (br
d, 1H, Phe-NH), 6.70 (d J 6.3 Hz, Leu-NH), 5.16 (d J 12.0 Hz, 1H, OCH2Ph),
5.09 (d J 12.0 Hz, 1H, OCH2Ph), 5.08 (br, 1H, Ala-NH), 4.87 (dd J 14.0, 6.4 Hz,
1H, Phe-NCH), 4.43 (dt J 14.0, 8.8 Hz, 1H, Leu-NCH), 4.07 (quin J 6.9 Hz, 1H,
Ala-NCH), 3.99 (dd J 14.0, 6.4 Hz, 1H, Gly-NCH2), 3.79 (dd J 16.8, 5.2 Hz, 1H,
Gly-NCH2), 3.15 (dd J 14.0, 6.0 Hz, 1H, CH2Ph), 3.06 (dd J 14.0, 6.8 Hz, 1H,
CH2Ph), 1.69-1.52 (m, 2H, CH2CHMe2), 1.50-1.37 (m, 1H, CHMe2), 1.44 (s, 9H,
OC(CH3)3), 1.32 (d J 6.8 Hz, 3H, NCHCH3), 0.87 (d J 6.8 Hz, 3H, CH(CH3)2), 0.85
(d J 6.8 Hz, 3H, CH(CH3)2); 13C NMR (100 MHz, CDCl3): δ= 173.7 (C=O), 171.8
(C=O), 171.5 (C=O), 169.0 (C=O), 155.8 (NC=O), 136.0 (ArC), 135.2 (ArC), 129.5
(ArCH), 128.7 (ArCH), 128.6 (ArCH), 128.5 (ArCH), 127.0 (ArCH), 77.4 (OCMe3),
67.4 (OCH2Ph), 53.4 (Phe-NCH), 52.0 (Leu-NCH), 50.7 (Ala-NCH), 43.3 (Gly-
NCH2), 40.1 (CH2CHMe2), 37.9 (CH2Ph), 28.5 (OC(CH3)3), 24.8 (CHMe2), 22.9
(CH(CH3)2), 22.1 (CH(CH3)2), 18.3 (NCHCH3); HRMS (ESI) m/z calculated for
C32H44N4NaO7 619.3108 (M+Na)+, found 619.3098, 1.0 ppm error.
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Boc-Lys(Z)-Ser(OBn)-Met-Val-OBn 2.107c
Boc-Lys(Z)-OH (61 mg, 0.16 mmol) and TFA·H-Ser(OBn)-Met-Val-OBn 2.106c
(100 mg, 0.16 mmol) were coupled according to the general coupling procedure.
The residue was then purified using flash column chromatography (60:40-70:30,
EtOAc:PE) to give Boc-Lys(Z)-Ser(OBn)-Met-Val-OBn 2.107c as a white solid (91
mg, 65%). RF = 0.44, (70:30, EtOAc:PE); m.p. 75-76 ◦C; [α]23D = 23.77 (c 1.0 in
MeOH); IR (Neat) νmax 3282 (w), 2930 (w), 1689 (m), 1635 (s) and 1519 (s) cm-1;
1H NMR (400 MHz, CDCl3): δ = 7.46 (d J 8.3 Hz, 1H, Met-NH), 7.40-7.21 (m,
15H, ArH), 7.06-6.93 (m, 2H, Ser-NH + Val-NH), 5.64 (d J 3.2 Hz, 1H, Lys-NH), 5.18
(d J 11.8 Hz, 1H, CO2CH2Ph), 5.15-5.04 (m, 4H, Lys-ε-NH + 3×CO2CH2Ph), 4.69
(dt J 8.6, 5.1 Hz, 1H, Met-NCH), 4.54 (d J 11.7 Hz, 1H, OCH2Ph), 4.51 (d J 11.7 Hz,
1H, OCH2Ph), 4.51-4.42 (m, 2H, Val-NCH, Ser-NCH), 4.07-3.99 (m, 1H, CH2OBn),
3.96-3.88 (m, 1H, Lys-NCH), 3.59 (dd, J 9.5, 4.6 Hz, 1H, CH2OBn), 3.30-3.09 (m,
2H, CH2NH), 2.51 (t J 7.5 Hz, 2H, CH2SMe), 2.37-2.23 (m, 1H, CH2CH2SMe),
2.20-2.10 (m, 1H, CHMe2), 2.04 (s, 3H, SCH3), 1.97-1.79 (m, 2H, CH2CH2SMe
+ (CH2)3), 1.74-1.61 (m, 1H, (CH2)3), 1.56-1.36 (m, 4H, (CH2)3), 1.35 (s, 9H,
OC(CH3)3), 0.90 (d J 6.9 Hz, CH(CH3)2), 0.89 (d J 6.6 Hz, CH(CH3)2); 13C NMR
(100 MHz, CDCl3): δ = 172.6 (C=O), 171.4 (C=O), 171.1 (C=O), 170.0 (C=O),
157.3 (C=O), 156.8 (NC=O), 137.3 (ArC), 136.5 (ArC), 135.7 (ArC), 128.7 (ArCH),
128.6 (ArCH), 128.4 (ArCH), 128.3 (ArCH), 128.2 (ArCH), 128.1 (ArCH), 128.0
(ArCH), 80.9 (OCMe3), 73.6 (OCH2Ph), 69.0 (CH2OBn), 66.9 (2×CO2CH2Ph),
57.7 (Val-NCH), 55.9 (Lys-NCH), 54.0 (Ser-NCH), 52.7 (Met-NCH), 39.0 ((CH2)4),
31.1 ((CH2)4), 31.0 (CHMe2), 30.5 ((CH2)4), 30.5 (CH2SMe), 29.7 (CH2CH2SMe),
28.3 (OC(CH3)3), 22.4 ((CH2)4), 19.1 (CH(CH3)2), 18.1 (CH(CH3)2), 15.2 (SCH3);
HRMS (ESI) m/z calculated for C46H63N5NaO10S 900.4193 (M+Na)+, found
900.4188, 0.1 ppm error.
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Boc-Gln(Trt)-Trp-Asp(OBn)-Val-OBn 2.107d
Boc-Gln(Trt)-OH (137 mg, 0.28 mmol) and TFA·H-Trp-Asp(OBn)-Val-OBn 2.106d
(200 mg, 0.28 mmol) were coupled according to the general coupling procedure. The
residue was purified using flash column chromatography (50:50, EtOAc:PE) to give
Boc-Gln(Trt)-Trp-Asp(OBn)-Val-OBn 2.1067d as an off white solid (166 mg, 78%).
RF = 0.23, (45:55, EtOAc:PE); m.p. 78-79 ◦C; [α]23D = − 27.4 (c 0.5 in MeOH);
IR (Neat) νmax 3301 (m), 2967 (w), 1666 (s) and 1513 (s) cm-1; 1H NMR (400
MHz, CDCl3): δ = 7.82 (s, 1H, NH), 7.54 (d J 8.0 Hz, 1H, ArH), 7.38-6.97 (m, 31H,
29×ArH + NH + Asp-NH), 6.93 (d J 7.1 Hz, 1H, Val-NH), 6.86 (d J 2.4 Hz, 1H,
Trp-NH), 5.60 (d J 4.9 Hz, 1H, Gln-NH), 5.18 (d J 12.2 Hz, 1H, OCH2Ph), 5.10
(d J 12.2 Hz, 1H, OCH2Ph), 4.98 (s, 2H, OCH2Ph), 4.79-4.75 (m, 1H, Asp-NCH),
4.56 (dt J 6.3, 6.0 Hz, 1H, Trp-NCH), 4.42 (dd J 8.7, 4.5 Hz, 1H, Val-NCH), 3.91
(dd J 6.2, 6.0 Hz, 1H, Gln-NCH), 3.30 (dd J 15.1, 6.2 Hz, 1H, Trp-CH2), 3.09 (dd
J 14.5, 6.2 Hz, 1H, Trp-CH2), 2.49 (dd J 16.7, 4.5 Hz, 1H, Gln-CH2CO), 2.41-
2.20 (m, 3H, 1×Gln-CH2CO + 2×CH2CO2Bn), 2.12 (oct J 6.7 Hz, 1H, CHMe2),
2.05-1.83 (m, 2H, Gln-CH2CH2CO), 1.34 (s, 9H, OC(CH3)3), 0.85 (d J 6.8 Hz, 3H,
CH(CH3)2), 0.82 (d J 6.8 Hz, 3H, CH(CH3)2); 13C NMR (100 MHz, CDCl3):
δ = 172.1 (C=O), 171.6 (C=O), 171.5 (C=O), 171.3 (C=O), 170.3 (C=O), 156.1
(NC=O), 144.6 (ArC), 136.2, (ArC), 136.2 (ArC), 135.7 (ArC), 128.8 (ArCH), 128.7
(ArC), 128.6 (ArCH), 128.4 (ArCH), 128.4 (ArCH), 128.1 (ArCH), 127.3 (ArCH),
127.3 (ArCH), 123.8 (ArCH), 122.3 (ArCH), 119.8 (ArCH), 118.9 (ArCH), 111.3
(ArCH), 109.6 (ArC), 80.2 (OCMe3), 70.9 (CPh3), 66.9 (OCH2Ph), 66.7 (OCH2Ph),
57.8 (Val-NCH), 54.6 (Gln-NCH), 54.2 (Asp-NCH), 49.4 (Trp-NCH), 35.2 (Trp-
CH2), 33.4 (CH2CH2CO), 31.0 (CHMe2), 28.5 (CH2CH2CO); 28.4 (C(CH3)3), 27.1
(CH2CO2Bn), 19.1 (CH(CH3)2), 17.8 (CH(CH3)2); HRMS (ESI) m/z calculated
for C63H68N6NaO10 1091.4895 (M+Na)+, found 1091.4889, − 0.7 ppm error.
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Boc-Tyr(OBn)-Pro-Aib-Leu-OBn 2.107e
Boc-Tyr(OBn)-OH (71 mg, 0.19 mmol) and TFA·H-Pro-Aib-Leu-OBn 2.106e (100
mg, 0.19 mmol) were coupled according to the general coupling procedure. The
residue was purified using flash column chromatography (5:95, MeOH:CH2Cl2) to
give Boc-Tyr(OBn)-Pro-Aib-Leu-OBn 2.107e as a white powder (105 mg, 72%).
RF = 0.21, (4:96, MeOH:CH2Cl2); m.p. 117-118 ◦C; [α]23D = − 23.0 (c 0.5
in MeOH); IR (Neat) νmax 3318 (w), 2957 (w), 1731 (m), 1682 (s), 1634 (s)
and 1510 (s) cm-1; 1H NMR (400 MHz, DMSO-d6, 80 ◦C): δ = 7.81 (s, 1H,
Aib-NH), 7.47-7.27 (m, 11H, 10×ArH, + Leu-NH), 7.21-7.10 (m, 2H, ArH), 6.93-
6.86 (m, 2H, ArH), 6.38 (br, 1H, Tyr-NH), 5.12 (s, 2H, OCH2Ph), 5.07 (s, 2H,
OCH2Ph), 4.41-4.29 (m, 3H, 3×NCH), 3.70-3.59 (m, 1H, CH2N), 3.48-3.88 (m, 1H,
CH2N), 2.96-2.68 (m, 2H, Tyr-CH2), 2.09-1.93 (m, 2H, CH2CH2CH2N), 1.91-1.78
(m, 1H, CH2CH2N), 1.66-1.49 (m, 4H, 1×CH2CH2N + CH2CHMe2), 1.41 (s, 3H,
C(CH3)2), 1.36 (s, 3H, C(CH3)2), 1.31 (s, 9H, OC(CH3)3), 0.85 (d J 5.9 Hz, 3H,
CH(CH3)2), 0.83 (d J 5.9 Hz, 3H, CH(CH3)2); 13C NMR (100 MHz, DMSO-
d6, 80 ◦C): δ = 173.9 (C=O), 172.2 (C=O), 171.1 (C=O), 170.5 (C=O), 156.9
(NC=O), 155.2 (ArC), 137.2 (CAr), 135.9 (ArC), 130.4 (ArCH), 129.8 (ArC), 128.4
(ArCH), 128.0 (ArCH), 127.8 (ArCH), 127.7 (ArCH), 127.6 (ArCH), 127.5 (ArCH),
114.4 (ArCH), 78.1 (OCMe3), 69.1 (OCH2Ph), 65.8 (OCH2Ph), 60.1 (NCH), 55.9
(NCH), 54.0 (NCH), 50.7 (NCMe2), 49.9 (CH2N), 39.6 (CH2CH2CH2N), 35.5 (Tyr-
CH2), 28.7 (CH2CHMe2), 28.2 (CHMe2), 28.1 (OC(CH3)3), 25.9 (C(CH3)2), 24.8
(CH2CH2CH2N), 24.1 (OC(CH3)2), 22.5 (CH(CH3)2), 21.8 (CH(CH3)2); HRMS
(ESI) m/z calculated for C43H56N4NaO8 779.3996 (M+Na)+, found 779.4010, −
2.4 ppm error.
Boc-Leu-Ala-Phe-OH 2.109
A solution of Boc-Leu-Ala-Phe-OBn 2.106a (325 mg, 0.6 mmol, 1.0 eq) in methanol
(5 mL) was added to a suspension of Pd/C (10% w/w) in methanol (5 mL)
212
7.2. Cyclic Carbonates as Solvents for Peptide Synthesis
under H2 (1 bar). The resulting mixture was stirred at room temperature for 16
h. The reaction mixture was then filtered through a short plug of Celite R© and
concentrated in vacuo to give Boc-Leu-Ala-Phe-OH 2.109 as an off-white solid (258
mg, 96%).251 m.p. 82-83 ◦C; [α]23D = − 13.5 (c 1.0 in MeOH); IR (Neat)
νmax 3300 (m), 2958 (m), 1644 (s) and 1514 (m) cm-1; 1H NMR (400 MHz,
CD3OD): δ = 7.24-7.13 (m, 5H, ArH), 4.58 (dd J 7.6, 5.3 Hz, 1H, Leu-NCH),
4.33 (dt J 7.1, 6.8 Hz, 1H, Phe-NCH), 4.10-4.01 (m, 1H, Ala-NCH), 3.15 (dd J
13.9, 5.4 Hz, 1H, CH2Ph), 2.97 (dd J 13.9, 5.4 Hz, 1H, CH2Ph), 1.64 (sept J 6.7
Hz, 1H, CHMe2), 1.45 (t J 7.2 Hz, 2H, CH2CHMe2), 1.40 (s, 9H, OC(CH3)3),
1.28 (d J 7.1 Hz, 3H, NCHCH3), 0.90 (d, J 6.7 Hz, 3H, CH(CH3)2), 0.88 (d
J 6.7 Hz, 3H, CH(CH3)2); 13C NMR (100 MHz, CD3OD): δ = 175.3 (C=O),
174.5 (C=O), 174.4 (C=O), 157.9 (NC=O), 138.2 (ArC), 130.4 (ArCH), 129.4
(ArCH), 127.8 (ArCH), 80.6 (OCMe3), 55.2 (Leu-NCH), 54.3 (Ala-NCH), 50.1 (Phe-
NCH), 42.1 (CH2CHMe2), 38.4 (CH2Ph), 28.7 (OC(CH3)3), 25.9 (CHMe2), 23.5
(CH(CH3)2), 21.8 (CH(CH3)2), 18.4 (NCHCH3); HRMS (ESI) m/z calculated for
C23H35N3NaO6 472.2424 (M+Na)+, found 472.2413, 1.2 ppm error.
TFA·H-Leu-Ala-Phe-OH 2.110
Acid 2.109 (90 mg, 0.2 mmol) was deprotected according to the general procedure
for Boc deprotections to give TFA·H-Leu-Ala-Phe-OH 2.110 as a white solid (90
mg, 97%).252 m.p. 189-191 ◦C; IR (Neat) νmax 3265 (w), 3036 (w), 3967 (w), 2401
(w), 2344 (w), 1735 (m), 1646 (s), 1555 (w) and 1514 (w) cm-1; 1H NMR (400 MHz,
TFA-d): δ = 7.20-7.09 (m, 3H, ArH), 7.07-7.00 (m, 2H, ArH), 5.01-4.85 (m, 1H, Phe-
NCH), 4.65-4.48 (m, 1H, Ala-NCH), 4.28-4.12 (m, 1H, Leu-NCH), 3.23 (dd J 14.3,
4.3 Hz, 1H, CH2Ph), 3.01 (dd J 14.3, 8.5 Hz, 1H, CH2Ph), 1.78-1.51 (m, 3H, Leu-
CH2CHMe2), 1.32 (d J 6.3 Hz, 3H, NCHCH3), 0.87 (d J 6.0 Hz, 3H, CH(CH3)2), 0.85
(d J 6.0 Hz, 3H, CH(CH3)2); 13C NMR (100 MHz, TFA-d): δ= 178.9 (C=O), 176.0
(C=O), 172.1 (C=O), 136.6 (ArC), 131.0 (ArCH), 131.0 (ArCH), 129.9 (ArCH), 56.2
(Phe-NCH), 55.8 (Leu-NCH), 52.5 (Ala-NCH), 42.4 (CH2CHMe2), 39.0 (CH2Ph),
26.5 (CH2CHMe2), 23.2 (CH(CH3)2), 22.2 (CH(CH3)2), 18.8 (NCHCH3); HRMS
(ESI) m/z calculated for C18H28N3O4 350.2080 (M+H)+, found 350.2076, − 0.8
ppm error.
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7.2.2 Solid-Phase Peptide Synthesis
7.2.2.1 General Procedure for Solid-Phase Peptide Synthesis in PC
The synthesis of peptides upon a solid-support was carried out in a 5 mL syringe
fitted with a polypropylene frit. Preloaded ChemMatrix-HMPB resin (200 mg, 0.6
mmol g-1) was first washed with PC (3 × 5 mL) and then swollen in PC (3.5 mL) for
1 h. In a separate vial, an Fmoc-amino acid (0.36 mmol, 3.0 eq.), HBTU (137 mg,
0.36 mmol, 3.0 eq.), HOBt (49 mg, 0.36 mmol, 3.0 eq.) and DIPEA (125 μL, 0.72
mmol, 6.0 eq.) were combined in PC (3.6 mL). After 3 min, this preactivated amino
acid solution was added to the resin. Coupling reactions were performed for 1 h at
ambient temperature and carried out in duplicate. Following each coupling reaction
the resin was washed using PC (3 × 5 mL). Fmoc-deprotections were performed
in duplicate (10 min followed by 20 min) using a freshly prepared solution of 20%
(v/v) piperidine in PC (10-12 mL g-1). Following deprotection the resin was washed
using PC (3 × 5 mL). Once the full sequence was constructed and the final Fmoc-
deprotection had been performed, the resin was washed using PC (3 × 5 mL) and 2-
MeTHF (3× 5 mL), and dried under reduced pressure. The peptide was then cleaved
from the resin using TFA:TIPS:H2O (95:2.5:2.5) (8-10 mL g-1) for 2 h at ambient
temperature. The resin was removed by filtration and the peptide precipitated into
cold Et2O, triturated and lyophilised.
7.2.2.2 Kaiser Test
Three reagent solutions were prepared according to the following protocol:
Reagent A: KCN (16.5 mg) was dissolved in 25 mL of deionised water. 1.0 mL of
this solution was then diluted in 49 mL of pyridine.
Reagent B: Ninhydrin (1.0 g) was dissolved in 20 mL of n-butanol.
Reagent C: Phenol (40 g) was dissolved in 20 mL of n-butanol.
A sample of resin (10-15 beads) was then treated with 5 drops of each solution in a
test tube. The mixture was heated at 110 ◦C for 5 min. A colour change from pale
green/yellow to dark blue/purple signifies the presence of a free primary amine.
7.2.2.3 Chloranil Test
Two reagent solutions were prepared according to the following protocol:
Reagent A: Acetaldehyde (1 mL) was mixed with 49 mL of DMF
Reagent B: Chloranil (1 g) was dissolved in 49 mL of DMF
A sample of resin (10-15 beads) was then treated with a drop of each solution in
a test tube. The mixture was allowed to stand at room temperature for 5 min. A
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colour change from yellow/orange to dark blue/purple indicates the presence of a
free secondary amine.
7.2.2.4 Solid-Phase Synthesis of TFA·H-Leu-Ala-Phe-OH 2.110
This tripeptide was prepared using the general method for solid-phase synthesis
starting with ChemMatrix-HMPB-Phe-H resin and adding Fmoc-amino acids in
the sequence Fmoc-Ala-OH then Fmoc-Leu-OH. TFA·H-Leu-Ala-Phe-OH 2.110
prepared in this way had identical analytical data to that prepared by solution
phase synthesis.
7.2.2.5 Solid-Phase Synthesis of Bradykinin 2.112
This nonapeptide was prepared using the general method for solid-phase synthesis
using ChemMatrix-HMPB-Arg(Pbf)-H resin and adding Fmoc-amino acids in the
sequence Fmoc-Phe-OH, Fmoc-Pro-OH, Fmoc-Ser(Bn)-OH, Fmoc-Phe-OH, Fmoc-
Gly-OH, Fmoc-Pro-OH, Fmoc-Pro-OH and Fmoc-Arg(Pbf)-OH. After each step,
successful coupling or deprotection was confirmed using either the chloranil or Kaiser
colormetric tests. After cleavage from the resin, the peptide was precipitated into
cold Et2O, triturated (3 × 20 mL Et2O) and lyophilized to give Bradykinin 2.112
as a white powder. Reverse phase HPLC retention time 11.8 min. MS (ESI)
m/z 1060.6 (M+H)+, 710.4, 642.3, 555.3, 530.8 (M+2H)2+; HRMS (ESI) m/z
calculated for C50H75N15O11 530.787976 (M+2H)2+, found 530.786911, − 2.0 ppm
error.
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7.3 Greener Solvents for Solid-Phase Synthesis
7.3.1 Determination of Resin Swelling
Resin (100 mg) was accurately weighed into a 2 mL syringe fitted with a
polypropylene disc (void volume = 0.12 mL). Solvent (2 mL) was added and
the syringe agitated for 1 h at room temperature. The solvent was removed by
compressing the syringe piston. The resin was then allowed to return to its maximum
volume by slowly withdrawing the piston. The volume was recorded and the degree
of swelling calculated using the following formula:
Degree of swelling (mL g-1) = 10 × (measured volume − 0.12)
7.3.2 Synthesis of α-Amide 3.52
To MeOH or 2-MeTHF (1.5 mL) was added benzhydrylamine (207 μL, 1.2 mmol)
and pentanal (128 μL, 1.2 mmol). The resulting solution was agitated at 28 ◦C for
10 min. To this solution was added benzoic acid (146.5 mg, 1.2 mmol) in anhydrous
MeOH or 2-MeTHF (3 mL) followed by cyclohexyl isocyanide (149 μL, 1.2 mmol).
The reaction was agitated for 1.5 h at 28 ◦C. The mixture was then evaporated in
vacuo and the residue dissolved in EtOAc (20 mL). The organic solution was washed
with 1 M HClaq (2× 10 mL), saturated NaHCO3 (2× 10 mL) and brine (2× 10 mL),
dried (anhydrous MgSO4) and filtered. The organic layer was concentrated in vacuo
and the residue purified using flash column chromatography (20:80, EtOAc:PE) to
give the α-amide 3.52 as a yellow oil (458 mg, 79% in MeOH; 434 mg, 75% in 2-
MeTHF). RF = 0.23, (20:80, EtOAc:PE); IR (Neat) νmax 3302 (w), 2928 (s), 2856
(w), 1663 (s), 1617 (m) and 1525 (m) cm-1; 1H NMR (400 MHz, CDCl3): δ =
8.05 (br, 1H, N-H), 7.45-7.18 (m, 15H, ArH), 6.27 (s, 1H, NCHPh2), 3.81-3.80 (m,
1H, NCHC=O), 3.66-3.57 (m, 1H, NHCH), 1.83-1.51 (m, 6H, (CH2)3Me), 1.40-0.99
(m, 10H, (CH2)5), 0.76 (t J 7.1 Hz, 3H, CH3); 13C NMR (100 MHz, CDCl3): δ =
174.3, 171.0, 137.2, 130.2, 129.3, 128.9, 128.7, 128.6, 128.2, 126.3, 77.4, 64.9, 47.6,
32.7, 32.6, 31.4, 29.1, 25.8, 24.6, 24.5, 22.5, 13.9; HRMS (ESI) m/z calculated for
C32H38N2NaO2 505.2820 (M+Na)+, found 505.2825, − 1.5 ppm error.
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7.3.3 Deprotection of α-Amino Amide 3.52
TFA (2 mL) was added to amide 3.52 (100 mg, 0.2 mmol) and the solution agitated
for 4 h at room temperature. The reaction mixture was evaporated in vacuo and
the residue purified using flash column chromatography (30:70, EtOAc:PE) to give
compound 3.53 as a white solid (44 mg, 67%). RF = 0.25, (30:70, EtOAc:PE);
m.p. 163-164 ◦C; IR (Neat) νmax 3264 (m), 3080 (w), 2934 (m), 2858 (w), 1659
(w) and 1551 (m) cm-1; 1H NMR (400 MHz, CDCl3): δ = 7.84-7.81 (m, 2H, ArH),
7.52-7.39 (m, 3H, ArH), 7.20 (d J 7.2 Hz, 1H, NH), 6.66 (d J 6.7 Hz, 1H, NH),
4.65 (dd J 14.7, 7.0 Hz, 1H, NCHCO), 3.80-3.71 (m, 1H, NCH), 1.93-1.56 (m, 6H,
(CH2)3Me), 1.40-1.09 (m, 10H, (CH2)5), 0.85 (t J 7.0 Hz, 3H, CH3); 13C NMR
(100 MHz, CDCl3): δ = 170.8, 167.1, 134.0, 131.6, 128.5, 127.1, 53.6, 48.3, 33.0,
32.8 (2 peaks), 32.7, 27.6, 25.4, 24.7, 22.5, 13.9; HRMS (ESI) m/z calculated for
C19H28N2NaO2 339.2040 (M+Na)+, found 339.2043, 1.1 ppm error.
7.3.4 Solid-Supported Synthesis of α-Amino Amide 3.56
Resin with an Fmoc-protected Rink Linker (100 mg, Merrifield 1.0 mmol g-1;
ChemMatrix 0.49 mmol g-1) was allowed to swell in DMF (2 mL) for 30 min. Then,
a 20% (v/v) solution of piperidine in DMF (2 mL) was added and the resin agitated
for 10 min. The resin was filtered and treated a second time with a 20% solution
of piperidine in DMF (2 mL) for 10 min. The deprotected resin was then filtered,
washed with DMF (2 mL), CH2Cl2 (2 mL), and dried under vacuum. A sample
was subjected to the Kaiser test to confirm the presence of primary amines. The
remaining resin was suspended in MeOH or 2-MeTHF (2 mL) for 30 min. Pentanal
(10 eq. based on the resin loading) and cyclohexyl isocyanide (10 eq. based on resin
loading) were added and the resin agitated for 18 h. The resin was then washed
with DMF (5 × 5 mL), CH2Cl2 (5 × 5 mL), and dried under vacuum. The resin was
treated with a 30% solution of TFA in CH2Cl2 (2 mL) for 3 h at room temperature.
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Resin was removed by filtration and the filtrate was concentrated in vacuo. The
residue was purified by flash column chromatography (30:70, EtOAc:PE) to give
compound 3.56 as a white solid in the yields quoted in Table 3.5. Analytical and
spectroscopic data were identical to those reported for compound 3.53 prepared by
a solution-phase approach.
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7.4 ROMP of an Amide Functionalised Oxanorbornene-
Lactone
2-[(1R,5S,7S)-4-oxo-3,10-dioxatricyclo-[5.2.1.01,5]dec-8-en-5-yl]acetic
acid 4.7
Acid 4.7 was prepared from itaconic anhydride and furfuryl alcohol using either of
the procedures described below.
Solvent Free: Itaconic Anhydride (3.0 g, 26.7 mmol, 1.0 eq) was suspended in furfuryl
alcohol (2.3 mL, 26.7 mmol, 1.0 eq), the slurry obtained was then allowed to stir at
ambient temperature. After circa 5 h, the suspension has thickened to a paste and
could no longer be stirred. The reaction mixture was left for a further 19 h until a
tan solid had formed. The crude material was then purified by recrystallisation from
acetone to give the target acid 4.7 as an off-white crystalline solid (3.81 g, 68%).
Reaction Solvent: Itaconic anhydride (25 g, 223 mmol, 1.0 eq) and furfuryl alcohol
(19.4 mL, 223 mmol, 1.0 eq) were suspended in acetonitrile (12 mL) and the slurry
allowed to stir at ambient temperature, after 24 h a white suspension had formed.
The solid was removed by filtration and the filtrate was concentrated in vacuo. The
concentrated filtrate was suspended in EtOAc (100 mL) and filtered. The solids
obtained were combined and recrystallised from acetone, to give the target acid 4.7
as an off-white crystalline solid (19.95g, 43%).181 m.p. 130-132 ◦C; IR (Neat) νmax
3100 (m), 1776 (s) and 1733 (s) cm-1; 1H NMR (400 MHz, CD3OD): δ = 6.59 (dd
J 5.9, 1.7 Hz, 1H, 1-H), 6.55 (d J 5.9 Hz, 1H, 2-H), 5.02 (dd J 4.7, 1.7 Hz, 1H,
6-H), 4.92 (d J 10.8 Hz, 1H, 7-H) 4.54 (d J 10.8 Hz, 1H, 7-H), 2.44-2.35 (m, 3H,
5/9-H), 1.55 (d J 12.3 Hz, 1H, 5-H); 13C NMR (100 MHz, CD3OD): δ = 180.0
(8), 173.0 (10), 139.3 (1), 131.5 (2), 95.6 (3), 80.1 (6), 70.0 (7), 53.3 (4), 40.7 (9),
37.7 (5); HRMS (ESI) m/z calculated for C10H10NaO5 233.0420 (M+Na)+, found
233.0417, 1.2 ppm error.
7.4.1 Synthesis of Trisubstituted Amides
7.4.1.1 General Procedure for the Synthesis of Trisubstituted Amides
Acid monomer 4.7 (2.0 g, 9.5 mmol) was suspended in anhydrous CH2Cl2 (5 mL)
under an argon atmosphere. The suspension was cooled to 0 ◦C and oxalyl chloride
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(12.0 mL of 2.0 M solution in CH2Cl2, 24.0 mmol) was added dropwise over 10
minutes, followed by DMF (4 drops). The suspension was stirred at ambient
temperature until a solution was obtained. The obtained solution was concentrated
in vacuo, to give a brown solid which was redissolved in anhydrous CH2Cl2 (10
mL) and cooled to 0 ◦C. A solution of disubstituted amine 4.38a-k (14 mmol)
and triethylamine (2.7 mL, 19.0 mmol) (or 5.4 mL, 38.0 mmol if using the TFA
salt of amine 4.38a-k) in CH2Cl2 (10 mL) was added dropwise over 10 minutes.
The solution was allowed to stir at ambient temperature overnight, then additional
CH2Cl2 (30 mL) and H2O (50 mL) were added. The organic layer was separated
and further washed with 1M HClaq (50 mL), 1M NaHCO3 (50 mL), H2O (50 mL)
and brine (50 mL). The organic layer was dried (MgSO4), filtered and concentrated
in vacuo. The residue was then purified using flash column chromatography.
N,N -Dimethyl-2-[(5S,7S)-4-oxo-3,10-dioxatricyclo[5.2.1.01,5]dec-8-en-5-
yl]acetamide 4.39a
Acid monomer 4.7 (2 g, 9.52 mol) and dimethylamine hydrochloride 4.38a (0.78
g, 9.52 mol) were coupled according to the general procedure for the synthesis
of trisubstituted amides. The crude material was purified using flash column
chromatography (0:100-10:90, MeOH:EtOAc) to give the target amide 4.39a as
a pale yellow crystalline solid (1.28 g, 57%). RF = 0.23, (10:90, MeOH:EtOAc);
m.p. 128-129 ◦C; IR (Neat) νmax 3067 (w), 2959 (w), 1767 (s), 1633 (s) and 1504
(m) cm-1; 1H NMR (400 MHz, CDCl3): δ = 6.64 (d J 5.5 Hz, 1H, 2-H), 6.45 (dd J
5.5, 1.7 Hz, 1H, 1-H), 5.03 (d J 10.2 Hz, 1H, 9-H), 4.97 (dd J 4.9, 1.7 Hz, 1H, 6-H),
4.50 (d J 10.2 Hz, 1H, 9-H), 2.97 (m, 4H, 11-H & 7-H), 2.90 (s, 3H, 11-H), 2.50
(dd J 11.8, 4.9 Hz, 1H, 5-H), 2.07 (d J 14.4 Hz, 1H, 7-H), 1.30 (d J 11.8 Hz, 1H,
5-H); 13C NMR (100 MHz, CDCl3): δ = 178.8 (8), 168.9 (10), 136.3 (1), 132.2 (2),
94.8 (3), 78.0 (6), 70.3 (9), 52.6 (4), 39.1 (7), 38.1 (11), 37.8 (5), 35.8 (11); HRMS
(ESI) m/z calculated for C12H15NNaO4 (M+Na)+ 260.0893, found 260.0891, 1.3
ppm error.
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N,N -diethyl-2-[(5S,7S)-4-oxo-3,10-dioxatricyclo[5.2.1.01,5]dec-8-en-5-
yl]acetamide 4.39b
Acid monomer 4.7 (2 g, 9.52 mol) and diethylamine 4.38b (0.98 mL, 9.52 mol)
were coupled according to the general procedure for the synthesis of trisubstituted
amides. The crude material was purified using flash column chromatography (90:10,
EtOAc:PE) to give the target amide 4.39b as a pale yellow crystalline solid (2.08 g,
82%). RF = 0.32, (90:10, EtOAc:PE); m.p. 95-96 ◦C; IR (Neat) νmax 2969 (w),
2937 (w), 1758 (s) and 1640 (s) cm-1; 1H NMR (400 MHz, CDCl3): δ = 6.70 (d J
5.9 Hz, 1H, 2-H), 6.45 (dd J 5.9, 1.5 Hz, 1H, 1-H), 5.05 (d J 9.9 Hz, 1H, 7-H), 4.98
(dd J 4.7, 1.4 Hz, 1H, 6-H), 4.50 (d J 9.9 Hz, 1H, 7-H), 3.56-3.37 (m, 2H, 11-H),
3.20-3.06 (m, 2H, 11-H), 2.96 (d J 14.5 Hz, 1H, 9-H), 2.52 (dd J 12.1, 4.7 Hz, 1H,
5-H), 2.01 (d J 14.3 Hz, 1H, 9-H), 1.28 (d J 12.1 Hz, 1H, 5-H), 1.12 (d J 7.0 Hz,
3H, 12-H), 1.09 (d J 7.0 Hz, 3H, 12-H); 13C NMR (100 MHz, CDCl3): δ = 178.8
(8), 168.2 (10), 136.0 (1), 132.6 (2), 94.9 (3), 77.9 (6), 70.5 (7), 53.0 (4), 42.8 (11),
40.7 (11) 38.8 (9), 37.9 (5), 14.5 (12), 13.1 (12); HRMS (ESI) m/z calculated for
C16H18NO4 (M+H)+ 288.1230, found 288.1219, 3.7 ppm error.
N,N -dipropyl-2-[(5S,7S)-4-oxo-3,10-dioxatricyclo[5.2.1.01,5]dec-8-en-5-
yl]- acetamide 4.39c
Acid monomer 4.7 (2 g, 9.52 mol) and dipropylamine 4.38c (1.31 mL, 9.52 mol)
were coupled according to the general procedure for the synthesis of trisubstituted
amides. The crude material was purified using flash column chromatography (50:50,
EtOAc:PE) to give the target amide 4.39c as a yellow oil (1.59 g, 57%). RF = 0.32,
(70:30, EtOAc:PE); IR (Neat) νmax 2965 (w), 2876 (w), 1765 (s) and 1631 (s) cm-1;
1H NMR (400 MHz, CDCl3): δ = 6.69 (d J 5.9 Hz, 1H, 2-H), 6.45 (dd J 5.9, 1.6
Hz, 1H, 1-H), 5.04 (d J 10.1 Hz, 1H, 7-H), 4.97 (dd J 4.7, 1.6 Hz, 1H, 6-H), 4.49
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(d J 10.1 Hz, 1H, 7-H), 3.52-3.41 (m, 1H, 11-H), 3.38-3.29 (m, 1H, 11-H), 3.05-2.91
(m, 3H, 11-H, 9-H), 2.52 (dd J 11.8, 4.7 Hz, 1H, 5-H), 2.00 (d J 14.5 Hz, 1H, 9-H),
1.61-1.41 (m, 4H, 12-H), 1.27 (d J 11.8 Hz, 1H, 5-H), 0.87 (td J 7.6, 2.8 Hz, 6H,
13-H); 13C NMR (100 MHz, CDCl3): δ = 178.8 (8), 168.6 (10), 135.9 (1), 132.7 (2),
94.9 (3), 77.9 (6), 70.5 (7), 53.0 (4), 50.3 (11), 48.1 (11), 38.9 (9), 37.9 (5), 22.4 (12),
21.0 (12), 11.4 (13), 11.3 (13); HRMS (ESI) m/z calculated for C16H24NNaO4
(M+Na)+ 316.1519, found 316.1523, −1.4 ppm error.
N,N -dibutyl-2-[(5S,7S)-4-oxo-3,10-dioxatricyclo[5.2.1.01,5]dec-8-en-5-
yl]acetamide 4.39d
Acid monomer 4.7 (2 g, 9.52 mol) and dibutylamine 4.38d (1.60 mL, 9.52 mol)
were coupled according to the general procedure for the synthesis of trisubstituted
amides. The crude material was purified using flash column chromatography (50:50,
EtOAc:PE) to give the target amide 4.39d as a colourless oil (2.33 g, 79%). RF =
0.32, (50:50, EtOAc:PE); IR (Neat) νmax 2958 (w), 2932 (w), 2873 (w), 1765 (s)
and 1631 (s) cm-1; 1H NMR (400 MHz, CDCl3): δ = 6.70 (d J 5.6 Hz, 1H, 2-H),
6.45 (dd J 5.6, 1.4 Hz, 1H, 1-H), 5.04 (d J 10.4 Hz, 1H, 7-H), 4.98 (dd J 5.1, 1.7 Hz,
1H, 6-H), 4.50 (d J 10.4 Hz, 1H, 7-H), 3.53-3.43 (m, 1H, 11-H), 3.41-3.31 (m, 1H,
11-H), 3.06-2.97 (m, 2H, 11-H), 2.96 (d J 14.7 Hz, 1H, 9-H), 2.52 (dd J 11.6, 5.1
Hz, 1H, 5-H), 1.99 (d J 14.7 Hz, 1H, 9-H), 1.54-1.39 (m, 4H, 12-H), 1.34-1.22 (m,
5H, 13-H, 5-H), 0.91 (t J 7.1 Hz, 3H, 14-H), 0.91 (t J 7.1 Hz, 3H, 14-H); 13C NMR
(100 MHz, CDCl3): δ = 178.8 (8), 168.5 (10), 135.9 (1), 132.7 (2), 94.9 (3), 77.9 (6),
70.5 (7), 53.0 (4), 48.5 (11), 46.2 (11), 38.9 (5), 37.9 (9), 31.4 (12), 29.9 (12), 20.3
(13), 20.1 (13), 14.0 (14), 13.9 (14); HRMS (ESI) calculated for C18H27NNaO4
(M+Na)+ 344.1832, found 344.1818, 3.7 ppm error m/z.
N,N -Dioctyl-2-[(5S,7S)-4-oxo-3,10-dioxatricyclo[5.2.1.01,5]dec-8-en-5-
yl]acetamide 4.39e
Acid monomer 4.7 (2 g, 9.52 mol) and dioctylamine 4.38e (2.88 mL, 9.52 mol)
were coupled according to the general procedure for the synthesis of trisubstituted
amides. The crude material was purified by flash column chromatography (20:80,
EtOAc:PE) to give the target amide 4.39e as a colourless oil (1.28 g, 31%). RF
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= 0.38, (40:60, EtOAc:PE); IR (Neat) νmax 2954 (s), 2924 (s), 2854 (s), 1768 (s)
and 1634 (s) cm-1; 1H NMR (400 MHz, CDCl3): δ = 6.70 (d J 5.9 Hz, 1H, 2-H),
6.45 (dd J 5.9, 1.8 Hz, 1H, 1-H), 5.03 (d J 9.7 Hz, 1H, 7-H), 4.98 (dd J 4.9, 1.8 Hz,
1H, 6-H), 4.49 (d J 9.7 Hz, 1H, 7-H), 3.54-3.29 (m, 2H, 11-H), 3.06-2.92 (m, 3H,
11-H/9-H), 2.51 (dd J 11.7, 4.7 Hz, 1H, 5-H), 1.99 (d J 14.4 Hz, 1H, 9-H), 1.57-1.38
(m, 4H, 12-H), 1.35-1.16 (m, 22H, 13-17-H/5-H), 0.88 (d J 5.6 Hz, 3H, 18-H), 0.86
(d J 6.3 Hz, 3H, 18-H); 13C NMR (100 MHz, CDCl3): δ = 178.8 (8), 168.5 (10),
135.9 (1), 132.7 (2), 94.9 (3), 77.9 (6), 70.5 (7), 53.0 (4), 48.7 (11), 46.5 (11), 38.9
(9), 37.9 (5), 31.9, 31.9, 29.5, 29.4, 29.4, 29.3, 27.8, 27.1, 26.9, 22.8, 22.7, 14.2 (18),
14.2 (18); HRMS (ESI) m/z calculated for C26H44NO4 (M+H)+ 434.3265, found
434.3248, 4.8 ppm error.
N,N -Bis(2-ethylhexyl)-2-[(5S,7S)-4-oxo-3,10-dioxatricyclo[5.2.1.01,5]dec-
8-en-5-yl] acetamide 4.39f
Acid monomer 4.7 (2 g, 9.52 mol) and bis(2-ethylhexyl)amine 4.38f (2.86 mL,
9.52 mol) were coupled according to the general procedure for the synthesis
of trisubstituted amides. The crude material was purified by flash column
chromatography (30:70, EtOAc:PE) to give the target amide 4.39f as a yellow
oil, containing a mixture of diastereoisomers (2.87 g, 70%). RF = 0.33, (30:70,
EtOAc:PE); IR (Neat) νmax 2957 (m), 2928 (m), 2873 (m), 1769 (s) and 1632 (s)
cm-1; 1H NMR (400 MHz, CDCl3): δ = 6.71-6.65 (m, 1H, 1-H), 6.47-6.41 (m,
1H, 2-H), 5.06-5.00 (m, 1H, 7-H), 4.99-4.95 (m, 1H, 6-H), 4.53-4.44 (m, 1H, 7-H),
3.64-3.51 (m, 1H, 11-H), 3.35-3.20 (m, 1H, 11-H), 3.07-2.91 (m, 2H, 9-H/11-H), 2.88-
2.78 (m, 1H, 11-H), 2.55-2.47 (m, 1H, 5-H), 2.04-1.95 (m, 1H, 9-H), 1.67-1.59 (m,
1H, 12-H), 1.54-1.43 (m, 1H, 12-H), 1.37-1.11 (m, 17H, 5-H/13-H/14-H/15-H/17-
H), 0.92-0.82 (m, 12H, 16-H/18-H); 13C NMR (100 MHz, CDCl3): δ = 178.7 (8),
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169.4 (10), 135.9 (2), 132.7 (1), 94.9 (3), 77.9 (6), 70.4 (7), 53.1/53.0 (4), 52.6/52.1
(11), 49.7/49.1 (11), 39.5/39.3 (9), 39.0/38.9 (12), 38.0/38.0 (5), 37.4/37.1 (12),
30.6, 30.4, 28.9, 28.8, 23.9, 23.6, 23.4, 23.2, 14.3 (16), 14.2 (16), 11.1/11.0 (18),
10.6/10.5 (18); HRMS (ESI) m/z calculated for C26H44NO4 (M+H)+ 434.3265,
found 434.3258, 0.5 ppm error.
N,N -Dibenzyl-2-[(5S,7S)-4-oxo-3,10-dioxatricyclo[5.2.1.01,5]dec-8-en-5-
yl]acetamide 4.39g
Acid monomer 4.7 (2 g, 9.52 mol) and dibenzylamine 4.38g (1.83 mL, 9.52 mol)
were coupled according to the general procedure for the synthesis of trisubstituted
amides. The crude material was purified by flash column chromatography (2:98,
MeOH:CH2Cl2) to give the target amide 4.39g as a yellow crystalline solid (1.73
g, 47%). RF = 0.18, (2:98, MeOH:CH2Cl2); m.p. 154-155 ◦C; IR (Neat) νmax
3014 (w), 1778 (s), 1636 (s) and 1603 (m) cm-1; 1H NMR (400 MHz, CDCl3): δ =
7.39-7.24 (m, 6H, Ar-H), 7.24-7.19 (m, 2H, Ar-H), 7.11-7.05 (m, 2H, Ar-H), 6.66 (d
J 5.8 Hz, 1H, 2-H), 6.43 (dd J 5.8, 1.7 Hz, 1H, 1-H), 5.05 (d J 10.1 Hz, 1H, 7-H),
5.02-4.96 (m, 2H, 6-H, 11-H), 4.66 (d J 17.8 Hz, 1H, 11-H), 4.54 (d J 10.1 Hz, 1H,
7-H), 4.29 (d J 17.8 Hz, 1H, 11-H), 4.18 (d J 14.8 Hz, 1H, 11-H), 3.02 (d J 14.8
Hz, 1H, 9-H), 2.52 (dd J 12.1, 4.3 Hz, 1H, 5-H), 2.17 (d J 14.8 Hz, 1H, 9-H), 1.26
(d J 12.1 Hz, 1H, 5-H); 13C NMR (100 MHz, CDCl3): δ = 178.8 (8), 169.9 (10),
136.6 (ArC), 136.3 (1), 136.1 (ArC), 132.3 (2), 129.1 (ArCH), 128.9 (ArCH), 127.9
(ArCH), 127.9 (ArCH), 127.7 (ArCH), 126.3 (ArCH), 94.8 (3), 78.0 (6), 70.4 (7),
52.9 (3), 50.7 (4), 48.9 (11), 39.2 (9), 37.8 (5); HRMS (ESI) m/z calculated for
C24H23NNaO4 (M+Na)+ 412.1519, found 412.1505, 4.2 ppm error.
Methyl-(2S)-1-[2-[(5S,7S)-4-oxo-3,10-dioxatricyclo[5.2.1.01,5]dec-8-en-5-
yl]acetyl] pyrrolidine-2-carboxylate 4.39h
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Acid monomer 4.7 (2 g, 9.52 mol) and proline methyl ester hydrochloride 4.38h
(2.30 g, 9.52 mol) were coupled according to the general procedure for the
synthesis of trisubstituted amides. The crude material was purified by flash column
chromatography (100:0, EtOAc:PE) to give the target amide 4.39h as a white
solid containing a mixture of diastereoisomers (2.47 g, 81%). RF = 0.24, (100:0,
EtOAc:PE); m.p. 102-103 ◦C; IR (Neat) νmax 3003 (w), 2957 (w), 1759 (s), 1736
(s) and 1632 (s) cm-1; 1H NMR (400 MHz, CDCl3): δ = 6.70-6.63 (m, 1H, 2-H),
6.49-6.39 (m, 1H, 1-H), 5.11-4.92 (m, 2H, 6-H/7-H), 4.53-4.38 (m, 2H, 14-H/7-H),
3.74-3.57 (m, 4H, 15-H/11-H), 3.56-3.39 (m, 1H, 11-H), 3.03-2.73 (m, 1H, 9-H),
2.55-2.44 (m, 1H, 5-H), 2.24-1.87 (m, 5H, 9-H/12-H/13-H), 1.40-1.15 (m, 1H, 5-H);
13C NMR (100 MHz, CDCl3): δ = 178.9/178.6 (8), 172.6/172.2 (15), 167.9/167.8
(10), 136.3/136.0 (1), 132.5/132.3 (2), 94.7/94.6 (3), 78.2/77.0 (6), 70.4/69.8 (7),
59.2/58.8 (14), 52.6/52.6 (4), 52.4/52.3 (16), 47.8 (11), 40.9/39.9 (9), 38.2/37.4
(5), 29.3 (13), 24.9/24.9 (12); HRMS (ESI) m/z calculated for C16H19NNaO6
(M+Na)+ 344.1105, found 344.1110, 2.0 ppm error.
Benzyl-2-[methyl-[2-[(5S,7S)-4-oxo-3,10-dioxatricyclo[5.2.1.01,5]dec-8-en-
5-yl]acetyl]amino]acetate 4.39i
Acid monomer 4.7 (2 g, 9.52 mol) and N -methyl glycine benzyl ester hydrochloride
4.38i (1.92 g, 9.52 mol) were coupled according to the general procedure for the
synthesis of trisubstituted amides. The crude material was purified by flash column
chromatography (80:20-100:0, EtOAc:PE) to give the target amide 4.39i as a yellow
crystalline solid (1.59 g, 45%). RF = 0.4, (100:0, EtOAc:PE); m.p. 98-99 ◦C; IR
(Neat) νmax 2953 (w), 2983 (w), 1764 (s), 1739 (s) and 1641 (s) cm-1; 1H NMR
(400 MHz, CDCl3, major rotamer): δ = 7.40-7.29 (m, 5H, ArH), 6.61 (d J 6.0 Hz,
1H, 2-H), 6.46 (dd J 6.0, 1.8 Hz, 1H, 1-H), 5.21-5.11 (m, 2H, 14-H), 5.02-4.91 (m,
2H, 6-H, 7-H), 4.47 (d J 10.4 Hz, 1H, 7-H), 4.32 (d J 17.3 Hz, 1H, 12-H), 3.88 (d
J 17.3 Hz, 1H, 12-H), 3.06-2.78 (m, 4H, 11-H, 9-H), 2.51 (dd J 12.0, 4.6 Hz, 1H,
5-H), 2.17 (d J 14.8, 1H, 9-H), 1.31 (d J 12.0 Hz, 1H, 5-H); 13C NMR (100 MHz,
CDCl3, major rotamer): δ = 178.6 (8), 169.8 (10), 168.8 (13), 136.3 (1), 135.3 (ArC),
132.1 (2), 128.8 (ArCH), 128.7 (ArCH), 128.6 (ArCH), 128.5 (ArCH), 94.6 (3), 78.0
(6), 70.1 (7), 67.1 (14), 52.4 (4), 49.9 (12), 38.9 (5), 38.0 (9), 37.5 (11); HRMS
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(ESI) m/z calculated for C20H21NNaO6 (M+Na)+ 394.1261, found 394.1247, 4.1
ppm error.
7.4.1.2 General Procedures for the Synthesis of Peptide Monomers 4.39j
and 4.39k
7.4.1.3 General Coupling Procedure for the Synthesis of Peptide
Monomers
To a suspension of N -Boc-Sar-OH (1 g, 5.29 mmol), an amino acid benzyl ester
(1.0 eq.) and HOBt (0.77 g, 5.82 mmol) in DMF:CH2Cl2 (75:25, 0.2 M), at 0 ◦C,
was added NEtiPr2 (2.76 mL, 15.87 mmol). EDC (1.03 mL, 5.82 mmol) was added
dropwise and the solution allowed to stir at room temperature for 16 h. The reaction
mixture was then diluted using EtOAc (50 mL) and washed with 1 M HClaq (3 ×
25 mL), saturated Na2CO3 (3 × 25 mL) and H2O (3 × 25 mL). The organic layer
was dried (MgSO4), filtered and concentrated in vacuo and purified as detailed for
each compound below.
7.4.1.4 General Procedure for the Boc Deprotection of Dipeptides
Dipeptide (500 mg) was dissolved in CH2Cl2 (5 mL). TFA (60 eq.) was added and
the solution allowed to stir at room temperature for 3 h. The solution was then
concentrated in vacuo to give the dipeptide TFA salt which could be used without
further purification.
Boc-Sar-Gly-OBn
Boc-Sar-OH (1 g, 5.29 mmol, 1.0 eq.) and HCl·H-Gly-OBn (1.07 g, 5.29 mmol, 1.0
eq.) were coupled according to the general coupling procedure for the synthesis of
dipeptides. The crude material was then purified using flash column chromatography
(50:50, EtOAc:PE) to give the target Boc-Sar-Gly-OBn dipeptide as a yellow oil
which crystallised upon standing (1.33 g, 75%). RF = 0.3, (50:50, EtOAc:PE);
m.p. 87-89 ◦C; IR (Neat) νmax 3304 (w), 2972 (w), 1749 (m), 1692 (s), 1664 (s),
1558 (m) cm-1; 1H NMR (400 MHz, CDCl3): δ = 7.39-7.30 (m, 5H, ArH), 6.77-
6.36 (br, 1H, NH), 5.17 (s, 2H, OCH2Ph), 4.09 (d J 5.4 Hz, 2H, CH 2NH), 3.90 (s,
2H, CH2NMe), 2.93 (s, 3H, NMe), 1.46 (s, 9H, OC(CH3)3); 13C NMR (100 MHz,
CDCl3): δ = 169.8 (C=O), 169.6 (C=O), 135.2 (ArC), 128.8 (ArCH), 128.7 (ArCH),
128.5 (ArCH), 80.9 (C (CH3)3), 67.3 (OCH2Ph), 52.3 (CH2NMe), 41.2 (CH2NH),
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35.8 (NCH3), 28.4 (C(CH3)3); HRMS (ESI) m/z calculated for C17H24N2NaO5
(M+Na)+ 359.1577, found 359.1584, 1.7 ppm error.
Boc-Sar-Sar-OBn
Boc-Sar-OH (1 g, 5.29 mmol, 1.0 eq.) and para-toluenesulfonate H-Sar-OBn (1.86
g, 5.29 mmol, 1.0 eq.) were coupled according to the general coupling procedure
for the synthesis of dipeptides. The crude material was then purified using flash
column chromatography (60:40, EtOAc:PE) to give the target Boc-Sar-Sar-OBn
dipeptide as a yellow oil (1.74 g, 94%). RF = 0.3, (60:40, EtOAc:PE); m.p. 78-
79 ◦C; IR (Neat) νmax 3007 (w), 2978 (w), 1741 (s), 1681 (s), 1659 (s) cm-1; 1H
NMR (400 MHz, CDCl3, major rotamer): δ = 7.39-7.28 (m, 5H, ArH), 5.13 (s, 2H,
OCH2Ph), 4.20-3.88 (m, 4H, 2 × MeNCH 2), 3.03 (s, 3H, NMe), 2.90 (s, 3H, NMe),
1.45 (s, 9H, OC(CH3)3); 13C NMR (100 MHz, CDCl3, major rotamer): δ = 169.4
(C=O), 169.1 (C=O), 156.3 (ArC), 128.7 (ArCH), 128.5 (ArCH), 128.4 (ArCH),
80.0 (OC (CH3)3), 67.0 (OCH2Ph), 50.1 (MeNCH2), 49.7 (MeNCH2), 35.6 (NMe),
35.5 (NMe), 28.4 (OC(CH3)3); HRMS (ESI) m/z calculated for C18H26N2NaO5
(M+Na)+ 373.1734, found 373.1740, − 2.4 ppm error.
TFA·H-Sar-Gly-OBn 4.38j
Boc-Sar-Gly-OBn (500 mg, 1.49 mmol, 1.0 eq.) was deprotected according to the
general procedure for the deprotection of dipeptides to give TFA·H-Sar-Gly-OBn
4.38j as a yellow oil (480 mg, 92%). IR (Neat) νmax 3091 (w), 2828 (w), 1738
(m), 1667 (s) and 1563 (m) cm-1; 1H NMR (400 MHz, CDCl3): δ = 7.42-7.24 (m,
5H, ArH), 5.18 (s, 2H, CH2OBn) 4.08 (s, 2H, CH2NH), 3.85 (s, 2H, CH2NHMe),
2.71 (s, 3H, NHMe); 13C NMR (100 MHz, CDCl3): δ = 170.8 (COOBn), 167.1
(CONH), 160.9 (q J 37.4 Hz, 1C, CF3COOH), 137.1 (ArC), 129.6 (ArCH), 129.4
(ArCH), 129.3 (ArCH), 117.0 (q J 287.3 Hz, 1C, CF3COOH), 68.1 (CH2OBn), 50.4
(CH2NHMe), 42.0 (CH2NH), 33.5 (NHCH3); HRMS (ESI) m/z calculated for
C12H17N2O3 (M-CF3COO-)+ 237.1234, found 237.1236, − 0.8 ppm error.
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TFA·H-Sar-Sar-OBn 4.38k
Boc-Sar-Sar-OBn (500 mg, 1.42 mmol, 1.0 eq.) was deprotected according to the
general procedure for the deprotection of dipeptides to give TFA·H-Sar-Sar-OBn
4.38k as a yellow oil (497 mg, 96%). IR (Neat) νmax 3035 (w), 2821 (w), 1779
(w), 1744 (m) and 1659 (s) cm-1; 1H NMR (400 MHz, CDCl3, major rotamer):
δ = 7.45-7.28 (m, 5H, ArH), 5.18 (s, 2H, CH2COOBn), 4.25 (s, 2H, CH2NMe),
4.13 (s, 2H, CH2NHMe), 3.07 (s, 3H, NMe), 2.73 (s, 3H, NHMe); 13C NMR
(100 MHz, CDCl3, major rotamer): δ = 170.3 (COOBn), 167.4 (CONH), 160.9
(q J 38.6 Hz, 1C, CF3COOH), 137.0 (ArC), 129.6 (ArC), 129.4 (ArCH), 129.3
(ArCH), 117.1 (q J 289.7 Hz, 1C, CF3COOH), 68.1 (CH2COOBn), 51.2 (CH2NMe),
50.4 (CH2NHMe), 35.8 (NMe), 33.5 (NHMe); HRMS (ESI) m/z calculated for
C13H18N2NaO3 (M+Na)+ 273.1210, found 273.1212, − 0.7 ppm error.
benzyl-2-[[2-[methyl-[2-[(5S,7S)-4-oxo-3,10-dioxatricyclo-[5.2.1.01,5]dec-
8-en-5-yl]acetyl]amino]acetyl]amino]acetate 4.39j
Acid monomer 4.7 (372 mg, 1.7 mmol, 1.0 eq.) and TFA·H-Sar-Gly-OBn 4.38kj
(620 mg, 1.77 mmol, 1.0 eq.) were coupled according to the general procedure for
the synthesis of trisubstituted amides. The crude material was purified by flash
column chromatography (80:20, EtOAc:Acetone) to give the target amide 4.39j as
a clear oil (493 mg, 65%). IR (Neat) νmax 3348 (w), 2011 (w), 2951 (w), 1749 (s)
and 1641 (s) cm-1; 1H NMR (400 MHz, CDCl3, major rotamer): δ = 7.39-7.29 (m,
5H, ArH), 6.92 (t J 5.7 Hz, 1H, N-H), 6.57 (d J 6.1 Hz, 1H, 2-H), 6.53 (dd J 6.1,
1.4 Hz, 1H, 1-H), 5.16 (s, 2H, 16-H), 5.02 (dd J 5.0, 1.4 Hz, 1H, 6-H), 4.95 (d J
10.6 Hz, 1H, 7-H), 4.56 (d J 10.6 Hz, 1H, 7-H), 4.31 (d J 16.0 Hz, 1H, 12-H), 4.12
(dd J 17.9, 5.7 Hz, 1H, 14-H), 4.01 (dd J 17.9, 5.7 Hz, 1H, 14-H), 3.80 (d J 16.0
Hz, 1H, 12-H), 3.03 (s, 3H, 11-H), 2.63 (d J 14.7 Hz, 1H, 9-H), 2.48 (dd J 12.6, 5.1
Hz, 1H, 5-H), 2.41 (d J 14.7 Hz, 1H, 9-H), 1.56 (d J 12.6 Hz, 1H, 5-H); 13C NMR
(100 MHz, CDCl3, major rotamer): δ = 178.9 (8), 169.9 (15), 169.5 (13), 168.7 (10),
228
7.4. ROMP of an Amide Functionalised Oxanorbornene-Lactone
137.6 (1), 135.3 (ArC), 131.2 (2), 128.8 (ArCH), 128.7 (ArCH), 128.6 (ArCH), 128.5
(ArCH), 94.4 (3), 78.5 (6), 69.8 (7), 67.2 (16), 52.8 (4), 51.9 (12), 41.2 (14), 37.8
(9), 37.6 (11), 37.0 (5); HRMS (ESI) m/z calculated for C22H24N2NaO7 (M+Na)+
451.1476, found 451.1475, − 0.1 ppm error.
benzyl-2-[methyl-[2-[methyl-[2-[(5S,7S)-4-oxo-3,10-dioxatricyclo-
[5.2.1.01,5]dec-8-en-5-yl]acetyl]amino]acetyl]amino]acetate 4.39k
Acid monomer 4.7 (330 mg, 1.57 mmol, 1.0 eq.) and TFA·H-Sar-Sar-OBn 4.38k
(573 mg, 1.57 mmol, 1.0 eq.) were coupled according to the general procedure for the
synthesis of trisubstituted amides. The crude material was purified by flash column
chromatography (100:0-80:20, EtOAc:Acetone) to give the target amide 4.39k as
a yellow oil (398 mg, 57%). IR (Neat) νmax cm-1; 1H NMR (400 MHz, CDCl3,
major rotamer): δ = 7.40-7.29 (m, 5H, ArH), 6.67 (d J 5.6 Hz, 1H, 2-H), 6.45 (dd
J 5.6, 1.8 Hz, 1H, 1-H), 5.21-5.11 (m, 2H, 17-H), 5.04-4.94 (m, 2H, 6-H/7-H), 4.61
(d J 16.4 Hz, 1H, 15-H), 4.48 (d J 9.8 Hz, 1H, 7-H), 4.33 (d J 17.5 Hz, 1H, 12-H),
3.98 (d J 17.5 Hz, 1H, 12-H), 3.81 (d J 16.4 Hz, 1H, 15-H), 3.08-2.94 (m, 6H, 11-
H/14-H), 2.91-2.69 (m, 1H, 9-H), 2.53 (dd J 12.0, 4.8 Hz, 1H, 5-H), 2.22 (d J 15.2
Hz, 1H, 9-H), 1.33 (d J 12.0 Hz, 1H, 5-H); 13C NMR (100 MHz, CDCl3, major
rotamer): δ = 178.8 (8), 169.8 (10), 169.0 (13), 168.3 (16), 136.3 (1), 135.3 (ArC),
132.3 (2), 128.7 (ArCH), 128.6 (ArCH), 128.4 (ArCH), 128.3 (ArCH), 94.7 (3), 78.1
(6), 70.1 (7), 67.2 (17), 52.5 (4), 49.8 (12), 49.6 (15), 39.0 (9), 38.2 (5), 37.6 (14),
35.8 (11); HRMS (ESI) m/z calculated for C23H26N2NaO7 (M+Na)+ 465.1632,
found 465.1636, − 0.9 ppm error.
7.4.2 Ring-Opening Metathesis Polymerisation of Tertiary
Amide Monomers
7.4.2.1 General Procedure for the ROMP of Amides 4.39a-k
The appropriate quantities of monomer(s) and catalyst G2 were separately dissolved
in (CH2Cl)2. Each solution was degassed by three cycles of freeze-pump-thaw.
The monomer solution was prewarmed to the desired temperature and the catalyst
solution added. The reaction mixture was then stirred for 72 h. After this time,
the polymerization was terminated by the addition of an excess of ethyl vinyl ether,
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followed by stirring for a further 30 minutes. The solution was then filtered through
a short plug of silica to remove catalyst residues. The solution was then precipitated
into hexane. After settling, the hexane was carefully decanted and the polymer dried
under reduced pressure.
7.4.2.2 Analytical Data and Spectra for Homopolymers 4.42a-k
Dimethyl Homopolymer 4.42a
1H NMR Spectrum
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TGA Trace
DSC Trace
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Infrared Spectrum
Diethyl Homopolymer 4.42b
1H NMR Spectrum
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TGA Trace
DSC Trace
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Infrared Spectrum
Dipropyl Homopolymer 4.42c
SEC Trace
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1H NMR Spectrum
TGA Trace
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DSC Trace
Infrared Spectrum
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Dibutyl Homopolymer 4.42d
SEC Trace
1H NMR Spectrum
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TGA Trace
DSC Trace
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Infrared Spectrum
Dioctyl Homopolymer 4.42e
SEC Trace
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1H NMR Spectrum
TGA Trace
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DSC Trace
Infrared Spectrum
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Bis-(2-ethylhexyl) Homopolymer 4.42f
SEC Trace
1H NMR Spectrum
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TGA Trace
DSC Trace
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Infrared Spectrum
Dibenzyl Homopolymer 4.42g
SEC Trace
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1H NMR Spectrum
TGA Trace
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DSC Trace
Infrared Spectrum
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Proline Methyl Ester Homopolymer 4.42h
1H NMR Spectrum
TGA Trace
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DSC Trace
Infrared Spectrum
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Sarcosine Benzyl Ester Homopolymer 4.42i
SEC Trace
1H NMR Spectrum
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TGA Trace
DSC Trace
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Infrared Spectrum
Sar-Gly Benzyl Ester Homopolymer 4.42j
1H NMR Spectrum
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TGA Trace
DSC Trace
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Infrared Spectrum
Sar-Sar Benzyl Ester Homopolymer 4.42k
1H NMR Spectrum
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TGA Trace
Infrared Spectrum
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7.4.2.3 Analytical Data and Spectra for Random Co-polymers 4.43a-d
Propyl Sarcosine Benzyl Ester Copolymer 4.43a
SEC Trace
1H NMR Spectrum
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TGA Trace
DSC Trace
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Infrared Spectrum
Ethyl Benzyl Copolymer 4.43b
SEC Trace
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1H NMR Spectrum
TGA Trace
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DSC Trace
Infrared Spectrum
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Butyl Proline Methyl Ester Copolymer 4.43c
SEC Trace
1H NMR Spectrum
260
7.4. ROMP of an Amide Functionalised Oxanorbornene-Lactone
TGA Trace
DSC Trace
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Infrared Spectrum
Methyl Sarcosine Benzyl Ester Copolymer 4.43d
1H NMR Spectrum
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TGA Trace
DSC Trace
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Infrared Spectrum
7.4.2.4 Procedure for the Synthesis of Dibenzyl/Diethyl Block
Copolymer 4.45
Dibenzyl amide 4.39g (39 mg, 0.1 mmol) and catalyst G2 were combined in
a Schlenk tube under argon. (CH2Cl)2 was degassed by three cycles of freeze-
pump-thaw, then (CH2Cl)2 (1 mL) was added to the Schlenk tube containing the
monomer/catalyst. The reaction mixture was then stirred at 40 ◦C for 13.6 h,
which corresponds to 80% conversion, as determined by the kinetic plot obtained
for monomer 4.39g. After 13.6 h, a sample was taken and immediately analysed
by 1H NMR spectroscopy to determine the conversion. A second sample was then
taken, end-capped by treatment with excess ethyl vinyl ether for 30 minutes, filtered
through a silica plug and precipitated into hexane. The hexane was decanted and
the sample dried under reduced pressure before being analysed by SEC. A solution
of diethyl monomer 4.39b (29 mg, 0.1 mmol) in (CH2Cl)2 (1 mL), which had been
subjected to degassing by three cycles of freeze-pump-thaw, was then added to the
reaction mixture. The reaction was monitored by SEC and 1H NMR spectroscopy
every 24 h for the next 48 h as the second block was incorporated according to
the previously described procedure. After 48 h the polymer was end-capped by
treatment with excess ethyl vinyl ether for 30 minutes. The polymer was then
filtered through a plug of silica and precipitated into hexane. The hexane was
decanted and the polymer dried under reduced pressure before being analysed by
1H NMR spectroscopy and SEC.
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7.4.2.5 General Procedure for Monitoring the Kinetics of Amide
Homopolymerisation
The appropriate quantities of monomer and catalyst G2 (1.7 mg, 1 mol%) were
separately dissolved in (CD2Cl)2 (0.5 mL). Tetramethylsilane (1 drop) was then
added to the monomer solution. Each solution was subjected to three cycles of
degassing by freeze-pump-thaw. The monomer and catalyst solution were then
combined. A sample of the reaction mixture was then transferred to an NMR tube
equipped with a Young tap. The sample was sealed under argon and 1H NMR
spectra recorded at 40 ◦C every 30 mins for 24 h. Conversion was then determined
by integrating monomer alkene peaks relative to the TMS peak.
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7.5 Synthesis of Spirocyclic Oxanorbornene-Imides
7.5.1 General Procedure for the Synthesis of Disubstituted
Amides
Acid 5.10 (2.0 g, 9.52 mmol, 1.0 eq) was suspended in anhydrous CH2Cl2 (5 mL)
under an atmosphere of argon. The suspension was cooled to 0 ◦C and oxalyl
chloride 2.0 M solution in CH2Cl2 (12 mL, 24 mmol, 2.5 eq) was added dropwise
over 10 min, followed by DMF (4 drops). The suspension was stirred at ambient
temperature until a solution was obtained. The obtained solution was concentrated
in vacuo, to give the crude acid chloride as a brown solid. The crude material
was redissolved in anhydrous CH2Cl2 (10 mL) and cooled to 0 ◦C. A solution of
monosubstituted amine (9.52 mmol, 1.0 eq) and pyridine (0.77 mL, 9.52 mmol, 1.0
eq, 2.0 eq if using the amine salt) in CH2CL2 (10 mL) was added dropwise over
10 min. The solution was allowed to stir at ambient temperature overnight before
diluting with CH2Cl2 (30 mL) and H2O (50 mL). The organic layer was separated
and further washed with 1 M HClaq (50 mL), H2O (50 mL) and brine (50 mL). The
organic layer was dried (MgSO4), filtered and concentrated in vacuo.
N -Isopropyl-2-[(1R,5S,7S)-4-oxo-3,10-dioxatricyclo[5.2.1.01,5]dec-8-en-5-
yl]acetamide 5.1a
Acid 5.10 (2 g, 9.52 mmol) and isopropylamine (0.82 mL, 9.52 mol) were coupled
according to the general procedure for the synthesis of disubstituted amides.
The crude material was purified using flash column chromatography (80:20-100:0,
EtOAc:PE) to give the target compound 5.1a as a yellow oil (1.27 g, 53%) RF =
0.19, (80:20, EtOAc:PE); IR (Neat) νmax 3307 (w), 2971 (w), 1765 (s), 1643 (s)
and 1536 (s) cm-1; 1H NMR (400 MHz, CDCl3): δ = 6.59 (d J 5.9 Hz, 1H, 2-H),
6.49 (dd J 5.9, 1.8 Hz, 1H, 1-H), 6.20-6.07 (br, 1H, N-H), 5.00 (dd J 4.8, 1.8 Hz,
1H, 6-H), 4.83 (d J 10.6 Hz, 1H, 7-H), 4.56 (d J 10.6 Hz, 1H, 7-H), 3.97 (dsep J 6.8,
5.6 Hz, 1H, 11-H), 2.48 (dd J 12.0, 4.8 Hz, 1H, 5-H), 2.30 (d J 14.3 Hz, 1H, 9-H),
2.19 (d J 14.3 Hz, 1H, 9-H), 1.29 (d J 12.0 Hz, 1H, 5-H), 1.11 (d J 6.6 Hz, 6H,
12-H); 13C NMR (100 MHz, CDCl3): δ = 179.1 (8), 167.7 (10), 137.2 (1), 131.6
(2), 94.5 (3), 78.4 (6), 69.7 (7), 52.9 (4), 42.7 (9), 41.8 (11), 36.6 (5), 22.5 (12), 22.4
(12); HRMS (ESI) m/z calculated for C13H17NNaO4 274.1050 (M+Na)+, found
274.1056, − 2.3 ppm error.
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N -Butyl-2-[(1R,5S,7S)-4-oxo-3,10-dioxatricyclo[5.2.1.01,5]dec-8-en-5-
yl]acetamide 5.1b
Acid 5.10 (2 g, 9.52 mmol) and butylamine (0.94 mL, 9.52 mol) were coupled
according to the general procedure for the synthesis of disubstituted amides.
The crude material was then purified using flash column chromatography (80:20,
EtOAc:PE) to give the target compound 5.1b as a white solid (1.71 g, 68%). RF
= 0.18, (80:20, EtOAc:PE); m.p. 83-84 ◦C; IR (Neat) νmax 3240 (m), 3078 (w),
2961 (m), 2876 (w), 1768 (s), 1631 (s) and 1562 (m) cm-1; 1H NMR (400 MHz,
CDCl3): δ = 6.60 (d J 5.9 Hz, 1H, 2-H), 6.51 (dd J 5.9, 1.7 Hz, 1H, 1-H), 6.30 (br,
1H, N-H), 5.02 (dd J 4.8, 1.7 Hz, 1H, 6-H), 4.84 (d J 10.7 Hz, 1H, 7-H), 4.59 (d
J 10.7 Hz, 1H, 7-H), 3.20 (dt J 7.1, 2.5 Hz, 2H, 11-H), 2.50 (dd J 11.9, 4.8 Hz,
1H, 5-H), 2.33 (d J 14.3 Hz, 1H, 9-H), 2.26 (d J 14.3 Hz, 1H, 9-H), 1.51-1.42 (m,
2H, 12-H), 1.38-1.27 (m, 3H, 1×5-H + 2×13-H), 0.90 (t J 6.7 Hz, 3H, 14-H); 13C
NMR (100 MHz, CDCl3): δ = 179.3 (8), 168.5 (10), 137.4 (1), 131.5 (2), 94.6 (3),
78.5 (6), 69.7 (7), 52.8 (4), 42.7 (9), 39.7 (11), 36.6 (5), 31.4 (12), 20.1 (13), 13.8
(14); HRMS (ESI) m/z calculated for C14H19NNaO4 288.1202 (M+Na)+, found
288.1206, 1.5 ppm error.
N -Hexyl-2-[(1R,5S,7S)-4-oxo-3,10-dioxatricyclo[5.2.1.01,5]dec-8-en-5-
yl]acetamide 5.1c
Acid 5.10 (2 g, 9.52 mmol) and hexylamine (1.26 mL, 9.52 mol) were coupled
according to the general procedure for the synthesis of disubstituted amides. The
crude material was then purified using flash column chromatography (70:30-100:0,
EtOAc:PE) to give the target compound 5.1c as a yellow crystalline solid (870 mg,
31%). RF = 0.19, (70:30, EtOAc:PE); m.p. 62-62 ◦C; IR (Neat) νmax 3303 (m),
2927 (m), 2855 (m), 1767 (s), 1669 (m), 1649 (s) and 1541 (s) cm-1; 1H NMR
(400 MHz, CDCl3): δ = 6.60 (d J 5.7 Hz, 1H, 2-H), 5.67 (dd J 5.7, 1.6 Hz, 1H,
1-H), 6.39-6.32 (br, 1H, N-H), 5.01 (dd J 4.6, 1.6 Hz, 1H, 6-H), 4.84 (d J 10.5 Hz,
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1H, 7-H), 4.57 (d J 10.5 Hz, 1H, 7-H), 3.18 (dt J 7.1, 6.8 Hz, 1H, 11-H), 2.49 (dd
J 12.1, 4.6 Hz, 1H, 5-H), 2.32 (d J 14.6 Hz, 1H, 9-H), 2.25 (d J 14.6, 1H, 9-H),
1.52-1.41 (m, 2H, 12-H), 1.33-1.20 (m, 7H, 5-H, 13-H, 14-H, 15-H), 0.86 (t J 7.2
Hz, 3H, 16-H); 13C NMR (100 MHz, CDCl3): δ = 179.3 (8), 168.5 (10), 137.3 (1),
131.5 (2), 94.5 (3), 78.5 (6), 69.7 (7), 52.8 (4), 42.7 (9), 39.9 (11), 36.6 (5), 31.5
(15), 29.3 (12), 26.6 (13), 22.6 (14), 14.1 (16); HRMS (ESI) m/z calculated for
C16H23NNaO4 316.1519 (M+Na)+, found 316.1525, − 1.9 ppm error.
N -Octyl-2-[(1R,5S,7S)-4-oxo-3,10-dioxatricyclo[5.2.1.01,5]dec-8-en-5-
yl]acetamide 5.1d
Acid 5.10 (2 g, 9.52 mmol) and octylamine (1.57 mL, 9.52 mol) were coupled
according to the general procedure for the synthesis of disubstituted amides. The
crude material was purified using flash column chromatography to give the target
amide 5.1d as a pale yellow crystalline solid (2.12 g, 69%). RF = 0.3, (90:10,
EtOAc:PE); m.p. 75-76 ◦C; IR (Neat) νmax 3302 (m), 2918 (m), 2851 (m), 1767
(s), 1669 (m), 1649 (s) and 1543 (s) cm-1; 1H NMR (400 MHz, CDCl3): δ = 6.60 (d
J 6.1 Hz, 1H, 2-H), 6.50 (dd J 6.1, 1.6 Hz, 1H, 1-H), 6.37-6.28 (br, 1H, N-H), 5.01
(dd J 4.8, 1.6 Hz, 1H, 6-H), 4.84 (d J 10.8 Hz, 1H, 7-H), 4.57 (d J 10.8 Hz, 1H, 7-H),
3.18 (dt J 12.3, 6.3 Hz, 2H, 11-H), 2.49 (dd J 12.3, 4.8 Hz, 1H, 5-H), 2.33 (d J 14.6
Hz, 1H, 9-H), 2.24 (d J 14.6 Hz, 1H, 9-H), 1.51-1.40 (m, 2H, 12-H), 1.34-1.17 (m,
11H, 5-H, 13-H, 14-H, 15-H, 16-H, 17-H), 0.86 (t J 7.1 Hz, 3H, 18-H); 13C NMR
(100 MHz, CDCl3): δ = 179.3 (8), 168.5 (10), 137.3 (1), 131.6 (2), 94.5 (3), 78.5 (6),
69.7 (7), 52.8 (4), 42.7 (9), 40.0 (11), 36.6 (5), 31.9 (12), 29.4 (13), 29.3 (14/15),
26.9 (16), 22.7 (17), 14.2 (18); HRMS (ESI) m/z calculated for C18H27NNaO4
344.1832 (M+Na)+, found 344.1837, − 0.9 ppm error.
N -Benzyl-2-[(1R,5S,7S)-4-oxo-3,10-dioxatricyclo[5.2.1.01,5]dec-8-en-5-
yl]acetamide 5.1e
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Acid 5.10 (2 g, 9.52 mmol) and benzylamine (1.04 mL, 9.52 mol) were coupled
according to the general procedure for the synthesis of disubstituted amides.
The crude material was purified using flash column chromatography (70:30-90:10,
EtOAc:PE) to give the target material 5.1d as a white crystalline solid (1.67 g,
58%). RF = 0.30, (80:20, EtOAc:PE); m.p. 106-107 ◦C; IR (Neat) νmax 3286 (m),
1765 (s), 1636 (s) and 1547 (s) cm-1; 1H NMR (400 MHz, CDCl3): δ = 7.31-7.25
(m, 2H, ArH), 7.24-7.18 (m, 3H, ArH), 6.75-6.66 (br, 1H, N-H), 6.54 (d J 5.8 Hz,
1H, 2-H), 6.45 (dd J 5.8, 1.6 Hz, 1H, 1-H), 4.95 (dd J 4.8, 1.6 Hz, 1H, 6-H), 4.75
(d J 10.6 Hz, 1H, 7-H), 4.51 (d J 10.6 Hz, 1H, 7-H), 4.37 (dd J 14.6, 5.8 Hz, 1H,
11-H), 4.30 (dd J 14.6, 5.8 Hz, 1H, 11-H), 2.41 (dd J 12.0, 4.9 Hz, 1H, 5-H), 2.32 (d
J 14.8 Hz, 1H, 9-H), 2.23 (d J 14.8 Hz, 1H, 9-H), 1.25 (d J 12.0 Hz, 1H, 5-H); 13C
NMR (100 MHz, CDCl3): δ = 179.2 (8), 168.6 (10), 137.8 (1), 137.4 (ArC), 131.4
(2), 128.8 (ArCH), 127.8 (ArCH), 127.6 (ArCH), 94.5 (3), 78.5 (6), 69.6 (7), 52.8
(4), 43.9 (11), 42.5 (9), 36.6 (5); HRMS (ESI) m/z calculated for C17H17NNaO4
322.1050 (M+Na)+, found 322.1049, 0.3 ppm error.
Benzyl-2-[[2-[(1R,5S,7S)-4-oxo-3,10-dioxatricyclo[5.2.1.01,5]-dec-8-en-5-
yl]acetyl]amino]acetate 5.1f
Acid 5.10 (2 g, 9.52 mmol) and glycine benzyl ester hydrochloride (1.92 g, 9.52 mol)
were coupled according to the general procedure for the synthesis of disubstituted
amides. The crude material was purified using flash column chromatography (80:20-
100:0, EtOAc:PE) to give the target amide 5.1f as a white crystalline solid (1.86
g, 55%). RF = 0.38, (80:20, EtOAc:PE); m.p. 109-110 ◦C; IR (Neat) νmax 3394
(m), 3300 (w), 1769 (s), 1742 (s), 1667 (m), 1647 (s) and 1547 (m) cm-1; 1H NMR
(400 MHz, CDCl3): δ = 7.39 (m, 5H, ArH), 6.98-6.91 (br, 1H, N-H), 6.56 (d J 5.6
Hz, 1H, 2-H), 6.50 (dd J 5.6, 1.5 Hz, 1H, 1-H), 5.16 (s, 2H, 13-H), 4.99 (dd J 4.9,
1.7 Hz, 1H, 6-H), 4.82 (d J 10.4 Hz, 1H, 7-H), 4.57 (d J 10.4 Hz, 1H, 7-H), 4.13 (dd
J 17.9, 5.9 Hz, 1H, 11-H), 3.91 (dd J 17.9, 5.9 Hz, 1H, 11-H), 2.50 (dd J 12.2, 4.9
Hz, 1H, 5-H), 2.41 (d J 14.9 Hz, 1H, 9-H), 2.34 (d J 14.9 Hz, 1H, 9-H), 1.36 (d J
12.2 Hz, 1H, 5-H); 13C NMR (100 MHz, CDCl3): δ = 179.2 (8), 169.5 (12), 169.0
(10), 137.7 (1), 135.2 (ArC), 131.2 (2), 128.7 (ArCH), 128.6 (ArCH), 128.5 (ArCH),
94.4 (3), 78.6 (6), 69.4 (7), 67.3 (13), 52.4 (4), 41.9 (9), 41.6 (11), 36.7 (5); HRMS
(ESI) m/z calculated for C19H19NNaO6 380.1105 (M+Na)+, found 380.1103, − 0.1
ppm error.
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(1R,4S,6S)-1’-Butyl-1-(hydroxymethyl)spiro[7-oxabicyclo[2.2.1]hept-2-
ene-6,3’-pyrrolidine]-2’,5’-dione 5.2
Acid 5.10 (2 g, 9.52 mmol, 1.0 eq) was suspended in CH2Cl2 (5 mL) under an
atmosphere of argon. The suspension was cooled to 0 ◦C and oxalyl chloride 2.0
M in CH2Cl2 (12 mL, 24 mmol, 2.5 eq) was added dropwise over 10 min. The
suspension was stirred for 2 h or until a solution was obtained. The solution was
concentrated in vacuo and the crude material redissolved in CH2Cl2 (10 mL). The
solution was cooled to 0 ◦C and a solution of butylamine (48 mmol, 5.0 eq) in CH2Cl2
(10 mL) was added dropwise. The solution was allowed to stir at room temperature
overnight before diluting with CH2Cl2 (30 mL) and H2O (50 mL). The organic layer
was separated and further washed with 1 M HClaq (50 mL), H2O (50 mL) and
brine (50 mL). The organic phase was dried (MgSO4), filtered and concentrated in
vacuo. The crude material was purified using flash column chromatography (80:20,
EtOAc:PE) to give the target imide 5.2 as a white crystalline solid (839 mg, 33%).
RF = 0.25, (80:20, EtOAc:PE); m.p. 69-70 ◦C; IR (Neat) νmax 3396 (m), 3024
(w), 2946 (m), 2874 (m), 1767 (m), 1674 (s) and 1685 (s) cm-1; 1H NMR (400
MHz, CDCl3): δ = 6.65 (dd J 5.7, 1.7 Hz, 1H, 1-H), 6.48 (d J 5.7 Hz, 1H, 2-H),
5.13 (dd J 4.8, 1.7 Hz, 6-H), 4.02 (d J 11.6 Hz, 1H, 7-H), 3.90 (dd J 11.6, 4.1 Hz,
1H, 7-H), 3.50 (t J 7.4 Hz, 2H, 11-H), 2.72-2.61 (m, 2H, 5-H/9-H), 2.47-2.37 (m,
2H, OH/9-H), 1.59-1.48 (m, 3H, 12-H/5-H), 1.37-1.25 (m, 2H, 13-H), 0.91 (t J 7.3
Hz, 3H, 14-H); 13C NMR (100 MHz, CDCl3): δ = 180.4 (8), 176.2 (10), 140.3
(1), 135.1 (2), 92.8 (3), 79.1 (6), 60.3 (7), 49.9 (4), 44.0 (5), 40.1 (9), 39.0 (11), 29.7
(12), 20.1 (13), 13.7 (14); HRMS (ESI) m/z calculated for C14H19NNaO4 288.1214
(M+Na)+, found 288.1206, − 2.7 ppm error.
7.5.2 General Procedure for the Hydrogenation of Secondary
Amides to Imides
Secondary amide (1.88 mmol, 1.0 eq) was dissolved in MeOH (1 mL) under argon,
the addition of EtOAc may be necessary in some cases to obtain a solution. In a
separate flask Pd/C (10% w/w) was suspended in MeOH (1 mL) under argon. H2
was bubbled through the suspension of Pd/C for 10 min. The solution of secondary
amide was then added to the catalyst suspension. The reaction mixture was allowed
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to stir at room temperature for 16 h under H2 (1 bar). The reaction mixture was
then passed through a pad of Celite R© and concentrated in vacuo.
(1R,2S,4R)-1’-Butyl-1-(hydroxymethyl)spiro[7-oxabicyclo[2.2.1]heptane-
2,3’-pyrrolidine]-2’,5’-dione 5.45b
Butyl amide 5.1b (100 mg) was hydrogenated according to the general procedure
for the hydrogenation of alkyl/benzyl secondary amides. The crude material was
purified using flash column chromatography (80:20-90:10, EtOAc:PE) to give the
target compound 5.45b as a clear oil (77 mg, 76%). RF = 0.33, (90:10, EtOAc:PE);
IR (Neat) νmax 3460 (w), 2958 (w), 2874 (w), 1771 (w) and 1685 (s) cm-1; 1HNMR
(400 MHz, CDCl3): δ = 4.72 (t J 5.3 Hz, 1H, 6-H), 3.93 (d J 5.3 Hz, 2H, 7-H), 3.49
(t J 7.3 Hz, 2H, 11-H), 2.97 (d J 17.9 Hz, 1H, 9-H), 2.71 (d J 17.9 Hz, 1H, 9-H), 2.52
(ddd J 12.1, 5.5, 2.6 Hz, 1H, 5-H), 2.02-1.91 (m, 2H, 1-H), 1.78-1.62 (m, 3H, 2-H,
OH), 1.59-1.49 (m, 3H, 12-H/5-H), 1.37-1.23 (m, 2H, 13-H), 0.91 (t J 7.3 Hz, 3H,
14-H) ; 13C NMR (100 MHz, CDCl3): δ = 180.5 (8), 175.7 (10), 90.4 (3), 77.4 (6),
62.7 (7), 52.6 (4), 45.3 (5), 39.2 (9), 38.8 (11), 31.3 (2), 29.7 (12/1), 20.1 (13), 13.7
(14); HRMS (ESI) m/z calculated for C14H21NNaO4 290.1363 (M+Na)+, found
290.1368, − 2.5 ppm error.
(1R,2S,4R)-1’-Hexyl-1-(hydroxymethyl)spiro[7-oxabicyclo[2.2.1]heptane-
2,3’-pyrrolidine]-2’,5’-dione 5.45c
Hexyl amide 5.1c (400 mg) was hydrogenated according to the general procedure
for the hydrogenation of alkyl/benzyl secondary amides. The crude material was
purified using flash column chromatography (80:20, EtOAc:PE) to give the target
compound 5.45c as a clear oil (378 mg, 94%). RF = 0.32, (80:20, EtOAc:PE);
IR (Neat) νmax 3460 (w), 2931 (m), 2859 (w), 1771 (m) and 1686 (s) cm-1; 1H
NMR (400 MHz, CDCl3): δ = 4.68 (t J 5.2 Hz, 1H, 6-H), 3.89 (s, 2H, 7-H), 3.44
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(t J 7.5 Hz, 2H, 11-H), 2.96 (d J 18.4 Hz, 1H, 9-H), 2.68 (d J 18.4 Hz, 1H, 9-H),
2.48 (ddd J 11.9, 5.2, 2.5 Hz, 1H, 5-H), 2.34-2.18 (br, 1H, OH), 2.02-1.82 (m, 2H,
1-H/2-H), 1.75-1.60 (m, 2H, 1-H/2-H), 1.58-1.47 (m, 3H, 5-H/12-H), 1.30-1.19 (m,
6H, 15-H/14-H/13-H), 0.84 (t J 7.2 Hz, 3H, 16-H); 13C NMR (100 MHz, CDCl3):
δ = 180.5 (8), 175.8 (10), 90.4 (3), 77.1 (6), 62.6 (7), 52.6 (4), 45.2 (5), 39.2 (9), 39.0
(11), 31.4 (12), 31.2 (1), 29.6 (2), 27.5 (13), 26.5 (14), 22.6 (15), 14.1 (16); HRMS
(ESI) m/z calculated for C16H25NNaO4 318.1676 (M+Na)+, found 318.1676, 0.1
ppm error.
(1R,2S,4R)-1-(Hydroxymethyl)-1’-octyl-spiro[7-
oxabicyclo[2.2.1]heptane-2,3’-pyrrolidine]-2’,5’-dione 5.45d
Octyl amide 5.1d (100 mg) was hydrogenated according to the general procedure
for the hydrogenation of alkyl/benzyl secondary amides. The crude material was
purified using flash column chromatography (70:30) to give the target compound
5.45d as a clear oil (98 mg, 98%) RF = 0.26, (70:30, EtOAc:PE); IR (Neat) νmax
3452 (w), 2926 (m), 2856 (m), 1771 (w) and 1688 (s) cm-1; 1H NMR (400 MHz,
CDCl3): δ = 4.69 (t J 4.9 Hz, 1H, 6-H), 3.90 (s, 2H, 7-H), 3.45 (t J 7.3 Hz, 2H,
11-H), 2.97 (d J 18.3 Hz, 2H, 9-H), 2.69 (d J 18.3 Hz, 1H, 9-H), 2.52-2.45 (m, 1H,
5-H), 2.13-2.04 (br, 1H, OH), 2.01-1.88 (m, 2H, 1-H), 1.77-1.61 (m, 2H, 2-H), 1.58-
1.47 (m, 3H, 5-H, 12-H), 1.30-1.18 (m, 10H, 13-H, 14-H, 15-H, 16-H, 17-H), 0.85 (t
J 6.3 Hz, 3H, 18-H); 13C NMR (100 MHz, CDCl3): δ = 180.5 (8), 175.8 (10), 90.4
(3), 77.4 (6), 62.7 (7), 52.6 (4), 45.3 (5), 39.2 (9), 39.1 (11), 31.9 (31.3), 29.6 (1),
29.3 (2), 29.2 (14), 27.6 (15), 26.9 (16), 22.7 (17), 14.2 (18); HRMS (ESI) m/z
calculated for C18H29NNaO4 346.1989 (M+Na)+, found 346.1992, − 0.5 ppm error.
(1R,2S,4R)-1’-Benzyl-1-(hydroxymethyl)spiro[7-
oxabicyclo[2.2.1]heptane-2,3’-pyrrolidine]-2’,5’-dione 5.45e
Benzyl amide 5.1e (400 mg) was hydrogenated according to the general procedure
for the hydrogenation of alkyl/benzyl secondary amides. The crude material was
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purified using flash column chromatography (80:20-90:10, EtOAc:PE) to give the
target compound 5.45e as a clear oil (381 mg, 95%). RF = 0.36, (90:10, EtOAc:PE);
m.p. 129-130 ◦C; IR (Neat) νmax 3490 (m), 2978 (w), 1772 (m) and 1692 (s) cm-1;
1H NMR (400 MHz, CDCl3): δ = 7.40-7.35 (m, 2H, ArH), 7.31-7.23 (m, 3H, ArH),
4.67 (t, J 5.7 Hz, 1H, 6H), 4.65 (d J 14.1 Hz, 1H, 11-H), 4.60 (d J 14.1 Hz, 1H,
11-H), 3.80-3.67 (m, 2H, 7-H), 2.99 (d J 18.4 Hz, 1H, 9-H), 2.70 (d J 18.4 Hz, 1H,
9-H), 2.49 (ddd J 12.1, 5.7, 2.4 Hz, 1H, 5-H), 2.03-1.86 (m, 2H, 2-H, 1-H), 1.77-1.57
(m, 3H, 2-H, 1-H, OH), 1.53 (d J 12.1 Hz, 1H, 5-H); 13C NMR (100 MHz, CDCl3):
δ = 180.2 (8), 175.3 (10), 136.0 (ArC), 129.0 (ArCH), 128.7 (ArCH), 128.1 (ArCH),
90.3 (3), 77.2 (6), 62.9 (7), 52.9 (4), 44.9 (5), 42.6 (11), 39.3 (9), 31.3 (2), 29.9
(1); HRMS (ESI) m/z calculated for C17H19NNaO4 324.1206 (M+Na)+, found
324.1206, 0.2 ppm error.
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A.1 General
Amino Acid Abbreviations
Table A.1: Amino acid abbreviations.
Full Name Abbreviation
3-Letter
Abbreviation
1-Letter
Alanine Ala A
Arginine Arg R
Asparagine Asn N
Aspartate Asp D
Cysteine Cys C
Glutamate Glu E
Glutamine Gln Q
Glycine Gly G
Histidine His H
Isoleucine Ile I
Leucine Leu L
Lysine Lys K
Methionine Met M
Phenylalanine Phe F
Proline Pro P
Serine Ser S
Threonine Thr T
Tryptophan Trp W
Tyrosine Tyr Y
Valine Val V
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A.2 Cyclic Carbonates as Solvents for Peptide Synthesis
Chromatograms for Additional Racemisation Studies
Figure A.1: Chiral HPLC chromatograms for Boc-Leu-Ala-Phe-OBn tripeptide,
(S,S,S )-top 2.99, (R,S,S )-middle 2.100 and racemic mixture-bottom.
Figure A.2: Chiral HPLC chromatograms for the microwave assisted synthesis of
Boc-Ala-Phe-OBn dipeptide 2.89 in CH2Cl2:DMF-top and PC-bottom.
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Figure A.3: Chiral HPLC chromatograms for Boc-Leu-Phe-OBn dipeptide, (S,S )-
top 2.97, (R,S )-middle 2.98 and racemic mixture-bottom, samples prepared by RA
under the supervision of SL.
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A.3 Greener Solvents for Solid-Phase Organic Synthesis
Allocation of Solvent Training Set to Groups
Merrifield Resin
Maximum swelling 6.3 mL g-1; minimum swelling 1.8 mL g-1
n = 6
Swelling Range (mL g-1) Solvents Rank
1.80 - 2.55 1, 2, 3, 4, 19, 20, 21, 22, 23 6
2.55 - 3.30 11, 17, 18 5
3.30 - 4.05 8 4
4.05 - 4.80 3
4.80 - 5.55 29 2
5.55 - 6.30 7, 12, 28, 30 1
n = 5
Swelling Range (mL g-1) Solvents Rank
1.80 - 2.70 1, 2, 3, 4, 19, 20, 21, 22, 23 5
2.70 - 3.60 11, 17, 18 4
3.60 - 4.50 8 3
4.50 - 5.40 29 2
5.40 - 6.30 7, 12, 28, 30 1
n = 4
Swelling Range (mL g-1) Solvents Rank
1.80 - 2.93 1, 2, 3, 4, 17, 19, 20, 21, 22, 23 4
2.93 - 4.05 8, 11, 18 3
4.05 - 5.18 29 2
5.18 - 6.30 7, 12, 28, 30 1
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ParaMax Resin
Maximum swelling 7.8 mL g-1; minimum swelling 1.8 mL g-1
n = 6
Swelling Range (mL g-1) Solvents Rank
1.80 - 2.80 1, 2, 3, 19, 20, 21, 22, 23 6
2.80 - 3.80 5
3.80 - 4.80 17 4
4.80 - 5.80 4, 8, 11 3
5.80 - 6.80 2
6.80 - 7.80 7, 12, 28, 29, 30 1
n = 5
Swelling Range (mL g-1) Solvents Rank
1.80 - 3.00 1, 2, 3, 19, 20, 21, 22, 23 5
3.00 - 4.20 4
4.20 - 5.40 4, 8, 11, 17, 18 3
5.40 - 6.60 2
6.60 - 7.80 7, 12, 28, 29, 30 1
n = 4
Swelling Range (mL g-1) Solvents Rank
1.80 - 3.30 1, 2, 3, 19, 20, 21, 22, 23 4
3.30 - 4.80 16 3
4.80 - 6.30 4, 8, 11, 18 2
6.30 - 7.80 7, 12, 28, 29, 30 1
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JandaJel Resin
Maximum swelling 8.8 mL g-1; minimum swelling 1.8 mL g-1
n = 6
Swelling Range (mL g-1) Solvents Rank
1.80 - 2.97 1, 2, 3, 4, 18, 21, 22, 23 6
2.97 - 4.13 17 5
4.13 - 5.30 19 4
5.30 - 6.47 8, 20, 29 3
6.47 - 7.63 2
7.63 - 8.80 7, 11, 12, 28, 30 1
n = 5
Swelling Range (mL g-1) Solvents Rank
1.80 - 3.20 1, 2, 3, 4, 18, 21, 22, 23 5
3.20 - 4.60 17 4
4.60 - 6.00 8, 19, 20 3
6.00 - 7.40 29 2
7.40 - 8.80 7, 11, 12, 28, 30 1
n = 4
Swelling Range (mL g-1) Solvents Rank
1.80 - 3.55 1, 2, 3, 4, 18, 21, 22, 23 4
3.55 - 5.30 17, 19 3
5.30 - 7.05 8, 19, 29 2
7.05 - 8.80 7, 11, 12, 28, 30 1
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TentaGel Resin
Maximum swelling 5.5 mL g-1; minimum swelling 1.8 mL g-1
n = 6
Swelling Range (mL g-1) Solvents Rank
1.80 - 2.42 20, 22, 23 6
2.42 - 3.03 18, 19, 21 5
3.03 - 3.65 2, 4, 12 4
3.65 - 4.27 1, 3, 8, 11, 17, 28, 29 3
4.27 - 4.88 7 2
4.88 - 5.50 30 1
n = 5
Swelling Range (mL g-1) Solvents Rank
1.80 - 2.54 20, 22, 23 5
2.54 - 3.28 18, 19, 21 4
3.28 - 4.02 1, 2, 3, 4, 8, 11, 12, 17, 28, 29 3
4.02 - 4.76 2
4.76 - 5.50 7, 30 1
n = 4
Swelling Range (mL g-1) Solvents Rank
1.80 - 2.73 18, 19, 20, 22, 23 4
2.73 - 3.65 2, 4, 12, 21 3
3.65 - 4.58 1, 3, 8, 11, 17, 28, 29 2
4.58 - 5.50 7, 30 1
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ArgoGel Resin
Maximum swelling 7.7 mL g-1; minimum swelling 1.8 mL g-1
n = 6
Swelling Range (mL g-1) Solvents Rank
1.80 - 2.78 20, 22, 23 6
2.78 - 3.77 5
3.77 - 4.75 1, 2, 4, 12, 18, 19, 21 4
4.75 - 5.73 3, 8, 11, 17, 28, 29 3
5.73 - 6.72 7 2
6.72 - 7.70 30 1
n = 5
Swelling Range (mL g-1) Solvents Rank
1.80 - 2.98 20, 22, 23 5
2.98 - 4.16 1, 4, 21 4
4.16 - 5.34 2, 3, 8, 11, 12, 17, 18, 19, 28, 29 3
5.34 - 6.52 7 2
6.52 - 7.70 30 1
n = 4
Swelling Range (mL g-1) Solvents Rank
1.80 - 3.28 20, 22, 23 4
3.28 - 4.75 1, 2, 4, 12, 18, 19, 21 3
4.75 - 6.23 3, 7, 8, 11, 17, 28, 29 2
6.23 - 7.70 30 1
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HypoGel 200 Resin
Maximum swelling 4.8 mL g-1; minimum swelling 1.8 mL g-1
n = 6
Swelling Range (mL g-1) Solvents Rank
1.80 - 2.30 20, 21, 22, 23 6
2.30 - 2.80 2, 18, 19 5
2.80 - 3.30 1, 4, 8, 17 4
3.30 - 3.80 3, 11 3
3.80 - 4.30 12 2
4.30 - 4.80 7, 28, 29, 30 1
n = 5
Swelling Range (mL g-1) Solvents Rank
1.80 - 2.40 2, 19, 20, 21, 22, 23 5
2.40 - 3.00 1, 4, 8, 17, 18 4
3.00 - 3.60 3, 11 3
3.60 - 4.20 12 2
4.20 - 4.80 7, 28, 29, 30 1
n = 4
Swelling Range (mL g-1) Solvents Rank
1.80 - 2.55 2, 19, 20, 21, 22, 23 4
2.55 - 3.30 1, 4, 8, 17, 18 3
3.30 - 4.05 3, 11, 12 2
4.05 - 4.80 7, 28, 29, 30 1
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NovaGel Resin
Maximum swelling 5.8 mL g-1; minimum swelling 1.8 mL g-1
n = 6
Swelling Range (mL g-1) Solvents Rank
1.80 - 2.47 19, 20, 21, 22, 23 6
2.47 - 3.13 1, 2, 18 5
3.13 - 3.80 4, 8, 11, 12, 17 4
3.80 - 4.47 3 3
4.47 - 5.13 7, 28, 29 2
5.13 - 5.80 30 1
n = 5
Swelling Range (mL g-1) Solvents Rank
1.80 - 2.60 19, 20, 21, 22, 23 5
2.60 - 3.40 1, 2, 8, 17, 18 4
3.40 - 4.20 4, 11, 12 3
4.20 - 5.00 3, 7, 28 2
5.00 - 5.80 29, 30 1
n = 4
Swelling Range (mL g-1) Solvents Rank
1.80 - 2.80 1, 2, 18, 19, 20, 21, 22, 23 4
2.80 - 3.80 4, 8, 11, 12, 17 3
3.80 - 4.80 3, 28 2
4.80 - 5.80 7, 29, 30 1
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ChemMatrix Resin
Maximum swelling 9.8 mL g-1; minimum swelling 1.8 mL g-1
n = 6
Swelling Range (mL g-1) Solvents Rank
1.80 - 3.13 20, 23 6
3.13 - 4.47 4, 22 5
4.47 - 5.80 8, 12, 18, 20 4
5.80 - 7.13 1, 2, 7, 11, 17, 21 3
7.13 - 8.47 3, 28, 29 2
8.47 - 9.80 30 1
n = 5
Swelling Range (mL g-1) Solvents Rank
1.80 - 3.40 20, 23 5
3.40 - 5.00 4, 8, 19, 22 4
5.00 - 6.60 2, 11, 12, 17, 18 3
6.60 - 8.20 1, 7, 21, 28, 29 2
8.20 - 9.80 3, 30 1
n = 4
Swelling Range (mL g-1) Solvents Rank
1.80 - 3.80 20, 22, 23 4
3.80 - 5.80 4, 8, 18, 12, 19 3
5.80 - 7.80 1, 2, 7, 11, 17, 21, 28, 29 2
7.80 - 9.80 3, 30 1
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SpheriTide Resin
Maximum swelling 5.3 mL g-1; minimum swelling 1.8 mL g-1
n = 6
Swelling Range (mL g-1) Solvents Rank
1.80 - 2.38 1, 2, 18, 19, 20 6
2.38 - 2.97 3, 4, 8, 12, 17, 23 5
2.97 - 3.55 11 4
3.55 - 4.13 7, 21, 22 3
4.13 - 4.72 2
4.72 - 5.30 28, 29, 30 1
n = 5
Swelling Range (mL g-1) Solvents Rank
1.80 - 2.50 1, 2, 18, 19, 20 5
2.50 - 3.20 3, 4, 8, 11, 12, 17, 23 4
3.20 - 3.90 7, 21, 22 3
3.90 - 4.60 2
4.60 - 5.30 28, 29, 30 1
n = 4
Swelling Range (mL g-1) Solvents Rank
1.80 - 2.68 1, 2, 8, 18, 19, 20 4
2.68 - 3.55 3, 4, 11, 12, 17, 23 3
3.55 - 4.43 7, 21, 22 2
4.43 - 5.30 28, 29, 30 1
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3D Plots of HSPiP Predictions
Merrifield Resin
n = 5 groups
n = 4 groups n = 6 groups
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ParaMax Resin
n = 5 groups
n = 4 groups n = 6 groups
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JandaJel Resin
n = 5 groups
n = 4 groups n = 6 groups
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TentaGel Resin
n = 5 groups
n = 4 groups n = 6 groups
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ArgoGel Resin
n = 5 groups
n = 4 groups n = 6 groups
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HypoGel 200 Resin
n = 5 groups
n = 4 groups n = 6 groups
293
Appendix A.
NovaGel Resin
n = 5 groups
n = 4 groups n = 6 groups
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ChemMatrix Resin
n = 5 groups
n = 4 groups n = 6 groups
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SpheriTide Resin
n = 5 groups
n = 4 groups n = 6 groups
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Resin Swelling for Predicted Solvents
Figure A.4: The graph below is presented as a plot of amount of swelling rather than
the % swelling shown in the main chapter. This is less appropriate for comparison
between resins, but does indicate the amount of swelling relative to the 4.0 mL g-1
threshold for a good solvent (only SpheriTide did not meet this threshold). Resins are
ranked from highest predicted swelling (left) to lowest (right) with the RMS deviation
of the solvent parameters for dimethyl isosorbide 3.30 from those of an ideal solvent
given as a number above each bar.
Figure A.5: The graph below is presented as a plot of amount of swelling rather than
the % swelling shown in the main manuscript. This is less appropriate for comparison
between resins, but does indicate the amount of swelling relative to the 4.0 mL g-1
threshold for a good solvent. Resins are ranked from highest predicted swelling (left)
to lowest (right) with the RMS deviation of the solvent parameters for cyclopentyl
methyl ether 3.31 from those of an ideal solvent given as a number above each bar.
Where no number is given, the deviation is so large that the solvent is not in the
“Predictions of solvents to swell each resin” table for that solvent.
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Figure A.6: The graph below is presented as a plot of amount of swelling rather than
the % swelling shown in the main manuscript. This is less appropriate for comparison
between resins, but does indicate the amount of swelling relative to the 4.0 mL g-1
threshold for a good solvent. Resins are ranked from highest predicted swelling (left)
to lowest (right) with the RMS deviation of the solvent parameters for butan-2-one
3.20 from those of an ideal solvent given as a number above each bar.
Figure A.7: The graph below is presented as a plot of amount of swelling rather
than the % swelling shown in the main manuscript. This is less appropriate for
comparison between resins, but does indicate the amount of swelling relative to the
4.0 mL g-1 threshold for a good solvent. Resins are ranked from highest predicted
swelling (left) to lowest (right) with the RMS deviation of the solvent parameters for
4-methylpentan-2-one 3.21 from those of an ideal solvent given as a number above
each bar. Where no number is given, the deviation is so large that the solvent is not
in the “Predictions of solvents to swell each resin” table for that solvent.
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Figure A.8: The graph below is presented as a plot of amount of swelling rather
than the % swelling shown in the main manuscript. This is less appropriate for
comparison between resins, but does indicate the amount of swelling relative to the
4.0 mL g-1 threshold for a good solvent. Resins are ranked from highest predicted
swelling (left) to lowest (right) with the RMS deviation of the solvent parameters for
isopropyl acetate 3.24 from those of an ideal solvent given as a number above each
bar. Where no number is given, the deviation is so large that the solvent is not in
the “Predictions of solvents to swell each resin” table for that solvent.
299
Appendix A.
Solvent List and Parameters Used for Mixed Solvent Study
Solvent D P H BPt FPt V@25 MPt
3.16 18 21.7 5.1 248 143 0.009 36
3.17 20 18 4.1 242 135 0.004 -48
3.18 18.8 10.6 6.9 - - - -
3.19 15.5 10.4 7 56 -17 232 -95
3.20 16 9 5.1 80 -5 90.3 -87
3.21 15.3 6.1 4.1 116 16 19.8 -84
3.22 17.9 11.9 5.2 131 - 10.3 -51
3.23 15.8 5.3 7.2 77 -3 96.5 -84
3.24 14.9 4.5 8.2 89 - 60.4 -73
3.25 15.1 3.7 6.3 117 - 17.2 -99
3.26 16.9 11.5 6.3 186.5 72.4 0.549 -29.4
3.27 16.9 5 4.3 79 - 96.1 -137
3.29 17.8 4.4 6.9 154 - 3.4 -38
3.30 17.6 7.1 7.5 234 105 0.03 -50
3.31 16.7 4.3 4.3 106 0 35.5 -140
3.32 15.5 8.6 9.7 90 - 50 0
3.33 15.1 6.3 3.5 127 - 10 -43
3.34 17.2 1.8 4.3 177 43 1.61 -74
3.35 17.3 2.4 2.4 182.7 55.5 0.914 -45.1
3.36 14.7 12.3 22.3 65 12 128 -98
3.37 15.8 8.8 19.4 78 13 59.1 -114
3.38 15.8 6.1 16.4 82 14 43.4 -88
3.39 16 5.3 11.7 176 - 0.308 -34
3.40 15.5 16 42.3 100 - 21.8 0
300
A.4. Ring-Opening Metathesis Polymerisation of a Novel Bio-based Monomer
Framework
A.4 Ring-Opening Metathesis Polymerisation of a Novel Bio-
based Monomer Framework
Crystal Structure Data
N,N -Diethyl-2-[(5S,7S)-4-oxo-3,10-dioxatricyclo[5.2.1.01,5]dec-8-en-5-
yl]acetamide 4.39b
Empirical formula
Formula weight
Temperature/K
Crystal system
Space group
a/Å
b/Å
c/Å
α/◦
β/◦
γ/◦
Volume/Å3
Z
ρcalcg/cm3
μ/mm-1
F(000)
Crystal size/mm3
Radiation
2θ range for data collection/◦
Index ranges
Reflections collected
Independent reflections
Data/restraints/parameters
Goodness-of-fit on F2
Final R indexes [I>=2σ(I)]
Final R indexes [all data]
Largest diff. peak/hole / e Å-3
Flack parameter
C14H19NO4
265.30
110.05(10)
monoclinic
Pc
7.5433(6)
7.1072(5)
12.2710(7)
90
99.243(6)
90
649.33(8)
2
1.357
0.819
284.0
0.215 × 0.119 × 0.108
CuKα (λ = 1.54184)
12.454 to 134.038
-5 ≤ h ≤ 9, -8 ≤ k ≤ 8, -14 ≤ l ≤ 13
2127
1339 [Rint = 0.0292, Rsigma = 0.0405]
1339/2/174
1.028
R1 = 0.0344, wR2 = 0.0839
R1 = 0.0396, wR2 = 0.0890
0.19/-0.17
-0.1(3)
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N,N -Dibenzyl-2-[(5S,7S)-4-oxo-3,10-dioxatricyclo[5.2.1.01,5]dec-8-en-5-
yl]acetamide 4.39g
Empirical formula
Formula weight
Temperature/K
Crystal system
Space group
a/Å
b/Å
c/Å
α/◦
β/◦
γ/◦
Volume/Å3
Z
ρcalcg/cm3
μ/mm-1
F(000)
Crystal size/mm3
Radiation
2θ range for data collection/◦
Index ranges
Reflections collected
Independent reflections
Data/restraints/parameters
Goodness-of-fit on F2
Final R indexes [I>=2σ(I)]
Final R indexes [all data]
Largest diff. peak/hole / e Å-3
Flack parameter
C24H23NO4
389.43
110.05(10)
orthorhombic
Pna21
11.74335(11)
9.93941(9)
16.35387(18)
90
90
90
1908.85(3)
4
1.355
0.746
824.0
0.184 × 0.13 × 0.061
CuKα (λ = 1.54184)
10.416 to 134.156
-14 ≤ h ≤ 14, -11 ≤ k ≤ 11, -16 ≤ l ≤ 19
12874
3108 [Rint = 0.0210, Rsigma = 0.0166]
3108/1/263
1.078
R1 = 0.0236, wR2 = 0.0623
R1 = 0.0242, wR2 = 0.0631
0.15/-0.16
-0.07(8)
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Methyl-(2S)-1-[2-[(5S,7S)-4-oxo-3,10-dioxatricyclo[5.2.1.01,5]dec-8-en-5-
yl]acetyl] pyrrolidine-2-carboxylate 4.39h
Empirical formula
Formula weight
Temperature/K
Crystal system
Space group
a/Å
b/Å
c/Å
α/◦
β/◦
γ/◦
Volume/Å3
Z
ρcalcg/cm3
μ/mm-1
F(000)
Crystal size/mm3
Radiation
2θ range for data collection/◦
Index ranges
Reflections collected
Independent reflections
Data/restraints/parameters
Goodness-of-fit on F2
Final R indexes [I>=2σ(I)]
Final R indexes [all data]
Largest diff. peak/hole / e Å-3
Flack parameter
C16H19NO6
321.32
110.05(10)
monoclinic
I2
10.00340(10)
7.17690(10)
21.1803(2)
90
92.4690(10)
90
1519.19(3)
4
1.405
0.908
680.0
0.282 × 0.081 × 0.061
CuKα (λ = 1.54184)
8.356 to 142.35
-10 ≤ h ≤ 12, -8 ≤ k ≤ 8, -25 ≤ l ≤ 25
7598
2748 [Rint = 0.0168, Rsigma = 0.0164]
2748/1/226
1.076
R1 = 0.0291, wR2 = 0.0751
R1 = 0.0296, wR2 = 0.0759
0.14/-0.20
0.01(5)
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Homopolymerisation Kinetic Data
Polymerization of Monomer 4.39a
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Polymerization of Monomer 4.39d
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Appendix A.
Polymerization of Monomer 4.39e
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A.4. Ring-Opening Metathesis Polymerisation of a Novel Bio-based Monomer
Framework
Polymerization of Monomer 4.39g
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Polymerization of Monomer 4.39i
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A.5 Investigation into the Synthesis and Application of an
Unusual Spirocyclic Imide Species
Crystal Structure Data
N -Butyl-2-[(1R,5S,7S)-4-oxo-3,10-dioxatricyclo[5.2.1.01,5]dec-8-en-5-
yl]acetamide 5.1b
Empirical formula
Formula weight
Temperature/K
Crystal system
Space group
a/Å
b/Å
c/Å
α/◦
β/◦
γ/◦
Volume/Å3
Z
ρcalcg/cm3
μ/mm-1
F(000)
Crystal size/mm3
Radiation
2θ range for data collection/◦
Index ranges
Reflections collected
Independent reflections
Data/restraints/parameters
Goodness-of-fit on F2
Final R indexes [I>=2σ(I)]
Final R indexes [all data]
Largest diff. peak/hole / e Å-3
C14H19NO4
265.30
195.05(10)
monoclinic
P21/c
10.289(2)
15.4869(14)
8.8304(13)
90
108.988(20)
90
1330.6(4)
4
1.324
0.800
568.0
0.245 × 0.145 × 0.108
CuKα (λ = 1.54184)
9.09 to 142.204
-12 ≤ h ≤ 11, -18 ≤ k ≤ 16, -10 ≤ l ≤ 10
8452
2550 [Rint = 0.0820, Rsigma = 0.0673]
2550/0/177
1.048
R1 = 0.0633, wR2 = 0.1656
R1 = 0.0990, wR2 = 0.1982
0.34/-0.27
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(1R,4S,6S)-1’-Butyl-1-(hydroxymethyl)spiro[7-oxabicyclo[2.2.1]hept-2-
ene-6,3’-pyrrolidine]-2’,5’-dione 5.2
Empirical formula
Formula weight
Temperature/K
Crystal system
Space group
a/Å
b/Å
c/Å
α/◦
β/◦
γ/◦
Volume/Å3
Z
ρcalcg/cm3
μ/mm-1
F(000)
Crystal size/mm3
Radiation
2θ range for data collection/◦
Index ranges
Reflections collected
Independent reflections
Data/restraints/parameters
Goodness-of-fit on F2
Final R indexes [I>=2σ(I)]
Final R indexes [all data]
Largest diff. peak/hole / e Å-3
C14H19NO4
265.30
110.00(10)
monoclinic
P21/n
10.1424(3)
6.9391(2)
18.4871(6)
90
95.827(3)
90
1294.38(7)
4
1.361
0.822
568.0
0.199 × 0.118 × 0.047
CuKα (λ = 1.54184)
9.56 to 134.09
-12 ≤ h ≤ 11, -8 ≤ k ≤ 7, -21 ≤ l ≤ 22
4354
2316 [Rint = 0.0139, Rsigma = 0.0205]
2316/0/249
1.054
R1 = 0.0306, wR2 = 0.0756
R1 = 0.0345, wR2 = 0.0783
0.29/-0.18
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(1R,2S,4R)-1’-Benzyl-1-(hydroxymethyl)spiro[7-
oxabicyclo[2.2.1]heptane-2,3’-pyrrolidine]-2’,5’-dione 5.45b
Empirical formula
Formula weight
Temperature/K
Crystal system
Space group
a/Å
b/Å
c/Å
α/◦
β/◦
γ/◦
Volume/Å3
Z
ρcalcg/cm3
μ/mm-1
F(000)
Crystal size/mm3
Radiation
2θ range for data collection/◦
Index ranges
Reflections collected
Independent reflections
Data/restraints/parameters
Goodness-of-fit on F2
Final R indexes [I>=2σ(I)]
Final R indexes [all data]
Largest diff. peak/hole / e Å-3
C17H19NO4
301.33
110.05(10)
triclinic
P-1
7.0699(3)
8.8388(3)
12.4503(4)
73.353(3)
77.663(3)
82.866(3)
726.54(5)
2
1.377
0.806
320.0
0.482 × 0.234 × 0.135
CuKα (λ = 1.54184)
7.544 to 142.086
-8 ≤ h ≤ 7, -10 ≤ k ≤ 10, -15 ≤ l ≤ 15
13157
2775 [Rint = 0.0150, Rsigma = 0.0086]
2775/0/203
1.043
R1 = 0.0363, wR2 = 0.0913
R1 = 0.0368, wR2 = 0.0918
0.25/-0.25
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Figure A.9: Catalyst structures supplied by DEMETA S.A.S.
Table A.2: Demeta catalyst screening for the commercial diacid monomer.
Entry Catalyst Temp
(◦C)
Conc.
(M)
Time
(h)
Conv.
(%)a
Mnb Mwb Ðc
1 M73 SiPr rt 0.1 24 100 25,514 32,791 1.29
2 M831 SiPr rt 0.1 24 100 12,867 18,219 1.42
3 D899 rt 0.1 24 - - - -
4 D995 rt 0.1 24 100 36,675 45,989 1.25
5 M833 SiPr rt 0.1 24 100 21,008 23,260 1.11
6 G2 rt 0.1 24 100 41,264 54,817 1.33
7 M833 SiPr rt 0.1 3 100 18,540 20,059 1.08
8 D996 rt 0.1 8 100 24,670 32,088 1.30
All polymerisations were carried out using a monomer:catalyst ratio of 100:1.a Conversion
was determined by 1H NMR spectroscopy.b Determined by SEC in THF at 23 ◦C and
calibrated relative to polystyrene standards.c Ð= Mw/Mn.
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Imide Species
Figure A.10: Plot of relative molecular mass against lipophilicity for 5.44a-f
highlighting lead-like chemical space.
Figure A.11: PMI analysis of structures 5.44a-f.
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List of Abbreviations
◦C Degrees celsius
Ð Dispersity
(CH2Cl)2 1,2-Dichloroethane
CH2Cl2 Dichloromethane
CO2 Carbon dioxide
NEt3 Triethylamine
α Hydrogen bond donor
β Hydrogen bond acceptor
δ Hildebrand solubility parameter
ε Dielectric constant
v/v Volume to volume
w/w Weight to weight
δc Hydrogen bonding index
δd Dispersion energy
δh Hydrogen bonding energy
δp Dipolar energy
δs Hydrogen bonding solubility
pi* Dipolarity/polarizability
2-MeTHF 2-Methyltetrahydrofuran
ACS American Chemical Society
AN Acceptor number
API Active pharmaceutical ingredient
Bn benzyl
Boc tert-butyloxycarbonyl
Cbz Carboxybenzyl
CDI 1,1’-Carbonyldiimidazole
CEFIC The European Chemical Industry Council
cLogP Partition coefficient
COSY Correlation spectroscopy
CPME Cyclopentyl methyl ether
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List of Abbreviations
D Dipole moment
d.e. Diastereomeric excess
DAD Diode array detector
DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene
DEC Diethyl carbonate
DEPT Distortionless enhancement by polarization transfer
DFF 2,5-Furandicarboxaldehyde
DIC N,N ’-Diisopropylcarbodiimide
DIPEA N,N -Diisopropylethylamine
DMA N,N -Dimethylacetamide
DMC Dimethyl carbonate
DMF N,N -Dimethylformamide
DN Donor number
DOE Department of Energy
DSC Differential scanning calorimetry
DVB Divinylbenzene
EC Ethylene carbonate
EDC N -Ethyl-N -(3-dimethylaminopropyl)carbodiimide
EHS Environmental health and safety
EPA Environmental Protection Agency
ESI Electrospray ionisation
EtOAc Ethyl acetate
EtOH Ethanol
FDCA 2,5-Furandicarboxylic acid
Fmoc Fluorenylmethyloxycarbonyl
FT-IR Fourier-transform infrared spectroscopy
GCIPR Green Chemistry Pharmaceutical Round Table
GSK GlaxoSmithKline
GVL γ-Valerolactone
HBTU O-(Benzotriazol-1-yl)-N,N,N ’,N ’-tetramethyluronium
hexafluorophosphate
HCl Hydrochloric acid
HMBC Heteronuclear multiple bond correlation
HMF Hydroxymethylfurfural
HMPB 4-(4-Hydroxymethyl-3-methoxyphenoxy)butyric acid
HMQC Heteronuclear multiple quantum coherence
HOAt 1-Hydroxy-7-azabenzotriazole
HOBt 1-Hydroxybenzotriazole
HPLC High performance liquid chromatography
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List of Abbreviations
HRMS High-resolution mass spectrometry
HSP Hansen solubility paramteres
HSPiP Hansen Solubility Paramteres in Practice
IMI Innovative Medicines Initiative
IPA Isopropyl alcohol
IR Infra red
Kobs Observed rate constant
LC Liquid chromatograph
LLAMA Lead-likeness and molecular analysis
Mw Weight average molecular weight
Mn Number average molecular weight
MeCN Acetonitrile
MEK Methyl ethyl ketone
MeOH Methanol
MIBK Methyl isobutyl ketone
NBP N -Butylpyrrolidinone
NMP N -Methyl-2-pyrrolidone
NMR Nuclear magnetic resonance
NOx Nitrogen Oxide
OECD Organisation for Economic Co-operation and Development
PA Polyamide
Pbf 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl
PC Propylene carbonate
PE Petroleum ether
PEF Polyethylene furanoate
PEG Polyethylene glycol
PET Polyethylene terephthalate
PMA Phosphomolybdic acid
PMI Principal moments of inertia
PS Polystyrene
RF Retardation factor
R0 Interaction radius
Ra Relative HSP distance
REACh Registration, Evaluation, Authorisation & restriction of CHemicals
ROMP Ring-opening metathesis polymerisation
scCO2 Supercritical carbon dioxide
SEC Size-exclusion chromatography
SOx Sulfur oxide
SPOS Solid-phase organic synthesis
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List of Abbreviations
SPPS Solid-phase peptide synthesis
SVHC Substance of very high concern
Tg Glass transition temperature
T10% Thermal decomposition temperature
TFA Trifluoroacetic acid
TGA Thermogravimetric analysis
THF Tetrahydrofuran
TLC Thin layer chromatography
TMO 2,2,5,5-Tetramethyltetrahydrofuran
Trt Trityl
UN United Nations
UV Ultra violet
VOC Volatile organic compound
wt% Weight percent
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